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Abstract
Malignant catarrhal fever (MCF) is a sporadic but fatal lymphoproliferative viral
disease of cattle, deer and other ruminants. The causative agents are highly-cell-
associated herpesviruses of the subfamily gammaherpesvirinae including
Alcelaphine herpesvirus-1 (A1HV-1) and Ovine herpesvirus-2 (OvHV-2). The
identification of MCF-affected animals is based on the detection of antibodies to
A1HV-1 in a variety of assays including indirect-immunofluorescence tests (IFAT)
and a competitive-inhibition enzyme-linked immunosorbent assay (CI-ELISA),
although histopathological examination remains the most recognised diagnostic
procedure. PCR assays are also available for the detection of MCFV DNA.
The aim of this project was to develop a serological assay based on
recombinant antigens derived from the OvHV-2 genome and validation of the EL1SA
test using clinical serum samples. Eight OvHV-2 genes were selected for expression
in three bacterial systems. Four genes could be expressed in at least one system, but
only a fragment of the Ov8 protein and ORF65 were found to be recognised by anti-
MCF sera. Additionally Ov2.5, expressed in mammalian cells, was not recognised by
anti-MCF sera. Three genes were expressed in an in vitro transcription-translation
system (Ov8, Ov8.5 and ORF65). Protein purification, using epitope-tag affinity
purification and conventional chromatography, was unsuccessful so that these
polypeptides could not be evaluated as recombinant EL1SA antigens, requiring
further work on large scale expression and purification.
Due to the lack of recombinant antigen expression, crude antigen preparations
from cultured A1HV-1 and OvFlV-2 infected cells were analysed. Antigens suitable
for the detection of MCF virus specific serum antibodies could not be extracted from
an OvHV-2 infected cell line but A1F1V-1 WC11 antigen could be used to
differentiate MCF-positive and -negative sera. An ELISA based on this crude antigen
was established, designated WC11 -ELISA. Initial validation revealed over 93%
concordance between WC11-ELISA and commercial ELISA, while a comparison
with serological assays, a PCR test and final veterinary evaluations, showed good
agreement between tests. The WC11-ELISA showed 57% agreement to PCR while
commercial CI-ELISA showed 66% agreement for the same samples. This indicates
the value of the ELISA as an economical, rapid and specific serological assay for the
detection of antibodies against MCFV.
Potentially antigenic components of the ELISA lysate were analysed by
western blotting in comparison with other bovine herpesviruses, and fractionation by
gel filtration showed clear antigenic bands in the eluent. Proteomic analysis of
antigenic bands identified proteins encoding viral thymidine kinase (ORF21), a virus
capsid protein (ORF5), ORF52 (homologue to tegument protein HSV UL49) and a
viral antigen (ORF54) which encodes a dUTPase.
The simplicity of the WC11-ELISA and its lack of cross-reactivity make this
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Malignant catarrhal fever (MCF) is an acute, sporadic and usually fatal
disease affecting domestic and wild ruminants and in particular species of the
subfamily Bovinae and family Cervidae. MCF is characterised by the recognition of
lymphoid cell accumulations in non-lymphoid organs and T-lymphocyte hyperplasia
in lymphoid organs (Office des International, 2004), and can be caused by either of
two gammaherpesviruses; Alcelaphine herpesvirus-1 (A1HV-1) and Ovine
herpesvirus-2 (OvHV-2). The natural hosts of A1FIV-1 are wildebeest, while the
natural hosts of OvHV-2 include all species of wild and domestic sheep. Affected
carriers remain asymptomatic. A1HV-1 is found in cattle in regions of Africa and in a
variety of ruminant species in zoological collections world-wide, while OvHV-2 is a
welfare issue of economic significance worldwide.
The disease may present a variety of clinical manifestations ranging from the
acute form were death may occur within hours, to chronic cases characterised by
high fever, bilateral corneal opacity, profuse catarrhal discharges from the eye and
nose and necrosis of the muzzle. Current diagnosis is reliant on histopathological
examination, though detection of viral DNA by PCR and serological assays are
available.
1.2. The Herpesviruses
Herpesviruses are a large, clearly defined group of viruses (Bowman et ah,
2003) found in all species of animal and birds. Several herpesviruses have been
isolated from humans, including; herpes simplex virus 1 and 2 (HSV-1, HSV-2),
human cytomegalovirus (HCMV), varicella-zoster (VZV), Epstein Barr virus (EBV)
and human herpesvirus 6 and 7 (HHV-6 & 7) and Kaposi's sarcoma associated
herpesvirus (KSHV, HHV-8). Of over 130 herpesviruses identified, approximately
100 have been partially characterised to date (Roizman, 2001; Minson, 2000), and
the genomes of at least 19 have been sequenced. Within livestock species these
include equine herpesviruses 1, 2 and 4, bovine herpesvirus-1, bovine herpesvirus-5,
alcelaphine herpesvirus-1 and ovine herpesvirus-2.
Herpesviruses are fragile and are therefore do not survive well outside the
body. In nature, each herpesvirus is closely associated with a single host species,
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where transmission of these viruses requires close contact, and in particular mucosal
contact. Subsequently closely confined populations allow the possibility for modes of
transmission such as via sneezing and coughing. The virus is released in aerosol
droplets were it might be inhaled by a susceptible host (Roizman and Pellett, 2001).
Herpesviruses survive in nature due to persistent, latent infections from which the
virus is intermittently reactivated and shed.
1.2.1. Biological Properties of Herpesviruses
All known herpesviruses share four significant biological properties
(Roizman, 2001).
1. All herpesviruses specify a large range of enzymes involved in nucleic
acid metabolism, DNA synthesis and possibly in the processing of
proteins.
2. The synthesis of viral DNAs and assembly of capsids occurs within the
nucleus.
3. Production of infectious progeny virus is invariably accompanied by the
irreversible destruction of the infected cell
4. They possess the ability to remain latent in their natural hosts. If the virus
is latent, the viral genome takes the form of closed, circular molecules.
Originally, herpesviruses were categorised on the basis of their biological
properties. However, the primary means for identification is through virus structure.
With the determination of the DNA sequence of the viral genome, the herpesviruses
have now been classified into genera, based on DNA sequence homology and the
antigenic relatedness of the viral proteins.
Some herpesviruses have a wide host range, and can multiply and infect cells
rapidly, such as HSV-1. Others possess a narrow host range, such as EBV, or have
long replicating life cycles, such as HCMV. Although all herpesviruses have a latent
phase, differences arise in the exact site of latency.
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1.2.2. Virion properties and structure
The structure of the herpes virion is complex with characteristic symmetrical
and nonsymmetrical components. Herpesvirus virions are enveloped and are about
200-250nm in diameter (Figure 1.1). A typical virion consists of (a) a core
containing linear double stranded DNA, (b) an icosahedral nucleocapsid, (c) the
tegument and (d) a typical lipoprotein membrane designated the envelope (Castro et
al., 1985; Van Regenmortel et al., 2000; Flach et al., 2002; Bowman et al., 2003).
The core is comprised of the viral genome (125-245kbp), which is packaged
as a single, linear, double-stranded DNA molecule (Davidson, 2002). This is
enclosed in a protein capsid. The structural features of this protein capsid are
characteristic of herpesviruses (lOOnm in diameter and 162 capsomeres) (Roizman,
1996). Surrounding the capsid is a globular layer, known as the tegument, a term
introduced by Roizman and Furlong (1974), which is employed to describe the
structures present between the capsid and the envelope. These structures have no
distinctive feature, though contain many proteins and polypeptides, some of which
are not required in vitro and are therefore not needed for the formation of virions.
These proteins and polypeptides vary among the different members of the
Herpesviridae family (Bowman et al., 2003).
On the outer surface of the virus structure is the lipoprotein envelope, a lipid
bilayer that is associated to the outer surface of the tegument, and is known to
contain at least 10 integral membrane proteins, including a variety of viral
glycoproteins required for entry into the host cell (Van Regenmortel et al., 2000).
1.2.3. Classification of herpesviruses
Based upon the general molecular characterisations, such as nucleotide sequence and
phylogenetic analyses, the family Herpesviridae is divided into three subfamilies.
They are termed; Alphaherpesvirinae, Betaherpesvirinae and Gammaherpesvirinae
(Roizman, 1996). Viruses belonging to the subfamilies of herpesviruses are







Figure 1.1: Diagram of herpesvirus. Main structural components of the
herpesvirus virion. Herpesvirus virions are approximately 200-250nm in diameter. A
typical virion consists of (a) a core containing linear double stranded DNA, (b) an
icosahedral nucleocapsid, (c) the tegument and (d) a typical lipoprotein membrane




Members of this group are classified on the basis of a relatively short
reproductive cycle, efficient destruction of infected cells and a variable host range.
Alphaherpesviruses commonly possess the capacity to establish latent infections in
neurons. The subfamily includes the genera Simplexvirus (e.g. Herpes simplex-l and
2, Bovine herpesvirus-2), Varicellovirus (e.g. Varicella zoster virus, Bovine
herpesvirus-1) and Mardivirus and Iltovirus (Marek's disease). Commonly, members
of the genera Simplexvirus are viruses found in primates while members of the
genera Varicellovirus are found in a wide range of mammalian hosts (Van
Regenmortel el al., 2000). Mardivirus and Iltovirus viruses are found in birds and are
commonly associated with malignancy such as shown in Marek's disease.
Herpes simplex virus
Herpes simplex virus was the first human herpesvirus to be identified. In
1893, human transmission of the virus was described from one individual to another
(Whitley, reviewed in Fields Virology). Host immune responses were described in
the 1930's, defining the presence of neutralising antibodies in serum of infected
patients. The recurrence of lesions after the primary infection resulted in the
demonstration of a unique biological property whereby viruses can recur in the
presence of humoral immunity of the host. This response was known as the
reactivation of latent infection (Whitley, reviewed in Fields Virology).
Advances in molecular technology have resulted in an increased understanding of
epidemiology and infection and led to the discrimination of HSV types 1 and 2.
HSV-1 (human herpesvirus 1, HHV-I) and HSV-2 (human herpesvirus 2, HHV-2)
are widespread human pathogens, generally associated with oral and genital
infections. Nahmias and Dawdle (1968) showed antigenic and biological variations
between these two types. HSV-1 is frequently associated with non-genital infections
causing ocular herpes and is an important cause of encephalitis and infects 60-80%
of people worldwide (Cunningham et al., 2006). HSV-2 is commonly associated





Herpes simplex-1 Human Cold sores, keratitis
Herpes simplex-2 Human Genital herpes
Varicella zoster virus Human Chicken pox and shingles
Bovine herpesvirus-] Bovine Infectious bovine rhinotracheitis,
Genital disease, abortions
Bovine herpesvirus-2 Bovine Bovine herpes mammilitis, Pseudo-
lumpy skin disease
Feline herpesvirus-1 Cats Feline viral rhinotracheitis
Porcine herpesvirus-1 Pigs Pseudorabies (Aujzesky's disease)
Equine herpesvirus-1 Horses Abortion, neurological disease
Gallid herpesvirus-2 Chickens Marek's disease
Betaherpesvi ruses
Human cytomegalovirus Human Mononucleosis, multi-system disease in
immunocompromised patients
Porcine cytomegalovirus Pigs Rhinitis in piglets
Murine cytomegalovirus Mice




Epstein-Barr virus Human Infectious mononucleosis, Burkitt's
lymphoma, PTLD, nasopharyngeal
carcinoma,
Kaposi's sarcoma Human Kaposi's sarcoma, Body cavity
associated herpesvirus lymphomas, MCD
Equine herpesvirus-2 Horses ? Respiratory disease in foals
Bovine herpesvirus-4 Cattle ? Conjunctivitis, metritis, mastitis
Herpesvirus saimiri Squirrel Fatal lymphoproliferations in cottontail
monkey rabbits & new world monkeys e.g.
marmosets
Herpesvirus ateles Spider Lymphomas in new world primates
monkey
Rhesus rhadinovirus Rhesus Lymphoproliferative disease in
monkey immunosuppressed host




Alcelaphine herpesvirus-1 Wildebeest Malignant catarrhal fever in cattle, deer
Ovine herpesvirus-2 Sheep and other ruminants





Bovine herpesvirus-1 is a member of the herpesvirus subfamily
Alphaherpesvirinae, genus Varicellovirus. BHV-1, commonly associated with
infectious bovine rhinotrachetitis (IBR) and infectious pustular vulvovagnititis (IPV)
was first described in Europe in 1913 (Babiuk et al., 2004). The virus occurs
worldwide, where aside from the bovine host, other ruminants such as goats, sheep
(Whetstone and Evermann, 1988; Thiry et al., 2006), deer (Thiry et al., 2006) and
buffalo (Ibrahim et al., 1983) may be susceptible. In susceptible animals, the virus
can cause mild to severe clinical disease.
Clinical symptoms include rhinotracheitis, conjunctivitis, reduced milk yield
and genital infections (Hurk, 2006). Although it affects cattle of all ages it is
commonly recognised in animals over six months old. This suggests young animals
are protected as a result of passive immunity, possibly acquired from colostrum.
Transmission of the virus is through direct contact with infected animals nasal
secretions and excretions entering food and water sources. Diagnosis of BHV-1 is
reliant on either direct identification of the agent (histopathology) or assays to detect
virus or antibody in the host (Babiuk et al., 2004). Viral antigens can be detected in
nasal or genital swabs by assays including; immunofluorescence, ELISA, virus
neutralisation and immunohistochemistry. These tests prove beneficial as a method
of control, where herds can be screened for BHV-1 virus.
The BHV-1 genome consists of double-stranded linear DNA approximately
140kbp and codes for over 70 proteins (Mayfield et al., 1983). Based on genomic
characterisation, two subtypes of bovine herpesviruses have been recognised,
designated subtype 1 (BHV-1.1) and subtype 2 (BoHV1.2) (Miller et al., 1995;
D'Arce et al., 2002; Spilka et al., 2005). The epidemiological importance of these
two disease subtypes, however, remains unknown (Spilka et al., 2005).
Bovine Herpesvirus-2 (BHV-2)
Bovine herpesvirus-2 is a member of the subfamily Alphaherpesvirinae,
genus Simplexvirus. BHV-2 was first reported in South Africa in 1957 (Reviewed by
Gibbs, 2004), and later in the UK in 1964 (Martin et al., 1966) and is commonly
associated to two clinical forms: bovine herpes mammilitis and pseudo-lumpy skin
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disease (Imai et al., 2004). BHV-2 infections are commonly subclinical, however
some clinical signs can be presented including ulcerated or necrotic lesions of the
udder and teat, oedematous teat swelling and inflamed dermis. In dairy cattle, a
decline in milk production and mastitis may be observed resulting in economic losses
(Imia et al., 2002). Initial diagnosis is primarily based on the presence of the
characteristic lesions on the udder and teats. Virus isolation and histopathology,
including microscopic examination of skin biopsies, are the most recognised methods
for the detection of the virus. However, serological assays such as virus
neutralisation may also confirm the presence of antibodies against the virus (Imai et
al., 2004). PCR methods have also been used in the diagnosis of viral diseases
including BHV-2 (Imai et al., 2002). Pseudo-lumpy skin disease can be characterised
by generalised skin lesions (Imai et al., 2004).
The mode of BHV-2 transmission is still unclear, but it is assumed to be a
mechanical transmission by insect vectors. Domestic cattle such as dairy herds are
affected, the significance of BHV-2 in wildlife is unknown and raises further doubt
regarding the route of transmission (Imai et al., 2004).
1.2.3.2. Betaherpesvirinae
Members of the subfamily betaherpesvirinae have a restricted host range and
are species-specific. Unlike alphaherpesviruses, members of this group have a long
reproductive cycle and the infection progresses slowly in culture. The virus remains
cell-associated and may be maintained in a latent form in monocytes, in regions such
as the kidneys, secretory glands and other tissues. Members of this group include the
genera Cytomegalovirus (e.g. Human cytomegalovirus, Porcine cytomegalovirus),
Muromegalovirus (e.g. murine cytomegalovirus) and Roseolovirus (e.g. Human
Herpesvirus-6 [HHV-6] and Human Herpesvirus-7 [HHV-7]).
1.2.3.3. Gammaherpesviridae
The subfamily gammaherpesvirinae is comprised of herpesviruses which are
lymphotropic. Members of this subfamily have a narrow host range. The viruses
establish latency in lymphocytes and lymphoid tissues and may cause lytic infections
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in fibroblastic and epithelial cells. Infection is therefore associated with
lymphoproliferative disorders, and malignancies of lymphoid tissues.
Gammaherpesviruses are divided into two groups; yi-herpesvirus (genus
Lymphocryptovirus) and y2-herpesviruses (genus Rhadinovirus) (Honess & Watson,
1977; Roizman, 1982; Honess, 1984; Roizman et al., 1992).The
Lymphocryptoviruses (LCV) include viruses such as Epstein-Barr virus (EBV),
known to infect B lymphocytes in culture, the site of latent infection. The
Rhadinoviruses (RDV) include viruses such as human-herpesvirus-8 (Kaposi's
sarcoma virus), Herpesvirus saimiri (HVS), equine herpesvirus-2 (EHV-2) and
bovine herpesvirus-4 (BoHV-4) (Plowright et al., 1972), alcelaphine herpesvirus-1
and ovine herpesvirus-2, where latent infection is reported in T and B lymphocytes
(Van Regenmortel et al., 2000).
1.2.4. Herpesvirus genome
The composition, size and organisation of the genome of herpesviruses are
found to vary significantly. The majority of the DNA from virions is linear, double
stranded molecules ranging in size from 125-235kb. Furthermore the percentage of
guanine plus cytosine (G + C) is found to vary between 32 and 75% (Roizman,
1996). Although herpesviruses share some significant biological properties, they are
also shown to be vastly different in others. While some have a wide cell range, and
can multiply efficiently, rapidly destroying the cells they infect (HSV-1, HSV-2),
others have a limited host range (such as EBV and HHV-6) and multiply slowly
(human cytomegaloviruses (HCMV)).
According to DNA sequence arrangement, herpesviruses may be divided into
six groups (Figure 1.2). These are termed A-F (Roizman, 2001).
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Group A - A large sequence from one terminus is shown directly repeated at the
other terminus. An example of this is channel catfish herpesvirus.
Viruses of the subfamily Betaherpeviridae Roseolovirus are
represented by this group (Human herpesviruses 6 & 7).
Group B - The terminal sequence is directly repeated frequently at both termini.
Additionally, the number of reiterations at both termini may also vary.
This is shown in the subfamily Gammciherpesvirus rhadinovirus
viruses which include Herpesvirus saimiri, Alcelaphine herpesvirus-1
and Ovine herpesvirus-2.
Group C - In genomes such as Epstein-Barr virus (EBV), there are less terminal
reiterations, though there may be other internal unrelated sequences
(normally greater than lOObp) which are directly repeated and may
subdivide unique sequences of the genome into several sections. This
group represent the subfamily Gammaherpesvirus lymphocryptovirus.
Group D - In group D viral genomes, the subfamily alphaherpesvirus
Varicellovirus such as Varicella zoster virus (VZV) and bovine
herpesvirus-1 (BHV-1), the sequence at one terminus (TR) is repeated
in an inverted orientation internally (IR). This divides the unique
region into long unique (Ul) and short unique (Us) regions. The short
region can invert, resulting in two isomers of viral DNA.
Group E - One terminus contains N repeats of sequence A next to a longer
sequence B. The other terminus has one directly repeated sequence A
next to a sequence C. The terminal sequences are inserted in an
inverted form internally ( B' A'N, C'). Both the long and short regions
can invert, forming four isomers. This is observed in viruses of the
subfamilies alphaherpesvirus Simplexvirus (Bovine herpesvirus-2,




Group F - The two termini are not identical in members of group F, and are not
repeated directly. Group F are exemplified by the tupaia herpesvirus,




R4 R3 R2 R1
■i






Figure 1.2: Sequence Arrangements of Herpesvirus Genomes. The sequence
arrangements of the six categories of viral genomes of the herpesvirus family are
shown (Illustration taken from Roizman, 2001).
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1.2.5. Herpesvirus Life Cycle and Replication
The herpesviruses life cycle has two stages, the lytic stage and the latent
stage. The lytic cycle is comprised of viral replication, production of new virions and
the subsequent release from the cell, which normally causes the infected cell to lyse.
The latent stage involves the virus genome persisting in the cell as an episome, with
no production of new virions and expression of only a small subset of viral genes. As
many replication genes are conserved within herpesviruses, the principles of
replication are likely to be applicable to most herpesviruses and are known to involve
numerous stages. As HSV-1 is well characterised, the general process of replication
has been studied in detail (Roizman and Knipe, 2001) and is described here as a
prototype of the process in other herpesviruses (Figure 1.3).
Virus attachment and entry
Initially, the virus attaches to cell surface receptors, which involves the
interaction between viral glycoproteins present in the viral envelope. Glycoproteins
(gPs) are known to mediate attachment and penetration to the cell surface. There are
ten viral glycoproteins designated gB, gC, gD, gE, gG, gH, gl, gK, gL and gM,
although not all subfamilies have all gPs and some have other gPs such as EBV
gP340. The envelope glycoproteins, gB and gC, are essential for attachment, as they
bind to cell surface glycosaminoglycans such as surface heparin sulphate or
chondroitin sulfate. (Reviewed in Rajcani & Vojvodva, 1998). The subsequent step
involves the interaction of the viral glycoproteins with several cellular co-receptors,
which is necessary for fusion of the viral envelope with the host cell membrane. This
involves the interaction of glycoprotein gD and cellular receptors. For HSV-1, these
cellular receptors include members of the tumour necrosis factor (TNF) receptor
family, members of the immunoglobulin superfamily, designated nectins on the basis
of their cellular function, and the 3-O-sulphated heparin sulphates (reviewed in
Spears et ai, 2000).
Fusion requires the interaction of gD, gB and the heterodimer gH-gL,





Figure 1.3: The replication cycle of Herpes Simplex virus. (1) Specific proteins in
the viral envelope attach to host cell receptors on the cell membrane (2) viral
envelope fuses with the cell membrane releasing the nucleocapsid directly into the
cytoplasm. (3) the viral DNA is transported into the nucleus (4) the viral DNA is
transcribed into early mRNAs which are transported to the cytoplasm for the
translation of early proteins, which participate in the replication of the virus DNA.
The viral DNA is then transcribed into the late mRNAs which exit to the cytoplasm
for translation into the late (nucleocapsid and envelope) proteins (5). The capsid
proteins assemble (6) The nucleocapsids are enveloped by budding through the
nuclear membrane, and the mature viruses are released from the cell through




receptor and are present following penetration. Following fusion, some tegument
proteins remain in the cytoplasm while others are transported to the nucleus or
remain associated with the nucleus. The capsids, with associated tegument proteins,
are then transported to the nuclear pore. At the nuclear pore, the nucleocapsid
releases DNA into the nucleus. The tegument proteins are introduced to the cell with
the capsid and may play a role in preparing the host cell for viral replication.
After entering the cell nucleus, the viral DNA circularises and viral gene
expression initiates. Transcription and replication of viral DNA occur in the nucleus,
while viral proteins are synthesised in the cytoplasm. The capsid is assembled in the
nucleus. Viral DNA is transcribed by host RNA polymerase and mRNA is translated
in the cytoplasm (Roizman & Spears, 1990). Gene expression in the lytic phase
occurs in a chronological order that can be grouped into three categories; immediate
early (IE), early (E) and late (L).
1.2.6. Viral replication
The cellular cytoskeleton is thought to mediate the transport of the capsid to
the nucleus. Capsids of HSV-1 accumulate at nuclear pores and release viral DNA
into the nucleoplasm. The capsid therefore may act as a vector for transporting viral
DNA, such as tegument proteins which are thought to play an important role in the
initiation of replication.
The initial viral genes expressed are the immediate early genes. In HSV-1
infections, the virion tegument protein, VP 16, which is released into the cell
following fusion of the virus to the host plasma membrane (Hancock et al., 2006),
binds cellular factors host cell factor (HCF) and octamer DNA-binding protein (Oct-
1) which binds to target sequences within immediate early (IE) genes. The VP 16
protein stimulates the expression of six IE genes (ICP4, ICPO, ICP22, ICP27, ICP47
and Us 1.5) which encode proteins required to transactivate early (E) gene expression
and drive the lytic cycle.
Expression of early genes requires the function of the immediate early gene,
ICP4. Early proteins include enzymes that are required for the replication of the viral
genome and expression of late gene transcription. Late genes are required for the
onset of virion viral synthesis. Most viral genes involved in nucleic acid metabolism
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are classed as late genes. Late genes are divided into two groups, group 1 (leaky-late
or early-late) are expressed for a short time in association with the synthesis of
immediate-early genes. Group 2 late genes (true-late) are expressed after expression
of early genes and are linked to replication. Once expressed, late genes localise in the
nucleus and assemble onto the parental DNA to form structures called prereplicative
sites. It is at these prereplicative sites that viral DNA synthesis and replication are
initiated. Expression of the late genes is increased during replication.
Virus capsid assembly and egress
Capsid proteins are transported to the nucleus of the infected cell, where
capsid assembly takes place. Capsids are assembled first containing an internal
scaffold protein, which is lost on insertion of the viral DNA. The virus matures and
acquires infectivity by budding through the inner lamella of the nuclear membrane,
although it is still unclear how the fully enveloped particle is generated. The most
recent data suggests that the virion is enveloped at the inner nuclear membrane and
then de-enveloped and released into the cytoplasm (Mettenleiter, 2002). The
enveloped virus is then transported, through the endoplasmic reticulum and Golgi
apparatus, out of the nucleus. Viral membrane proteins are glycosylated as they are
synthesised. The mature virion is conveyed to the outer membrane of the host cell
inside vesicles. The release of progeny virus is followed by cell death.
1.2.7. Latency
One of the unique characteristics of herpesviruses is in their ability to
establish latent infection. Latency is defined as a persistent infection characterized by
the fact that no infectious virus can be isolated and no viral antigen can be
demonstrated in the latently infected cells (Engles and Ackermann, 1996). Following
infection, herpesviruses establish lifelong latent infection at a particular cellular
location, where either a continuous low level of virus is produced or episodes of
reactivation produce virus (Crawford, 2001).
In HSV, latency is established by the entry of the viral genome into the
sensory nerve cell nuclei of the peripheral nervous system (Chen et al., 1995; Jones,
2003). The major viral gene products expressed during the latency are the latent-
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associated transcripts (LATs), which play an essential role in the down-regulation of
lytic gene expression. The major LAT accumulated during latent infection is in the
form of a nonpolyadenylated, stable 2kb intron, which can be spliced to give two
smaller fragments, 1.5kb and 1.4kb RNA molecules. Two promoter (LAP1 and
LAP2) fragments, located upstream of the start site of LAT, direct the expression of
LAT in the sensory neurons. LAP1 is essential for LAT expression in the sensory
neurons while LAP2, located upstream of the 2kb LAT, promotes expression of LAT
during productive infection. LAP1 and LAP2 play complementary roles during viral
life cycle. During lytic infection, LAP2 is the major control element while LAP1 is
the dominant control element during latent infection (Chen et al., 1995; Jones, 2003).
The exact mechanism by which LATs perform their function is not clearly
understood. It is predicted that latency is established in the absence of immediate-
early gene expression. The absence of these transcripts would result in the lack of
early and late virus gene expression. LATs are complementary to the IE gene ICPO
and are predicted to inhibit ICPO, which results in the reduction of lytic gene
expression and therefore reduces virus replication and aids the establishment of
latency (Mador et al., 1998). ICPO is required for IE promoter activation, activation
of expression in all classes of viral genes, binds cellular proteins and is required for
efficient HSV-1 reactivation from latency (Jones, 2003; Freeman et al., 2005).
Recent data has shown LATS encode miRNAs, which inhibit apoptosis
(Gupta et al., 2006). LAT inhibits apoptosis and maintains latency by promoting the
survival of infected neurons, contributing to the persistence of infection. By
promoting the survival of infected neurons during latency, LATs increase the number
of latently infected cells, thus preventing premature death of neurons prior to the
release of infectious virus. The mode which regulates this process however remains
unclear. To gain an insight into this mechanism, computational analysis was
performed and revealed transforming growth factor-P (TGF-P) and SMAD3 as
targets of miRNA-LAT. TGF-P is a known inducer of apoptosis and inhibitor of cell
growth (Gupta et al., 2006).
Latency lasts for the life of the host. Reactivation from latency may be
activated by external stimuli such as immunosuppression, which may stimulate viral
gene expression. This reactivation results in the recurrence of virus transmission and
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disease (Jones, 2003). Recent studies regarding the association of HSV-1 reactivation
and immunosuppression combined with retention of CD8+ T cells suggest CD8+ T
cells play an important role in maintaining a latent infection (Freeman et al., 2005).
CD8+ T cell function is regulated by the interaction between an epitope comprised of
an antigenic peptide, bound to MHC class I molecules on the surface of the target
cell. For CD8+ T cells to regulate latency, the target cells would be the neurons,
where virus establishes latent infection. Evidence supporting the role of CD8+ T cells
in controlling HSV-1 reactivation has been shown in ex vivo cultures of latently
infected trigeminal ganglia (TG) of mice, where CD8+ T cells present in infected TG
were shown to inhibit reactivation in culture (Liu et al., 2000). Latency-reactivation
of HSV-1 may be categorised into three stages; establishment, maintenance and
reactivation. Establishment of latency involves entry of the viral genome into a
sensory neuron. Maintenance of latency may last the lifetime of the host, and
involves the continued expression of LAT. It is during this stage that the virus may
not be detected by virus isolation methods and PCR. Reactivation is the stimulation
of viral replication. Viral expression can be detected in the sensory neurons, and
virus can be isolated from the infected animal (Jones, 2003).
1.3. The Gammaherpesviruses
The gammaherpesviruses are significant pathogens in both humans and animal
species and may be characterised by their ability to replicate in lymphoblastoid cells
in vitro, to establish latent infections in lymphoid tissue in vivo and to cause
lymphoproliferative diseases (Roizman, 1995; Coulter et al., 2001).
Members of this virus family are specific to either T- or B-lymphocytes and
establish latent infections in the lymphoid system following an initial viremia that is
controlled by the hosts' immune system (Roizman, B., 1996; Flach et al., 2002).
Serious disease may result in an immunocompromised host, incapable of controlling






In the 1950's, a British surgeon, Denis Burkitt, treating children with
extranodal lymphomas observed unusual epidemiological and clinical features of a
lymphoma. Tony Epstein and colleagues, on obtaining tumour biopsies, identified a
herpesvirus of the tumour cells. This herpesvirus differed from all known human
herpesviruses. The herpesvirus responsible was later identified by Epstein, Achong
and Barr in 1964 (Epstein et al., 1964) and subsequently became the first candidate
human tumour virus (Kieff and Rickinson, 2001). EBV can cause a variety of
diseases, the most commonly recognised being Burkitt's lymphoma (BL), infectious
mononucleosis (IM), nasopharyngeal carcinoma (NPC) and X-linked
lymphoproliferative syndrome and Hodgkin's lymphoma (EIL).
EBV is a member of the gammaherpesvirus subfamily, and is the only human
herpesvirus of the yi-herpesvirus genus Lymphocryptovirus (LCV). EBV infects B
lymphocytes of over 90% of the general population before adulthood (Crawford,
2001). Primary infection results in transient viremia, followed by a rapid immune
response. The yi and y2-herpesviruses show similarities in structure and gene
organisation, and share genes found in most herpesviruses, such as those encoding
structural components proteins involved in the replication of viral DNA, nucleotide
metabolism, as well as genes specific to gammaherpesviruses. Despite these
similarities, antigenic cross-reactivity between EBV and other human herpesviruses
is rare.
EBV structure
EBV was the first herpesvirus to have its complete genome cloned and
sequenced (Arrand et al., 1981; Baer et al., 1984) The EBV genome was sequenced
from a BamVW library, and this is reflected in many EBV gene names, which have a
B prefix. Similar to all other herpesviruses, EBV is comprised of a protein core,
containing double-stranded DNA (172kbp), a nucleocapsid with approximately 162
capsomeres, a protein tegument layer and an outer envelope (Kieff and Rickinson,
2001). EBV has a range of envelope glycoproteins, including homologues of well-
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conserved herpesvirus glycoproteins gH (EBV gp85/BXLF2), gB (gpl 10/ BALF4),
and gM (gp84/l 13/BBRF3).
The characteristic features of the genome include 0.5kbp reiterated terminal
direct repeats at both termini and a reiterated 3kbp internal direct repeats. These
divide the genome into unique long (UL) and unique short (Us) regions. The unique
long and short regions contain imperfect tandem DNA repeats, mainly found within
ORFs. The unique long region contains a duplicate region (DL) at the left end of UL,
which consists of multiple, highly conserved tandem 125bp repeats and 2kbp of
unique DNA. The DL region is homologous to the Dr region, located at the right end
of Ul- The Dr region consists of multiple, highly conserved tandem 102bp repeats
and a lkbp of unique DNA. DL and DR include the origin for initiation of viral DNA
replication in lytic infection. The reiteration frequency of the EBV tandem repeats is
variable during viral DNA replication. During EBV infection, the genome becomes
an episome with a number of tandem repeats. The EBV genome of the infected
progeny cells will have the same number of terminal repeat units as the parent
genome, including variation to the parental genome introduced during viral DNA
replication.
Two EBV types exist, namely type 1 and type 2. Type 1 is more common in
most populations, while type 2 is common in Africa and in people with human
immunodeficiency virus (HIV). The main differences between the two types lie in
the genes encoding the EBV nuclear antigens (EBNA).
EB V Replication
EBV is transmitted via saliva where it interacts with the host in three distinct
ways (i) firstly EBV infects the host's B lymphocytes and induces proliferation of
infected cells, (ii) the virus can enter into a latent phase following proliferation and
subclinical disease (iii) and finally the virus can become reactivated to produce
infectious virus for the reinfection of cells and the transmission of disease (Figure




Three types of latency are distinguished for EBV described in various tumour cell
lines and infected B cells, as a result of the RNA synthesised (Ackermann, 2006). In
type I (Burkitts' lymphoma), only EBV-encoded nuclear antigen, EBNA-1, and
Epstein Barr encoded small RNA (EBERs) are expressed. EBNA-1 has an
association with chromosomes which allows the persistence of episomes in EBV-
infected cells (Yates et al., 1984). In type II (nasopharyngeal carcinoma), EBERs and
EBNA-1 are expressed with the latent membrane proteins LMP-1, LMP-2A and
LMP-2B (Gilden et al., 2007). LMP-1 is an oncoprotein which affects multiple cell
signalling pathways, contributing to EBV-associated oncogenesis (Chang et al.,
2004).
EBV infection of primary B lymphocytes results in type III latency. In
addition to the genes seen in Latency II (EBER-1, 2, EBNA-1, LMP-1, 2A and 2B),
type III (lymphoproliferative diseases) latency expresses viral nuclear antigens
EBNA-3A, 3B, 3C and EBNA-LP, and the highly spliced Bam A rightward
transcripts (BARTs) which have a variety of roles in the up and down-regulation of
viral and cellular gene expression as well as transformation of B cells.
Kaposi's sarcoma herpesvirus (KSHV)
Moritz Kaposi first described Kaposi's sarcoma (KS), in the 1870's, as an aggressive
tumour that primarily affected a young age group. Kaposi's sarcoma (KS) is a
highly vascularized tumor-like lesion affecting the skin, lymph nodes and
viscera, which develops nodular tumors composed predominant of spindle cells
(Pyakurel et al., 2007).
Kaposi's sarcoma-associated herpesvirus (KSHV) or human herpesvirus-8
was discovered in the search for an infectious agent in KS (Chang et al., 1994) and
epidemiological evidence has since demonstrated that KSHV is the causative agent
of all forms of KS (Sarid et al., 1999).There are three proliferative diseases
associated with KSHV: Kaposi's sarcoma (KS), a tumour of endothelial cells;
primary effusion lymphoma (PEL), a B-lymphoma, and a plasma cell form of
multicentric castleman's disease (MCD). Castleman's disease is a B-cell
lymphoproliferative disorder. All of these tumours are frequently demonstrated in
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immunosuppressed patients, and in particular patients with acquired
immunodeficiency syndrome (AIDS) (Moore and Chang, 1999). KSHV also occurs
in the absence of immunosuppression, for example classical KS tumours are
common in elderly Mediterranean and African men (Moore and Chang, 2001).
Figure: 1.4: Stages of gammaherpesvirus infected cells (illusion taken from
Ackermann et at., 2006). (1) Viral DNA is transported to the nucleus and becomes
circularised allowing the cell to become activated. (2) After the infection of B
lymphocytes, latency may be established, whereby EBV immobilises the cell, prior
to (2a) or following viral replication (2b). Viral genes expressed during latency
determine whether infected cells will replicate. The immune response may then be
manipulated by the signalled release of host-dependent viral cytokines and
chemokines. (4-6) such signalling in the reactivation of latency may result in lysis of




Gammaherpesviruses of animals are of particular interest, not only as agents
of disease, but as models to illustrate the variability and similarity of genome
arrangements within members of the gammaherpesviruses subfamily. Animal
gammaherpesviruses include equine herpesvirus-2 (EHV-2), equine herpesvirus-5
(EHV-5), bovine herpesvirus-4 (BoHV-4), herpesvirus saimiri (HVS), alcelaphine
herpesvirus-1 (AlHV-l) and ovine herpesvirus-2 (OvHV-2).
Herpesvirus saimiri (HVS)
Herpesvirus saimiri (HVS) is the prototype of the herpesvirus genus
Rhadinoviridae (Fickensher and Fleckenstein, 2001) and is closely related to KSHV.
The natural host of HVS is the Squirrel monkey (Saimiri sciureus), a native of South
American rainforests. The squirrel monkeys are infected via contact with infected
saliva, usually within the first two years of life (Fickensher and Fleckenstein, 2001).
HVS is asymptomatic in the natural host (Melendrez et al., 1968), while infections of
other species of monkey may result in acute peripheral T-cell lymphomas (Schafer et
al., 2003) after experimental infection.
Herpesvirus saimiri was the first rhadinovirus to be completely sequenced
(Albrecht et al., 1992) and is known to consist of a 113kb low GC content unique
region (34.5%), flanked by about 35 non-coding high GC repeats of 1.4kb (70.8%).
The genomes of HVS and EBV are predominantly collinear and homologous genes
are in approximately equivalent locations and relative orientations (Albrecht et al.,
1992). The genome organization of HVS had also an overall colinearity with that of
the gammaherpesviruses BHV-4 (Bublot et al., 2005).
Equine herpesviruses 2 and 5
Five herpesviruses are associated with diseases of horses. Virus has been
isolated from horses suffering a range of diseases such as upper respiratory tract
disease, perinatal disease, myeloencephalopathy and abortion. EHV-1, EHV-3 and
EHV-4 are all alphaherpesviruses, while EHV-2 and EHV-5 are
gammaherpesviruses (Telford et al., 1993; Galosi et al., 2005).
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EHV-2 was first described in 1962 and was the first gammaherpesvirus to be
recovered from horses. The virus causes respiratory disease, including pneumonia in
foals and upper respiratory disease in adults. Approximately 80% of horses show
serological evidence of EHV-2 infection, as horses carry the gammaherpesvirus in
the latent phase of infection for many years, in circulating B lymphocytes (Reviewed
by Allen & Murray, 2004). Both viruses are suggested to play a role in upper
respiratory tract disease, immune suppression, conjunctivitis and lymphoadenopathy
(Telford et al., 1995; Holloway et al., 1999). Diagnosis of the viral agent is difficult;
therefore diagnosis is achieved by serological assays. One problem with the use of
such tests is the likelihood for cross-reactivity between EHV-2 and EHV-5 viruses
due to their close antigenic similarity (Holloway et al., 1999). EHV-5 has only
recently been characterised, though little is known regarding the pathogenicity of the
disease or the prevalence (Dunowska et al., 1999).The clinical significance of both
EHV-2 and EHV-5 remains unknown (Dunowska et al., 2000).
Both EHV-2 and EHV-5 are members of the gammaherpesvirinae subfamily,
Rhadinovirus genus. EHV-2 shows homology to gammaherpesviruses such as HVS
(52% homology) and EBV (46% amino acid sequence homology). The linear
double-stranded DNA EHV-2 genome is approximately 192kbp and consists of a
unique region of 156kbp flanked by a short direct repeat (18kbp). Unique regions in
both HVS and EHV-2 are shorter and are flanked by multiple copies of direct
repeats; therefore EHV-2 shows a different genome structure to HVS and EBV.
Homology is also shown between EHV-2 and other bovine herpesviruses such as
bovine herpesvirus-4 (BoHV-4), alcelaphine herpesvirus-! (A1HV-1) and ovine
herpesvirus-2 (OvHV-2) (Telford et al., 1995; Holloway et al., 1999). The distinct
EHV-2 and EHV-5 group within the Rhadinovirus genus shows a marginally closer
association to A1HV-1 than to other viruses in the Rhadinovirus genus (Holloway et
al., 1999).
Bovine Herpesvirus-4
Bovine herpesvirus-4 (BoHV-4) was first isolated in 1963 in Hungary from
calves showing clinical signs of respiratory and ocular disease (Bartha et al., 1966).
BoHV-4 is now recognised worldwide, and has been isolated from cattle suffering a
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wide variety of diseases; bovine reproductive disorders (Deim et al., 2006) and
respiratory diseases, mammary pustular dermatitis (Reed et al., 1977; Li et al.,
1991), pneumonia and lymphosarcoma, as well as from seemingly healthy animals
(Goyal and Naeem, 1992; Zimmerman et al., 2001). The role of BoHV-4 in the
pathogenesis of these diseases however, remains unclear since the virus is found in
healthy animals and ones showing clinical disease (Goyal & Naeem, 1992; Chang
and Santen, 1992; Izumi et al, 2006). Bovine species are recognised as the natural
host, however recent studies indicate buffalo as the original host (Dewals et al.,
2006) as a survey of wild African buffaloes revealed over 94% had anti-BoHV-4
antibodies (Dewals et al., 2005).
The BoHV-4 genome consists of approximately 145kbp, containing a unique
1 lOkbp region which is flanked by tandem repeats of high G-C content (Bublot et
al., 1990). The virus was originally classified as a betaherpesvirns due to the
formation of inclusion bodies and giant cells after infection of tissue culture cells,
characteristic of cytomegalovirus (Storz et al., 1984), as well as the genomic
structure (Roizman et al., 1982; Bublot et al., 1990; Bublot et al., 1992). However,
further studies on the genome revealed the virus as a gammaherpesvirus (Ehlers et
al., 1985; Bublot et al., 1992; Lomonte et al., 1995; Lomonte et al., 1996). Its
structure, proteins and biology are typical for a gammaherpesvirus (Thiry et al.,
1992; Goyal and Naeem, 1992; Egyed, 2000; Fabian and Egyed., 2004).The genomic
structure is characteristic of some gammaherpesviruses, typically y2-herpesviruses
such as HVS (Bornkamm et al., 1976) and yi-herpesviruses EBV (Lomonte et al.,
1996). The targets for viral replication are the lymphoid organs, the upper respiratory
tract and alimentary tracts (Goyal and Naeem, 1992; Asano et al., 2002).
BoHV-4 establishes latent infection in lymphocytes in its natural host (Osorio
and Reed, 1983) as well as in experimental hosts such as rabbits (Osorio et al., 1982;
Donofrio et al., 2006). It is thought that the site of persistence is a cell of the
macrophage/monocyte lineage, while latent infection is established in cells of the
immune and nervous systems months later (Donofrio et al., 2001).
BoHV-4 can be transmitted by both horizontal and vertical routes (Donofrio
et al., 2000) such as via aerosol droplets and foetal infection (placental tissues).
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Virus has also been demonstrated in the cell fraction of milk from infected cattle and
it is thought that virus may be transmitted to calves through nursing (Donofrio et al.,
2000; Deim et al., 2006). Diagnosis of BoHV-4 is difficult to determine. The virus
elicits low-affinity neutralising antibodies which are difficult to identify using
neutralisation tests, moreover, in cell culture a cytopathic effect (CPE) is slow to
develop (Galik et al., 1993). Detection of BoHV-4 is reliant on serological assays
such as indirect-immunofluorescence test, complement fixation and the indirect
enzyme-linked immunosorbent assay (Wellinberg et al., 1999). Additional limits to
diagnostic tests include the potential for cross-reactivity with other herpesviruses
(Osorio et al., 1985). Studies by Rossiter (Rossiter et al., 1989) suggested that a
serological antigenic relationship between BoHV-4 and MCF alcelaphine
herpesvirus-1 may offer a protective immune response (Dewals et al., 2005). In
contrast to this, a survey on BoHV-4 and MCF ovine herpesvirus-2 showed no
significant correlation between serological responses to the two viruses (Collins et
al., 2000).
1.4. Malignant Catarrhal Fever (MCF)
Malignant catarrhal fever (MCF) is a fatal lymphoproliferative viral disease
of cattle, deer and other ungulates (Plowright, 1960; Castro & Daley, 1982; Abu
Elzein et al., 2003), whose causative agents are alcelaphine herpesvirus-1 (A1HV-1)
or ovine herpesvirus-2 (OvHV-2). A1HV-1, carried by wildebeest, is primarily found
in Africa though it has occurred in zoos and animal parks where wildebeest are
present (Straver et al., 1979;Hatkin, 1980; Fleuschele, 1982).
In addition to the A1HV-1 isolate, other antigenically related viruses have
been isolated. A1HV-2 has been isolated from topi and hartebeest (Mushi et al.,
1981; Roya et al., 1994). However, A1HV-2 is an apathogenic virus. Experimental
infections of cattle A1HV-2 produce no discernible effects and does not generate
antibody protection against a subsequent A1HV-1 challenge (Mushi et al., 1981, Reid
and Bridgen, 1991; Klieforth et al., 2002). A third distinct gammaherpesvirus was
isolated from lymph nodes of roan antelope and was termed HiHV-1 (Reid and
Bridgen, 1991). Serology and PCR/sequencing show many more y2-herpesviruses in
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ungulates (Li et al., 2005). A1HV-1 was initially designated as part of the y2-
herpesvirus subfamily, due to its biological properties and genome structure
(Roizman et al., 1981; Bridgen et al., 1989; Bridgen et al., 1991). This was
confirmed when the viral genome was sequenced in 1997 (Ensser et al., 1997).
OvHV-2 was defined in Europe as a disease of cattle, which followed contact with
sheep. This disease termed "sheep-associated" malignant catarrhal fever, occurs
worldwide though is predominately found in Europe, North and South America and
New Zealand (Reid et al., 1984). OvHV-2, on the basis of the DNA homology to
A1HV-1, is also categorised as a y2-herpesvirus (Coulter et al., 2001).
The impact of MCF is difficult to estimate as suspected MCF cases are
usually euthanized on diagnostic confirmation. A recent report from the Veterinary
Laboratories Agency indicated an increasing incidence of MCF in the UK (Anon,
2006). This increase may simply be due to more effective detection and diagnosis of
the disease.
There is an increasing possibility of MCF, particularly that caused by A1HV-
1, becoming a more prevalent disease in ranched cattle and other ruminants in
countries such as North America subsequent to the increase in wild game ranches,
and zoos (Li et al., 1999; Zarnke et al., 2002; Office International des Epizooties,
2005). Infected carriers are asymptomatic, though susceptible animals such as
farmed and wild cattle and deer may develop severe and often fatal disease, therefore
MCF is of economic and welfare significance worldwide (Plowright et al, 1975;
Bridgen et al., 1989; Brenner et al., 2002). Studies by Li et al., (1995) and Sausker
and Dyer (2002) suggested a low percentage of cattle and deer are seropositive to
MCF but display no clinical signs for the disease. A recent survey to evaluate MCF
in cattle with no clinical signs (Powers et al., 2005) supported this supposition,
showing that OvHV-2 infection can occur without the subsequent development of
clinical MCF. Furthermore, subclinical infection is not necessarily associated with
the onset of clinical disease (O'Toole et al., 2002; Powers et al., 2005) and some
recovered cases were documented.
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1.4.1. History of Malignant Catarrhal Fever
Malignant catarrhal fever was initially demonstrated as a disease in Europe in
1789, and was later described by Bugnion in 1877, as a specific, infectious disease
affecting cattle (Berkman & Barner, 1958). No cause was originally established,
though sheep were implicated as the likely source of infection (Piercy, 1954; Selman
et al., 1978; Reid et al., 1984). Numerous attempts to investigate this hypothesis
(Piercy, 1954; Pierson et al., 1974) experimentally proved futile, with the exception
of studies such as Gotze in 1930 which supported the assumption as cattle were
successfully inoculated with MCF (Selman et al., 1978). This finding and subsequent
studies confirmed sheep acted as a reservoir host and thus established the term sheep-
associated MCF (Plowright, 1964; Buxton, 1980).
A similar disease "snotsiekte", recognised by the Masai tribe in Africa for
centuries, was found in cattle (Mettam, 1923; Plowright et al., 1960; Reid et al.,
1984). It was determined that this disease occurred when domestic cattle grazed in
pastures where wildebeest were calving. The causative agent of this African disease,
a herpesvirus, was isolated in 1960 (Plowright et al., 1960).
1.4.2. Hosts
All species of wildebeest, hartebeest and topi are carriers of alcelaphine
herpesvirus-1, while domestic and wild sheep are considered reservoir hosts for
ovine herpesvirus-2 (Figure 1.5). Furthermore epidemiological evidence indicates the
likelihood of goats also being a reservoir for OvHV-2 (Reid 1984). When infected,
antibodies develop but no clinical signs are demonstrated. Sheep and wildebeest are
therefore asymptomatic carriers of OvHV-2 and A1HV-1.
1.4.3. Host Range
The range of host species susceptible to pathogenic strains of MCF is very
wide. MCF occurs primarily in all breeds of domestic cattle, where it equally infects
male and female cattle of all ages (Berkman and Barner, 1958). Initially, the highest
incidence of MCF was believed to occur between 2 and 5 years of age (Marshall et





Figure 1.5: Reservoir hosts of MCF. Reservoir hosts of AIHV-1 include all species
of Wildebeest (a), Hartebeest (c) and topi (e). Reservoir hosts of OvHV-2 include all
species of wild (d) and domestic sheep (b).
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Several ruminant species other than cattle are also susceptible to MCF
(Figure 1.6). Deer species are particularly susceptible to MCF and it has been
recognised in over thirteen species of deer, including: red deer (Reid et al., 1979;
Audige et al., 2001), rusa deer (Tomkins et al., 1997) barbary red deer (Klieforth et
al., 2002), fallow deer, white-tailed deer (Li et al., 2000; Li et al., 2003), sika deer
(Keel et al., 2003) and axis deer. Pere David's deer (Elaphurus davidianus) is
reportedly more susceptible to MCF than other species of deer (Reid et al, 1987; Orr
and Mackintosh, 1988). This is a concern as this species survives only in captivity.
MCF is an increasing concern in zoos, regarding exotic game animals, and in
particular captive wild ruminants such as antelope, bison, water buffalo and banteng.
Farmed bison herds are similarly susceptible to MCFV, with losses between 33% and
95% in some herds (Schultheiss et al., 2000; Li et al., 2006). Outbreaks in zoos and
wildlife parks, however, have led to the identification of novel pathogenic MCF
viruses (Flach et al., 2002; Klieforth et al., 2002). The discovery of MCF in pigs in
Norway (Loken et al., 1998), Switzerland (Albini et al., 2003), Germany and Finland
(Syrjala et al., 2006) has expanded the range of susceptible hosts of the MCF viruses
to include non-ruminant species. Furthermore, animals that have been experimentally
infected and found to be MCF susceptible include rabbits (Daubney & Hudson,
1936; Piercy, 1955; Schock and Reid, 1996), hamsters (Reid et al., 1986; Reid et al.,
1987), guinea pigs, and rats.
1.4.4. Transmission
The MCF virus associated with wildebeest is predominately cell-associated in
adult animals and thus is rarely transmissible. Most wildebeest calves are infected
with AlHV-l before two months of age (Li et al., 2000). The Masai believed that
cattle became infected through contact with placenta from a wildebeest (Rossiter,
1983). Although virus has not been detected in the placenta, free virus has been
found in nasal and ocular secretions, faecal deposits, and hair follicles of neonatal
wildebeest ranging in age from 4 days to 4 months. This has also been demonstrated
in adult wildebeest that have been subject to stress (Rossiter, 1983). It is now known




Figure 1.6: Host Range of MCF. The wide range of host species include all breeds
of cattle (f), over thirteen species of deer, including: fallow deer (b), axis deer (c),
sika deer (e), white-tailed (g) and Pere David deer (i), and exotic wild and captive
animals including: cape buffalo (d), antelope (h), and water buffalo (a), bison (j).
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and occasional intrauterine transmission, and are known to shed virus in oculo-nasal
secretions until about 3^4 months of age (Mushi et al., 1980; Kim et al., 2003).
Early work by Plowright and colleagues (Plowright et al., 1972) showed
some evidence of congenital infection. In the first instance, cows during late
pregnancy developed acute MCF while no virus was demonstrated in the foetuses. A
further animal gave birth after inapparent infection with MCFV. Thyroid monolayers
were prepared from the calf born, and CPE thought to be caused by MCF was
observed. The same animal produced a further three calves 80 months post-infection.
All calves were shown to be MCF-positive (Plowright et al., 1972).
Recent studies suggest that OvHV-2 transmission within sheep is similar, but
not identical, to transmission of A1HV-1 (Kim et al., 2003). With regard to the sheep
associated MCF, cases are shown to recur on premises for years, particularly when
the sheep or "source" of the virus has not been removed. Most sheep are considered
carriers. Furthermore, there is some evidence suggesting that the incidence of MCF
in cattle may be higher when ewes are lambing. In contrast to A1HV-1 transmission
in newborn wildebeest, the majority of lambs do not appear to be infected until about
2-3 months of age (Li et al., 1998).
Transmission of the two forms of MCF, to susceptible hosts, is most likely a
result of inhalation of virus in aerosol droplets. Studies on the transmission of
OvHV-2 have shown that the major transmission route is aerosol transmission of
nasal secretions from animals suffering virus shedding episodes (Li et al., 2001,
2004). Recent studies by Taus et al., (2006) supported this hypothesis as viral
OvFIV-2 DNA was detected in nasal secretions in sheep aged between 6 and 9
months. Therefore this study showed that nasal secretions were the predominant
mode of transmission as infectivity was demonstrated by inhalation of OvHV-2
secretions into control animals. To study the pathogenesis of the MCF virus, an
experimental aerosol infection model was developed in sheep (Taus et al., 2005).
Consequently, studies by Taus et al., (2006) showed that nasal secretions collected
from sheep were infectious and capable of inducing MCF.
Other transmission mechanisms have also been analysed, including sexual
transmission. Studies by Flussy et al., (2002) and Li et al., (2004) regarding the
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presence of OvHV-2 DNA in serum and placental/amniotic fluid also indicate a
possible minor route of transmission.
1.4.5. Clinical Signs
MCF shows a variety of symptoms, where the course of the MCF infection
varies from acute to chronic and is almost invariably fatal (Figure 1.7), though there
have been rare reports of recovered cases. It is now thought that infected cattle may
show all or no signs of this disease (Reid et al., 1984). This implies that symptomless
cases may occur and therefore had previously gone undetected. This also suggested
that there may be a higher percentage of animals recovering from this disease than
was once thought (O'Toole et al., 1997; Penny, 1998).
Clinical manifestations of MCF are high body temperature, rising to 41-42°C
(Selman et al., 1974; Reid et al., 1979), inflammation of conjunctival, nasal and
ocular mucosa, leukopenia, lymphadenopathy (Metzler, 1991; Jones et al., 1997),
nasal and ocular secretions (Selman et al., 1978; Howard, 1993). Depending on the
form of MCF, diarrhoea or constipation may occur. Necrosis and vasulitis in addition
to lymphocyte proliferation and tissue infiltration have been demonstrated (Metzler,
1991). Lesions and erosions may be demonstrated in the respiratory and alimentary
tract as well as pneumonia, pharyngitis, laryngitis and tracheitis (Florezinek, 1990).
A variety of skin lesions may be observed (Howard, 1993), extensive muscle
tremors, incoordination and aggressive behaviour may also be observed.
Clinical MCF can be categorised into four forms. These are:
i. The Peracute form
ii. The Intestinal form
iii. The Head and eye form, and
iv. The Catarrhal form
The peracute form is the most severe of the four categories, where the animal
initially exhibits fever, depression and may die within a few hours of these visible
symptoms (Reid et al., 1984), commonly due to haemorrhagic gastroenteritis. In
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Figure 1.7: Clinical signs of MCF in cattle and Red deer. Characteristic signs of
MCF in cattle include bilateral corneal opacity (a, c & e), profuse catarrhal discharge
from the eyes and nose (a, e & f) and necrosis of the muzzle (f). Characteristic signs
of MCF in deer include catarrhal discharge (b) and diarrhoea (d).
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deer, the peracute form, clinical signs may be minimal before death occurs within
hours. Clinical signs include a loss of appetite (Reid et al., 1984). The intestinal
form, similar to the peracute form, may be characterised by severe enteritis and
diarrhoea. Animals commonly die of intestinal MCF within four to nine days. The
typical form of MCF, the head and eye form, is characterised by symptoms primarily
restricted to the head of the animal. The muzzle epidermis may become encrusted
causing an obstruction to the nostrils and may be characterised by open-mouthed
breathing and drooling. Nasal discharge is commonly shown to progress from serous
to mucopurulent or purulent. Mucopurulent discharge from the ocular mucosa is also
common, while progressive corneal opacity is commonly shown in the eyes. The
course of this form of MCF, which is invariably fatal, is usually 7 to 18 days. Mild
MCF is characteristically associated with experimentally-induced infection with
attenuated viruses. This form is generally non-fatal and reports of cattle which are
seropositive suggest either an undiagnosed case of MCF or the recovery of an MCF-
infected animal (Pierson et al., 1978; O'Toole et al., 1997; Penny, 1998).
1.4.6. Pathology
The severity of gross pathological changes observed in post-mortem
examination of an MCF-infected animal may vary depending on the course of the
disease, duration of illness and severity of clinical signs. Aside from lesions affecting
the external orifices (skin, eyes and mouth), lesions may be shown on a variety of
organs and tissue (Figure 1.8) such as; the respiratory tract, lymph nodes, brain,
alimentary tract, joints, liver and kidneys (Selman et al., 1974).
The respiratory tract can be severely affected, commonly giving rise to a
mucopurulent discharge. Additionally, the larynx, trachea and bronchi can be
hyperaemic, with irregular catarrhal accumulations and erosions occurring on the
oropharynx and tongue (Selman et al., 1974; Reid et al., 1984; Office des Epizootes,
2005). Ulcers may be located in any area of the oral cavity (Berkman et al., 1960). In
general, the involvement of the lymph nodes varies within animals. Lymph nodes
may become enlarged, oedematous and may be haemorrhagic and necrotic. Erosions
and haemorrhages may be found in the gastrointestinal tract. Changes include
extensive haemorrhage and oedema of the intestines, and in particular the bowel. The
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Figure 1.8: MCF gross pathology. Characteristic MCF haemorrhagic lesions
shown on a variety of organs such as; the bladder (a), mesenteric lymph nodes (b),
buccal pappilae (c), kidney (d, f) and reticulum (e).
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abomasum is a common site for congestion, haemorrhage and ulcers (Berkman et al.,
1960). The kidneys may become affected with white spots, while haemorrhages may
be shown in the liver (Reid et al., 1984).
1.4.7. Histopathology
The microscopic pathology of MCF may be summarised as cellular infiltrates
and tissue necrosis (Selman et al., 1974; Liggitt et al., 1978). The main
histopathological finding was the widespread accumulation of lymphoid cells around
blood vessels (Roberts and Jagger 1961). The lesions demonstrated by MCF
infections are characterised by epithelial degeneration, hyperplasia, vasculitis and
necrosis of lymphoid organs and the widespread distribution of lymphoid cells in
nonlymphoid organs. Organs and tissues mainly affected include the oral and nasal
mucosa, gall bladder, urinary bladder, skin, lymph nodes, joints and lungs (Figure
1.9). Infiltrates are localised around blood vessels and are frequently associated with
epithelial necrosis and sloughing (Liggit et al., 1978). Pathological changes, such as
hyperplasia, are commonly shown in the ileum, caecum and colon. Marked
hyperplasia of the lymphocytes may also be seen in all lymph nodes. Lymphocytic
vasculitis was detected in the kidney, while the liver showed large numbers of
lymphocytes and macrophages particularly around the portal tracts (Roberts and
Jagger 1961; Liggit et al., 1978).
No specific tissue has been demonstrated as the site of replication of MCFV
in any host. One study demonstrated the presence of virus in nasopharyngeal tissues
in sheep, although does not suggest a specific site of entry or replication (Li et al.,
2004). Preliminary analysis on diagnostic samples also indicates detectable OvHV-2
DNA in lymph nodes, spleen and kidney (Russell, per. comm).
Simple immunoperoxidase staining of samples does not detect viral antigen
and classically MCF is regarded as a disease where viral antigen can not be detected.
Viral DNA can, however, be detected by PCR. As MCF does not follow a normal
herpesvirus lifecycle, it is difficult to predict which antigens would be expressed at a
level sufficient to detect protein.
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Figure 1.9: Histopathological examination of tissues infected with MCK. H&H
staining showing characteristic accumulation of lymphocytes. Cellular infiltrates and
tissue necrosis characterised by widespread distribution of lymphoid cells in
nonlymphoid organs of a cow experimentally infected with AIHV-1. H&H stained
sections include; focal lesions on the (a) kidney, (b) liver, and (a,b) sections of buccal
papillae with early MCF lesion. In addition to areas of haemorrhage (H), the stained
section shows epidermal erosion (E) and areas of early lymphocyte infiltration (1).




Currently, control of MCF infection is generally based on the separation of
susceptible animals from infected carriers such as sheep and wildebeest, particularly
around lambing and calving time. This, however, is difficult to achieve in zoos and
wildlife parks. Therefore these parks are encouraged to consider introducing only
serologically negative animals (Office International des Epizooties, 2005). Treatment
of MCF with a range of antiviral and immunosuppressive drugs can be effective
(Milne and Reid, 1990) but the duration of treatment and expense make treatment a
non-viable option for the control of disease, particularly in developing countries.
Another possibility for control is vaccination. A number of approaches to
develop a vaccine have so far been attempted and have failed. Initial attempts to
vaccinate cattle involved inoculation of living or inactivated tissue culture grown
AlHV-l, combined with incomplete adjuvant. High levels of virus neutralising
antibody were detected in these vaccinated animals however no protection against
the disease was demonstrated after challenge with virulent AlHV-l. This suggested
that humoral immunity on its own was not important in protection against AlHV-l
(Plowright et al., 1975). Rabbits were vaccinated with the inactivated virulent C500
strain of AlHV-l (Russell, 1980). Four of the six rabbits remained healthy for up to
five months after two challenges with the C500 strain. This outcome was
encouraging, suggesting the vaccination with inactivated C500 strain AlHV-l may
be of use in protecting cattle. A further study on rabbits, inoculated with inactivated
cell-free C500 strain of AlHV-l in complete Freund's adjuvant showed protection
against challenge with virulent cell-free but not cell-associated virus (Edington and
Plowright, 1980). The difference in protection between these findings and the
previous experiments in cattle may be due to a number of factors such as the virus
strain used, the presence of killed Mycobacterium tuberculosis in the adjuvant or the
susceptibility of the host animals used.
A subsequent study by Mirangi in 1991 showed that it was indeed possible to
protect cattle against the virulent C500 strain of AlHV-l, using a vaccination
programme. Protection was not always demonstrated however, and multiple
injections of the virus were required to induce protection, which alone risked
induction of an MCF-like disease. Cattle inoculated with attenuated or inactivated
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MCFV have been resistant to challenge inoculation, but results to date have not been
consistent enough to make vaccination practical. (Milne and Reid, 1990).
These studies suggest that a neutralising antibody response was not sufficient
for protection, with the possible exception of the cell-free viral challenge shown in
rabbits. The immunity shown in the recovered cattle, described by Plowright (1964)
may be due to a cell-mediated immune response. The production of an attenuated
A1HV-1 strain that remains cell-associated for use as a candidate vaccine has been
hampered by the genomic instability of the virus in culture.
The recent cloning of the A1HV-1 genome into a bacterial artificial
chromosome (BAC) may allow development of specifically attenuated mutant
viruses capable of inducing strong cell-mediated immunity but not disease (Dewals
et al., 2006).
1.4.9. Diagnosis
As clinical and gross pathological descriptions of this disease are varied,
specific diagnosis originally depended upon the identification of typical histological
lesions in tissues (Reid et al., 1979). Malignant catarrhal fever would normally be
considered if an animal begins exhibiting typical clinical signs and lesions. A
speculative diagnosis may be reinforced if the infected animal has been in contact
with sheep, goats, or alcelaphine antelope.
Serological confirmation is now required as the clinical signs alone may
indicate numerous diseases. If MCF is suspected, blood samples are sent to a
diagnostic laboratory for identification. If the virus to be identified is from a dead
animal, blood and tissue specimens; such as spleen, lymph nodes, thyroid glands and
lung, should be collected immediately as the virus is inactivated within an hour after
death. For A1FIV-1, virus isolation can be attempted using foetal bovine or ovine
kidney, thyroid and spleen cell cultures, and intraperitoneal inoculation of domestic
rabbits or intravenous inoculation of cattle. Virus neutralization,




The advances in molecular and serological diagnostic assays for the detection
of malignant catarrhal fever have provided powerful tools for investigating the
pathogenesis and epidemiology of MCF (Hsu et al., 1990: Li et al., 2000).
Antibody can be identified from infected animals, however in some cases of
acute MCF antibody may not be present resulting in a disadvantage to serological
tests. Sensitive and specific PCR assays have been developed for the detection of
MCFV.
Characteristically, little viral antigen can be detected within affected animal
tissue by tests including immunofluorescence and ultrastructural examination (Patel
and Edington, 1980). It is possible, however, to amplify the viral genome by culture
or by PCR. Sensitive and specific PCR assays have been developed for the detection
of MCFV. Several PCR methods have now been developed which include assays to
detect A1HV-1 (Hsu et al., 1990) and OvHV-2 DNA (Baxter et al., 1993).
Based on the molecular cloning of a genomic DNA fragment from the A1HV-1
strain WC11 (Shi et al., 1988), a diagnostic PCR was first developed for the
detection of A1HV-1 viral infection (Hsu et al., 1990). The PCR detected picogram
amounts of A1HV-1 DNA from a lysate of infected cells and proved a sensitive and
specific method. Following the success of this assay, a two-stage nested PCR using
different primer sets from an A1HV-1 sequence was developed to amplify both
A1HV-1 and A1HV-2 isolates (Katz et al., 1991). Isolation of DNA from bovine
samples showed this to be a sensitive assay, detecting 0.01 TCID50 of A1HV-1 DNA.
These tests were established using experimentally infected animals (Roya et al.,
1994), and therefore may not prove sensitive in the diagnosis of clinical cases.
PCR tests have also been designed for the detection of OvHV-2 DNA, using
specific primers based on generic PCR primers (Baxter et al., 1993). The assay
proved effective in detecting OvHV-2 DNA in peripheral blood leucocytes (PBL)
from clinical and experimental cases of MCF. No product was detected from testing
target DNA derived from A1HV-1 and BoHV-4, showing the PCR to be specific for
OvHV-2 (Baxter et al., 1993). The development of this diagnostic PCR assay,
specific for OvHV-2 may improve the accuracy of diagnosis in clinically infected
animals (Baxter et al., 1993). These assays provide information regarding
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epidemiological aspects of the OvHV-2 virus and its natural ovine host (Baxter et al.,
1993; Li et al., 1994; Wiyono et al., 1994; Sausker & Dryer, 2002). The provision of
these tests would therefore prove beneficial in developing control measures to
determine the MCF carrier status of animals introduced into a new population.
Alternative PCR methods have been sought and developed. These methods
include a competitive PCR (cPCR) developed for the quantitative measurement of
OvHV-2 DNA (Hua et al., 1999), and a conventional PCR to discriminate between
A1HV-1 and OvHV-2 in a nested format (Flach et al, 2002). Real-time PCR assays
for the quantitative determination of OvHV-2 DNA (Hussy et al., 2001) and A1HV-1
(Traul et al., 2005) have also been developed for analysis of clinical samples.
Disadvantages of conventional PCRs include the risk of contamination
resulting in false-positive samples. A quantitative PCR assay was designed for
measuring OvHV-2 DNA (Hussy et al., 2001) and compared it to the conventional
assay established by Baxter in 1993. Total agreement was shown between the two
assays (100%, n = 152) and therefore the real-time PCR was as effective in the
accurate determination of OvHV-2 DNA. However in a comparative study between
an A1HV-1 nested assay and A1HV-1 Real-time PCR assay (Traul et al., 2005, the
nested PCR remained more sensitive (=1 log), although the real-time PCR was
specific in the detection of A1HV-1 DNA (described by Li et al., 2000).
To improve study of the epidemiology of A1HV-1, a real-time A1HV-1 PCR
has also been developed, targeting A1HV-1 orf3, which encodes a tegument protein
(Traul et al., 2005). Comparing this assay to an A1HV-1 nested assay based on the
A1HV-1 transactivator gene ORF50 (described by Li et al., 2000), the nested PCR
remained more sensitive (=1 log). Although they are not as sensitive as nested PCR,
the real-time PCR assays for both A1HV-1 and OvHV-2 offer the potential to
quantify levels of viral and cellular DNA. This may offer advantages in vaccination
and epidemiology/transmission studies, where viral loads present in tissues, blood or
nasal secretions may be examined (Li et al., 2004).
After the initial infection, usually as a lamb, OvHV-2 becomes latent in sheep
and may reappear during later life. As OvHV-2 is a member of the subclass
Rhadinoviruses, it is lymphotropic indicating the virus resides in B cells. Nested
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PCR, if performed on buffy coat DNA should give a PCR positive result, however
real-time PCR assays are not sensitive enough to detect virus. The window of
positivity for asymptomatic animals remains unknown
The sensitivity of the PCR methods has allowed the monitoring of MCF
infection in carrier and susceptible animals, enabling the pathogenesis of the viral
disease to be investigated (Baxter et al., 1993). Histopathological examination is the
recognised diagnostic procedure to confirm clinical cases of MCF. Flowever, since
the PCR assays have proved sensitive and specific, such methods may be established
as a new "gold standard" for diagnosis following validation studies between
laboratory tests.
1.4.11. Serology
MCF antibody can be detected using virus neutralisation, complement
fixation or indirect immunofluorescence. Virus neutralisation and
immunofluorescence tests have been employed to ascertain the MCF carrier status of
an animal and for the confirmation of MCF in susceptible species (Wan et al., 1988).
Of these tests, the virus neutralisation test is the most virus-specific, as antibodies to
other bovine herpesviruses may cross-react in tests such as IFAT (i.e. bovine
herpesvirus-1, bovine herpesvirus-2 and bovine herpesvirus-4).
Studies have been performed analysing the possible serological cross-
reactivity between MCFV and other herpesviruses (Li et al., 1994; Dubuisson et al.,
1989; Li et al., 1995). One study by Osorio et al., (1985) showed bovine herpesvirus-
1 (BHV-1) and bovine herpesvirus-2 (BHV-2) did not serologically cross-react with
other bovine herpesviruses by indirect immunofluorescence. Cross-reactivity has
been shown in immunofluorescence serologic assays between MCF A1HV-1 and
bovine herpesvirus-4 (Schmitz & Grumbein, 1981; Wan et al., 1988), where the
number of seropositive cattle detected by IFAT was always equal to or greater than
the number detected by ELISA tests. Furthermore, a recent study by Dewals et al.,
(2005) showed that BoHV-4 antiserum stained antigens expressed in the nucleus of
A1HV-1 infected cells, and indicated a unidirectional relationship as A1HV-1 serum
showed no detectable staining of BoHV-4 infected cells.
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There are disadvantages to the virus neutralisation tests, for example; the
antibody response in clinically affected animals may be limited, with no or low
levels of neutralising antibody. Furthermore a cytopathic strain of the alcelaphine
hepesvirus-1 virus is employed in the virus neutralisation test, with a significant
incubation period of approximately 10 to 12 days (Heuschele and Fletcher, 1984;
Wan et al., 1988). This disadvantage results in a significant period before diagnosis
can be reached.
Other serological assays, such as complement fixation, immunodiffusion,
counter-immunoelectrophoresis or immunoperoxidase have also been employed to
measure specific antibodies to A1HV-1 MCF with some degree of success (Rossiter
and Jessett, 1980; Rossiter, 1980; Rossiter, 1981). At present, a commercial enzyme-
linked immunosorbent assay (ELISA), utilising commercially prepared alcelaphine
herpesvirus-1 monoclonal antibody is available for the detection of antibodies
against the A1HV-1 strain of MCF (Li et al., 1994, 2001). This commercially
available kit, as well as providing a fast, competent method of testing, additionally
reduces the risk of possible laboratory-acquired infections during virus growth and
errors within the diagnostic laboratory. Furthermore operator errors may be limited
due to the utilisation of single serum dilutions, a straightforward protocol and a
numerical readout of results. As this ELISA utilises A1HV-1 antigens it may be of
limited value for OvHV-2 antibody detection. There is therefore a need to develop an
ELISA to identify OvHV-2 specific antibodies in sera that would benefit routine
diagnostic, surveillance of MCF cases and for the analysis of the epidemiology of
MCF in sheep and cattle.
Serological tests offer economical, rapid and specific methods for the
detection of antibodies against MCFV. The simplicity and lack of cross-reactivity of
serological assays offer a reliable, low cost method for routine MCFV diagnosis,
epidemiological studies and long-term monitoring.
Powers et al. (2005) showed by monitoring OvHV-2 infection and clinical
signs of MCFV that OvHV-2 infection may occur in cattle without the simultaneous
development of clinical MCF. A proportion of cows tested were positive by serology
but remained negative by PCR. This may indicate a low level of viral DNA present
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in the sample, possibly as a result of latent rather than lytic subclinical infection. It
could also indicate that no virus was present in the blood at the time of sampling.
Commonly, only animals with MCF, or affected herds, have been tested. Clinical
MCF has a high mortality rate, but testing herds shows some animals with viral DNA
or antibody but no clinical signs. It may be possible that some animals get infected
and recover or do not show clinical signs. Some reports of animals with a chronic
form of MCF and recovery exist (Berkman and Barner, 1958; Flamilton, 1990; Milne
& Reid, 1990; Baxter et al., 2003; O'Toole et al., 1995 and 1997). In cases such as
these chronic non-fatal forms of MCF, recovery with recrudescent disease and
complete recovery, the originally reported rate of fatality (90-95%) is lowered
(O'Toole et al., 1995; Brenner et al., 2002). O'Toole et al., (1995) suggested a
recovery rate of between 20-50%, with 30% developing atypical chronic MCF. A
report of an outbreak in Finland similarly reported a 35% rate of recovery (Stenius
1952, cited in Berkman & Barner, 1958). Eleven cattle which had recovered from an
MCF-like disease, over a three year period were investigated (O'Toole et al., 1997)
using pathology, serological tests (CI-ELISA) and the OvHV-2 PCR for diagnosis
(Baxter et al., 1993). Of the animals examined, ten showed clinical signs of acute
MCF, ranging from one to four weeks duration. Six animals recovered clinically with
the exception of corneal oedema and perforating keratitis. All recovered animals
remain persistently infected (Baxter et al., 1993; O'Toole et al., 1997). All animals
tested positive by OvHV-2 PCR. The CI-ELISA, however, proved less reliable, with
eight positive and three negative animals.
OvHV-2 infections in cattle result in clinical signs within weeks but in some
cases may take months to develop. Similar findings (Otter et al., 2002) suggest that
cattle may become OvHV-2 infected, develop clinical MCF and recover. In this
study, an outbreak of MCF resulted in 12 animals with clinical MCF. Of these
animals, one animal, which had demonstrated typical clinical signs of MCF,
recovered after 10 days. This study additionally detected OvFIV-2 viral DNA and
antibody in animals which did not develop clinical disease and suggests silent
infections can occur in outbreaks (Otter et al., 2002).
It is of interest to monitor the immune status of both sheep and cattle for
MCFV. Sheep have a lifelong antibody to the virus, as they are expected to carry the
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virus asymptomatically. In cattle however, since most animals die from the infection
there is no opportunity for the immune response of an individual to drop. Therefore
the period in which an animal is antibody positive would not have implications in a
serological assay.
1.4.12. Unique genes to the MCF viruses, AIHV-1 and OvHV-2.
Of the seventy genes that have been identified in the determination of the
DNA sequence of the OvHV-2 genome, twelve genes are considered unique to MCF
viruses (Table l .2). Moreover, three of these twelve genes are unique to the OvHV-2
genome. Several of the open reading frames (ORFs) found within regions of the
genome demonstrate significant homology with cellular proteins, suggesting they
have been acquired from host DNA during co-evolution of the virus and its host
(Coulter et al., 2001). Included are genes with a role in cytokine signalling (IL10
homologue) and regulation of apoptosis (bcl2 homologues). The genes unique to
AIHV-1 were designated ORFs A1-A10, while the equivalent OvHV-2 genes were
designated ORFs Ov2-OvlO (Table 1.2).
ORFA1
ORF Al encodes 97 amino acids and shows no significant sequence or
structural homology to any known proteins (Ensser et al., 1997). There is no OvHV-
2 homologue to ORF Al.
ORFA2 and ORF Ov2
ORF A2 encodes a spliced protein of 199 amino acids. A2 is positioned
equivalent to a transformation-associated gene of HVS strain C though the amino
acid sequence shows no homology to the saimiri transformational protein (STP-C)
(Jung et al., 1999; Damania et al., 2000). The recent sequencing of the OvHV-2
genome (Hart et al., 2007) shows that Ov2 encodes a protein containing leucine
zipper motif (bZIP) and is a homologue to activating transcription factors (ATF)
such as cAMP responsive binding element (CREB) and Jun dimerisation proteins.
The similarity between AIHV-1 and OvHV-2 is confined to the N-terminal half of






A2 Ov2 Transcriptional Regulation
- Ov2.5 IL-10 Homologue
A3 Ov3 Semaphorin family of cell signalling
molecules
- Ov3.5 Unknown, Secreted?
A4 - Unknown, Secreted?
A4.5 Ov4.5 bcl2 family (apoptosis-regulatory)
A5 Ov5 G-protein coupled receptors




A9 Ov9 Bcl2 family (apoptosis-regulatory)
A10 OvlO Transcriptional Regulation
Table: 1.2: Unique MCF genes. AIHV-1 and OvHV-2 ORFs and possible functions
(based on sequence homologues).
ORF A3 and ORF Ov3
AIHV-1 ORF A3 and Ov3 are homologous to the cellular semaphorin gene
family of cell signalling molecules (Ensser and Fleckenstein, 1995), although Ov3 is
some 200 amino acids shorter than A3 at the C-terminus (Hart et al., 2007).
Semaphorins are a large gene family of over 20 proteins, and are consequently
categorised into eight distinct groups in accordance with their primary structure.
Semaphorins have been implicated in many functions, which include tumour
suppression, rheumatoid arthritis and immunoregulation. One member of the
semaphorin family is expressed on the surface of T and B lymphocytes, natural killer
cells (NK), monocytes and neutrophils, and through an association with CD45, a cell
surface protein tyrosine phosphatase, is thought to result in the activation of T
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lymphocytes. This semaphorin (CD 100) also promotes B-cell survival and
aggregation (Bougeret et al., 1992).
Furthermore, a recently demonstrated human semaphorin is expressed in
lymphoid tissues including lymph nodes, thymus and the spleen (Lange et al., 1998)
and shows homology to the viral semaphorins (46% amino acid identity) of A1HV-1.
The occurrence of semaphorins in the genomes of herpesviruses and poxviruses
implicate semaphorins in viral subversion of the normal immune response
immunoregulation (Comeau et al., 1998).
ORFA4
The A4 ORF shows no homology to any recognised sequence and therefore
its function remains unknown. Sequence analysis of the 121 amino acid gene product
suggests it has an N-terminal signal sequence and so may be exported. Although
ORF A4 is positionally homologous to OvHV-2 ORF Ov3.5, the sequences are
unrelated. Flowever, A4 and Ov3.5 are of similar sizes and both have N-terminal
signal sequences, implying they may serve similar functions (Hart et al., 2007).
ORF A4.5 and ORF Ov4.5
A1HV-1 A4.5 was not initially reported in the sequencing of the A1HV-1
genome (Ensser et al., 1997; Coulter et al., 2001), but was recently added (Mills et
al., 2003). ORF A4.5 and Ov4.5 encode proteins of approximately 212 amino acids
that share limited similarity with the bcl2 family of apoptosis-regulatory genes and
are therefore thought to be involved in the control of cell death. The encoded proteins
also show homology to EBV BALF1, a cellular Bcl-2 protein. EBV BALF1 is 0.7 kb
in size and encodes a 220-amino-acid protein in a region of early EBV transcripts
(Cabras et al., 2005). BALF1 is analogous to the antiapoptotic BCL-2 homologues
present in gammaherpesviruses including HSV and KSHV (Bellows et al., 2002).
ORF A 5 and ORF Ov5
These genes share limited identity (49% amino acid identity) and appear to
encode proteins with seven transmembrane helical domains (Ensser et al., 1997).
This arrangement is characteristic of G-protein coupled receptors (GPCRs). GPCRs
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are a protein family of transmembrane receptors that transduce an extracellular,
ligand binding signal into an intracellular signal termed G-protein activation. The
GPCRs are the largest protein family known, and are involved in all types of
stimulus-response pathways Palczewski et al., 2000).
Positional homologues to A5 and Ov5 have been found in EBV (BILF1) and
EHV-2, and these are also predicted to encode GPCRs. Homologues are not found in
any other sequenced gammaherpesviruses and therefore their specific function is still
unknown, though they are thought to contribute to viral pathogenesis through
interactions with the host's immune system (Coulter et al., 2001).
ORF A 6 and ORF Ov6
A1HV-1 ORF A6 and Ov6 encode proteins with weak homology to the EBV
BZLF1 viral transactivator (Ensser et al,. 1997). The EBV BZLF1 gene encodes a
DNA-binding transcriptional activator similar to the AP-1 bZIP family of
transcription factors. Expression of this gene results in the activation of gene
expression, causing a shift from latent infection to the lytic cycle (Countryman &
Miller 1985; Miller, 1990). Furthermore, this gene also functions in viral DNA
replication through binding to the lytic replication origin oriLyt (Fixman et al.,
1992). HHV-8 ORF K8, positionally equivalent to ORF A6 and Ov6, also shows
homology to BZFL1. Although positionally equivalent, there is no experimental
evidence that A6 and Ov6 are functionally equivalent to BZFL1 (Coulter et al.,
2001).
ORF A 7 and ORF Ov7
ORF A7 and Ov7 are positional homologues to EBV BZLF2 which encodes a
glycoprotein, gp42 Tm region? (Li et al., 1995; Ensser et al., 1997). Gp42 is known
to interact with the pi domain of the MHC class II protein, encoded by the HLA-DR
gene (Spriggs et al., 1996; Coulter et al., 2001). A soluble version of gp42, which
does not impede the binding of EBV particles to receptors on B cells, though it is
known to block B-cell transformation, and consequently is thought to be involved in
viral entry (Li et al., 1997). Evidence to support the assumption of gp42 being
involved in viral entry, possibly penetration of the B-cell membrane, was proved in a
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study by Wang and Hutt-Fletcher in 1998, which showed a virus that lacked gp42
could bind to B cells though could not infect or transform B lymphocytes. It is still
unknown whether A7 and Ov7 play a similar role in MCF virus entry into the cells.
ORF A8 and ORF Ov8
Analysis of the A1HV-1 and OvHV-2 sequences identified multiple splice
sites in the Ov7 and Ov8 sequence (Flart et al., 2007). Sequence analysis of the
A7/A8 region shows homology with the Ov7/Ov8 region. ORF A8 and Ov8 are
positional homologues to the EBV gene (BLLF1) which encodes a glycoprotein,
namely gp350/220 (Coulter et al., 2001). Although the MCF genes show a limited
sequence homology to this glycoprotein, they demonstrate structural similarities and
are therefore also thought to encode glycoproteins (Ensser et al., 1997). Glycoprotein
genes found at the same locus on genomes of gammaherpesviruses analysed include
the K8.1 gene of FIHV-8, which also encodes glycoproteins (Li et al., 1999; Zhu et
al., 1999).
ORF A 9 and ORF Ov9
The gene products ORF A9 and Ov9, are assumed to play important roles in
cell death regulation, as they share limited similarity with the bcl2 family of
apoptosis-regulatory genes (Ensser et al., 1997). All gammaherpesviruses have bcl-2
homologues, although none are similar to A9 or Ov9. In EBV, two bcl-2 homologues
are encoded, BF1RF1 and BALF1 (described in section A4.5/Ov4.5). EBV BHRF1 is
a cellular anti-apoptotic protein which is transcribed in both latent and lytic infection
as an immediate-early (IE) gene (Cabras et al., 2005; Li et al., 2006b). Although
A4.5/Ov4.5 have some similarity to BALF1, no such similarity is observed between
A9/Ov9 and BHRF1.
ORF A10 and ORF Ov 10
The ORFs A10 and OvlO appear to encode a glycoprotein which may be
involved in the attachment or entry of the virus into the cell. OvHV-2 has little
similarity with A1HV-1 ORF10 (Hart et al., 2007).
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1.4.13. Genes unique to the OvHV-2 genome
The DNA sequences of both A1HV-1 and OvHV-2 revealed twelve genes
unique to the MCF viruses (Figure 1.10), and three further genes which are unique to
the OvFIV-2 genome (Thonur et al., 2006; Hart et al., 2006). These genes are
designated ORF Ov2.5, ORF Ov3.5 and ORF Ov8.5. The 182 amino acid gene
Ov2.5 encodes a homologue of cellular interleukin 10 (IL-10) spliced over five exons
(Rosbottom, 2003). IL-10 is a regulatory cytokine involved in the control of immune
responses. Homologues of ORF Ov2.5 include EBV BCRF-1 (Hsu et al., 1990) and
CMV ULllla (Kotenko et al., 2000). Expression in eukaryotic cells has been
demonstrated for Ov2.5, where it was shown to be both secreted and functional (D.
Haig, J., Stewart, unpublished data). ORF Ov3.5 encodes a protein with a predicted
signal peptide sequence. This 163 amino acid gene product shows no homology to
any known genes and the function of this protein is still unknown. ORF Ov8.5
encodes a protein of 390 amino acids with unusual amino acid composition. Similar
to ORF Ov3.5, ORF Ov8.5 shows no homology to any other gene.
1.5. Project background
Current diagnosis of MCF infection is to date reliant on an indirect
immunofluorescence test (IFAT) and a PCR assay. Although there is an ELISA
commercially available (Wan et al., 1988, McGuire et al., 2001), it is of limited
value in the detection of OvHV-2 antibodies as it was developed utilising alcelaphine
herpesvirus-1 (A1HV-1) antigens. The recent determination of the DNA sequence of
the OvHV-2 genome (Hart et al., 2007) has allowed about seventy genes to be
identified, of which twelve are unique to the MCF viruses and three are unique to
OvHV-2. Consequently, these genes may prove good candidates for the development
of a specific OvHV-2 detection assay (Table 1.3).
Preliminary studies following a review of the gamma-herpesvirus literature on
diagnostic testing demonstrated recombinant OvHV-2 antigens could be expressed in
vitro and reacted with MCF case sera (Russell, pers commun). No in-vivo trials were
initiated. The genes were cloned into bacterial expression vectors and the expression
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also suggested that these genes could be detected by MCF sera, providing reagents
that could be utilised to initiate the current study.
MCF unique Stage of infectious Abundance
Genes cycle (Dominant product















Table: 1.3: Summary of MCF genes, Stating gene kinetics (stage in infectious
cycle) and gene abundance during infection.
1.6. Project Aim
Despite the severity of MCF in susceptible animals, little virus or viral
antigen can be detected and as a consequence, MCF infections prove difficult to
detect (Coulter et al., 2001). Therefore the main aim of this research is to advance
the current position in the diagnosis of MCF. Detection of antibodies against OvHV-
2 antigens will be examined with the aim of developing an enzyme-linked
immunosorbent assay (ELISA). In order to achieve this aim several approaches will
be considered, including the expression of OvHV-2 candidate antigens as







Serum samples from cattle submitted for MCF testing were used throughout.
These included cattle with clear signs of MCF and others with clinical signs only
indicative of enteric disease. Differential diagnosis between MCF and other viruses
such as BVDV can be made on the basis of MCFV testing. Sera from cattle with
clinical symptoms indicative of potential MCF were submitted to the Virus
Surveillance Unit at the Moredun Research Institute, for routine testing by IFAT.
Clinical evaluation and histopathological testing were carried out to provide a final
diagnosis for some samples. All sera were stored at -20°C until required.
2.1.2. Experimental AIHV-1 MCF in cattle
Four experimentally infected animals, immunised with high-pass AlFlV-l
strain C500 prior to challenge with virulent A1F1V-1 virus, were used to establish an
in-house direct immunosorbent assay (termed WC11 ELISA) and in a longitudinal
study evaluating the antibody response identified by the WC11-ELISA (protocol
described in section 2.6.4.1).
The four cattle derived from two groups, given attenuated AIHV-1 (titre 107 5/ml) virus
intramuscularly, followed at weeks 2 and 16 by either an AlHV-l/chitosan intranasal boost (animal
numbers 200819 and 400821), or a chitosan/medium intranasal boost (animal numbers 400251 and
500815). All animals were then intramuscularly challenged with low pass virulent free AIHV-1 at
week 22. Blood samples were collected weekly until clinical signs indicated the animal had MCF,
such as a sustained increase in body temperature (>40°C for 2-3 days) or ocular/nasal discharge.
Rectal body temperatures and physical examination findings were recorded daily for the initial six
weeks from these calves, scoring clinically for loss of appetite and increases in temperature. The
calves, housed together, were sampled weekly until 212 days post infection. Following inoculation,
blood was collected from all calves weekly for analysis by neutralization assays to detect MCF virus
specific antibody in plasma.
This work was performed for a vaccine experiment by the MCF group,
Moredun Research Institute. Blood collected was subsequently analysed for the
validation of the WC11-ELISA. The protocol for the WC11-ELISA is described in




Pathogen-free New Zealand white rabbits (Harlan, UK) were used for sera
production. Rabbits were housed in individual cages and supplied with proprietary
food and water ad libitum. Serum was collected from two rabbits, one of which was
immunised with OvHV-2 virus-infected mesenteric lymph node, and the second
rabbit was immunised with low-pass A1HV-1 strain C500. Blood was collected at the
onset of clinical signs (increased temperature > 40°C). Both animals showed clinical
signs and pathology consistent with MCF.
This work was performed by Iris Campbell, MCF group, Moredun Research Institute for
RNA extraction from infected lymph node.
2.2. Reference Viruses
2.2.1. MCF Viral strains
The virus used for the production of AlHV-l MCF ELISA antigen was the
high-passage culture virus strain WCll, originally described by Plowright et al.,
(1965). The virus was initially isolated in primary calf thyroid cultures inoculated
with leucocytes from the blood of a wildebeest calf, and has subsequently been
passaged in primary bovine turbinate (BT) cells. AlHV-l MCF ELISA antigen was
also prepared from virus strain C500, originally described by Plowright et al.,
(1975).
The source of virus antigen used for the production of MCF OvHV-2 ELISA
was a LGL cell line (Strain BJ1035), derived from a cow naturally infected with
OvHV-2 (Schock et al,. 1994).
2.2.2. Bovine herpesvirus stains
The virus used for the production of BHV-1, strain 6660, (IBR) was
originally described by Nettleton & Sharp, (1980). The virus was initially isolated in
primary calf thyroid cultures inoculated with leucocytes from the blood of a calf, and
has subsequently been passaged in primary bovine turbinate (BT) cells. The virus
used for the production of BHV-2 cell lysate was a field sample submitted in 2005
from a severe BHV-2 outbreak in dairy cattle (05/1299). The virus used for the
56
Methods and Materials
production of BoHV-4, V-test strain (Belgium), was originally described by Thiry et
al., (1981).
2.2.3. Titration of virus
Virus was diluted from a virus stock 10"' to 10"7 in diluent (Iscove's medium
10% v/v FBS) and 25pl added to 4 wells of a 96 well tissue culture plate.
Uninoculated control wells were also prepared (25pel diluent). 25pl of diluent was
added to every well, including the control wells. lOOpl of a BT cell suspension (2
xlO3 cells/ml) was inoculated into every well of the virus dilutions and control and
incubated at 37°C (5% CO2). Plates were read 5-7 days after setting up, for signs of
cell growth and cytopathic effect.
2.2.4. Sucrose gradient purification of AIHV-1 virus (strain WC11)
Four I50cm2 flasks of BT cells were inoculated with 4mls of cell culture
grown WCl l virus (4x103 TCIDso/ml) and incubated at 37°C until 90-100% CPE
was observed. The cell-associated virus supernatant was harvested after freeze-
thawing at -70°C and clarified by centrifugation at 3000 x g for 10 minutes, and virus
particles were pelleted at 23,500 x g for three hours. The pellets were resuspended in
TNE buffer (50mM Tris pH7.4, lOOmM NaCl & lOmM EDTA) and layered onto a
discontinuous sucrose density gradient containing sucrose solutions from 20-55 %.
The gradient was then centrifuged at 25,000 x g for 16 hours. 500pl fractions were
collected and stored at -70°C.
2.3 Cell Culture
2.3.1. Cell growth and maintenance
Maintenance of OvHV-2 LGL cell lines was based on methods described by
Reid et al., 1989. There is currently no productive culture system for OvFlV-2,
therefore a BJ1035 LGL cell-line from an OvHV-2-infected animal (Shock et al.,
1998) was grown in 25cm2 flasks and maintained in IMDM (Gibco Invitrogen,
Paisley, UK) supplemented with 10% heat-inactivated foetal bovine serum, 2mM
glutamine, 100 IU/ml penicillin, lOOpg/ml streptomycin and 350 IU/ml of IL-2
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(Proleukin, Chiron Therapeutics, Emeryville, CA). Medium was routinely replaced
twice a week.
Bovine turbinate (BT) cells were grown in 225cm2 flasks and maintained in
IMDM supplemented with 10% heat-inactivated foetal bovine serum, 2mM
glutamine, 100 lU/ml penicillin, 100p.g/ml streptomycin. A monolayer formed in the
flasks after about 3-4 days, at which point they could be subcultured.
Virus was grown in the two different cell lines as OvHV-2 has never been
propagated in monolayer culture, despite an incomplete enveloped virus detected by
electron microscopy from infected rabbits (Rosbottom et al., 2002). As it has been an
established cell-line for the continued growth of A1HV-1, by the VSU laboratory at
Moredun Research Institute, BT cells were used to obtain cell-associated virus.
2.3.2. Cell passage
For bovine turbinate (BT) cells, medium was removed from the flask and
cells washed twice with PBS (37°C). Cells were removed from the flasks using
trypsin (0.25%v/v)/versene (0.02%v/v) incubated at 37°C, in a humidified
atmosphere of 5% C02 in air for 2 minutes. The flask was gently shaken to remove
bound cells and medium containing FBS was added to neutralise the trypsin. Cells
were passaged twice a week.
In the case of the OvHV-2 LGL cell line, cells were resuspended in the flasks by pipetting.
From a 10ml suspension, 5mls were added to a new flask containing 5mls of IMDM medium
supplemented with IL-2, while 5mls of medium was added to the original flask. Flasks were incubated
at 37°C, in a humidified atmosphere of 5% C02.
2.3.3. Cell growth and viability
A 20p.l sample of cells was mixed with 180pl of 0.1% (w/v) nigrosine
(Sigma), in PBS. Live and dead cells were counted in a haemocytometer, where
dead cells were identified by the presence of nigrosine in the cells. Live cells do not
allow the entry of the dye. The percentage viability was calculated (i.e. number of




2.4.1. PCR Amplification and Optimisation
Reactions were typically done in 50pi total volume containing 5pl lOx PCR
reaction buffer (PCR buffer for KOD Hot Start DNA polymerase), supplied by
enzyme manufacturer, 2pl MgS04 (l.OmM final concentration), 5pl dNTPs (2mM)
(Novagen, Germany), 3pl of each primer (5pmol/pJ) obtained from MWG-Biotech,
1 jul heat-stable DNA polymerase (1 U/jul) and 1 pi DNA template (100-500ng
genomic BJ1035 DNA for amplification of OvHV-2 genes). Samples were made up
to the correct volume using water. The heat-activated ultra-high fidelity KOD Hot
Start DNA polymerase (Novagen) was used in these experiments to reduce unwanted
incorporation errors and to allow hot-start PCR reactions. Reactions were incubated
for 2 minutes at 94°C followed by 30 cycles of denaturing [15 seconds at 94°C]
annealing [30 seconds at 60°C] and extension stages [20 seconds/kbp at 72°C],
Reactions were carried out in 0.5ml microcentrifuge tubes using a Hybaid Omingene
thermal cycler (Hybaid Ltd).
The melting temperatures (Tm) of the primers used in PCR were between
56°C and 70°C. To establish the optimal annealing temperature for each primer pair,
an annealing temperature gradient was used. Annealing temperatures varied
depending on the PCR primers used and were calculated using the following
formula: [(Number of Gs + Cs) x 4] + [(Number of As + Ts) x 2] = annealing
temperature (Suggs et al., 1981), (where G = guanine; C = cytosine; A = adenine; T
= thymine). However, any bases that were not homologous to the target sequence,
such as added restriction sites, were not included in the above calculation.
To analyse PCR products, lOpl of PCR product was mixed with 2pl of
loading buffer (80% (v/v) glycerol, lx TE Buffer, 0.1% (w/v) bromophenol blue) and
analysed on a 1% agarose gel. Amplicon size was estimated by comparison with size
standards (Hyperladder I, Bioline).
2.4.2. Fragment Purification
Purification of PCR products was performed for the efficient recovery of
clean DNA fragments from amplification reactions. PCR products were purified
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using the QIAprep PCR purification kit, in accordance with the manufacturer's
directions (QIAprep Miniprep Handbook 03/2002). Bound DNA was eluted in 50pl
of EB Buffer (lOmM Tris-Cl, pH8.5). Eluted samples were stored at -20°C. lOpl of
the eluant was run on a 1% agarose gel to estimate the yield of the purified DNA
fragments.
Where multiple PCR products were obtained, or where primer-dimers were
seen, the specific product band was purified using the QIAquick Gel Extraction Kit
in accordance with the manufacturer's directions (QIAquick Spin Handbook
07/2002). The DNA was eluted in 50pl of buffer EB (10mM Tris-Cl, pH8.5) and
stored at -20°C. lOpl of the eluent was run on a 1% agarose gel to confirm the
presence of the purified DNA fragments.
2.4.3. Ethanol Precipitation
To concentrate the nucleic acids obtained from gel extraction or PCR
purification steps, ethanol precipitation was performed following the protocol of
Sambrook et al., (1989). One-tenth volume 3M sodium acetate (pH 5.2) and two
volumes of ice-cold ethanol (v/v) were added to each sample, before storing for 30
minutes at -20°C to allow the precipitate to form. To improve yield of small
fragments DNA, RNA and nuclease free glycogen (5pl=50pg) was added as carrier
to some precipitations. The DNA was recovered by centrifugation at 12000 x g for
10 minutes. The pellet was washed with 500pl of 70% ethanol, air-dried briefly and
resuspended in lOpl distilled water.
2.4.4. DNA Ligations
PCR products were ligated in accordance with the manufacturer's directions
stated in the pGEM®-T Easy Vector system technical manual (manual No. 042
revised 2003, Promega corporation). Each reaction contained 5pi 2x rapid ligation
buffer, lpl pGEM®-T Easy Vector (50ng), lpl T4 DNA ligase (3 Weiss units/pl)
and up to 3pi PCR product, in a reaction volume of lOpl. Negative control reactions
were included to check for self-ligation of the plasmid. Ligation reactions were
incubated at room temperature for 1 hour then overnight at 4°C.
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2.4.5. Transformation using the pGEM®-T Easy Vector ligation
reactions
PCR products ligated into pGEM®-T Easy were transformed into chemically-
competent JM109 cells. 50pl of JM109 high efficiency competent cells were mixed
with 2pl of ligation or control reactions in a 1.5ml tube. The transformation mix was
placed on ice for 20 minutes, then incubated at 42°C for 45 seconds and immediately
returned to ice for a further 2 minutes. SOC medium (SOB medium [2% (w/v)
Trypone, 0.5% (w/v) yeast extract, 0.05% (w/v) NaCl, 2.3mM KC1, lOmM MgCE]
plus 20mM glucose) was added to each transformation, which was then incubated at
37°C for 1.5 hours. Reactions were inoculated onto LB agar plates containing
ampicillin (100p.g/ml), X-Gal (5-bromo-4-chloro-3-indolyl-beta-D-
galactopyranoside) (20p.g/ml) and incubated overnight at 37°C.
2.4.6. Treatment of Blunt-Ended PCR Products
KOD Hot Start DNA polymerase generates blunt-ended fragments. Such
PCR fragments are not suitable for direct cloning by TA cloning approaches, but can
be modified using an A-tailing procedure with Taq DNA polymerase and ligated into
the pGEM®-T Easy Vector. Reactions were performed in lOpl total volume
containing 7pl PCR product, lpl PCR buffer (lOx) with ImM MgS04, 5 units Taq
DNA Polymerase and lpl of dNTPs. Samples were incubated at 70°C for 30 minutes
and then stored at -20°C.
2.4.7. Subcloning into expression vectors
Ncol was used for cloning into all expression vectors. Ncol digestion of
plasmid vector was done in 20pl total volume containing lpl plasmid DNA, lOx
Promega buffer D and lp.1 (10 units) restriction enzyme Ncol (Promega). Digests
were incubated at 37°C for an hour. To prevent self-ligation of the Ncol-digested
vector, a de-phosphorylation reaction was performed during the final 30 minutes of
the Ncol digestion by the addition of 2jul shrimp alkaline phosphatase (SAP). Ncol
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digested, dephosphorylated vector fragments were then gel purified as described in
section 2.4.2.
Fragments were ligated into expression vectors pBAD, pET and pTrxFus in
accordance with the manufacturer's directions. Each reaction contained 5pl 2x rapid
ligation buffer (Promega), lpl vector (50ng), lpl T4 DNA ligase (3 Weiss units/pl)
and up to 3pl Ncol-digest insert DNA, in a reaction volume of lOpl. Negative
control reactions were included to check for self-ligation of the plasm id. Ligation
reactions were incubated at room temperature for 1 hour then overnight at 4°C.
2.4.8. Analysis of Transformants
2.4.8.1. Single Colony Analysis
A rapid lysate method was used to analyse plasmids for the presence of an
insert. Individual colonies or cells scraped from a bacterial patch were lysed by
resuspension in 150pil of SDS lysis buffer (2% (w/v) Ficoll, 1% (w/v) SDS, 0.012%
(w/v) bromophenol blue in lxTAE [40mM Tris.Cl, 20mM CH3COONa, ImM
EDTA, pH8.2]), containing RNase A (100p.g/ml). After 15 minutes at room
temperature, lysates were spun at 13,000 x g for 15 minutes to pellet insoluble
material. The soluble cell lysate (20-50pl) was analysed on a 0.8% agarose gel.
2.4.8.2. Plasmid Preparation by QIAprep Spin Miniprep
Plasmid DNA was used for the initial screening of cloned DNA fragments. A
single bacterial colony was picked and grown in 10ml of LB broth containing
100p.g/ml ampicillin at 37°C overnight with shaking. Bacterial cells were pelleted by
centrifugation at 13000 x g for 10 minutes at room temperature and plasmid DNA
was extracted using a QIAprep spin miniprep kit in accordance with the
manufacturer's instructions (Qiaprep Miniprep handbook 03/2002, Qiagen). Briefly,
the pelleted cells were resuspended in 250pil of buffer PI (resuspension buffer
containing RNase), followed by 250pl of buffer P2 (lysis buffer) and mixed by
inversion. Genomic DNA and proteins were precipitated by the addition of 350pl of
buffer N3 (neutralising buffer) mixed by inversion and then centrifuged in a
microcentrifuge at 13000 x g for 10 minutes. The supernatant was drawn through a
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QIAprep spin column (Qiagen), using a vacuum manifold. Unbound material was
discarded, and the column was washed with 0.5ml of buffer PB, to remove any
remaining traces of nuclease activity. The column was washed with 0.75ml of buffer
PE (containing ethanol), unbound material was discarded and the column was
centrifuged at 13000 x g for 1 minute to remove any residual wash buffer and
ethanol. Unbound material was discarded and the column was placed into a fresh
microcentrifuge tube and DNA was eluted by the addition of 50ql of buffer EB
(lOmM Tris.Cl, pEl 8.5) and centrifuged for 1 minute. DNA was stored at -20°C
until required.
2.4.8.3. Sequencing
Nucleotide sequencing of PCR products cloned in pGEM-T Easy was carried
out by the Functional Genomics Unit at Moredun Research Institute using a
MegaBACE capillary DNA sequencer (Amersham) with universal primers. Sequence
data was returned as chromatogram files.
2.4.8.4. Glycerol stocks
Glycerol stocks were made by growing E. coli bacterial cultures in 10ml L-
broth containing 100p.g/ml ampicillin at 37°C overnight with shaking. Bacterial cells
were pelleted by centrifugation at 3000 x g for 10 minutes at room temperature,
before being resuspended in L-broth with 50% glycerol (v/v). Samples were stored at
-70°C.
2.4.8.5. Quantification of nucleic acids
DNA was quantified by spectrophotometry. DNA samples were diluted in
distilled water (1:20), and using distilled water as a control, the OD26o and OD28o
were determined using a Cecil CE 2041, 2000 series spectrophotometer. The nucleic
acid concentration was determined by using the following formula:
OD26o reading of 1 = 50qg/ml double-stranded DNA. The purity of the test




2.4.9. Preparation of Competent E. coli.
Strains of E. coli are regularly used as hosts for cloning and expression
vectors for specific gene sequences. Many common E. coli hosts are commercially
available as competent cells to allow rapid transfer of plasmid between strains. For
more specific/specialised applications, such as in expression systems, host genotype
requirements may mean that specific strains of E. coli must be used and competent
cells must be made by standard chemical methods.
The E. coli strain LMG194 was used as it is capable of growth on minimal
medium allowing repression of pBAD by glucose and induction by addition of
arabinose. E. coli strain BL21 (DE3) carries the gene encoding T7 RNA polymerase
and was used for the expression of the pET-22b vector, which is under control of the
lac promoter, inducible by IPTG. All expression work for the Thioredoxin
expression system was performed in E. coli strain GI724. This strain contains the
bacteriophage-A cl repressor gene under the control of the trp promoter inducible by
addition of tryptophan. Additionally GI724 is routinely use for the expression of
proteins below 30°C.
Competent cells of strains LMG194 and GI 724 were made as follows:
Single colonies from overnight plates were used to inoculate 10ml volumes of
LB media and the cultures were incubated overnight at 37°C (shaking at 225rpm).
2.5ml of overnight culture was used to inoculate 100ml of LB media containing 0.2%
glucose and the cultures were incubated at 37°C (shaking at 225rpm) until an OD600
of 0.2 was achieved. Cultures were chilled on ice and harvested by centrifugation at
4000 x g for 15 minutes at 4°C. The supernatant was removed and the cell pellet
resuspended in 50ml ice-cold 0.1M CaCh and was placed on ice for 20 minutes.
Cultures were centrifuged at 4000 x g for 15 minutes at 4°C and the pellet
resuspended in 1ml ice-cold 0.1M CaCI2 with 10% glycerol. Aliquots of competent
cells were snap-frozen and stored at -80°C.
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2.4.10. Transformation of chemically-competent E. coli
Plasmid DNA was transformed into competent E. coli strain as follows: 2pl
of each plasmid was added to a sterile 1.5ml microcentrifuge tube on ice. A
transformation control was used to measure the transformation efficiency of the
competent cells by transformation with 2pl of 0.1ng/pl control plasmid (pUC19).
50pl aliquots of each E. coli strain competent cells were mixed with plasmid DNA
and the controls. The transformations were then treated as stated for pGEM®-T Easy
Vector ligation reactions (as described in section 2.4.5).
2.4.11. Agarose Gel Analysis
DNA was analysed by gel electrophoresis on l% agarose gels containing
0.5pg/ml (w/v) ethidium bromide (Sigma), in TBE buffer (134mM Tris, 44mM boric
acid, 2.6mM EDTA). DNA samples were prepared with l/lO volume loading buffer
(15% (w/v) ficoll type, lxTE buffer, 0.1% (w/v) bromophenol blue). Electrophoresis
was carried out at 100V in a horizontal tank (Bio-Rad) containing TBE buffer. The
size of DNA bands was estimated by comparison with DNA mass and size standards
(Hyperladder I, Bioline). Bands were visualised by UV transillumination and images
were captured using an Alphaimager 2200 (Alpha Innotech).
2.4.12. Restriction Endonuclease Digestion of Plasmid DNA
Reactions were made up to a 20pl total volume containing lpl (200-1 OOOng)
plasmid DNA, lpl of selected restriction enzyme (4-10u/pl) and 2pl of lOx specific
reaction buffer for the chosen enzyme. The digests were incubated at 37°C for at
least 1 hour. Digested samples were run on 0.8% agarose gel for one hour at 100
volts.
2,5 Protein Analysis
2.5.1. Total Protein Estimation
To determine the concentration of protein present in soluble extracts, total
protein estimation was done using the bicinchoninic acid (BCA) method (Smith et
al., 1985) in accordance with the manufacturer's directions (Pierce and Warriner) for
65
Methods and Materials
the micro-scale assay, done in 96-welI plates. For each assay a standard curve was
constructed using bovine serum albumin, 12.5pg/ml to 2mg/ml. The test was read
using a Bio-tek ELx808iu Microplate Reader 562at nm.
2.5.2. Polyacrylamide gel electrophoresis (SDS-PAGE)
Protein extracts were run on 10-12% NuPAGE Bis-Tris or Tris-Glycine polyacrylamide gels using the
XCell Surelock™ MiniCell. Both chambers of the MiniCell were filled with lxSDS running buffer
(24mM Tris, 250mM glycine, 0.1% (w/v) SDS) running buffer in distilled water). Samples for
analysis were diluted 1:1 in 2 x SDS-PAGE sample buffer (lOOmM Tris (pH6.8), 4% (w/v) SDS, 4%
(v/v) P-Mercaptoethanol, 20% (v/v) glycerol, 0.1% (v/v) bromophenol blue) and heated in a boiling
water bath for 10 minutes before loading onto the gel. A sample of 5 - 25pl was then loaded onto the
SDS-PAGE gel. The samples included a 5pl sample of broad range pre-stained SDS-PAGE standards
(Invitrogen, SeeBlue® Plus2) in order to estimate protein molecular weight relative to the standards.
All polyacrylamide gels were run at 200V for 1 hour. Gels were used for Western blotting or were
stained using Coomassie blue stain, SimplyBlue™ Safestain or Sypro ruby stain (section 2.5.4).
2.5.3. Staining of SDS-PAGE Gels
Polyacrylamide gels were stained in Coomassie blue stain (0.25% (w/v)
Coomassie brilliant blue, 10% (v/v) glacial acetic acid, 50% (v/v) methanol)
overnight and de-stained over a period of 4-8 hours in Coomassie destain (50% (v/v)
methanol, 10% (v/v) acetic acid) until excess stain had been removed. The gel was
soaked in a 6% glycerol solution, and then dried onto 3MM paper using a model SE
1106 slab gel dryer (Hoefer Scientific instruments) under vacuum.
Gels were also stained with SimplyBlue™ SafeStain (Invitrogen) and dried
onto clearfilm (40p pore size) using DryEase® mini-gel drying system (Invitrogen).
The gels were washed in 100ml distilled water and stained in Simplyblue for 3 hours.
Gels were equilibrated in 35ml gel-dry drying solution (10% Ethanol, 0.5%
Methanol and 0.5% Isopropanol) for 5 minutes. The gels were placed between pre-
wetted cellophane films, ensuring no air bubbles were trapped between the films and
supported in a drying frame. Gels were dried for 12-36 hours. Drying by this method
allowed subsequent scanning or photography.
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2.5.4. Sypro Ruby Stain
SYPRO Ruby stain detects minimally expressed proteins which less sensitive
Coomassie Blue staining techniques are unable to detect. Gels were fixed with 100ml
of fix solution (50% methanol, 7% acetic acid) and agitated on a shaker for 30
minutes. The gel was stained overnight with 60ml SYPRO ruby gel stain. To
minimise background staining, the gel was washed in wash buffer (10% (v/v)
methanol, 7% (v/v) acetic acid) and rinsed in distilled water prior to visualisation
using a Molecular Imager FX Pro Plus imager (Bio-Rad).
2.5.5. Sample Preparation
To analyse crude extracts, bacterial cells were resuspended in sample buffer
(bis-tris gels 4x LDS, tris-glycine gels 2 x SDS) with 10% NuPAGE reducing agent
0.5M DTT to give an approximate OD6oo of 25. Samples were lysed and solubilised
by heating at 85°C for 5 minutes then centrifuged at 13,000rpm for 10 minutes. To
analyse soluble extracts prepared by other lysis methods, equal volumes of extract
and 2x sample buffer were mixed.
2.5.6. Western Blotting
Western blotting was performed to evaluate the expression and antigenicity of recombinant
proteins expressed in pBAD, pET and pTrxFus extracts. After SDS-PAGE, proteins were transferred
to a nitrocellulose membrane using the XCell Surelock™ MiniCell. The apparatus was assembled
according to the manufacturer's instructions and the tank filled with transfer buffer (25mM Tris,
250mM Glycine, 20% (v/v) methanol) and transfer carried out at 100V for 2 hours.
Two methods were used for preventing non-specific binding of proteins:
membranes were incubated for 1 hour in either 3% non-fat milk in PBST (lx
phosphate buffered saline with 0.05%Tween-20) or high-salt buffer (0.5M NaCl,
0.05% Tween-20).
Blots were then incubated with primary antibody (anti-HisTag/Anti-Thio) or
antiserum for 1 hour followed by a secondary conjugate (e.g. IgG anti-mouse HRP)
which recognizes the primary antibody. Chemiluminescent peroxidase substrate
(Pierce SuperSignal© ELISA Femto, Alpha Innotech Chemiglow chemiluminescent
substrate) was applied to the membrane prior to exposure to x-ray film for exposures
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of 1 second to 10 minutes. The exposed film was developed using an automatic film
processor (X-OGRAPH Compact X2).
2.5.7. HisProbe™-HRP Technology
HisProbe™-HRP (Pierce, Rockford, Illinois) is a nickel-activated derivative
of horseradish peroxidase (HRP) which allows the direct detection of recombinant
polyhistidine-tagged fusion proteins. HisProbe™-HRP, diluted 1/1000 in high salt
wash buffer (lxPBS, 0.5M NaCl and 0.05% v/v Tween-20) was used in the same
way as a primary antibody. Chemiluminescent substrate (Pierce SuperSignal® West
Pico Chemiluminescent Substrate) was applied to the membrane prior to exposure to
x-ray film for exposures of 1 second to 10 minutes. The exposed film was developed
using an automatic film processor (X-OGRAPH Compact X2).
2.6. Diagnosis
2.6.1. Chemical and Biological Reagents - ELISA Kits
The competitive-inhibition (CI-) ELISA kit was supplied by Veterinary
Medical Research & Development Inc., (VMRD, Inc. Pullman, USA). The Bio-X
BoHV-4 ELISA was supplied by Bio-X Diagnostics, VMRD, Inc.
2.6.2. Indirect Immunofluorescence analysis (IFAT)
The indirect immunofluorescence analysis assay protocol is a modified
version of that described by Rossiter et al., (1977). A bovine turbinate (BT) cell
suspension (lxl07cells/ml) was inoculated with WC11 cell culture grown virus
supernatant (4 xl(f TCIDso/ml) and incubated at 37°C for 1 hour. Uninoculated
control cultures were also prepared. Iscove's Modified Dulbecco's Medium (IMDM)
with 10% fetal bovine serum (FBS), was added to give a final concentration of 10s
cells/ml. 300pl of control or infected cell suspension were pipetted onto wells on a
microscope slide and incubated at 37°C at 5% C02 until -25% cytopathic effect
(CPE) was visible. The medium was removed from the slides, and the cell monolayer
washed twice with phosphate buffered saline (PBS). The slides were fixed by
immersion in acetone (-20°C) for 10 minutes.
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As an initial blocking stage, 50pl of 1/20 horse serum in PBS was added to
each well and incubated at 37°C for 30 minutes in a moist chamber. The slides were
then washed for 2x10 minutes in PBS and stirred continually, using a magnetic
stirrer. 50jal of 1/10 dilution of test and control sera was added to the appropriate
well, and incubated at 37°C for 30 minutes in a moist chamber. After washing, 50pl
of diluted 1/100 Donkey anti-sheep fluorescein isothiocyanate (FITC) conjugate (The
Binding Site Limited, Birmingham, UK) was added to each sample and incubated at
37°C for 30 minutes in a moist chamber. Following a further washing stage, the
slides were covered with a large coverslip using buffered glycerol as a mountant. The
prepared slides were then examined using a UV fluorescence microscope.
2.6.3. Virus Neutralisation assay
The virus neutralisation assay protocol is a modified version of that described
by Mushi and Plowright (1979).
All serum samples were heat inactivated at 56°C for 30 minutes. Starting at a
neat concentration, 25pl of test serum was added to four wells per two-fold dilution
in tissue culture medium (IMDM) in a 96-well flat-bottomed microtitre plate. 25pl
A1HV-1 WC11 virus, calculated to be 100 TCID5o, was added to each well and
incubated for 1 hour at 37°C. 25pl 10-fold diluted WC11 virus was back-titrated as a
control. 50pl/well of SxlO^cells/ml BT cell suspension were coated onto the plate
and incubated in a humidified C02 atmosphere at 37°C for 7-10 days before being
examined microscopically for CPE. The assay is validated by the back titration of
virus, which should give a value of 100 TCID50 with a permissible range 30-300, and
by the positive and negative control sera.
The test serum results are determined by the Spearman-Karber method (Grist
et al., 1966) as the dilution of serum that neutralised the virus in 50% of the wells
(Log TCD50 = L - d (S- 0.5) where L = lowest dilution, d = difference between log
dilution steps, S = sum of proportions of "positive" tests e.g. cells showing CPE).
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2.6.4. Enzyme-linked Immunosorbent Assay
The following diagnostic assays for the detection of MCF and BHV-4
antibodies were used:
2.6.4.1 MCF WC1 l-ELISA (developed in Chapter Five).
2.6.4.2 Cl-ELISA - Malignant Catarrhal Fever Virus Antibody Test Kit
(VMRD, Inc. USA)
2.6.4.3 BIO-X BoHV-4 ELISA kit (Bio-X Diagnostics, Belgium).
2.6.4.1. MCFWC11-ELISA
Infected virus antigen (AlHV-l WCl 1) was coated onto rows 1, 2, 5 and 6,
while control antigen prepared from the BT cell line used to propagate the virus, was
coated onto rows 3, 4, 7 and 8 of a M129B microELISA plate (Greiner Bio-one) at
an initial concentration of 0.5mg/ml, as determined by BCA protein assay, in
carbonate buffer (pH9.6). The plate was incubated overnight at 4°C. The negative
control acts to differentiate the specific anti-viral antibody from antibodies directed
against antigenic determinants of the cell line used, and therefore aims to reduce the
number of false positives and establish background reactivity for each antiserum.
Between each stage the plates were washed four times in ELISA fluid wash buffer
(PBS plus 0.05% (v/v) Tween-20, [PBST]) using an ELISA plate washer (Ultrawash
plus, Dynatech laboratories).
All subsequent dilutions were made in PBST containing 10% (v/v) horse
serum (PBSTFI). 1 OOju.1 volumes were used. Test sera were added to duplicate
infected and control wells, at a constant dilution of 1/100. Furthermore, a MCF-
positive and -negative serum were used as test control. The plate was incubated for 1
hour at 37°C. After washing, conjugate (Rabbit anti-bovine IgG horseradish
peroxidase [Sigma, Poole,UK]) was added at a 1/1000 dilution to all wells. The plate
was incubated for a further one hour at 37°C, washed, and lOOpl chromogen
tetramethylbenzidine (TMB) peroxidase substrate 1-component added (KPL Insight
Biotechnology Limited, Middlesex, UK). The reaction proceeded at room
temperature (22±5°C) for 5 minutes before being stopped by the addition of 1 OOjul
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0.18M H2S04. The optical densities were read using a MRX plate reader (DYNEX
Technologies, Virginia, USA) with a 450nm filter. Results were calculated as mean
corrected optical densities, i.e. mean OD of infected antigen paired samples minus
mean OD of control antigen paired samples.
2.6.4.1.2. ELISA antigen preparation - Alcelaphine herpesvirus-1
Four 150cm2 flasks of BT cells were washed twice with Flanks Balanced
Salts Solution (HBSS). Two flasks were inoculated with 4mls (4xl05 TClD50/ml) of
cell culture grown virus WC11 supernatant, while the remaining two flasks were
inoculated with 4mls of HBSS and used both as a negative control and to prepare the
negative coating antigen.
All flasks were incubated for one hour at 37°C, with occasional rocking to
ensure even distribution of inoculum. 50mls of IMDM medium supplemented with
10% (v/v) FBS, 1% (w/v) glutamine and 1% (w/v) penicillin with streptomycin
(lOOpg/ml) were added to each flask and the flasks were incubated at 37°C until 90-
100% CPE was observed normally after 3-4 days.
Infected and control flasks were handled separately. The medium from the
flasks, containing infected and detached cells, was decanted into 50ml centrifuge
tubes. 50mls of PBS was added to each flask to wash remaining cells. The medium
and wash supernatant were centrifuged at 2000 x g for 10 minutes at 4°C, and the
cell pellets were re-suspended in lOOmls of PBS and re-centrifuged. The supernatant
from each tube was discarded. The cell pellets were re-suspended in 1.5ml of 1%
Nonylphenylpolyethylene glycol (Nonidet-P40; NP40) detergent in PBS and placed
back into the original cell culture flask, to detach the remaining cells. The flasks
were incubated for two hours at 4°C, tilting every 15 minutes to remove attached
cells. Lysates were removed from each flask, pooled and clarified at 1 1,600 x g for 5
minutes at room temperature (22 ± 5°C). Supernatant was removed and the pellet
discarded. The supernatant was stored at -70°C until required.
ELISA antigen was also prepared using the A1HV-1 strain C500 by the same




2.6.4.2. Malignant Catarrhal Fever Virus Antibody Test Kit
This test allows the detection of antibodies against MCFV using a
competitive ELISA technique. If antibodies to MCF are present in a test sample,
binding to the MCFV antigen occurs, thus inhibiting subsequent binding of the
horseradish peroxidase (FlRP)-labelled MCF-specific monoclonal antibody (MAb
15-A). If antibodies to MCFV are absent, competitive inhibition does not occur and
the MCF-specific monoclonal antibody binds to the MCFV antigen. Determination
of results is measured whereby the intensity of colour in the wells is inversely
proportional to the concentration of specific anti-MCFV antibodies.
96-well microELISA plates for this assay, coated with MCFV antigen, were
supplied by VMRD, Inc. The first six wells in column one served as controls for the
test. The controls were provided with the kit and consisted of a positive control,
tested in duplicate (wells 2 and 3), and a negative control, tested in triplicate, (wells
4, 5 & 6). Well 1 served as a blank control where no reagents were added in order to
measure background absorbance.
Fifty microlitres of control and test sera (diluted 1:5 with serum/conjugate
dilution buffer) were pipetted into wells of the MCFV antigen-coated plate, one well
per serum. The plate was then covered and incubated for 1 hour at room temperature
(21-25°C). After the 60-minute incubation, the plate was washed. The washing
procedure consisted of four washes in ELISA fluid wash (PBS plus 0.1% Tween-20)
in the ELISA plate washer (Ultrawash plus, Dynatech laboratories).
Antibody-peroxidase conjugate was then prepared by diluting antibody-
peroxidase conjugate (lOOx) in serum/conjugate dilution buffer. 50pl of diluted
conjugate was added to each well, with the exception of the blank control. The plate
was covered and incubated at room temperature (21-25°C) for 60 minutes. Following
a final washing stage, lOOpl of substrate (chromogen tetramethylbenzidine (TMB)
was added to every well, except the blank control. The plate was then incubated
uncovered at room temperature for 60 minutes. The reaction was stopped by the
addition of lOOpl of 0.18M sulphuric acid (H2S04). Intensity of colour is inversely




The cut-off threshold was established by adding 3 SD to the mean OD of a pool of
19 OvHV-2 negative sheep, which equalled 25% inhibition. The optical densities (OD)
were measured using a plate reader (MRX model, DYNEX technologies) at 450nm
filter. The results were expressed as a percentage inhibition, derived by the following
formula: 100 - |(mean OD450 of test seum x 100)/(mean OD450 of negative control)|.
For the test to be valid, the mean OD of the negative controls must fall between 0.4 and 2.0,
and the positive control must have a percentage inhibition of greater than 25.
2.6.4.3. The BIO-X BoHV-4 ELISA
This test allows the detection of antibodies against BoHV-4 using a direct
ELISA technique. If antibodies to BoHV-4 are present, they remain bound to the
microwell that contains the viral antigen and the secondary antibody-enzyme
conjugate catalyses the transformation of the colourless chromogen into a pigmented
compound. The intensity of colour in the wells is proportionate to the concentration
of specific BoHV-4 antibodies.
96-well microELISA plates for this assay, coated with BoHV-4 antigen, were
supplied by Bio-X Diagnostics. The first well in column one and two serve as
positive and negative controls for this test, supplied with the kit. All controls and
serum samples had to be diluted 1/100 for the test. lOOpl of the diluted sample was
then added to the appropriate well and the plate incubated for 60 minutes at 37°C in a
humid chamber. After washing, IOOp.1 of conjugate (HRP-labelled anti-bovine IgG
monoclonal antibody) was added to each well, and the plate incubated at 37°C in a
humid chamber. After the final washing stage, 100pl of the substrate (TMB) was
added to each well. The reaction was stopped after 10 minutes of incubation in the
dark at room temperature, by addition of 50p.l of 1M phosphoric acid (H3PO4).
Optical densities were measured with a plate reader (MRX model, DYNEX
technologies), at a wavelength of 450nm.
The washing procedure consisted of triplicate hand washings, at each stage,
with washing buffer provided by Bio-X Diagnostics.
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2.6.4.4. Analysis of ELISA results
The ELISA plates were read and the results were expressed as absorbance
readings at 450nm. For the WC11-ELISA, if A1HV-1 specific immunoglobulins
were present in the test sera, they would be bound by the immobilised A1HV-I
antigen. The secondary antibody binds the antigen-antibody complex and the
conjugated enzyme catalysed a colour change proportional to the concentration of
specific A1HV-1 antibody in the sample tested. The mean value of the negative virus
control was calculated and subtracted from wells containing A1HV-1 antigen to
remove background interference.
For the MCF CI-ELISA, the blank control was subtracted from all wells to
remove background interference, and the mean value of the negative controls and
positive controls were calculated. To obtain the percentage of inhibition, the OD
increase of the sample over the mean negative control value was calculated as a
percentage, and then subtracted from 100. A positive or negative interpretation was
then determined (Table 2.1.).
For the BoHV-4 ELISA, the control (negative antigen) was subtracted from
each of the corresponding positive wells. The O.D. signal for each sample was then
divided by the positive control serum O.D. and multiplied by 100 to express the
result as a percentage (Table 2.2.).
100- Sample O.D. x 100 — % Inhibition
Mean Negative control O.D.
Percentage Inhibition (%) Interpretation
<25 Negative
>25 Positive
Table 2.1: MCF CI-ELISA. The manufacturers recommended interpretation of




O.D - Mean Neg. x 100 (%) Interpretation
< 16.35 Negative
16.35 <59.87 +
59.87 < 103.39 ++
103.39 < 146.91 +++
146.91 < 190.43 ++++
>190.43 +++++
Table 2.2: Bio-X Diagnositics direct ELISA. The manufacturers recommended
interpretation of results, sample considered positive if yields a result that is greater
than or equal to one plus sign (+).
2.6.4.5. ELISA Specificity
The potential cross-reactivity of the WC11-ELISA antigen for other
herpesviruses of cattle was investigated using the following bovine sera:
hyperimmune calf serum produced in a calf immunised with gradient purified
infectious bovine herpesvirus-1 (BHV-1 strain 6660, Nettleton & Sharp, 1980).
Bovine herpesvirus-4 (BoHV-4) positive serum (BioX Diagnostics, Belgium) and a
hyperimmune calf serum produced in a calf intranasally infected with BVDV (strain
NADL).
2.6.4.6. Statistical Analysis
Where applicable, standard statistical analysis was carried out through the
calculation of standard deviations and mean, using Minitab statistical software
(Release 13.1).
Sensitivity and specificity of the MCF ELISA test were measured against one
another as well as against the I FAT test, PCR and histopathology/veterinary
diagnosis. The proportion of known infected reference animals that tested positive in
the assay determined diagnostic sensitivity, while the proportion of uninfected
reference animals that tested negative in the assay determined specificity (Office
International des Epizooties, 2005). All assays were analysed in duplicate.
The Cohen kappa test is used to determine the level of agreement between
tests, where no standard test is available. The observed proportion of agreement, OP,
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between the tests compared is calculated using the total positive and negative
samples of each test (Tables 2.3 & 2.4).
[OP = (a + d)/n\
Where n is equal to the total number of samples tested (n = a + b + c + d).
Test One
Test Two Positive Negative
Positive a b
Negative c d
Table 2.3: Determination of the Observed kappa value, OP.
The expected proportion of agreement by chance, EP, is calculated thus:
EP = [{a + b)/n}x {a + c)ln}\ + [{c + d)/it}x{b + d)/n}[
Observed agreement - expected agreement = OP - EP
The maximum possible agreement beyond chance may be calculated, by
subtracting the expected agreement value from one (1 - EP). Kappa is the excess
agreement over that expected by chance, divided by the potential excess:
kappa = {OP - EP) / (J-EP)
Level of Agreement Kappa range
Poor Agreement 0
Slight Agreement 0- 0.20
Fair Agreement 0.21-0.40
Moderate Agreement 0.41 -0.60
Substantial Agreement 0.61-0.80
Almost perfect Agreement 0.81-1.0
Complete Agreement 1.0





2.7.1. Slide-A-Lyzer® Dialysis system
Dialysis was performed in a 3ml Slide-A-lyzer dialysis cassette (Pierce) with
3mls of experimental and field serum samples. The Slide-A-Lyzer Dialysis Cassette
was used for buffer exchange and desalting. The cassette membrane was composed
of low-binding regenerated cellulose with a sealed chamber to maintain the highest
possible sample retention. To increase flexibility, the membrane was initially
hydrated in dialysis buffer (0.1M NaHP04, 0.5M NaCl, pH 8.3), before loading the
sample onto the cassette through a gasket on the cassette using an 18-gauge
hypodermic needle. Excess air was then removed from the cassette using the syringe,
so the sample contacts a greater surface area. The cassette was floated in constantly
moving dialysis buffer, approximately 500 times the volume of the sample, at 4°C
for 3 hours. The buffer was then changed, and the sample dialysed overnight. To
remove the sample, air is injected into the cassette to separate the membranes, and
the sample is withdrawn into a syringe.
2.7.2. Gel Filtration
Superdex2oo columns (10,000-600,000 globular protein, Average particle
size 13pm, flow rate O.lml/min) were used for high performance gel filtration of
proteins from crude lysates. Gel filtration allows the separation of molecules,
dependent on size as they pass through the filtration column. Superdex2oo columns
are produced by the covalent bonding of dextran to highly porous cross-linked
agarose beads (Amersham product manual).
Prior to applying the sample, the column was washed using two column
volumes of distilled water, followed by one column volume of 0.04% CHAPS in
PBS (pH 8.2), to ensure the column was free of the bacteriostat (20% ethanol),
present in the packaged column. Crude lysate (0.5mls) was applied directly to the
column via the Akta FPLC system. The column was eluted with 0.04% CHAPS in
TBS. Fractions (lml) were eluted and fractions corresponding to protein peaks were
analysed by gel electrophoresis and Western blotting, using a HisTag monoclonal




HisTrap columns are used for the purification of Histidine-tagged
recombinant proteins by metal ion affinity chromatography. HisTrap columns consist
of cross-linked agarose beads charged by immobilized chelating metal Nickel ions
(GE Healthcare Instruction Manual 71-5027-68AE). The column was attached to an
Akta FPLC system, and washed with equilibration buffer (PBS), to ensure the
column was free of the bacteriostat (20% ethanol), present in the packaged column.
Crude extracts of HisTagged proteins, diluted 1:5 in binding buffer (20mM
NaH2P04, 0.5mM NaCl, 20mM imidazole under native conditions and 0.1M
NaH2P04, 8M urea pH8 under denaturing conditions), and was loaded onto the
column. The column was washed extensively with binding buffer and proteins
bound to the column were eluted using elution buffer (20mM NaH2P04, 0.5mM
NaCl, 500mM Imidazole under native conditions and 0.1M NaH2P04, 8M urea
pH4.5 under denaturing conditions). Fractions (1ml) were eluted and fractions
corresponding to protein peaks were analysed by gel electrophoresis and Western
blotting, using a HisTag monoclonal antibody (HisProbe-HRP). Samples were stored
at -70°C.
2.7.4. Sample Preparation
To analyse crude lysate fractions, samples were concentrated 10-fold using
Microcon® centrifugal filtration devices with a nominal molecular weight limits
(NMWL) of 10,000 (Millipore. Billerica, USA). Concentrated samples were
resuspended in SDS sample buffer. Samples were denatured at 85°C for 5 minutes.







In initial studies performed by a visiting scientist, three OvHV-2 genes were
selected for expression after a review of the gamma-herpesvirus literature on
diagnostic testing. Most work had involved Human Herpesvirus-8 (Kaposi's sarcoma
herpesvirus), where the antigens used diagnostically are the K8.1 glycoprotein,
ORF65 (capsid protein) and the bcl2 homologue ORF 16. K8.1 and ORF65 were
found to be two of the most antigenic HHV-8 proteins being employed in diagnostic
tests such as peptide-based enzyme immunoassays (Perez et al., 2006).
OvHV-2 genes that were positional or sequence homologues (ORF Ov8
(glycoprotein), ORF 65 (capsid protein) and ORF Ov9 (bcl2 homologue) were
selected. The genes were cloned into bacterial expression vectors and the expression
of OvHV-2 ORF Ov8 and ORF 65 was demonstrated using western blotting with
epitope-tag-specific antibodies. There was also some evidence that these genes could
be detected by MCF sera, but background was high in the E. coli lysates, probably
due to cross-reactivity of the sera with bacterial proteins. Nevertheless, these studies
provide reagents that were utilised to initiate the current study.
The elucidation of the sequence of the OvHV-2 genome (Hart et al., 2007)
enabled the design of PCR primers to amplify selected genes and gene fragments.
The gene fragments were given terminal Ncol sites, whereby the central ATG was in
frame with the gene of interest, allowing fusion at both ends of the gene. Each PCR
fragment was directly cloned into a TA vector, and then inserts with the correct
sequence were transferred into expression vectors and transformed into the correct E.
coli expression host. The vectors chosen were the pBAD/His expression system, the
pET-22b expression system and the pTrxFus thioredoxin fusion vector.
The pBAD system is designed for high-level expression of recombinant
proteins in E. coli, based on the tightly-regulated araBAD operon, which is induced
by L-arabinose. The pBAD/His series of plasmids are highly inducible expression
vectors designed for the regulation of dose-dependent recombinant protein
expression and purification in E.coli. They are pBR322-derived, allowing the
production of soluble recombinant proteins using the araBAD promoter and araC
regulator from E.coli (Figure 3.1). This controlled promoter-regulator system enables
the growth and production of soluble and insoluble proteins in high-cell-density E.
coli cultures (Lim et al., 2000).When a gene is cloned downstream of the pBAD
promoter, expression of the gene is controlled by the araC regulator. The araC
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product is a transcriptional regulator, which binds to the 02 and I2 half sites of the
araBAD promoter, in the absence of L-arabinose, forming a DNA loop and blocking
transcription. AraC product binding to the 02 region therefore represses
transcription. In the presence of L-arabinose, the araC gene product releases the 02
region and binds to the I2 region which activates transcription. L-arabinose is
therefore essential for expression to occur (figure 3.2). The metal binding region
encoded by the histidine tag on the polylinker allows the purification of recombinant
protein by methods such as affinity chromatography. pBAD includes a C-terminal
6xHis tag as well as a Ncol site which places the cloned gene at the start of the
translated product (Figure 3.1). pBAD only encodes epitope tags for fusion with the
gene in question.
The pET system was designed for the cloning and expression of recombinant
proteins in E. coli. pET is a bacterial system intended for high-level expression of
recombinant proteins using the strong phage T7 promoter and E. coli strains
expressing T7 RNA polymerase, designed to produce large quantities of protein and
has several essential components (Figure 3.3).
In 1986, Studier et al. developed an advanced expression system, where
target genes are cloned under the control of the strong bacteriophage T7 promoter.
T7 RNA polymerase is provided from a chromosomal copy of the gene in a specific
host (Rosenberg et al., 1987: pET system manual, Seventh Edition). T7 RNA
polymerase is highly selective and specific for the T7 promoter. These sequences do
not occur naturally in E.coli and are not recognized by E.coli RNA polymerase.
The target genes, cloned into the pET vector, were transformed into the
expression host (BL21) which contains the T7 RNA polymerase gene (A.DE3
lysogen) required for protein expression. The T7 RNA polymerase gene is controlled
by the lac promoter (lacUV5). When the lac operon inducer, lactose or isopropyl-b-
D-thiogalactopyranoside (IPTG), is present, transcription of the T7 RNA polymerase
gene is induced. IPTG prevents the lac repressor from binding to the lac operator
allowing transcription to proceed (Figure 3.4). Expression of T7 RNA polymerase at
high level following IPTG induction, leads to the strong transcription of genes with
T7 promoter sequences and their subsequent overexpression.
A wide variety of pET vectors are available, with a variety of fusion tags and
expression signals. The pET-22b vector was selected as it was designed for the
fusion of proteins to a signal sequence that facilitates their export to the periplasm.
80
Icq) ATG 6 x His
Figure 3.1: The pBAD/His expression system (adapted from Invitrogen). This vector carries a araBAD
promoter for tightly regulated expression, an enterokinase cleavage site and an N-terminal polyhistidine
(6xHis) tag for purification with nickel-chelating resin.
Figure 3.2: Regulation of the araC promoter, a) In the absence of arabinose, the araC dimer binds to 02 on the
araBAD operator, inhibiting transcription, b) In the presence of arabinose, binding to the araC occurs and releases the
02 site, and binds to the l2 region. The cAMP activator protein binds to the DNA and stimulates the binding of the araC
to the l2 site and allows transcription to occur (Illustration adapted from Invitrogen).
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Figure 3.3: The pET vector (Illustration adapted from Novagen). This vector carries a drug resistant marker
for ampicillin resistance, the lacl gene, the T7 promoter and a polylinker region. The polylinker region contains a pelB
signal sequence for potential periplasmic localisation at the N-terminus and a His tag at the C-terminus to aid detection
and purification.
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Conditions in the periplasm are known to promote proper protein folding and
disulphide bond formation and so may enhance the solubility and activity of the
target protein (pET system manual, Novagen catalog 2006/2007). The target genes
were cloned into the pET-22b polylinker, downstream of the T7 promoter (Figure
3.3). The pET-22b vector carries an N-terminal pelB signal sequence which
facilitates periplasmic localization and a C-terminal HisTag sequence which aids
detection and purification (Figure 3.3). Cloning into the Ncol site places the gene
between the signal peptide and the HisTag.
The ThioFusion Expression system was designed to enhance the expression
of proteins which have proved insoluble or difficult to express in other bacterial
systems. Genes cloned in the ThioFusion expression system vector pTrxFus are
expressed as fusions to the E. coli protein thioredoxin (trxA) (Figure 3.5). Fusion to
thioredoxin can improve the solubility of many eukaryotic proteins expressed in
bacteria. In addition, thioredoxin fusions may have unique cellular locations, as
thioredoxin localises on Bayer's patches on the cytoplasmic side of the inner
membrane (Lunn, et ah, 1984), aiding purification by osmotic shock. However,
pTrxFus lacked an Ncol site and 6 x HisTag, so to make it compatible with the
chosen subcloning approach, and to aid in purification/detection, an oligonucleotide
linker (Figure 3.6) was inserted to extend the multiple cloning site and add a C-
terminal 6xHis affinity tag (G. Russell, unpublished data).
The plasmid pTrxFus uses a promoter (PL) from bacteriophage-?, to regulate
expression. Expression from pTrxFus is blocked when the bacteriophage-A. cl
repressor binds to the operator sequence adjacent to the Pl promoter (Figure 3.5).
The cl repressor gene is present in the chromosome of the E. coli cell host (GI 724)
and is regulated by the trp promoter. For transcription from the Pl promoter to
proceed, expression must be induced by the presence of Tryptophan. When E. coli
GI 724 cells are cultured in tryptophan-free medium, the cl repressor is transcribed
and binds to the PL promoter inhibiting transcription. However in the presence of the
tryptophan, cl repressor synthesis is repressed and transcription from the PL promoter
may occur (Figure 3.7). The target genes, once cloned into the plasmid are
transformed into the thioredoxin expression host (GI 724) to allow regulated
















Figure 3.4: Regulation of the lac promoter. T7 RNA polymerase is controlled by the lac promoter and
regulates transcription. Figure adapted from the pET expression system manual (Illustration adapted from
Novagen).
Figure 3.5: The pTrxFus vector for the thioredoxin expression system (Illustration taken from





Figure 3.6: Expression of the ThioFusion Expression system, induced by tryptophan. Illustration
adapted from Invitrogen ThioFusion Expression System manual.
Trx forward priming site
I
2997 GTG GGT GCA CTG TCT AAA GGT CAG TTG AAA GAG TTC CTC GAC
Val Pro Ala Leu Ser Lys Gly Gin Leu Lys Glu Phe Leu Asp
EK recognition site
I I I
3039 GCT AAC CTG GCC GGT TCT GGT TCT GGT GAT GAC GAT GAC AAG
Ala Asn Leu Ala Gly Ser Gly Ser Gly Asp Asp Asp Asp Lys a
Xma I EK cleavage site
Kpn I Sma I BamH I Nco I EcoRI 6 x His
3081 GTA CCC GGG GGA TCC A TG GAA TTC \CAT CAT CAT CAT CAT CAT]
Val Pro Gly Gly Ser Met Glu Phe His His His His His His
Sal I Pst\ aspA transcriptional terminator
3123 ATG TCG ACC TGC AGT AAT CGT ACA GGG TAG TAC AAA TAA AAA
Met Ser Thr Cys Ser Asn Arg Thr Gly
3165 AGG CAC GTC AGA TGA CGT GCC TTT TTT CTT GTG AGC AGT AAG
Trx reverse sequencing priming site
I 1
3207 CTT GGCACTGGC CGTCGT TTTA CAACGTCGTG
Figure 3.6: 6-HisTag Polylinker. A polylinker designed to add a 6 x His tag to aid
purification and detection was added between the Xmal and Sail sites of pTrxFus
(shown in italics). The linker also adds Nco I and Eco Rl sites for cloning in of
amplified OvHV-2 genes
3.1.1 Proteins selected for Expression
OvHV-2 ORF Ov8 is a positional homologue to EBV BLLFl (gp350/220),
KSHV/HHV-8 K8.1 and MHV-68 ORF51, which are known to encode glycoproteins
involved in binding to cellular receptors and therefore the Ov8 protein may play a
similar role. OvHV-2 Ov8 consists of two exons, with splice sites that are conserved
in the homologous ORF A8 of AlHV-l. Analysis of the OvHV-2 sequence identified
the presence of multiple potential splice sites in the Ov7 and Ov8 sequence, possibly
used to splice the sequences together. Sequence analysis of the Ov7/Ov8 region
shows the greatest homology with A7 and A8 of AlHV-l is located in distinct blocks
suggesting a possible significance to gene structure and function. The Ov7 sequence
contains a hydrophobic signal sequence but no membrane anchor, while the Ov8
sequence contains a hydrophobic membrane anchor but no obvious signal sequence
and therefore suggested the ORFs might form one gene, spliced together to produce
one protein product, namely a membrane glycoprotein (J. Rosbottom, PhD thesis.
University of Edinburgh 2005).
OvHV-2 ORF Ov9 encodes a protein homologous to the HHV-8 gene ORF
16, which has homology to cellular bcl-2. A number of viruses have been shown to
carry apoptosis-inhibiting genes which may play a role in aiding viruses escaping the
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host response. Homology between Ov9, ORF16 and members of the bcl-2 family
therefore suggests a prolonged life span of persistently infected cells (Neipel et al.,
1997). HHV-8 ORF16 has been used studied for possible use in a diagnostic assay.
An immunoblot assay, comprised of three HHV-8 recombinant proteins (ORF16,
ORF57 and ORF71) was used to test the seroprevalence of HHV-8 in Taiwan (Wang
et al., 2002).
ORF65 encodes a protein which is homologous to the HHV-8 small viral
capsid antigen (sVCA) ORF65, the EBV gene EFRF3 and to structural components
of other herpesviruses including VP26 of herpes simplex virus (HSV), herpes virus
saimiri (HVS) and a small capsid protein of human cytomegalovirus (CMV). These
proteins are assumed to share related biological functions (Lin et al., 1997) and it is
likely that OvHV-2 ORF65 has the same function. They are capsid proteins and
therefore likely to be expressed during the lytic cycle of viral replication. In EBV
infections, antibodies to the viral capsid antigen persist, so that any antibody
response to the capsid proteins is likely due to infection (Simpson et al., 1996). There
appears to be no antigenically cross-reactive response between HHV-8 ORF65 and
the EBV gene EFRF3, despite homology (Lin et al, 1997). The HHV-8 ORF65
protein is an immunogenic lytic cycle-associated protein (Simpson et al., 1996; Lin
et al., 1997). Herpesvirus virions share a characteristic architecture where the double-
stranded DNA genome is surrounded by an icosahedral protein capsid, a tegument
layer and a lipid bilayer envelope. The function of KSHV pORF65 is currently
unknown, although its position on the outer regions of the capsid suggests that, it
may regulate capsid-tegument interactions, in addition to possible DNA interactions.
As a means of identifying further potential antigens, the recent sequencing of
the OvHV-2 genome provides the opportunity to identify genes of interest for the
development of MCF-specific diagnostic reagents. It also allows the design of gene-
specific PCR primers to amplify, clone, express and study isolated viral proteins.
Seventy genes have been identified in the DNA sequence of OvHV-2, of which
twelve are considered unique to MCF viruses and three are unique to the OvHV-2
genome (Hart et al., 2007). These OvHV-2 unique genes are designated ORF Ov2.5,
ORF Ov3.5 and ORF Ov8.5 (Hart et al., 2007).
These genes were also selected as candidates for preliminary work due to
their unique nature, since they were less likely to cross-react with other viruses.
OvHV-2 ORF Ov2.5 encodes a 182-residue secreted protein, spliced from 5 exons,
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with homology to IL-10. It encodes a functional IL-10 molecule which may block
cytokine secretion by the proliferation of macrophages and mast cells (Stewart et al.,
unpublished data). In contrast, the ORF Ov3.5 gene encodes a 163 residue secreted
protein of unknown function, containing a putative signal peptide suggesting the
encoded protein is secreted from infected cells. ORF Ov8.5 encodes a 390 residue
protein with no similarity to any known protein (Hart et al., 2007).
Additionally, polypeptides likely to be exported or expressed on the cell
surface were selected as potential candidate antigens since they were more likely to
be exposed to the immune system. ORF Ov7, a positional homologue of the EBV
gene BZLF2, that encodes the glycoprotein g42 (Coulter et al., 2001), was selected.
The BZLF2 gene is involved in entry of virus into B cells via binding to HLA-DR
(Sprigs et al., 1996; Hart et al., 2007), and is thought to be involved in receptor
binding. Ov7 appears to encode the N-terminal part of this protein and may splice
with the Ov8a and b exons to form the complete Ov7/Ov8 glycoprotein.
This chapter describes the bacterial expression of selected OvHV-2 genes.
The expression of OvHV-2 genes ORF Ov8, Ov9 and ORF65 cloned in bacterial
expression vectors was demonstrated using western blotting with epitope-tag-specific
antibodies and anti-MCF antibodies in serum. Furthermore, genes Ov2.5, Ov3.5,
Ov7 and Ov8.5 were selected as candidates due to their unique nature and were
cloned and expressed to study the isolated viral proteins.
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3.2 Materials and Methods
3.2.1 Amplification/ Cloning of OvHV-2 Unique Genes
3.2.1.1 Primer Design and SignalP V2.0.
Primers for OvHV-2 genes; Ov2.5, Ov3.5, Ov7 and Ov8.5 were designed
with the program Primer 3 (Table 3.2) (URL: 1). OvHV-2 genes Ov8 Exon 1 2.1kb,
Ov9 and ORF65 were previously cloned into expression vectors (Russell and
Wiyono, unpublished data). Primers used to clone these genes are included in Table
3.2 for completeness. To create in-frame fusions when cloned into the expression
vectors all of the gene fragments were given terminal Ncol sites in which the central
ATG was in frame with the gene of interest.
OvHV-2 Start Stop Length A1HV-1% identity Possible Function
ORF codon codon (aa) (similarity)
Ov2.5 3081 3960 293 N/A 11-10 homologue
Ov3.5 6416 6907 163 N/A Unknown. Secreted?
Ov7 80406 80630 75 60 Glycoprotein
Ov8 2kb 81019 83209 - - Glycoprotein
Ov8 0.5kb 83209 83408 - 41 Glycoprotein
Ov8.5 117282 118454 390 N/A Unknown
Ov9 124941 125561 206 50 Bcl2 homologue
ORF65 108568 107933 211 41 Capsid protein
Table 3.1: OvHV-2 gene fragments, coordinates, similarity to AIHV-1 and
function. Gene start and stop positions are relative to OvHV-2 sequence
coordinates. Two Ov8 exon 1 fragments were used, based on different predicted
splice sites.
3.2.2. Expression Systems
Each OvHV-2 gene fragment was cloned into a TA vector (described in
section 2.4.7) to check that PCR-amplified sequences were correct prior to transfer
into expression vectors and transformation into the correct E. coli expression host.
All cloned fragments had Ncol sites in-frame at both ends and the vectors used had
C-terminal 6xHisTags for detection and purification. As this method was non-
directional, cloned fragments were subject to restriction analysis to define insert
orientation, using unique restriction sites in both the vector and insert. Restriction
91
Bacterial 1 Expression
enzymes (Promega) used include; Pst I (pTrxFus-ORF65, pET22b-Ov9, pET22b-
ORF65, PBAD-Ov9 and pBAD-ORF65), Kpn I (PTrxFus-Ov8 and PBAD-Ov8) and
Psp OMI (PET22b-Ov8).
Genes Signal Primer Orientation Sequence
Peptide coordinates
Ov2.5 Yes 3163-3180 Forward 5'-CCATGGTCCTCCCCCTACGAGGTAA-3'
3625-3651 Reverse 5'-CCATGGTGACCCCAAAGTAGCTTTCC-3'
Ov3.5 Yes 6483-6505 Forward 5'-CCATGGCCGCGGTAGACAGCTC-3'
6882-6907 Reverse 5'-CCATGGCAGGTGGGGACTGTTGAGG-3'
Ov7 Yes 80498-80521 Forward 5'-CCATGGCCCTCTACAGGCAGCTA-3'
80625-80649 Reverse 5'-CCATGGGGTAGCTGAACTCCACAC-3'
Ov8 No 81181-81200 Forward 5'-GGCGCGCCCATGGGGCCTGCGTACCCCAACTGA-3'
0.5kb 81651-81671 Reverse 5'GGCCGGCCCCATGGGCAGGTTGGTCAGTCGGTTAGG-3'
Ov8 No 81513-81527 Forward 5'-CTCTCCTGACGCGCCACCGTCCATGG-3'
2.1 kb 83613-83593 Reverse 5'-TCAGCCCATGGATCCG-3'
Ov8.5 No 117282-11703 Forward 5'-CCATGGTGTCCCGGCTTCCT-3'
118433-118456 Reverse 5'-CCATGGCAATAGACGGCGCCTGA-3'
Ov9 No 125435-125455 Forward 5'-CCATGGTGGAAGCTGGCATACT -3'
126043-126025 Reverse 5'-CCATGGCGCGTGTGCATAACAGAAGCA-3'
ORF65 No 109065-109044 Forward 5'-CCATGGCGTACGCCAGGCCTCG-3'
108447-108468 Reverse 5'-TCAGCCCATGGATCCCTTTTTGGGAGCTATGGGCT-3'
Table 3.2: OvHV-2 Primer sequences, primer orientation and signal peptide
prediction by SignalP 3.0 server (CBS prediction server) program and URL: 2.
Primer coordinates according to NCBI Blast, using the published sequence. Primer
sequences for Ov8 (2.1 kb), Ov9 and ORF65 were designed using an early
annotation of the OvHV-2 sequence.
3.2.2.1. pBAD/His Expression System
Escherichia coli LMG194 cells were transformed with pBAD or pBAD with
cloned OvFIV-2 genes. The transformants were grown in LB containing 2 ml/l
glycerol as the carbon source, supplemented with 50p.g/ml-carbenicillin, in conical
flasks at 37°C (225rpm). For expression, glycerol stock cultures of E. coli LMG194,
carrying pBAD-Ov8 Exon l 2.1 kb, pBAD-Ov9 and pBAD-ORF65 were used to
inoculate RM media (Appendix 1: 10ml containing 100p.g/ml ampicillin). Cultures
were incubated at 37°C (225rpm) until an OD6oo of 0.5 was achieved. Cultures were
induced with 0.2% L-arabinose and incubated at 37°C for optimum growth. Four
hours after induction, the inoculated cultures were centrifuged at 3000 x g for 10
minutes. The supernatant was removed and the cell pellet stored at -20°C.
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3.2.2.2. pET Expression System
Glycerol stock cultures of E. coli BL21 (DE3) carrying pET22b-Ov8 Exon 1
2.1 kb, pET22b-Ov9 and pET22b-ORF65 were used to inoculate LB media (10ml
containing 100p.g/mg Ampicillin). Cultures were incubated at 37°C (225rpm) until
an OD6oo of 0.6-1 was achieved. Cultures were induced, with either IPTG (0.4mM)
or the lactose-based Overnight Express™ Autoinduction System, and incubated at
37°C for optimum growth. Three hours after IPTG induction, the cultures were
harvested at 3000 x g for 10 minutes. The supernatant was removed and the cell
pellet stored at -20°C.
3.2.2.2.1. Overnight Express Autoinduction system (Novagen)
The Overnight Express™ Autoinduction Systems regulates protein
expression in E. coli without addition of the synthetic inducer IPTG during growth.
The overnight express autoinduction system is also intended to induce high-level
protein production in IPTG-inducible bacterial expression systems without the need
for monitoring of cell growth. Cell mass and target protein yield can be increased
several fold as compared with conventional protocols using induction with IPTG
(Novagen product user protocol TB363).
The Autoinduction system is comprised of three components: an induction
solution (OnEx™ Solution 1) a buffering solution (OnEx Solution 2) and a
magnesium solution (OnEx Solution 3). These three components allow regulated cell
growth while maintaining culture pH, enabling high levels of target protein
expression (Novagen user protocol, TB383 Rev. H. 1005).
Two hundred microlitres of the induction solution, 500pl of buffering
solution and 10pl of magnesium solution were added to 9.29ml L-broth (glucose
free), containing 100pg/ml ampicillin. The medium was inoculated with 10pl of
glycerol stock and incubated at 37°C for 16 hours, shaking at 225 rpm. Following
incubation, the cultures were centrifuged at 3000 x g for 10 minutes, and the cell
pellet stored at -20°C.
3.2.2.3. ThioFusion™ Expression System
The target genes, once cloned into the pTrxFus plasmid, were transformed
into the thioredoxin expression host (GI724) to allow regulated expression of the
fusion protein. Glycerol stock cultures of E. coli G1724 carrying pTrxFus-Ov8 Exon
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1 2.1 kb and ORF65 were inoculated onto RM Medium agar plates with ampicillin
(100|ug/ml) and incubated overnight at 30°C. Single colonies were used to inoculate
100ml induction medium (RM media with 20g casamino acids/1) containing
100p.g/mg ampicillin and the cultures were incubated at 30°C (225rpm) until an
OD550 of 0.5 was achieved. Cultures were induced with 100pg/ml tryptophan and
incubated at 37°C for optimum growth. Four hours after induction, the cultures were
harvested by centrifugation at 3000 x g for 10 minutes. The supernatant was removed
and the cell pellets stored at -20°C.
3.2.3. Expression Analysis
3.2.3.1. Preparation of cleared lysates for protein purification
In order to determine whether the expressed proteins were soluble, crude
extracts were made by mechanical lysis of bacterial cultures using an Eaton Press
pressure chamber. Cells were resuspended in lysis buffer (50 mM NaH2P04, 300
mM NaCl, 10 mM imidazole. pH 8.0) and placed into a chilled (-70°C) pressure cell.
The frozen pellet liquefies under pressure and passes from the upper chamber to the
lower chamber of the cell, the resulting rapid drop in chamber pressure causing cell
lysis. The cell lysates were collected and the insoluble debris pelleted by
centrifugation for 30 minutes at 11,250 x g. Sample aliquots were stored at -20°C.
3.2.3.2. Protein Miniprep of 6xHis-Tagged proteins from E. coli under
native conditions
Small-scale purifications of Flis-tagged fusion proteins were carried out on
lml of soluble protein lysates in order to test proteins present in the expressing cells.
This procedure was carried out in accordance with the manufacturer's instructions
(The QIAexpressionist 08/2002, Qiagen).
The cell lysate supernatants were centrifuged for 1 minute at 12000 x g to
remove any cellular debris and were transferred to a fresh 1.5ml microcentrifuge
tube. 20pl of a 50% slurry of Ni-NTA resin (Ni-NTA Agarose, Qiagen) was added to
lml cell lysate and mixed gently for 30 minutes at 4°C. The mixture was then
centrifuged for 10 seconds at 1000 x g to pellet the resin and the supernatant was
removed and kept. The pelleted resin was washed twice in 100pl of wash buffer (50
mM NaH2P04, 300 mM NaCl, 20 mM imidazole. pH 8.0) to remove unbound and
weakly interacting proteins. The supernatant from each wash was stored at -20°C.
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Bound proteins were then eluted by washing three times in 20pl elution buffer (50
mM Naf^PC^, 300 mM NaCl, 250 mM imidazole. pH 8.0). The resulting
supernatants were removed and combined. Both the remaining Ni-NTA slurry pellet
and all supernatants were stored at -20°C.
3.2.3.3. Gel Filtration - Superdex200
As an alternative to purification using the Ni-NTA resin, gel filtration was





Three different expression vectors were used for the expression of OvHV-2
recombinant proteins, each encoding a 6-histidine tag to facilitate protein
purification: (i) pBAD/His (Invitrogen), (ii) pET-22b (Novagen) and (iii) pTrxFus
(Invitrogen). Results of bacterial expression systems tested are summarised in table
3.3, and described in detail in section 3.3.2-3.3.5.
Cloning of the OvHV-2 genes was accomplished by using OvHV-2 genomic
DNA as the template for PCR-based amplification with appropriate oligonucleotide
primers carrying terminal Ncol sites. The PCR products were cloned into Ncol sites
of each selected vector. Of all of the gene/vector combinations selected, only the
Ov9-pTrxFus cloning was unsuccessful, despite several attempts (Russell & Wiyono,
unpublished finding). Analysis of several clones from these attempts showed a
significant level of rearrangement when Ov9 was cloned into pTrxFus, therefore
pTrxFus-Ov9 was considered unviable.
OHV-2 Possible functions Bacterial Soluble (S) or Purified
gene Expression Insoluble (I)
Ov2.5 IL-10 homologue PT I ND
Ov3.5 Unknown. Secreted? X X ND
Ov7 Glycoprotein PT I ND
Ov8 (2.1kb) Glycoprotein pB, pE, pT I X
Ov8 (0.5kb) Glycoprotein PT s X
Ov8.5 Unknown X X X
Ov9 bcl2 family X X ND
ORF65 Capsid protein pB, pE, pT s Enriched
Table: 3.3: Summary of OvHV-2 gene functions, bacterial expression systems
tested, solubility and purification. pB represents the pBAD expression system, pE
represents the pET expression system (pET-22b) and pT represents Thioredoxin
expression system (pTrxFus). x indicates unsuccessful expression or purification,
ND - not done.
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3.3.2. pBAD Expression System:
3.3.2.1. OvHV-2 Ov8 Exon 1 2.1 kb, Ov9 and ORF65 in the pBAD/His
Vector
OvHV-2 clones in the pBAD expression vector were analysed in E. coli strain
LMG194. Cultures of each clone, together with the empty pBAD vector, were grown
and induced by the addition of L-arabinose. Cells were harvested four hours after
induction. Samples of induced cultures were lysed in 2x SDS loading buffer and 10pl
of diluted supernatant (1:2) from each lysate was electrophoresed on a 10%
NuPAGE tris-glycine polyacrylamide gel. The gel was stained with Coomassie blue
stain. No obvious bands for pBAD-Ov8 Exon 1 2.1 kb, pBAD-Ov9 or pBAD-ORF65
were distinguished, indicating no protein over-expression (Figure 3.8a).
A western blot was performed using an anti-HisTag monoclonal antibody, to
determine whether any recombinant protein was present (Figure 3.8b). The pBAD
vector alone expressed a single polypeptide at approximately 16kDa representing a
45 residue polypeptide encoded by the empty vector. pBAD-Ov8 Exon 1 2.1 kb
expressed two bands at approximately 80kDa and lOOkDa (expected size 80kDa),
while pBAD-ORF65 expressed a single band at approximately 25kDa, with an
expected size of 28kDa. No expression was observed for pBAD-Ov9, which has an
expected size of 25kDa (Figure 3.8b).
3.3.2.2. pET Expression System:
3.3.2.2.1. OvHV-2 Ov8 Exon 1 2.1 kb, Ov9 & ORF65 in the pET-22b Vector
OvHV-2 clones in the pET-22b expression vector were analysed in E. coli
strain BL21 (DE3). Ten millilitre cultures of each clone, together with the empty
pET22b vector, were grown in LB media, and induced by 1PTG (0.4mM), while
replicate cultures were induced by the Overnight Express system (Novagen).
Samples of induced cultures were lysed in SDS loading buffer at equivalent cell
densities and lOpl of each crude extract were electrophoresed on 10% NuPAGE tris-
glycine gels. The gels were stained with Coomassie blue stain or transferred to
nitrocellulose for antibody staining (Figure 3.9.). No obvious pET22b-Ov8 Exon 1
2.1 kb (80kDa), pET22b-Ov9 (25kDa) or pET22b-ORF65 (28kDa) bands were
distinguished, indicating no obvious protein over-expression.
To confirm the presence of pET22b-Ov8 Exon 1 2.1 kb, pET22b-Ov9 and
pET22b-ORF65 His-tagged proteins in the lysates, a western blot using anti-HisTag











Figure 3.8a: Electrophoretic analysis of pBAD expression. Total cell lysates
(10pl) of bacteria containing plasmids pBAD-Ov8, pBAD-Ov9, pBAD-ORF65 were
separated by electrophoresis on a 10% NuPAGE Novex tris-glycine gel and stained
with Coomassie blue. Bacteria containing the empty pBAD vector (pB) were present
















Figure 3.8b: Chemiluminescent analysis of pBAD expression system
Whole bacterial lysates (20jliI) containing pBAD plasmids pBAD-Ov8, pBAD-Ov9
and pBAD-ORF65 were separated by electrophoresis, on a 10% NuPAGE Novex
tris-glycine gel, together with the pBAD empty vector (pB) and pTrxFus-orf65
(pT65), present as controls. The lysates were analysed by western blotting using
anti-HisTag antibody as a primary antibody followed by anti-mouse HRP conjugate.
The bound conjugate was detected by chemiluminescence using the Pierce
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Figure 3.9: Electrophoretic analysis of total cell lysates from pET system.
Ten microlitres (duplicate) of whole bacterial lysate for pET22b-Ov8, pET22b-Ov9,
pET22b-ORF65 and the pET-22b vector (v), induced by either IPTG (a and b) or the
Overnight Express (OE) Autoinduction System (c and d). Proteins were separated
on a 10% NuPAGE Novex tris-glycine gel and were either stained with Coomassie
blue (a & c) or analysed by western blot (b & d) using an anti-HisTag monoclonal
antibody and visualised with chemiluminescence using the Pierce Supersignal
ELISA femto HRP substrate.
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non-specific bands but no OvHV-2 protein bands were seen. The His-tagged
thioredoxin control and pTrxFus-ORF65 were detected on the gel containing the
overnight express system-induced cultures suggesting induction of pTrxFus was
more efficient by over night expression.
Repeating the standard IPTG induction method, a western blot of the gene
products was carried out. pET22b-Ov9 and pET22b-ORF65 gene products showed
no His-Tagged bands, while the pET22b-Ov8 Exon 1 2.1 kb crude lysate showed two
bands, of approximately 80kDa and lOOkDa in size (Figure 3.10). A possible
explanation for the two bands may simply be that the pET22b-Ov8 Exon 1 2.1 kb
protein has been cleaved into two stable products, with and without the vector-
encoded leader peptide sequence (21aa). However, the size difference of 30kDa
suggests a larger fragment may be cleaved off the Ov8 fragment. The Ov8 gene was
also cleaved in the pBAD system, implying this occurs within the Ov8 sequence. In
the pET-22b expression system only the OvHV-2 cloned Ov8 fragment expressed a
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Figure 3.10: IPTG induced gene products. Total bacterial cell lysates from
bacteria containing pET22b plasmids pET22b-Ov8, pET22b-Ov9, pET22b-ORF65
were separated by electrophoresis on a 10% NuPAGE Novex tris-glycine gel, and
analysed by western blot using an anti-HisTag monoclonal antibody and visualised
with chemiluminescence using the Pierce Supersignal ELISA femto HRP substrate.
Bands present were compared to a protein marker (15-150kDa). pTrxFus-ORF65
was used as a positive control.
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3.3.2.2.2. Batch purification of pET-22b Ov8
Since initial pET-22b-Ov8 Exon 1 2.1kb extracts showed an expressed His-
tagged protein, a second batch of pET22b-Ov8 Exon 1 2.1 kb culture (50ml) was
grown to analyse the presence of expressed pET22b-Ov8 protein. The cells were
mechanically lysed and a western blot was performed using anti-HisTag monoclonal
antibody (Figure 3.11).
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Figure 3.11a, b & c: Chemiluminescent western blot to determine solubility of
pET22b-Ov8 gene product. Ten microlitres of bacterial lysate containing pET22b-
Ov8 a) whole cell crude lysate and b) cell pellet was separated by electrophoresis
on a 10% NuPAGE Novex tris-glycine gel, were analysed by western blotting, using
anti-HisTag monoclonal antibody as a primary conjugate, c) To aid solubility, 50pl of
the insoluble gene product was treated with two concentrations of urea (4M and
8M). The numbers given to each samples represent different OvHV-2-pET22b-Ov8
clones. The blot was visualised with chemiluminescence using the Pierce
Supersignal ELISA femto HRP substrate and any bands compared to a 15-150kDa
protein marker.
The pET22b-Ov8 Exon 1 2.1 kb soluble lysate showed some background but
no over-expressed protein in the expected position (Figure 3.1 la). The cell pellet had
a signal near the expected position (Figure 3.1 lb) but no clear bands were seen. This
suggested that the pET22b-Ov8 Exon 1 2.1 kb protein was insoluble and reduced
poorly on SDS-PAGE polyacrylamide gels. Concentrated urea solution (8M) was
used to dissolve the cell pellet. 20pil aliquots of the urea-treated samples were then
electrophoresed on a 10% NuPAGE tris-glycine gel and a western blot was
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performed, using anti-HisTag antibody (Figure 3.11c). In this case high background
was seen in the low molecular weight part of the gel but no clear over-expressed
pET22b-Ov8 Exon 1 2.1kb bands could be distinguished. The proteins may have
solubilised to a certain extent in the presence of concentrated urea, although most of
the signal in the soluble urea material seemed to be due to low molecular weight
proteins or fragments. It is therefore possible that the pET22b-Ov8 Exon 1 2.1 kb
product was essentially insoluble. Alternatively, the western blot may not have
worked properly, as indicated by the high background when compared by western
blots such as figure 3.11a.
3.3.2.3. ThioFusion Expression System
3.3.2.3.1. OvHV-2 ORF Ov8 Exon 1 2.1 kb & ORF65 in the pTrxFus Vector
pTrxFus carrying the OvHV-2 Ov8 Exon 1: 2.1 kb and ORF65 genes in E.
coli GI724 and the empty pTrxFus vector, were grown in 10ml cultures, in RM
media until an OD55o of 0.5 was reached. The cultures were induced by the addition
of lOOpg/ml tryptophan. Cells were harvested four hours after induction. Bacterial
lysates were prepared in SDS loading buffer and lOpl of each lysate was
electrophoresed on a 10% NuPAGE bis-tris polyacrylamide gel. The gel was stained
with Coomassie blue stain (Figure 3.12a). No obvious bands at the expected size for
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Figure 3.12a: Coomassie blue stained gel of total cells lysate extracts from
Thiofusion expression system cultures. Samples of bacterial cultures containing
the vector, pTrxFus-Ov8 and pTrxFus-ORF65 were taken at hourly intervals after
induction with Tryptophan (1-4 hours) were electrophoresed on a 10% NuPAGE




To determine whether the pTrxFus, pTrxFus-Ov8 Exon 1 2.1kb and pTrxFus-
ORF65 protein were found in the soluble phase, the induced cultures (4 hours
induction with L-arabinose) were mechanically lysed and the soluble fraction was
analysed on a western blot, using an anti-HisTag monoclonal antibody (Figure
3.12b). The pTrxFus vector and pTrxFus-Ov8 Exon 1 2.1kb expressed a single His-
tagged band at approximately 16.5kDa, the size expected for unfused thioredoxin,
while pTrxFus-ORF65 expressed a single band at approximately 32kDa, the size
expected for the ORF65 fusion. So pTrxFus and pTrxFus-ORF65 expressed a soluble
band of the expected size, while pTrxFus-Ov8 Exon 1 2.1kb showed a band of the
same size as thioredoxin. One explanation for the inconsistency regarding the
pTrxFus-Ov8 Exon 1 2.1kb fusion protein could be that the Ov8 clones do not have
the correct insert, or that the insert has been deleted. Alternatively, it may suggest a
problem with the expression of the pTrxFus-Ov8 Exon 1 2.1kb gene product or




Figure 3.12b: Western blot of Thiofusion expression system crude extracts.
Twenty micrograms of crude lysate pTrxFus-Ov8 and pTrxFus-ORF65 (> 4 hours
after induction with Tryptophan) were electrophoresed alongside the pTrxFus empty
vector (pT), present as a control. The electrophoresed protein lysate was analysed
by western blotting using anti-HisTag antibody as a primary antibody followed by
anti-mouse HRP conjugate. The bound conjugate was detected by
chemiluminescence using the Pierce Supersignal ELISA femto HRP substrate.
3.3.2.3.2. Ni-Resin Purification
To isolate target pTrxFus-Ov8 Exon 1 2.1kb and pTrxFus-ORF65 His-tagged
proteins, affinity purification was performed. Purification of the pTrxFus-Ov8 Exon
1 2.1kb and pTrxFus-ORF65 his-tagged soluble lysate was attempted using a nickel
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affinity resin purification technique. Ten microlitres of each wash and eluent, along
with the resin-bound residue, were subjected to electrophoresis on a 10% NuPAGE
bis-tris gel. The gel was stained overnight with Coomassie blue stain (Figures 3.13).
The soluble crude lysates of each sample were heavily loaded but no over-
expressed bands could be distinguished (Figure 3.13), suggesting all proteins are
bound to the column. Although the lysate has undergone a ten-fold dilution, the
bands in the crude extract are only faintly visible in the unbound supernatant,
suggesting most proteins in the lysates bound to the resin.
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Figure 3.13: Ni-NTA resin purification of pTxfus fusion proteins Ov8 and
ORF65. Purification of pTrxFus fusion proteins. Extracts from pTrxFus-Ov8 (08) and
pTrxFus-ORF65 (65), electrophoresed on a 10% NuPAGE" Novex bis-tris gels and
stained with Coomassie blue stain. The crude lysate shows a high level of protein
expression, while wash fractions and elution stages of the purification show a low
level of protein expression suggets the majority of protein remained bound to the Ni-
NTA resin. The empty pTrxFus vector (pT) was used as a control.
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An enriched protein band at 16.5kDa was clearly visible in the pTrxFus and
pTrxFus-Ov8 Exon 1 2.1kb eluent, while no enriched/purified band for pTrxFus-
ORF65 was obvious (Figure 3.13). pTrxFus-Ov8 shows unfused thioredoxin. The
resin-bound residue for pTrxFus and pTrxFus-Ov8 Exon 1 2.1kb showed non¬
specific background with an enriched protein band at 16.5kDa (Figure 3.13). The
presence of thioredoxin on the agarose beads was probably due to the high level of
expression and to difficulties eluting bound protein, using a simple batch method.
pTrxFus-ORF65 was not seen on the resin, presumably because there was possibly
either less bound protein or that it eluted better. Therefore while there was
enrichment of unfused thioredoxin derived bands in the eluent, there was no obvious
band representing pTrxFus-ORF65. Although this result may reflect a lower
expression level of the pTrxFus-ORF65 fusion in this system, expression of this
fusion protein in soluble form was clearly shown in the crude lysate (Figure 3.12b).
This result suggests there may have been a problem with the purification of the
protein by affinity purification methods, resulting in a low level of binding in the
eluted fraction, after being exposed to the nickel resin. A possible explanation for
this lack of protein binding may be a result of protein remaining bound to the
chelating metal resin agarose beads.
To confirm the presence of the His-tagged proteins, a western blot, using
anti-HisTag antibody, was performed (Figure 3.14a, b) on samples from the
purification procedure. A distinct band was observed in each of the crude lysate
samples analysed, indicating all samples contained expressed, His-tagged protein (as
seen in figure 3.12). pTrxFus and pTrxFus-Ov8 Exon 1 2.1kb wash supernatant
(unbound) showed a single 16.5kDa band, suggesting a proportion of these proteins
had not bound to the resin. No bands were observed in the pTrxFus-ORF65 wash
(Figure 3.14a). This probably reflected the relative expression level of each protein
and the ability of the resin to bind all of the His-tagged protein from each extract.
Eluted pTrxFus and pTrxFus-Ov8 Exon 1 2.1kb samples showed strong bands at
16.5kDa, representing enriched proteins, and this corresponded to the results of the
Coomassie stained gel (Figure 3.13). Additionally, pTrxFus-ORF65 was seen at
32kDa, with a weak band visible at 25kDa. This was clearly enrichment, but not a
clean purification since no distinct band of 32kDa was seen in figure 3.13.
Furthermore, the 25kDa band in the pTrxFus-orf65 eluent suggests that some
of the bound protein may have been degraded. The resin-bound residues of pTrxFus
and pTrxFus-Ov8 Exon 1 2.1kb showed HisTag positive bands at 16.5kDa, while the
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pTrxFus-ORF65 resin showed a strong band at 32kDa, suggesting that in all 3 cases
some of the bound protein was not eluted from the Ni-NTA resin.
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Figure 3.14: Chemiluminescent western blot of Ni-NTA purification.
pTrxFus-0v8 and pTrxFus-ORF65, electrophoresed on a 10% NuPAGE Novex bis-
tris gel, were analysed by western blotting using HisTag antibodies (a & b) and Anti-
Thio antibodies (c & d). The pTrxFus empty vector (pT) was present as a control.
Blots were visualised with chemiluminescence using the Pierce Supersignal ELISA
femto HRP substrate.
A western blot was also performed using anti-Thio antibody. The Anti-Thio
antibody detects thioredoxin (Figure 3.14c, d), binding to the N-terminal end of the
fusion proteins. This antibody was used to test whether the thioredoxin domain was
present on each fusion or degraded. As before, the same banding pattern was
observed with the exception that three bands (32kDa, 25kDa and 16.5kDa) were
observed in the pTrxFus-ORF65 crude extract sample further confirming that the
pTrxFus-ORF65 fusion was sensitive to degradation and that the thioredoxin
fragment of the fusion appeared to be one of the degradation products. Thus, both the
anti-HisTag antibody and the anti-Thio antibody show similar sized bands at 32kDa
and 25kDa, while the anti-Thio antibody showed an extra band at around 16kDa
suggesting degradation of the His-Tagged thioredoxin-orf65 protein. The HisTag is
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located on the C-terminus of the protein, while the anti-Thio epitope is located at the
N-terminus. The bands at 32 and 25kDa are likely a result of N-terminal degradation
since the HisTag is still present. However, cleavage to release the anti-Thio epitope
may also occur, as the 16kDa band is only deleted by the anti-Thio antibody.
Furthermore, a weak pTrxFus-Ov8 Exon 1 2.1kb band was visible at 25kDa
in the wash and eluent using anti-Thio antibody, which was not seen in the His-Tag
blot. This may indicate proteolysis of the fusion protein within the Ov8 segment. The
lack of a band at the expected size from the pTrxFus-Ov8 Exon 1 2.1kb construct
(80kDa) again suggests that the Ov8 clones prepared have an incorrect insert or
indicate a problem during expression. Therefore, the structure of the pTrxFus-Ov8
Exon 1 2.1kb from constructs was checked by digestion with restriction enzymes.
3.3.2.3.3. Analysis of pTrxFus Ov8 Exon 1 2.1 kb construct
Analysis of the Ov8 Exon 1 2.1kb clones within the three expression systems
highlighted a problem with the Ov8 insert. The pBAD and pET expression systems
show two bands at 80 and lOOkDa, rather than the single band expected. Possible
explanations for the expression of two bands may indicate the Ov8 has been cleaved.
As this cleavage was shown in both expression systems it indicates the Ov8 sequence
rather than the expression vectors is responsible. Further demonstration of an
inconsistency within the Ov8 Exon 1 2.1kb sequence was shown using the
thioredoxin expression system, as only a band representing the empty thioredoxin
vector was observed. This result confirmed an irregularity within the Ov8 clones and
suggests possible deletion of the insert. Therefore, to check that the pTrxFus-Ov8
Exon 1 2.1kb construct contained an insert of the correct size, pTrxFus-Ov8 Exon 1
2.1kb samples from four independent glycerol stocks in E. coli expression strain
GI724 (pTrxFus) were used to prepare plasmid DNA for restriction enzyme analysis.
The plasmid DNA was digested with Ncol, which was used to insert the Ov8
fragment, and electrophoresed on a 0.8% agarose gel (Figure 3.15).
The pTrxFus vector showed a single band of 4kb. The four independent
pTrxFus-Ov8 Exon 1 2.1kb isolates all showed the same two bands, a 4kb vector
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band and a 2kb band corresponding to the Ov8 insert (2085bp). For comparison,
pTrxFus-ORF65 showed a 4kb vector band and a 600bp band corresponding to the
ORF65 insert. Thus all of the constructs used, and all of the pTrxFus-Ov8 Exon 1
2.1kb isolates tested, had the expected structure. This did not explain the discrepancy
between the observed size of the anti-Thio and anti-HisTag reactive band and the
predicted size of the Ov8 thioredoxin fusion as the DNA appears intact.
A possible explanation for this discrepancy may simply be that the pTrxFus-
Ov8 Exon 1 2.1kb protein is rapidly degraded into two stable products of similar
size, one containing the N-terminal thioredoxin epitope and the other containing the
C-terminal HisTag epitope. This is supported by the detection of a small amount of a
24kDa band in the elution sample of pTrxFus-Ov8 Exon 1 2.1kb which is evidence





Figure 3.15: Analysis of thioredoxin protein fusions.
DNA was prepared from glycerol stocks using a QIAGEN miniprep kit. DNA from
pTrxFus-Ov8 and pTrxFus-ORF65 gene products were digested with restriction
endonuclease enzyme Ncol and electrophoresed on a 0.8% agarose gel alongside
a 1 kb DNA ladder. The empty pTrxFus (pT) vector was present as a control. The
numbers given to each DNA sample represent different glycerol stocks.
3.3.2.3.4. Batch purification of pTrxFus ORF65
Since the initial purification of pTrxFus-ORF65 showed possible degradation,
a second batch of pTrxFus-ORF65 culture was mechanically lysed in the presence of
Complete (TM) EDTA-free protease inhibitors (Roche) to minimise degradation.
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pTrxFus-0v8 Exon 1 2.1kb was not tested under these conditions due to insolubility.
When a cell is disrupted, proteases are released that can degrade any proteins. This
degradation results in a reduced protein yield during isolation and purification.
EDTA-free protease inhibitors were used as they do not affect the stability or
function of metal-dependent proteins (i.e. the HisTagged proteins).
A western blot (Figure 3.16), using anti-HisTag monoclonal antibody, was
employed to analyse the presence of pTrxFus-ORF65 protein in the pellet and
supernatant of the crude lysate. The pTrxFus cell pellet contained a high level of
insoluble thioredoxin protein with a main band of approximately 16.5kDa. This may
reflect solubility of His-Tagged thioredoxin, or incomplete cell lysis. The soluble
lysate showed two bands of approximately 16.5kDa and 30kDa. This may indicate
aggregation of thioredoxin in the presence of protease inhibitor or the effect of
EDTA. Interestingly, the pTrxFus-ORF65 cell pellet also showed two bands of
approximately 25kDa and 32kDa in size, while the soluble lysate showed a single
band at the expected size of 32kDa. The absence of the second band may indicate
that the degraded protein fragments remained insoluble. These results suggest that
the pTrxFus-ORF65 thioredoxin fusion is found mainly in the pellet material and is
subject to degradation.
Figure 3.16: Chemiluminescent western blot of pTrxFus-ORF65 soluble and
insoluble fractions. Ten microlitres of soluble and insoluble pTrxFus-ORF65
bacterial extract was electrophoresed alongside samples from pTrxFus extracts,
present as a control (pT). The electrophoresed protein was analysed by western
blotting using anti-HisTag primary antibody and visualised with chemiluminescence
using the Pierce Supersignal ELISA femto HRP substrate.
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Larger scale crude lysates of His-tagged pTrxFus and pTrxFus-ORl'65 were
purified using the nickel resin batch purification technique. The crude lysate. wash,
eluant and resin-bound residue were run on a 10% tris-glycine gel and stained with











Figure 3.17a: pTrxFus ORF65 Ni-NTA purification. Ni-NTA resin purified
pTrxFus-ORF65 and pTrxFus samples (10pil) were electrophoresed on a 10%
NuPAGE® Novex bis-tris gel and stained overnight in Coomassie blue stain. The gel
shows the four stages of Ni-NTA resin; (a) represents the untreated crude lysate (b)
represents samples in the wash fraction, while (c) and (d) represents the first and
third elution steps.
The pTrxFus crude lysate was heavily loaded, so no over-expressed band
could be distinguished. However, thioredoxin (16.5kDa) was visible in the wash
fraction suggesting it was highly over-expressed in this experiment and did not all
bind to the resin or was not tightly bound and washed off. This band was also seen in
the eluents, especially in the second eluent (Figure 3.17a) lane d where it is the only
band visible. These results corresponded with those in the western blot (Figure
3.17b). In contrast, there was no obvious purification of the pTrxFus-ORF65 fusion
protein on the stained gel (Figure 3.17a) with the wash and elution lanes not looking
significantly different (Figure 3.17a). The western blot showed two visible bands at
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25kDa and 32kDa in the pTrxFus-ORF65 crude lysate and wash-supernatant. The
wash-supernatant was 10 times more dilute than the lysate, with only 10% of the
overall fraction being used, while the eluent was 500 times more dilute than the
lysate, with 50% of the total being loaded onto the gel. It is clear that for ORF65 the
elution contains less total protein than the wash, but clearly has more His-tag signal
on the blot. pTrxFus-ORF65 appears to have been enriched. Interestingly, no bands
were visible in lane four, the final eluent, although two strong bands were visible in
the previous eluent suggesting all of the protein had eluted early. Thus while
pTrxFus appeared to be significantly purified by this method, pTrxFus-ORF65 was
only enriched by Ni-NTA but not purified. This may reflect a lack of stringency in
the wash procedure employed or the availability of the HisTag for binding to the
resin in this fusion protein, in addition to the poor expression of the pTrxFus-ORF65
fusion. It is also clear (Figure 3.17a) that the ORF65-thioredoxin fusion was less well
expressed than thioredoxin alone, and that other proteins bind to the resin and were
seen in the eluant. With thioredoxin, all other Ni-NTA binding proteins appeared to
be competed off the column.
Figure 3.17b: Chemiluminescent western blot of pTrxFus ORF65 Ni-NTA
purification. Ni-NTA purified pTrxFus-orf65 (1 Opel) was electrophoresed alongside
Ni-NTA purified pTrxFus (pT), present as a control. The electrophoresed protein was
analysed by western blotting using anti-HisTag antibody as a primary conjugate, and
was visualised with chemiluminescence using the Pierce Supersignal ELISA femto
HRP substrate. The western blot shows four stages of Ni-NTA resin; (a) represents
the crude lysate (b) represents wash fractions (c) and (d) represents the first and
third elution steps.
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3.3.3. Review of OvHV-2 sequence
As the candidate genes initially selected could not be expressed due to
showed solubility and purification problems, new candidates were sought that might
prove more successful for protein expression and purification. The sequencing of the
A1HV-1 and OvHV-2 genomes identified about 12 genes unique to the MCF viruses.
Of these genes, four were unique to the OvHV-2 genome (Hart el al., 2007) and ma>
also be good candidates for developing OvHV-2 specific reagents. These genes were
selected, since their protein products would be less likely to cross-react with other
viruses. In addition, polypeptides likely to be exported or expressed on the cell
surface were preferred since they might be more likely to be exposed to the immune
system.
Gene Length Tm % Orientation Product Sequence
(bp) GC size (bp)
Ov2.5 25 67.9 60 Forward 879 V C'C'ATGGTC •( T('(•( •( < "f A< (. AC i< 11 -X A •
26 66.4 53.8 Reverse 5 C'C'ATGGTG AC'('('( A A AC i'l XGC ri l l ( 5
Ov3.5 22 67.7 68.2 Forward 400 5 C'C'ATGGC'C 'GC 'GGT AG AC AGC T( c
25 69.5 64.0 Reverse 5 GC ATGGC AGGTGGGGAC TG ITG AGG >
Ov7 23 66.0 60.9 Forward 128 5 ('('ATGGCCCT( 'TA( AC Kit AGC 1 A >
24 66.0 58.3 Reverse V ( ( A I'GGGGI AC >( K, A AC "IX CM Al 1
Ov8.5 20 63.5 65 Forward 1151 5' C'C'ATGGTG TC C'C'CiC 1C "1T( C "1 1
23 66 60.9 Reverse 5 -C'C'ATGGC'AA'l'AG AC C1GC (rCC I'G A 1
Table 3.4: PCR Primer sequences. Primers were designed using Primer3,
excluding transmembrane or signal sequences as defined by SignalP. All primers
included terminal in-frame Ncol sites for cloning and gene fusion.
Using Primer3 (release 1.0: URL 1), primers were designed for OvHV-2
genes Ov2.5, Ov3.5, Ov7 and Ov8.5 (Tables 3.2 and 3.4), excluding predicted
transmembrane or signal sequences in order to improve solubility of the expressed
products. All sequences analysed showed 100% homology to the QvHV-2 sequence.
Signal peptides were assigned using the signal peptide prediction server. SignalP
(version 2.0: URL 2). PCR reactions were performed using the designed primers and
genomic DNA purified from the infected cattle cell line BJ 1035 (Hart a al., 2007).
Because Ov2.5 is a spliced gene, cDNA was used as the PCR template to provide a
continuous open reading frame suitable for expression in bacterial systems (Figure
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3.18c). Using the KOD Hot Start DNA polymerase (Novagen), PCR reactions were
optimised for each primer pair by adjusting the magnesium ion concentration and the
annealing temperature. A gradient PCR was performed, whereby temperatures
ranging between 55.5 and 70°C were analysed for each gene product (Figure 3.18a &
c). The optimal annealing temperature for Ov2.5, Ov3.5 and Ov7 was 60°C, while
the optimal annealing temperature for Ov8.5 was 72°C. In addition four different
magnesium concentrations were analysed, 0.5mM, l.OmM, !.5mM and 2.0mM











































Figure 3.18: PCR Optimisation.
DNA (cDNA in case of Ov2.5) from the cell line BJ1035 was used as a template for
PCR, using primers designed to amplify specific areas of Ov2.5 (463), Ov3.5
(400bp), Ov7 (128bp) and Ov8.5 (1151 bp) gene sequences. Primers were optimised
by performing (a) annealing temperature gradient PCR and (b) Mg++ titrations. cDNA
from BJ1035 was used as a template for Ov2.5. Annealing temperatures
investigated ranged from 55.5°C to 70.3°C, with increasing annealing temperatures
from 1-12 for each gene. Mg++concentrations analysed were 0.5mM (1), 1.0mM (2),
1.5mM (3) and 2.0mM (4). The PCR products were analysed by agarose gel
electrophoresis alongside a 1 kb DNA ladder (Hyperladder I, Bioline).
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Figure 3.19: Gel Extraction of PCR products
OvHV-2 ORF Ov2.5 (Spliced: Ov2.5p and Ov2.5c represents two different spliced
PCR products), Ov3.5, Ov7 and Ov8.5 purified PCR products. DNA samples were
prepared using QIAGEN gel extraction and PCR purification techniques and
concentrated by ethanol precipitation. The PCR products (1 Ojul) were analysed by
electrophoresis on a 0.8% agarose gel, alongside a 1 kb DNA ladder (Hyperladder I,
Bioline).
Following extraction the samples were concentrated by ethanol precipitation
prior to ligation into the pGEM-T easy vector and transformation into J Ml 09
competent cells. Plasmid minipreps of colonies with possible inserts were prepared
and the presence of inserts was confirmed by restriction digestion with EcoRl. Of 32
colonies analysed in this way, one colony with Ov2.5p insert (partially spliced), 5
colonies with Ov2.5c insert (completely spliced), 11 colonies with Ov3.5 insert, 3
colonies with Ov7 insert and 11 colonies with Ov8.5 insert were obtained (Figure
3.20).
Ten colonies were sequenced of which: 1 colony represented Ov2..\, I
colony represented Ov7; and 4 colonies each represented Ov2.5p and Ov.3.5
(highlighted in figure 3.20). Sequencing results confirmed the presence of insert
without any PCR errors in all colonies analysed.
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Figure 3.20: DNA miniprep analysis
DNA prepared from bacterial clones using a QIAprep spin miniprep kit. The DNA
was digested with EcoRI and the products electrophoresed on a 0.8% agarose gel
alongside a DNA marker (M). For Ov2.5 clones Ov2.5p represents partially sliced
insert and Ov2.5c represents completely spliced insert. Highlighted numbers
indicate colonies selected for sequencing. Positive (+) and negative (-) TA-cloning
controls were also included.
3.3.4. pTrxFus OvHV-2 Ov2.5, Ov3.5, Ov7 & Ov8.5
Ncol-digested insert DNA from OvHV-2 Ov2.5, Ov3.5, Ov7 and Ov8.5 clones was
ligated into the pTrxFus expression vector. Plasmid DNA carrying verified inserts
were transformed into E-coli G1724, the expression host for this vector. Cultures of
each clone were grown to an OD55o of 0.5 at 30°C then induced by the addition of
lOOjxg/ml tryptophan. Cells were harvested four hours after induction. Samples of
induced cultures were lysed in SDS loading buffer and 10pl of each lysate was
electrophoresed on a 10% NuPAGE bis-tris polyacrylamide gel. The gel was stained
with Coomassie blue stain (Figure 3.21). No obvious bands for any of the genes;
pTrxFus-Ov2.5, pTrxFus-Ov3.5, pTrxFus-Ov7 or pTrxFus-Ov8.5 were
distinguished, indicating no protein over-expression.
To identify whether pTrxFus-Ov2.5, pTrxFus-0\3.5. pTr\Fus-()\7 and
pTrxFus-Ov8.5 were expressed in the crude lysates, the electrophoresed protein
lysate was analysed by western blotting using anti-HisTag antibody as a pnmar\
antibody followed by anti-mouse FIRP conjugate (Figure 3.21b). The pTrxFus vector
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expressed a single His-tagged band at approximately 16.5kDa, the size expected for
thioredoxin, pTrxFus-Ov2.5 expressed a band at approximately 36kDa (expected size
of 34kDa) and pTrxFus-Ov7 expressed a single band at 22kDa (expected size of
22kDa). In contrast pTrxFus-Ov3.5 and pTrxFus-Ov8.5 showed no expression using
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Figure 3.21: Expression of OvHV-2 genes in the thiofusion expression system.
a) Coomassie blue stained 10% NuPAGE® Novex bis-tris gel, showing thiofusion
expression system cultures pTrxFus-Ov2.5, pTrxFus-Ov3.5, pTrxFus-Ov7 and
pTrxFus-Ov8.5 and the pTrxFus vector, four hours after induction with Tryptophan.
b) 20pl of whole cell lysate pTrxFus-Ov2.5, pTrxFus-Ov3.5, pTrxFus-Ov7 and
pTrxFus-Ov8.5 analysed by western blotting using anti-HisTag antibody as a
primary antibody followed by anti-mouse HRP conjugate and chemiluminescense.
pTrxFus empty vector (pT) present as a control.
To define whether pTrxFus-Ov2.5 and pTrxFus-Ov7 were soluble, cultures
were mechanically lysed and a western blot was performed on soluble and pellet
fractions using an anti-HisTag monoclonal antibody (Figure 3.22). The pTrxFus
vector expressed 2 His-tagged bands, at approximately 16.5kDa, the size expected
for thioredoxin, and at approximately 36kDa in both the soluble and insoluble
fractions. pTrxFus-Ov2.5 showed no protein expression in the soluble phase
although expressed His-tagged bands at approximately 36kDa and 64kDa were seen
in the pellet. pTrxFus-Ov7 also showed no expression in the soluble phase but
expressed bands at approximately 25kDa and 50kDa in the insoluble cell pellet.
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Figure 3.22: Chemiluminescent western blot of soluble and insoluble pTrxFus-
Ov2.5 and pTrxFus-0v7. Soluble and insoluble (1 Ojal) pTrxFus-Ov2.5 (Ov2.5) and
pTrxFus-0v7 (Ov7) extracts were electrophoresed alongside a pTrxFus extract
control (pT). The electrophoresed protein was analysed by Western blotting using
anti-HisTag primary antibody.
3.3.5. Analysis of the Ov8 Exon 1 0.5kb construct
The Ov8 gene fragment expressed in section 3.3.1.2.2 was based on an early
interpretation of the OvHV-2 genome, which indicated a 2.1kb Ov8 exonl. The final
annotation of OvHV-2 (Hart et al., 2007) has altered intron/exon boundaries that
suggest Ov8 exon 1 is only 1.2kb (Figure 3.23a). The remaining 0.8kb of the
previously cloned ORF may include sequences that are intronic. This may be the
cause of problems found expressing the Ov8 construct and its insolubility in the pET
expression system.
New primers were designed to amplify the newly-defined OvHV-2 Ov8
(Table 3.5), by the method described earlier (section 3.2.1.1), to exclude
transmembrane and signal sequences, which have low hydrophilicity. PCR reactions
were performed using genomic DNA purified from the infected cattle cell line
BJ1035. The Ov8 sequence showed 100% homology with the OvHV-2 sequence.
Although the Ov8 gene is 1.2kb, a 531 bp fragment, representing Ov8 exon 1 was
amplified, excluding regions of low hydrophilicity (Figure 3.23b). PCR reactions
were optimised for each primer pair by altering the magnesium ion concentration and
the annealing temperature. The optimal annealing temperature for Ov8 exon 1 was
60°C.
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Final OvHV-2 Final Annotation:
- Exon 1 start codon 81019 stop codon 82261
- Exon 2 start codon 83209 stop codon 83408
- OvHV-2 Ov8 0.5kb fragment (81181-81671)
Figure 3.23a: Annotation of Ov8 sequence. The original Ov8 primers were
designed using an earlier annotation of the OvHV-2 sequence. The original primers
designed amplify a 2.1 kb fragment highlighted in red. The published OvHV-2 shows
a change in the splice site resulting in a 1.2kb fragment (highlighted in green). The
primers designed for Ov8 Exon 1 (0.5kb) is highlighted in blue.
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Figure 3.23b: Hydrophobic regions of the OvHV-2 Ov8 sequence. Plot was
performed by DNAstar PROTEAN using the published OvHV-2 sequence taken
from Genbank. The plot shows regions of hydrophilicity (Kyte-Doolittle),
amphipathic regions and areas of protein folding. The hydrophobicity plot was
performed to analyse the best area of Ov8 Exon 1 to amplify, whereby solubility
issues may be resolved.
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Gene Length Primer Tm % Sequence
(bp) Coordinates GC
Ov8For 33 81640-81673 75 72.7 5'-GGCGCGCCCATGG(i(XVT(i('(iTA('('('( A ACT! IT V
Ov8Rev 36 82272-82308 75 69.4 5'-GGCCGGCCCCATGG(K'A('(iTr(i(iT( A(iT( (i( ifl AUG i
Table 3.5: Ov8 Exon 1 0.5kb PCR Primer sequences.
Primers were designed using Primer3, excluding transmembrane or signal
sequences as defined by SignalP. All primers included terminal in-frame Ncol sites
for cloning and gene fusion. Ov8 Exon 1 (0.5kb) forward and reverse primer used to
amplify a 531 bp product. Non-virus sequences are highlighted.
3.3.5.1. Cloning PCR products with pGEM®-T vector
OvHV-2 Ov8 Exon l 0.5kb was purified directly from the PCR reactions as
little background amplification was found. lOpJ of the purified PCR product was
electrophoresed to confirm recovery (Figure 3.24).
Figure 3.24: pTrxFus-Ov8 Exon 1 PCR product. Product was electrophoresed on
a 0.8% agarose gel alongside a DNA marker (Hyperladder I, Bioline).
Following extraction the DNA was concentrated by ethanol precipitation
prior to ligation and transformation into JM109 competent cells as described in
section 2.4.5. Plasmid minipreps of colonies with possible inserts were prepared and
the presence of insert was confirmed by restriction digestion with Ncol. Clones w ith
I2l
insert of the correct size were sequenced to confirm the identity of the insert and
exclude any clones with PCR errors.
3.3.5.2. OvHV-2 Ov8 Exon 1 0.5kb in the pTrxFus Vector
Insert DNA from a sequence-confirmed clone of OvHV-2 Ov8 Exon 1 0.5kb
was transferred into the pTrxFus expression vector (as described for other gene
fragments sections 3.2.2. and 3.2.2.3), prior to transformation into E. coli GI 724.
Cultures of Ov8 Exon 1 0.5kb clone and empty pTrxFus vector were grown and
induced by the addition of tryptophan. Cells were harvested up to four hours after
induction. Samples of induced cultures were lysed in SDS loading buffer and lOpl of
each lysate was electrophoresed on a 12% NuPAGE bis-tris polyacrylamide gel. The
gel was stained with SimplyBlue SafeStain (Figure 3.25a), and was analysed by
western blotting using HisProbe-HRP antibody (Figure 3.25b). No obvious
overexpression of pTrxFus-Ov8 Exon 1 0.5kb was seen by staining, but western
blotting visualised pTrxFus-Ov8 Exon 1 0.5kb as two bands close to 30kDa, the size
expected for the thioredoxin Ov8 fusion. As in the pET system (Section 3.3.1.2.), the
two bands may be a result of the protein being cleaved into two stable products. As
both constructs carry the N-terminal region of Ov8, the same cleavage site could be
responsible.
To test whether pTrxFus-Ov8 Exon 1 0.5kb protein was soluble, cultures
were mechanically lysed and soluble and insoluble fractions were analysed by
staining and western blotting (Figure 3.25c). Similarly to the crude lysate, pTrxFus-
Ov8 Exon 1 0.5kb soluble lysate showed two bands at approximately 30kDa. No
Ov8 fusion protein was detected in the cell pellet.
3.3.5.3. Purification under Denaturing conditions (8M Urea)
To isolate the target pTrxFus-Ov8 Exon 1 0.5kb His-tagged protein, affinity
purification was performed. Purification of the pTrxFus-Ov8 his-tagged crude lysate
was attempted using a HisTrap nickel affinity purification column (GE Healthcare).
Proteins containing the His-tag sequence should bind to cross-linked agarose beads
with immobilized nickel under native or denaturing conditions.
As native conditions proved unsuitable for the purification of the protein
fusions tested, denaturing conditions were employed using 8M urea in all buffers. To
confirm the presence of the His-tagged proteins, eluted fractions were pooled,
concentrated 30-fold and analysed by western blotting using HisProbe-HRP. The
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concentrated eluant showed no Ov8 fusion, suggesting that the His-tagged proteins
did not bind to the column (Figure 3.26). However, the unbound material was also
analysed alongside the eluant and again no Ov8 fusion protein was detected.
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Figure 3.25: Electrophoresis of pTrxFus-Ov8 (Exon 1) crude lysate. a)
Coomassie blue stained 12% NuPAGE® Novex bis-tris gel, showing Thiofusion
Expression system cultures pTrxFus-Ov8 (Exon 1) at hourly intervals for four hours
after induction with Tryptophan (1-4). M represents the protein marker. U represents
uninduced samples, (b) 20pl crude lysate of pTrxFus-08 Exon 1 were
electrophoresed alongside an empty vector control (pT). The electrophoresed
protein lysate was analysed by Western blotting using HisProbe-HRP. (c) 20pl of
soluble (S) and insoluble pellet (P) pTrxFus-Ov8 Exon 1 extracts (Eton-press) were
electrophoresed and analysed by Western blotting using HisProbe-HRP.
Furthermore, no protein was found in either the unbound material or eluent
by staining using SimplyBlue SafeStain. This may reflect the low level of protein in
the extract as a result of a dilution effect caused by the purification procedure or by
the loss of protein during purification. It was not possible to check for irreversible
binding to the column by analysing the resin.
3.3.5.4. Gel filtration/purification of pTrxFus Ov8 Exon 1 0.5kb
Since the initial HisTrap purification of Ov8 Exon 1 0.5kb fusion protein
proved ineffective, a further purification technique was investigated. Gel filtration
was used to fractionate crude lysates containing His-tagged fusion proteins according
to size. Separation was performed on a Superdex2oo column, using the Akta FPLC
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Figure 3.26: Chemiluminescent western blot of pTrxFus-0v8 (Exon 1, 0.5kb)
gene product. Gel electrophoresis of solubilised pTrxFus-Ov8 Exon 1 (subsequent
to purification via HisTrap affnity purification) performed on a 12% tris-glycine
polyacrylamide gel, and analysed by western blot using HisProbe-HRP. O
represents the orignal Ov8 supernatant, F represents the fall-through material from
the HisTrap column and E represents the eluant.
system. Five hundred microlitres of pTrxFus-Ov8 Exon 1 0.5kb soluble phase
collected following mechanical lysis was injected onto the column and 1ml fractions
were collected and analysed. Thirty fractions were collected and fractions which
corresponded to protein peaks on the FPLC system UV-trace were analysed by
Coomassie staining and western blotting using HisProbe-HRP antibody (Figure 3.27)
to detect the presence of pTrxFus-ORF Ov8 Exon 1 0.5kb protein in the eluted
fractions. The stained gels showed protein in all of the peak fractions, with apparent
molecular weights ranging from 14kDa to 97kDa. The initial peak, corresponding to
fractions 7 and 8, showed a single protein band at 64kDa. The second peak,
corresponding to fractions 12, 13 and 14, showed a high level of eluted proteins,
while fractions corresponding to the third fractionation peak (fractions 15/17)
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showed the majority of proteins ranged from 14 to 64kDa, and had a distinct band at
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Figure 3.27: Gel filtration of pTrxFus-Ov8 Exon 1. a) SimplyBlue Safestain
stained 12% NuPAGE® Novex bis-tris gel, showing 15pl fractions of the Thiofusion
Expression system culture pTrxFus-Ov8 (Exon 1) after gel filtration using the
Superdex20o column. M represents the protein marker. O represents original Ov8
crude lysate. b) 15pl Fractions (concentrated two-fold) of pTrxFus-08 Exon 1
protein lysate was analysed by Western blotting using HisProbe-HRP. The arrow
indicates a protein of 30kDa, which may represent the Ov8 protein.
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A western blot, using HisProbe-HRP antibody, of the same fractions detected
expression of two His-Tagged bands, at approximately 30kDa in size, present in the
third peak (fractions 15 & 16), corresponding to bands shown by staining (Figure
3.27b). As the Ov8 Exon 1 0.5kb fusion protein appeared to correspond to a stained
band, the fraction containing the detected band was analysed by western blotting
using crude MCF positive and negative sera and IgG purified from these same sera
(Figure 3.28).
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Figure 3.28: Chemiluminescent analysis of pTrxFus-Ov8 (Exon 1) wilh MCF
sera. Fractions (concentrated two-fold) of pTrxFus-Ov8 Exon 1 protein lysate
(fraction 15, Figure 1.2.21) was analysed by western blotting using a) FlisProbe-
FIRP b) MCF-positive crude serum c) MCF-positive IgG purified serum and d) MCF-
negative crude and e) MCF-negative IgG purified serum, followed by rabbit anti-
bovine HRP conjugate. Cr represents crude pTrxFus-Ov8 (exon 1) lysate, F
represents the concentrated pTrxFus-Ov8 fraction (fraction 15) while M represents
the protein marker (SeeBlue Plus2 Protein marker, Sigma). The arrows indicate a
protein of 30kDa, conserved in MCF-positive and negative serum.
Both positive and negative crude serum detected a low molecular band and a
range of high molecular weight bands (50-200kDa) in the crude extract. The MCF-
positive and -negative crude serum detected a 30kDa band in both the crude and gel-
filtered protein fractions. This result shows the 30kDa protein was detected
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by both MCF-positive and -negative crude serum, and suggests that some component
of the Ov8-thioredoxin fusion may be recognised by both sera. This may be a direct
result of thioredoxin itself, as thioredoxin is an E. coli protein. As thioredoxin is a
bacterial protein, it is possible that cattle sera have antibodies it) bacterial
thioredoxin. Thioredoxin may therefore be a poor fusion partner for this purpose.
Purification of IgG fractions from the crude MCF positive and negative sera
showed differences in protein degradation. The presence of the 30kDa band which
reacted with the IgG purified MCF-positive and -negative sera, in both crude and
gel-filtered protein fractions, suggests that the band identified would not be OvHV-2
specific due to being present in the control. Further experiments therefore need to be
performed for the continued recognition of the Ov8 protein. Additionally, a larger
pool of MCF-positive and negative crude, and IgG purified sera should be tested to
confirm this finding.
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Figure 3.29: Mass spectrometry band analysis of the fractionated pTrxFus-Ov8
Exon 1 (fraction 15). Match to: S0DM_EC057 Superoxide dismutase Taxonomy:
Escherichia coli, Sequence coverage of 55%. Matched peptides are shown in red
(Bold). The band sequenced is idicated by the arrow.
1 SYTLPSLPYA YDALEPHFDK QTMEIHHTKH HQTYVNNANA ALESLPEFAN
51 LPVEELITKL DQLPADKKTV LRNNAGGHAN HSLFWKGLKK GTTLQGDLKA
101 AIERDFGSVD NFKAEFEKAA ASRFGSGWAW LVLKGDKLAV VSTANQDSPL,
151 MGEAISGASG FPILGLDVWE HAYYLKFQNR RPDYIKEFWN WNWDEAAAR
201 FAAKK
The most abundant band from fraction 15 (Figure 3.27) was analysed by mass
spectrometry (Figure 3.29). It was not certain that the purified product was the
expressed Ov8 Exon 1 0.5kb protein, although the expressed protein was of the same
size as expected for the Ov8 Exon 1 0.5kb protein. The protein match identified E.
coli (0157:H7) superoxide dismutase, showing 55<7r sequence similarity. Although
the major protein was not Ov8, it is possible that the Ov8 fragment is expressed at a
lower level and is therefore masked behind the superoxide dismutase. This confirms
the observation that induction of Ov8 expression did not give rise to tin over-




Current diagnosis of MCF is reliant on an indirect immunofluorescence test
(IIF) and a PCR assay. Although there are ELISAs commercially available (Wan et
al., 1988, Li et al., 2001), they maybe of limited value in the detection of OvHV-2
specific antibodies, as MCF viruses are known to share antigens with other
herpesviruses. This may result in a general insensitivity or non-specificity that may
limit the test (Li et al., 1994).
The recent determination of the DNA sequence of the OvHV-2 genome has
allowed about seventy genes to be identified, of which twelve are unique to the MCF
viruses and three are unique to OvFlV-2 (Hart et al., 2007). Consequently, these
genes may prove good candidates for the development of specific assays for
detection of OvHV-2 infection. The aim of this work was to clone and express
OvHV-2 genes as recombinant proteins, which may be used to establish an ELISA
for the detection of anti-MCF antibodies in field serum. In order to determine
whether the recombinant proteins can be detected by antibodies in sera from MCF-
affected animals, purification is required to eliminate non-specific cross-reactivity
with components from bacterial expression systems such as E. coli.
Initial studies showed expression of the OvHV-2 genes Ov8 Exon 1 2.1kb
and ORF65 in bacterial expression systems; pBAD, pET-22b and pTrxFus.
Expression of OvHV-2 proteins from pTrxFus-Ov8 Exon 1 2.1 kb, pTrxFus-ORF65
and pET22b-Ov8 Exon 1 2.1 kb were demonstrated by western blotting using anti-
HisTag and anti-Thio antibody.
In the pBAD expression system, pBAD-Ov8 Exon 1 2.1kb and pBAD-
ORF65 were detected in the crude lysate, but no expression was detected for pBAD-
Ov9. These results, suggest a possible problem with the pBAD-Ov9 protein
expression under the conditions used and expression system employed. It could also
indicate a genetic problem, whereby the insert suffers rearrangement when cloned
into the expression vector, although no evidence for this was detected. However, Ov9
had previously been impossible to clone into the pTrxFus vector.
pBAD-Ov8 Exon 1 2.1kb expressed two bands at 80kDa and lOOkDa rather
than the expected single, 80kDa band. This may indicate specific protein degradation
into two stable products.
In the pET-22b expression system, only pET22b-Ov8 Exon 1 2.1 kb could be
detected, while no expression was detected for pET22b-Ov9 or pET22b-ORF65.
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These results suggest a possible problem with either the pET22b-Ov9 and pET22b-
ORF65 protein expression under the conditions used and expression system
employed. While Ov8 was expressed in this system, the protein was insoluble and
hence was not investigated further.
Although it appeared possible to clone Ov9 into the expression plasmids, it
was not possible to express in any system. Russell and Wiyono (unpublished data)
demonstrated plasmid rearrangement in pTrxFus and, although it was not
investigated in the constructs made here, it is possible that arrangements also
occurred that prevented expression in pET22b and pBAD. Alternatively, since the
cloned fragments of Ov9 included the hydrophobic C-terminal transmembrane
region, this may have resulted in problems with protein folding and consequent
stability.
Herpesvirus virions are surrounded by an icosahedral protein capsid
comprised of capsid proteins indicating ORF65. OvHV-2 ORF65 shares homology
with human herpesvirus-8 ORF65, which has been utilised in a serological assay for
the diagnosis of Kaposi's sarcoma (Perez et al., 2006). HHV-8 ORF65 has been
cloned and expressed as GST fusion proteins in bacterial and baculovirus expression
systems (pGEX-4T-l) (Zhu et al., 1999). Expression in the expression vector pQE-
42 has also been demonstrated (Simpson et al., 1996). Due to the structure and
function of OvHV-2 ORF65, aggregation may occur causing the protein to remain
insoluble, but these other systems may offer an alternative method for the successful
expression of OvHV-2 ORF65.
The expression vector pET-22b encodes a 21aa bacterial leader sequence,
which targets expression into the bacterial periplasm. Rather than the expected
single, 80kDa pET22b-Ov8 Exon 1 2.1kb band two bands at 80kDa and lOOkDa
were observed. A possible explanation for this 20kDa difference might have been
that cleavage of the leader peptide sequence present in the pET-22b expression
system occurred during export into the periplasm. The difference in migration
however, is much bigger than that expected from signal peptide cleavage, and for this
explanation to be true the presence of the leader peptide would have to significantly
influence the migration of the protein. An alternative explanation may be that the
protein underwent specific proteolytic cleavage at a different site at the N-terminus
of the expressed Ov8 Exon 1 2.1 kb protein.
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The pET22b-Ov8 Exon 1 2.1 kb protein was insoluble after mechanical lysis.
Furthermore, it did not appear to be solubilised from the pellet in the presence of
concentrated urea. This result may be due to problems in this western blot procedure,
as suggested by the high background. Further possibilities include very poor
solubility or aggregation of the pET22b-Ov8 Exon 1 2.1 kb product. Therefore further
studies should be performed on the pET22b-Ov8 Exon 1 2.1kb product to clearly
define its solubility.
High levels of expression of recombinant proteins in a bacterial system can
lead to the formation of insoluble aggregates, or inclusion bodies. Inclusion bodies
are dense aggregates of misfolded polypeptide. They are formed intracellular^ as a
result of either aggregating characteristics of the protein or insufficient cellular
processes which ensure expressed polypeptides are soluble and folded correctly.
Inclusion bodies are usually located in the bacterial cytoplasm, though secreted
proteins may form inclusion bodies in the periplasmic space. Some proteins, which
are incorporated into inclusion bodies, may possess elements of native structure, and
therefore, must be released from the inclusion body and refolded to give its native
structure (Middelberg, 2002). To solubilise these inclusion bodies, strong denaturing
agents such as 6M Guanidine-HCl (GuHCl) and 8M Urea can be used. Therefore, to
test whether pET22b-Ov8 could be solubilised strong denaturing agent, urea (8M),
was used to solubilise the whole cell crude lysate.
Additional trials could be performed in order to improve solubility of this
protein. Possible trials include the growth of bacterial cells at a lower temperature to
improve protein solubility and an IPTG titration to determine the optimal
concentration required to induce the pET-22b expression system.
Work to clarify the difficulty with the Ov8 Exon 1 2.1kb construct in the
expression vector pTrxFus led to the suggestion that the fragment of the Ov8 gene
used in initial expression studies contained some intron sequence. The latest analysis
of the OvHV-2 genome sequence (Hart et al., 2007) indicated that the cloned OvHV-
2 Ov8 Exon 1 2.1kb fragment actively contained about 800bp of intron. The
expression of an extended piece of coding intron may account for the insolubility of
the protein product. Therefore a smaller, 531 bp fragment encoding the N-terminal
half of the newly annotated Ov8 Exon 1 0.5kb, was designed to test expression and
solubility. Western blotting revealed the pTrxFus-Ov8 Exon 1 0.5kb fusion protein
could be detected in the soluble fraction. However, similar to the expression studies
on the original Exon 1 2.1kb Ov8 fragment in the pET system, the new Ov8 Exon 1
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0.5kb construct gave rise to two bands at about 30kDa, indicating a conserved
cleavage site in both Ov8 constructs. To isolate the target pTrxFus-Ov8 Exon 1 0.5kb
His-tagged protein metal-affinity purification was performed under denaturing
conditions. No protein was detected suggesting that the His-tagged proteins did not
bind to the column. Therefore, as metal-affinity purification methods had also proved
unsuccessful for the purification of pTrxFus-ORF65, alternative methods for
purification were sought. The lysate was fractionated using a Superdex gel filtration
column. This showed an enrichment of a 30kDa protein band the expected size of the
Ov8 Exon 1 0.5kb product which was detectable by Coomassie staining and western
blotting with the anti-his antibody. When tested using MCF-positive and -negative
crude serum, a low molecular band at 30kDa was detected in both the crude extract
and gel-filtered protein fraction. This result suggests that the 30kDa band may
possibly represent forms of the thioredoxin fusion protein and therefore may be
recognised by both sera. Further experiments may be required to separate recognition
of Ov8 from that of the thioredoxin fusion partner.
The attempt to express the Ov8 gene fragment in order to overcome solubility
issues proved successful. By analysing the hydrophobicity plot, primers could be
designed to exclude not only regions of transmembrane and signal sequence, but
regions of protein folding and hydrophobicity. By performing these plots and
sequence analysis prior to the development of primers, solubility issues in expression
systems may be eliminated.
When tested using IgG purified MCF-positive and negative serum, there was
enrichment of the 30kDa band in the positive sera, while the band was absent in the
negative sera. This result, contrasting to the tested crude serum, suggests the Ov8
may be an antigenic protein recognised by anti-MCF antiserum. This experiment
would have to be repeated with a larger selection of crude and IgG purified serum to
substantiate this finding.
Thioredoxin is a heat-stable redox protein, 12kDa, universally expressed in
yeast, plants, mammals and bacteria. It was originally isolated from yeast extracts
and subsequently from E. coli. In E. coli it acts as a hydrogen donor for
ribonucleotide reductase, an enzyme which controls the cellular concentration of
deoxyribonucleotides required for DNA synthesis. Mammalian thioredoxin has a
variety of biological functions in cell growth, transcription and immune function
(Matsui et al., 1996) as well as acting as hydrogen donor for ribonucleotide
reductase. It is therefore possible that most cows recognise bacterial thioredoxin, and
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therefore, cross-react with the fusion proteins expressed. A more likely explanation
however is that the crude bovine serum sample contains a number of proteins besides
host proteins which may result in cross-reactivity.
This explanation could be confirmed by cleavage of the thioredoxin fusion to
release the Ov8 Exon 1 0.5kb fragment from the MCF gene of interest. Western blots
using sera should show whether the Ov8 fragment is recognised by both MCF-
positive and -negative serum and whether thioredoxin is also recognised by both
serum samples.
Another explanation may be that the bands that are being detected are not
specific to the MCF gene but may represent a co-purified protein from the E. coli
used for culturing. This is unlikely as the His-tag bands are right in the same place.
In fact some E. coli proteins are detected but these are near the top of the gel. The
band was subjected to mass spectrometry. A protein match was identified as E. coli
superoxide dismutase, showing 55% sequence similarity. Although this suggests the
abundant band at 30kDa was not the pTrxFus-Ov8 Exon 1 0.5kb fusion, it is possible
that the Ov8 fragment is masked by the superoxide dismutase and was not detected
due to its lower protein concentration. However, due to time constraints, further
work on this was not performed to enable identification of the Ov8 Exon 1 0.5kb
fragment although from this expression study, Ov8 appears the best possibility for a
recombinant protein based diagnostic assay.
Work with the expression vector pTrxFus, revealed that the pTrxFus-ORF65
fusion protein could be detected in the soluble fraction, while pTrxFus-Ov8 Exon 1
2.1kb showed a band of the same size as the thioredoxin protein (16kDa). As the
pTrxFus-ORF65 crude extract contained a soluble, His-tagged protein of 32kDa, the
expected size for the ORF65 fusion, purification using a nickel resin was attempted.
The lack of success in purification may have reflected the low expression level of the
pTrxFus-ORF65 protein or poor affinity for the resin, possibly also affected by poor
accessibility of the tag.
This initial finding for Ov8 suggested either a problem with the Ov8
construct or proteolysis of the fusion protein. Restriction analysis, however, showed
that the correct construct structures were present in all isolates tested. Explanations
for the discrepancy may relate to low expression levels, conditions used for protein
expression or the degradation of the pTrxFus-Ov8 Exon 1 2.1kb fragment into
smaller, stable products of similar sizes. Degradation, being the most likely
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explanation, was substantiated by the detection of a weak 25kDa band and a 16kDa
band present in the elution samples from Ni-NTA purification.
The expression of recombinant proteins in Escherichia coli is a routinely used
method for the recovery of large amounts of mammalian proteins, however culture
conditions and induction of expression may cause inhibitory effects to the yield of
soluble, active proteins produced. Such effects may be frequently caused by protein
misfolding, degradation and aggregation (Hanning and Makrides 1998). Numerous
approaches have been used to improve the yield of recombinant proteins by
decreasing the rate of protein synthesis, such as slower cell growth, growth in
minimal media, lower induction and incubation temperatures which may offer better
conditions to proteins (Marco et ai, 2005). Under normal growth conditions,
aggregates or inclusion bodies may accumulate rather than the desired soluble, active
form of the protein. Therefore optimisation of the conditions may limit this
accumulation.
Further studies must therefore be performed on the thioredoxin expression
system, with particular reference to improving protein expression. This may be
achieved by using different growth conditions, such as varying the growth or
induction temperature between 25 and 37°C. This may also improve the solubility of
the fusion proteins and consequently aid purification of the target His-tagged
proteins. A further consideration may be trying different bacteria strains, such as
strains were codon usage is optimised for expression of mammalian cells.
Differences in codon usage between mammalian and bacteria may lead to a
variety of problems regarding gene expression. Bacterial strains such as the Rossetta
host strains (Novagen) allow expression of eukaryotic genes containing seven
codons; AUA, AGG, AGA, CUA, CCC, GGA, and CGG, which are rarely used in E.
coli.
Following the results on Ov8 Exon 1 2.1kb, Ov9 and ORF65, further studies
were initiated on a wider range of genes. Several of the unique open reading frames
(ORFs) in the OvFTV-2 genome demonstrate significant homology with cellular
proteins, suggesting they have been acquired from host DNA during co-evolution of
the virus and its host (Coulter et al., 2001). Included are genes encoding a
homologue of a cellular interleukin (IL10 homologue Ov2.5), regulation of apoptosis
(bcl2 homologues Ov4.5 and Ov9) and a virion glycoprotein (Ov7). The four genes
selected as candidates for analysis were amplified by PCR and cloned into the
bacterial expression vector pTrxFus so that they could be analysed to determine
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whether they may be detected by antibodies in sera from MCF-infected animals. The
thioredoxin vector system, pTrxFus, was used for this because it gave the best
expression results among the systems tested. Based on results from this study, the
solubility of the OvHV-2 proteins remained an issue, with the majority of proteins
being insoluble as expressed from pTrxFus vector. Subsequent purification of the
soluble proteins identified proved ineffective by His-tag specific methods.
In this system, pTrxFus-Ov2.5 and pTxFus-Ov7 were expressed but
insoluble, while no expression was detected for pTrxFus-Ov3.5 and pTxFus-Ov8.5.
Expression in eukaryotic cells has been recently demonstrated for Ov2.5, which was
shown to be both secreted and functional (D. Haig, J., Stewart, unpublished data).
HEK293T cells were transiently transfected with a vector (pVR1255) encoding
Ov2.5 with C-terminal haemagglutin (HA) epitope tags and harvested after 48 hours.
pVR1255 is a gene therapy vector which contains a CMV promoter and offers no
drug resistance for selection in mammalian cells (Manthorpe et al., 1993; Norman et
al., 1997). Modifications to this vector included the addition of multiple cloning sites
and a triple HA-tag for purification and detection of the cloned protein (G.Russell,
unpublished data).
The tagged protein was expressed at high level and could be purified from the
culture medium. However the Ov2.5 protein was not recognised by anti-MCF sera
(data not shown), indicating that Ov2.5 was not an antigenic target in infected
susceptible animals. Possible reasons for this result might be that Ov2.5 may not be
expressed in animals affected with MCF. Alternatively, it may only be expressed at
low levels. As Ov2.5 acts as a cytokine it is only required in small amounts, unlike
the large amounts required for structural proteins such as ORF65 or glycoprotein
Ov7, therefore there may not have been sufficient levels expressed to induce an
immune response.
This work has shown that pTrxFus-ORF65 and pET22b-Ov8 Exon 1 2.1 kb
can be expressed, although further work is required to resolve issues concerning
solubility and purification. The OvHV-2 genes studied may prove useful in the
development of an ovine herpesvirus-2 recombinant protein based diagnostic ELISA.
Alternative options to improve expression, solubility and purification issues may be
achieved by using several systems such as yeast, baculovirus or mammalian
expression systems. One aspect which may inhibit solubility is the presence of
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inclusion bodies in bacteria, therefore protein refolding may also have to be
considered for the insoluble proteins.
An additional option that could take advantage of the currently available
bacterial constructs and cloned genes may be the use of novel systems for the
expression of genes, such as the in vitro Rapid Translation System (RTS). RTS is a
high-yield cell-free protein expression system, based on the use of T7 RNA
polymerase and T7 promoter vectors to limit expression to genes of interest. This in
vitro transcription-translation system avoids culture and induction problems and
provides a rapid alternative for expression of candidate genes. As the system is cell-
free, the background interference caused by bacterial proteins may also be reduced.
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Chapter Four
In Vitro Expression Studies: The Rapid
Translation System
In Vitro Expression Studies
4.1 Introduction
Previous studies for the expression of candidate antigens were performed
using bacterial expression systems as they offer rapid expression of selected antigens
in a form which may be easily purified, through the addition of a His-epitope tag.
As it was not possible to express and purify these candidate antigens an
alternative expression system was sought. The in vitro Rapid Translation System
(RTS) was selected. The use of in vitro translation systems can have advantages over
in vivo gene expression when the product is insoluble or forms inclusion bodies,
when the protein undergoes rapid proteolytic degradation by intracellular proteases
or when the over-expressed product is toxic to the host cell (RTS application manual
for cell-free protein expression, Roche). RTS is a high-yield cell-free protein
expression system, based on the use of the T7 promoter and T7 RNA polymerase to
limit expression to genes of interest.
This in vitro transcription-translation system avoids culture and induction
problems and provides a rapid alternative for the expression of candidate genes. As
the system is cell-free, the background interference caused by bacterial proteins may
also be limited. The RTS system employs an enhanced E. coli lysate to perform
coupled in vitro reactions, where a continuous source of energy substrates,
nucleotides and amino acids combined with the removal of by-products (Figure 4.1)
ensures high yield protein production of up to several milligrams (Betton, 2003;
Roge & Betton, 2005).
E. coli cell-free systems consist of a crude extract that is rich in endogenous
mRNA. The extract is incubated during preparation so that this endogenous mRNA
is translated and subsequently degraded. As the levels of endogenous mRNA in the
prepared lysate are low, the exogenous product is easily identified. In comparison
with eukaryotic systems, the E. coli extract has a relatively simple translational
apparatus with less complicated control at the initiation level, allowing this system to
be very efficient in protein synthesis. Bacterial extracts are often unsuitable for
translation of RNA, because exogenous RNA is rapidly degraded by endogenous
nucleases. There are some viral mRNAs (TMV, STNV, and MS2) that translate
efficiently, because they are somewhat resistant to nuclease activity and contain
stable secondary structure. However, E. coli extracts are ideal for coupled
transcription-translation from DNA templates.
In standard translation reactions, purified RNA is used as a template for
translation. "Linked" and "coupled" systems, on the other hand, use DNA as a
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Figure 4.1: Illustration of RTS protein expression. Diagram modified
from the Roche RTS application manual. The continuous exchange cell-
free system (CECF) prevents the accumulation of inhibitory reaction by¬
products and prevents the exhaustion of reaction substrates. The
columns semi-permeable membrane enables a continuous supply of
substrates, while removing inhibitory products from the reaction chamber.
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template. RNA is transcribed from the DNA and subsequently translated without any
purification. Such systems typically combine a prokaryotic phage RNA polymerase
and promoter (T7, T3, or SP6) with eukaryotic or prokaryotic extracts to synthesize
proteins from exogenous DNA templates. DNA templates for transcription-
translation reactions may be cloned into plasmid vectors or generated by PCR
The candidate genes are cloned into an RTS-specific plasmid vector, one of
the pIVEX plasmid vectors. The pIVEX expression vectors are designed for high-
level protein expression and are optimized for expression using the RTS approach,
with T7 RNA polymerase and prokaryotic cell lysates. The vectors include the T7
gene translation enhancer, multiple cloning sites and aT7 transcription terminator.
The pIVEX family of vectors allows gene fusion to a variety of epitope tags
for protein isolation (Roge & Betton, 2005). The pIVEX2.3 and pIVEX2.4a vectors
were selected as they contained C- or N-terminal His-tags respectively (Figures 4.2
and 4.3). Cloning into the Ncol sites in these vectors places the gene between the
target peptide and the HisTag and so follows the cloning strategy designed for other
vectors.
This chapter describes the expression of OvHV-2 genes using the in vitro
Rapid Translation System. Previous study of OvHV-2 genes in bacterial expression
systems revealed that OvHV-2 ORF65 (major capsid protein) and OvHV-2 Ov8
Exon 1: 2.1 kb and 0.5kb (virion glycoprotein) could be expressed, although
problems regarding solubility and purification in the bacterial lysates remained an
issue. Although expression of Ov8.5 was not detected in the previous study using the
thioredoxin fusion system, Ov8.5 was included in this in vitro study due to its unique
nature. The expression of these OvHV-2 genes, cloned into in vitro expression
vectors plVEX2.3 or plVEX2.4a, was demonstrated using western blotting with
















Linker + Histag (712-738)
Stop (739-744)
Ecu R I (752)





Ori Eco RI (1295)
Figure 4.2: The pIVEX 2.3 expression vector (adapted from Roche). This vector
carries regulatory elements required for in vitro expression with T7 RNA polymerase and
prokaryotic cell lysates. plVEX2.3 contains multiple cloning sites and an C-terminal
polyhistidine (6xHis) tag for purification with nickel-chelating resin.
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Figure 4.3: The pIVEX 2.4a expression vector (adapted from Roche). This vector
carries regulatory elements required for in vitro expression with T7 RNA polymerase and
prokaryotic cell lysates. plVEX2.4a contains multiple cloning sites and an N-terminal
polyhistidine (6xHis) tag for purification with nickel-chelating resin.
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4.2. Material and Methods
4.2.1. Cloning into pIVEX Vectors
For this work, two vectors were used; pIVEX 2.3 (Figure 4.2) and pIVEX
2.4a (Figure 4.3). The name pIVEX represents the system ([n Vitro Expression);
while the first number represents the basic vector, and the second number indicates
the position of the His-tag within the vector (e.g. pIVEX 2.3 has a C-terminal HisTag
while pIVEX 2.4a has an N-terminal tag). The letter "a" on the pIVEX2.4 vector
represents a difference in open reading frame.
4.2.2. Digestion of pIVEX vectors
All cloned fragments had Ncol sites at both ends which could be cloned in-
frame into pIVEX2.3 or pIVEX2.4a. Digestion of the pIVEX vector with the
restriction enzyme Ncol was followed by de-phosphorylation to prevent self-ligation
of the vector. Linearized vector DNA was purified by gel extraction. The target gene
inserts Ov8 Exon 1: 2.1 kb, Ov8 Exon 1: 0.5kb, Ov8.5 and ORF65 were excised from
existing vectors by restriction digestion with restriction enzyme Ncol, as the genes
were already Hanked by Ncol sites.
4.2.3. Ligations using the pIVEX vectors (pIVEX 2.3 and 2.4a)
Ligation reactions contained 5pl 2x rapid ligation buffer, 1 jliI (50ng) vector,
!pl T4 DNA ligase (3 Weiss units/pl) and up to 3pl purified insert DNA, in a
reaction volume of lOpl. Negative control reactions were included to check for self-
ligation of the vector. Ligation reactions were incubated at room temperature for 1
hour then overnight at 4°C.
4.2.4. In Vitro Protein Expression
The target genes, once cloned into the pIVEX plasmid, were transformed into
E. coli strain JM109 to amplify the expression plasmid. Glycerol stock cultures of E.
coli carrying plasmids encoding fusion proteins were inoculated onto LB Medium
agar plates with ampicillin (100p.g/ml) and incubated overnight at 37°C. Single
colonies were used to inoculate 10ml L-broth (Appendix 11) containing lOOpg/mg
ampicillin and the cultures were incubated at 37°C (225rpm) overnight. The cultures
were harvested by centrifugation at 3000 x g for 10 minutes, and plasmid DNA was
purified using a QIAprep spin miniprep kit (method described in section 2.4.6.2).
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RTS reaction reagents were prepared as stated by the manufacturer (RTS 500
Instruction manual, version 2). Between 10-15pig of DNA (<50pl) was added to the
reaction solution and loaded into the 1ml RTS reaction chamber. After 24 hours
(30°C/120rpm), the reaction solution (1ml) was clarified at 1300 x g for 10 minutes
to determine solubility of the RTS extract
4.2.5. Affinity Purification under Native and Denaturing Conditions
Using a Ni-NTA affinity resin purification column under native conditions, a
total of 500pl of RTS extract (diluted 1:5 in binding buffer) was injected onto the
column using an Akta FPLC system (with in-line analysis at 280nm).
The column was washed with distilled water and binding buffer (flow rate
lml/min) prior to injecting the sample, to ensure no contaminants were present. The
diluted sample was then injected onto the column, and the column was washed with
binding buffer (50mM NaHiPCC, 300mM NaCl, 20mM imidazole, pH8.0) until a
constant baseline was reached. Elution buffer (50mM NaH2PC>4, 300mM NaCl,
500mM imidazole, pH8.0) was then applied to the column and 1ml fractions were
collected. Fractions corresponding to protein peaks on the FPLC system trace were
collected and analysed by staining and western blotting using FlisProbe-HRP
antibody.
As purification of the fusion proteins was not achieved using Ni-NTA affinity
purification under native conditions, purification under denaturing conditions
(lOOmM NaH2P04, lOmM Tris-Cl, 8M urea, pH8.0) was also performed.
4.2.6. NHS HisTrap purification
NHS HisTrap columns are commonly used for the purification of histidine-
tagged recombinant proteins using immobilized metal ion (Ni) affinity
chromatography. This purification column was used as an alternative purification
method utilizing the HisTag. The RTS extract (lOOp.1) was adjusted to the
composition and pH of the binding buffer by diluting in binding buffer (20mM
NaH2P04, 0.5M NaCl, 20mM imidazole) to a final volume of 500pl.
The column was washed with distilled water and binding buffer (flow rate of
lml/min) prior to injecting the sample, to ensure no contaminants were present in the
column. The diluted sample was then injected onto the column, and the column was
washed with binding buffer until a constant baseline was reached. Elution buffer
(20mM sodium phosphate, 0.5NaCl, 500mM imidazole pH7.4) was then applied to
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the column and fractions which corresponded to protein peaks on the FPLC system
trace were collected and analysed by staining and western blotting using HisProbe-
HRP antibody.
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4.3. Results
4.3.1. plVEX2.3-Ov8.5
The unique Ncol restriction site in the pIVEX vector was used for cloning
and resulting colonies were subject to restriction analysis to define insert orientation,
using the restriction enzyme Pcil. One colony showed the correct orientation (Figure
4.4).
Fifteen micrograms of plVEX2.3-Ov8.5 plasmid DNA was added to 1ml of
RTS working solution. The RTS reaction was run at 30°C for 24 hours, stirring at
120rpm to ensure distribution and prevent membrane congestion.
A sample of the Ov8.5 RTS extract was mixed with 2x SDS loading buffer
and 20pl was electrophoresed on a 14% NuPAGE tris-glycine polyacrylamide gel.
No negative control was used as there was no RTS reaction reagents prepared in the
absence of plasmid DNA. The stained gel showed no obvious bands for pIVEX2.3-
Ov8.5, suggesting the protein was not over-expressed (Figure 4.5a). A duplicate gel
was analysed by western blot using an anti-HisTag monoclonal antibody, to
determine the presence of recombinant proteins. The pIVEX2.3-Ov8.5 expressed a
clear polypeptide at 36kDa, which represents the Ov8.5 protein, with an expected
size of 40kDa. Further bands were identified at approximately 12, 20 and 30kDa
(Figure 4.5b), which suggests that there may be a level of protein degradation.
Bacterial expression systems proved unsuitable for the expression of OvHV-2
Ov8.5 (described in section 3.3.4), the cell-free in vitro system (RTS), however
proved effective.
4.3.1.2. plVEX-2.3 Ov8.5 affinity chromatography
In order to eliminate potential non-specific bands and clearly identify the
Ov8.5 fusion protein, the Ov8.5 RTS extract was purified under native conditions
using standard affinity (Ni-NTA) chromatography. Twenty microlitres of unbound
lysate, along with the resin-bound eluant, were subjected to electrophoresis and
stained with Sypro ruby stain (Figure 4.6a). The unbound and wash fractions were
heavily stained like the RTS extract. A band at 38kDa, the expected size of the Ov8.5
protein, was additionally observed in the unbound and wash fractions but was not
visible on the resin, suggesting that either most of the protein present remained
unbound or was non-specific. Bands were faintly visible in the eluted extract at 25,
28 and 49kDa which did not appear to represent highly expressed bands in the crude
extract. The presence of these expressed proteins could be due the occurrence of non-
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Figure 4.4: plVEX2.3 OvHV-2 Ov8.5.
Orientation determined by restriction digest reaction with enzyme Pcil (■).
Unique site in plVEX2.3 vector at 1667bp (3530bp), and 930bp in the insert
(1151 bp insert). Result in two bands at 3489kb and 1191 kb. ® represents















Figure 4.5: pIVEX2.3 Ov8.5 RTS extract detected by staining and
chemiluminescence western blot. Twenty microlitres of Ov8.5 RTS extract separated
by electrophoresed on a 14% tris-glycine polyacrylamide gel was analysed by a)
SimplyBlue SafeStain and b) western blotting using anti-HisTag antibody as a primary
antibody followed by anti-mouse HRP conjugate. The bound conjugate was detected by
chemiluminescence using the Pierce Supersignal ELISA femto HRP substrate
Negative control not shown.
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Figure 4.6: plVEX2.3 Ov8.5 Ni-NTA affinity purification under native conditions.
Twenty microlitres of the purified eluent (E) was fractionated on a 14% tris-glycine
polyacrylamide gel alongside the crude lysate (Cr), unbound material (U) and washing
stages 1-3 (W). The protein lysate was analysed by either staining with Sypro Ruby (a)
or western blotting (b) using anti-HisTag antibody as a primary antibody followed by
anti-mouse HRP conjugate. The bound conjugate was detected by chemiluminescence
using the Pierce Supersignal ELISA femto HRP substrate. No control was used.
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specific histidine binding to E. coli proteins which may interfere with the binding of
the Ov8.5 fusion protein.
To confirm the presence of His-tagged proteins a western blot, using anti-
HisTag antibody, was performed on samples from the purification procedure (Figure
4.6b). Similar to the stained gel, distinct His-tagged bands were observed in the RTS
extract, unbound and wash fractions at approximately 38, 50 and 60kDa. The 50 and
60kDa proteins are most likely to be E. coli products while the 38kDa may be the
Ov8.5 protein. No bands were observed in the SDS-treated pellet. This suggests that
the Ov8.5 protein did not bind to the NTA column and possibly reflects the relative
expression level of the Ov8.5 protein. Ni-NTA affinity purification was performed
under denaturing conditions and showed distinct His-tagged bands in only the whole
cell lysate, at approximately 28, 38, 50 and 60kDa (Figure 4.7). A distinct band at
38kDa was also detected in the wash fractions in the resin-bound eluant. This
indicates that there is either a relatively low level of Ov8.5 protein expression or the
Ni-NTA column resin binds this His-tagged protein poorly.
In order to determine whether the Ov8.5 protein remained in the fall-through
fraction, a second affinity purification method was performed using 5-fold more
material. The pre-packaged NHS-HisTrap column was loaded with Ov8.5 RTS
extract (2.5ml), diluted 1:5 in binding buffer (20mM Na^PCU, 0.5M NaCl, 20mM
Imidazole). Twenty-five (1ml) fractions were collected and analysed, and fractions
corresponding to protein peaks on the FPLC system UV trace were analysed by
staining and western blotting using HisProbe-HRP antibody (Figure 4.8). Stained
gels showed detectable protein bands in only peak fractions 12, 13 and 14, with
apparent molecular weights ranging from 50 to 148kDa. Fractions 12 and 13
correspond to the first and highest protein peak from the fractionation and showed
strong bands at 50 to 148kDa (Figure 4.8a). Fraction 14 also showed two major
protein bands at 55 and 60kDa. The expected size of the Ov8.5 protein is 40kDa. A
western blot, using an anti-HisTag antibody, of the same fractions showed that His-
tagged proteins eluted in the first protein peak with apparent molecular weights
ranging between 50 to 148kDa (Figure 4.8b). The second protein peak (Fraction 15-
16) showed no protein expression by staining, however a band at approximately
36kDa was observed by western blotting. This 36kDa band could represent the
Ov8.5 protein, but as no band was detected by SimplyBlue stain, it was assumed that
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Figure 4.7: plVEX2.3 Ov8.5 Ni-NTA affinity purification under denaturing
condition. Twenty microiitres of the RTS extract (E) was fractionated on a 14% tris-
glycine polyacrylamide gel alongside the crude lysate (Cr), unbound material (U) and
washing stages 1-3 (W). The protein lysate was analysed by either staining with
SimplyBlue SafeStain (a) or western blotting (b) using anti-HisTag antibody as a
primary antibody followed by anti-mouse HRP conjugate. The bound conjugate was
detected by chemiluminescence using the Pierce Supersignal ELISA femto HRP
substrate.
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Figure 4.8: Purification of plVEX2.3 Ov8.5 under denaturing conditions. plVEX2 3-
Ov8.5 extract was fractionated, on a 12% bis-tris polyacrylamide gel, alongside the
unbound material (U) and crude lysate present as a control (Cr). The fractions were
analysed by either staining with SimplyBlue Safestain (a) or western blotting using
HisProbe-HRP antibody (b). The bound conjugate was detected by chemiluminescence
using the Pierce Supersignal West Dura HRP substrate. Arrow indicates expected size
of plVEX2.3 Ov8.5 gene product.
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4.3.2. plVEX2.3-ORF65
The restriction enzyme BstXI was used to analyse the insert orientation of
pIVEX2.3-ORF65 and a colony showing the correct orientation was selected (Figure
4.9). Fifteen micrograms of DNA was added to the RTS working solution and
incubated (30°C/24hours). The reaction solution was removed and as there was
precipitate visible, the extract was centrifuged at 1300 x g for 10 minutes to
determine solubility of the extract. The soluble and insoluble phases were collected
and analysed by electrophoresis and western blotting to determine whether any
recombinant protein was present in the soluble phase. Using an anti-FlisTag
monoclonal antibody, no bands were shown in the insoluble phase suggesting that
the ORF65 protein was soluble (data not shown).
The soluble fraction was analysed by staining and western blot, using a
monoclonal HisTag antibody to detect the presence of the ORF65 fusion protein.
MCF-positive and -negative antisera were also tested to determine whether the
ORF65 protein is antigenically reactive to MCF serum (Figure 4.10b, c). Using the
HisTag monoclonal antibody, the crude extract contained many reacting bands
between 28 and 98kDa (expected size 38kDa). Both the MCF-positive and negative
antiserum identified bands ranging between 35 and 64kDa, although no distinct
protein band was shown. This could indicate that there was a high level of histidine
binding in the crude lysate, possibly due to E. coli proteins present in the RTS
reaction mix. Therefore, to remove any non-specific bands and to purify the ORF65
protein, the crude lysate was fractionated by Ni-NTA affinity purification under
native conditions.
4.3.2.1. plVEX-2.3-ORF65 affinity purification
Using the Atka FPLC system, twenty-eight 1ml eluted fractions were
collected from the Ni-NTA column. As fractions corresponding to protein peaks on
the FPLC system trace were difficult to identify, due to the presence of imidazole,
the first four fractions of the elution were pooled and concentrated 5-fold using a
0.5ml microcon filter. The pooled fractions were analysed by staining and western
blot, using HisProbe-HRP antibody, and showed no bands at the expected size for the
ORF65 fusion protein. A 55kDa band was seen in the eluant which implies the
presence of an E. coli product. It can therefore be assumed that either the ORF65
protein was not bound to the column or not eluted (Figure 4.11). A 45kDa band was
also seen in the SDS-treated pellet, and may similarly indicate an E. coli product.
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Figure 4.9: Orientation of plVEX2.3 OvHV-2 ORF65.
Orientation determined by restriction digest reaction with enzyme BstXI (;■]). Unique site in
plVEX2.3 vector at 763bp (3530bp), and 576bp in the ORF65 insert (636bp). The correct
orientation would yield bands of 4039bp and 126bp, while the opposite orientation would
yield bands of 3523bp and 642bp. represents Ncol restriction sites, Hyperladder I used
9
as DNA marker, Bioline. .
HisProbe MCF-neg MCF-pos
Figure 4.10: Chemiluminescent western blot of plVEX2.3-ORF65 RTS extract.
Expression of the soluble plVEX2.3-ORF65 extract was analysed by western blotting
using (a) HisProbe-HRP, (b) MCF-negative antiserum and (c) MCF-positive antiserum,
using a rabbit anti-bovine HRP conjugate. The bound conjugate was detected by
chemiluminescence using the Pierce Supersignal West Dura HRP substrate.
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Figure 4.11: Electrophoretic analysis of affinity purified plVEX2.3-ORF65. Twenty
microlitres of plVEX2.3-ORF65 crude extract (Re), the unbound fraction (U), eluent (E)
and SDS-treated column resin (SDS) were loaded onto a 10% tris-glycine
polyacrylamide gel and run at 100V for 1 hour. The samples were analysed by staining
using SimplyBlue SafeStain (a) and western blotting using HisProbe-HRP antibody (b).
The bound conjugate was detected by chemiluminescence using the Pierce
Supersignal West Dura HRP substrate.
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Similar to Ov8.5, purification under denaturing conditions using an NHS HisTrap
column was performed. Twenty-five 1ml fractions were collected, using the Akta
FPLC system, and fractions corresponding to the two protein peaks on the FPLC
system trace were analysed by electrophoresis and western blot (Figure 4.12).
Using SimplyBlue staining several protein bands were seen in the first elution
peak, corresponding to fractions 12 and 13, with apparent molecular weight between
30kDa and 148kDa. The second peak, corresponding to fraction 16, showed only a
single, faint band at approximately 80kDa. By western blot, using an anti-HisTag
antibody, a high level of His-positive protein expression in the crude lysate was
shown. In the fractions from the first peak, protein was detected at 60 and 65kDa. No
protein bands were detected in fractions from the second protein peak. Therefore, as
no His-tagged protein was detected at the size expected for the ORF65 fusion
protein, it was assumed that the level of protein expression was too low for detection
by western blot.
Expression of the pIVEX2.3-ORF65 fusion protein indicated a soluble
protein, though purification by native and denaturing conditions proved unsuccessful.
This might suggest that the HisTag epitope tag was embedded in the protein and
therefore not exposed to the column. To determine whether the tag was hidden, the
pIVEX2.4a vector was employed, with the HisTag present on the N-terminus rather
than the C-terminus.
4.3.3. pIVEX 2.4a-ORF65
The restriction enzyme PstI was used to analyse insert orientation of
pIVEX2.4-ORF65, and a colony showing the correct orientation was selected (Figure
4.13) and 12pg of DNA was loaded into the RTS reaction chamber. After 24 hours
(30°C/120rpm), the reaction solution was clarified at 1300 x g for 10 minutes to
determine solubility of the RTS extract and, like the pIVEX2.3-ORF65 fusion
protein, protein bands were found in the soluble fraction (Figure 4.14). Non-specific
bands were detected by both the His-Tag monoclonal antibody (Figure 4.14a, b) and
anti-MCF serum (Figure 4.14c, d) in both the soluble and insoluble fractions,
suggesting the presence of non-specific protein binding by both antibodies and
serum. A protein band at the size expected for ORF65 was not clearly detected by the
anti-MCF sera, however a band at approximately 40kDa was seen in the soluble
fraction, by the monoclonal HisTag antibody. This band may therefore represent
ORF65.
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Figure 4.12: Electrophoretic analysis of plVEX2.3-ORF65, purified under
denaturing conditions. Fractions collected by HisTrap purification performed on an
HPLC, were concentrated using a 0.5ml microcon filter and resuspended in equal
volumes with 2x SDS sample buffer. Each fraction (15pl) was analysed by SDS-PAGE
alongside the unbound material (U) and RTS extract (Re), present as controls. The
electrophoresed fractions were analysed by SimplyBlue staining (a) and western
blotting using HisProbe-HRP antibody (b). The bound conjugate was detected by
chemiluminescence using the Pierce Supersignal West Dura HRP substrate.
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Figure 4.13: Orientation of plVEX2.4a OvHV-2 ORF65.
Presence of insert demonstrated and orientation determined by restriction digest
reaction with enzyme Pstl (■). Unique site in plVEX2.4a vector at 793bp (3547bp),
and 530bp in the ORF65 insert (636bp). Result in two bands at 3980bp and 202bp.
O represents Ncol restriction sites, Hyperladder I used as DNA marker, Bioline.
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Figure 4.14: Chemiluminescent western blot of plVEX2.4a-ORF65 RTS extract.
Expression of the insoluble (P) and soluble fractions (S) from the plVEX2.4a-ORF65
extract were analysed by western blotting using (a,b) HisProbe-HRP, and (c, d) MCF-
positive antiserum, using a rabbit anti-bovine HRP conjugate. The bound conjugate was
detected by chemiluminescence using the Pierce Supersignal West Dura HRP
substrate.
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Purification was performed using an NHS HisTrap purification column under native
conditions (500mM Imidazole).Twenty-five 1ml fractions were collected from the
column, using the Atka FPLC system (Figure 4.15). Similar to pIVEX2.3-Ov8.5,
fractions corresponding to protein peaks were difficult to analyse due to the presence
of imidazole, therefore the first five fractions were concentrated 5-fold and analysed
by staining (Figure 4.15a) and western blotting using an anti-HisTag monoclonal
antibody (Figure 4.15b). No protein bands were found by staining. By western blot
using an anti-HisTag monoclonal antibody, a faint band was seen at approximately
25kDa and a more strongly reactive band was seen at 97kDa. This result, similar to
findings with the pIVEX2.3 vector, suggests the purification was ineffective in
isolating the target protein, ORF65, possibly as a result of ineffective binding to the
HisTrap column.
NHS HisTrap purification under denaturing conditions was performed.
Twenty-five 1ml fractions were collected and fractions corresponding to protein
peaks. Similar to pIVEX2.3-Ov8.5, fractions were analysed by staining (Figure
4.16a) and western blotting using an anti-HisTag monoclonal antibody (Figure
4.16b). Using SimplyBlue staining several protein bands were seen in the first
elution peak, corresponding to fractions 15, 16 and 17, with apparent molecular
weight between 39kDa and 97kDa.
By western blot, a high level of expression in the crude lysate was shown in
the presence of urea, and bands were detected in fraction 17, at between 50 and
65kDa. A faint band was additionally detected, at 65kDa, in fraction 23 from the
second protein peak. Therefore, as no His-tagged protein was detected at the size
expected for the ORF65 fusion protein, it was assumed that the level of protein
expression was too low for detection by western blot.
As the ORF65 protein could not be purified under native or denaturing
conditions, it was assumed that it was the level of ORF65 expression and not its
folding which was responsible for its lack of detection and therefore further analysis
of this capsid protein was not continued. Non-specific bands were detected by both
the His-Tag monoclonal antibody and anti-MCF serum. Although a band was
detected with the monoclonal antibody at 40kDa, no protein band was seen at the
size expected for ORF65 (38kDa) with anti-MCF sera. ORF65 was therefore not
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Figure 4.15: Electrophoretic analysis of HisTrap purified plVEX2.4a-ORF65.
Fractions (1ml) were collected from a HisTrap purification of plVEX2.4a-ORF65 by
HPLC. Fractions showing peaks on the chromatogram (fractions 9-13) were
concentrated in a 0.5ml micron filter and resuspended in equal volumes in sample
loading buffer. Individual fractions (15pl) were loaded onto a 10% tris-glycine
polyacrylamide gel and run at 100V for 1 hour, alongside the unbound material (U)
present as a control. The fractions were analysed by a) staining with SimplyBlue
SafeStain and b) western blotting using HisProbe-HRP antibody. The bound conjugate
was detected by chemiluminescence using the Pierce Supersignal West Dura HRP
substrate.
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Figure 4.16: HisTrap purification of plVEX2.4a-ORF65 under denaturing
conditions. Fractions (14-23) were electrophoresed alongside the RTS extract (Re)
present as a control. C represents a negative control. The fractions were analysed by a)
staining with SimplyBlue SafeStain and b) western blotting using HisProbe-HRP
antibody. The bound conjugate was detected by chemiluminescence using the Pierce
Supersignal West Dura HRP substrate.
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4.3.4. plVEX2.3-Ov8 Exon 1 (2.1 kb)
Although the pIVEX2.3-Ov8 Exon 1 2.1 kb was shown to be insoluble in
Chapter 3, an attempt to overcome solubility issues was performed. This was carried
out before conclusions were made regarding the analysis of the Ov8 gene fragment.
A clone of pIVEX2.3-Ov8 Exon 1 2.1kb (Figure 4.17) with correct orientation was
selected and 12.3pg of DNA was added to the RTS working solution. The RTS
reaction was run for 24 hours (30°C/ 120rpm). The reaction solution was removed
and centrifuged at 1300 x g for 10 minutes to determine solubility of the expressed
protein. The protein was almost totally insoluble (Figure 4.18).
The final annotation of the OvHV-2 genome indicated a shorter exon and
therefore the original construct may contain coded intron and thus may be
responsible for the expression and solubility problems shown in both bacterial and
cell-free in vitro expression systems. A 0.5kb fragment of Ov8 exon 1 was therefore
cloned and successfully expressed in the thioredoxin fusion expression system.
The insoluble Ov8 exon 1 2.1kb product was centrifuged at 1000 x g for 10
minutes, and the pellet was resuspended in either 2x SDS and incubated at 65°C for 5
minutes, or ELISA coating buffer (0.2M Na2C03, 0.2MNaHCO3, pH9.6). Samples
were fractionated on a 14% tris-glycine gel and analysed by western blotting using
either anti-HisTag monoclonal antibody or MCF-positive sera (Figure 4.19)
The Ov8 RTS product, diluted 10-fold, clearly shows a strong band at 90kDa,
the size expected for Ov8 exon 1 2.1 kb, and a faint band at 64kDa. Different
detergents, SDS and 1% Nonylphenylpolyethylene glycol (NP40) were used to
solubilise the Ov8 protein. Extraction of the insoluble pellet-material with SDS
showed a high level of non-specific proteins ranging from 16 to 250kDa by both
anti-FIisTag monoclonal antibody and polyclonal MCF-positive sera. Washing the
SDS-treated pellet in PBS appeared to remove the majority of non-specific bands,
with the exception of a band at 64kDa.
Extraction with NP40, a detergent used in the production of ELISA antigen
(described in section 5.1.1), apparently failed to solubilised any protein, using the
HisTag monoclonal antibody, while the MCF-positive sera showed a faint band
expressed at 64kDa, but not the size expected for Ov8 Exon 1 2.1 kb (90kDa).
Expression studies using the bacterial expression systems pBAD and pET22b
showed expression of the Ov8 Exon 1 2.1kb protein (described in chapter three).
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Figure 4.17: Orientation of plVEX2.3-08 (2kb).
Presence of insert demonstrated and orientation determined by restriction digest
reaction with enzyme EcoRV (■). Restriction sites in plVEX2.3 vector at 918bp and
1.1 kb (3547bp), and 234bp in the orf65 insert (2.1 kb). Result in three bands at 3.1 kb.
2kb and 191 bp. 0 represents Ncol restriction site, Hyperladder I used as DNA marker,
Bioline.
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Figure 4.18: Chemiluminescent western blot of plVEX2.3-Ov8 RTS extract (2kb).
Expression of the electrophoresed soluble (S) and insoluble (P) fractions of the
plVEX2.3-Ov8 (2kb) extract analysed by western blotting using HisProbe-HRP, using a
rabbit anti-bovine HRP conjugate. The bound conjugate was detected by
chemiluminescence using the Pierce Supersignal West Dura HRP substrate. M
represents protein marker SeeBlue Plus2 (Sigma), and shows a degree of reactivity
against the chemiluminescence reagent.
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a)
Figure 4.19: Chemiluminescent western blot of plVEX2.3-Ov8 RTS extract (2kb).
a) Expression of the electrophoresed insoluble (P) fractions of the plVEX2.3-Ov8 (2kb)
extract treated with SDS buffer (SDS), washed in PBS (W, and W2) and ELISA coating
buffer (E). The gels were analysed by western blotting using b) HisProbe-HRP and c)
MCF-positive sera, using a rabbit anti-bovine HRP conjugate. The bound conjugate was
detected by chemiluminescence using the Pierce Supersignal West Dura HRP
substrate.
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suggesting the protein may have undergone proteolytic cleavage. Purification issues
were also found for pET22b-Ov8, as the protein remained totally insoluble after
mechanical lysis and even treatment with urea.
The final annotation of the OvHV-2 genome indicated Ov8 Exon 1 was only 1.2kb,
and suggests the remaining 0.8kb in the construct used here may be responsible for
the expression and solubility problems shown in both bacterial and cell-free in vitro
expression systems. A 0.5kb fragment of Ov8 exon 1 was therefore cloned and
successfully expressed in the thioredoxin fusion expression system. Purification of
the pTrxFus-Ov8 protein under native and denaturing techniques
Purification of the pTrxFus-Ov8 protein under native and denaturing
techniques appeared to be unsuccessful, as only E. coli superoxide dismutase was
identified in proteomic analysis. The RTS cell-free system was therefore tested to
possibly resolve purification issues.
4.3.5. plVEX2.3-Ov8 Exon 1 (0.5kb)
A clone of the pIVEX2.3-Ov8 Exon 1 0.5kb (Figure 4.20) was selected and
14pg of DNA was added to the RTS working solution. After running the RTS
reaction (24 hours at 30°C/120rpm), the reaction solution was removed and
centrifuged at 1300 x g for 10 minutes to determine solubility of the expressed
protein. The soluble and insoluble phases were collected and resuspended in 2x SDS
loading buffer and analysed by electrophoresis and western blotting to determine
whether any recombinant protein was present in the soluble phase (Figure 4.21).
Using an anti-HisTag monoclonal antibody, the majority of Ov8 expression
was shown to be in the soluble phase, suggesting that the Ov8 exon 1 polypeptide
fragment (531bp) is soluble, unlike the product of the 2kb fragment. HisTag positive
bands were observed between 28 and 188kDa, although no distinct protein band was
seen at the expected size (38kDa). Using anti-MCF antiserum (Figure 4.21), again
proteins of between 28 and 188kDa were detected. Similar to the findings with Ov8.5
and ORF65, this could suggest a level of non-specific histidine binding in the crude
lysate. Therefore purification of the RTS extract was required. Work on the Ov8.5
and ORF65 proteins indicated that purification using the Ni-NTA affinity
chromatography was ineffective and therefore the Ov8 exon 1 fragment was purified











Figure 4.20: Orientation of plVEX2.3-08 (0.5 kb).
Presence of insert demonstrated and orientation determined by restriction digest
reaction with enzyme EcoRV ( ■ ). Restriction sites in plVEX2.3 vector at 918bp and
1.1 kb (3547bp), and 234bp in the orf65 insert (2.1 kb). Result in three bands at 3 1 kb.




Figure 4.21: Chemiluminescent western blot of plVEX2.3-Ov8 (Exon 1) RTS
extract. Expression of the electrophoresed soluble (s) and insoluble (p) fractions of the
plVEX2.3-Ov8 exon 1 RTS extract, were analysed by western blotting using (a)
HisProbe-HRP, (b) MCF-positive antiserum, using a rabbit anti-bovine HRP conjugate.
The bound conjugate was detected by chemiluminescence using the Pierce
Supersignal West Dura HRP substrate.
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4.3.5.1. Affinity purification of plVEX-Ov8 (0.5kb)
RTS extract of Ov8 exon 1 (IOOjliI) was applied to the HisTrap column under
denaturing conditions, using the Atka FPLC system. Twenty-four 1ml eluted
fractions were collected. Fractions corresponding to protein peaks on the FPLC
system trace were difficult to assign due to the presence of imidazole, so that the
seven fractions of the peak were analysed by staining and western blot. The stained
gel showed no protein bands in any fraction, although bands were clearly observed in
the RTS extract and in the fall-through between 38kDa and 97kDa (Figure 4.22a).
Analysis of the same fractions by western blotting, using HisProbe-HRP
antibody, was similar to the stained gel with protein expression observed in both the
RTS extract and fall-through supernatant. However, a faint band at approximately
97kDa was observed in fractions 12 and 24 (Figure 4.22b).
4.3.5.2. plVEX2.3-OV8 gel filtration
Since the initial HisTrap, native and denaturing, purification of Ov8 Exon 1
fusion protein proved ineffective, a further purification technique was performed.
Gel filtration was used to fractionate lysates containing the His-tagged fusion protein
according to size. Separation was performed on a Superdex2oo column, using the
Akta FPLC system. 0.5ml of pIVEX2.3-Ov8 exon 1 RTS extract was injected onto
the column and 1ml fractions were collected and analysed. Thirty fractions were
collected and fractions which corresponded to the four protein peaks on the UV trace
(Figure 4.23) were analysed by staining and western blotting, using HisProbe-HRP
antibody (Figure 4.24) to detect the presence of pIVEX2.3-Ov8 Exon 1 protein in the
eluted fractions.
The initial two peaks, fractions 8, 9 and 13, showed faint protein bands
ranging from 40 to 97kDa. The third peak, corresponding to fractions 15, 16 and 17,
showed three distinct bands at 38, 50 and 64kDa. Fractions corresponding to the third
fractionation peak, fractions 20 and 21, showed no protein present. The expected size
of the pIVEX-Ov8 gene product is 26kDa which was not shown in any fraction
analysed (Figure 4.24a).
A western blot, using HisProbe-HRP antibody, of the same fractions detected
one His-Tagged band at approximately 64kDa in size (Figure 4.24b), present in the
second peak (fraction 13), which corresponds to a band shown by staining (Figure
4.24a). Although this tagged protein may not be Ov8, it is possible that the Ov8
fragment was migrating aberrantly, or was covalently modified. It is however
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surprising that only one band was detected in the fractionated lysate while main
bands appeared to be detected in the crude RTS product.
Figure 4.22: HisTrap purification of plVEX2.4a-ORF65 under native conditions.
Fractions (12-24) were electrophoresed alongside the RTS extract (Re) present as a
control, and unbound material (F). The electrophoresed fractions were analysed by
a) staining with SimplyBlue SafeStain and b) western blotting using HisProbe-HRP
antibody. The bound conjugate was detected by chemiluminescence using the
Pierce Supersignal West Dura HRP substrate.
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Figure 4.23: plVEX2.3-Ov8 Exon 1 (0.5kb) chromatogram.
Gel filtration of plVEX2.3 Ov8 Exonl 0.5kb. Fractions collected in 1ml aliquots from the



















Figure 4.24: plVEX2.3-Ov8 Exon 1 Gel Filtration.
Fractions (9-13) were electrophoresed alongside the unbound material (U) present as a
control. The electrophoresed fractions were analysed by a) staining with SimplyBlue
SafeStain and b) western blotting using HisProbe-HRP antibody. The bound conjugate
was detected by chemiluminescence using the Pierce Supersignal West Dura HRP
substrate.
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4.4. Discussion
Initial work on OvHV-2 genes using bacterial expression systems showed
that genes such as ORF65 and Ov8 Exon 1 could be expressed. However, due to
problems with solubility, purification and isolation of target proteins, an alternative
system was sought to allow the antigenicity of the proteins to be evaluated. Three
OvHV-2 genes (Ov8, Ov8.5 and ORF65) were analysed using the high-yield cell-
free in vitro Rapid Translation System (RTS).
The in vitro synthesis of proteins in cell-free extracts is an important
molecular tool with a variety of applications, including the rapid identification of
gene products by proteomics and protein folding studies. The in vitro translation
systems can have advantages over in vivo gene expression when the over-expressed
product is toxic to the host cell, such as the OvHV-Ov9 gene in the thioredoxin
expression system, described in section 3.3.1. Further advantages include when the
product is insoluble (pET22b-Ov8, pTrxFus-Ov2.5, pTrxFus-Ov7) or when the
protein undergoes rapid proteolytic degradation (pTrxFus-Ov8). The RTS system
showed successful expression of all OvHV-2 genes tested as detected by western
blotting of RTS extracts by anti-HisTag antibodies.
The Ov8.5 gene is unique to OvHV-2 with no homology to any other viral or
cellular protein (Hart et al., 2007) and appears to be expressed (Thonur et al., 2006).
Two tandem repeats are contained within the N-terminal coding region of Ov8.5, at
the same position as a number of other gammaherpesviruses such as bovine
herpesvirus-4 and Kaposi's sarcoma herpesvirus, where the underlying DNA
sequences are involved in the lytic origin of replication (Zimmermann et al., 2001;
Hart et al., 2007). Further studies are required to assign a function for Ov8.5.
In previous expression studies using the thioredoxin bacterial expression
system, the OvHV-2 Ov8.5 fusion was not expressed. In the RTS system, however,
pIVEX2.3-Ov8.5 was detected in the RTS extract. pIVEX2.3-Ov8.5 expressed four
bands at 12, 20, 30 and 36kDa, rather than the expected single band at 40kDa, which
may be due to protein degradation. It is unlikely that all these bands are Ov8.5
derived, and may suggest non-specific protein interaction. Bands of similar sizes
were not shown in any other plVEX2.3-Ov8.5 western blots. Purification of the
Ov8.5 protein, using standard affinity chromatography proved partially successful as
the 36kDa fraction was determined by western blot. No band was visible after
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Coomassie staining. As only a low level of Ov8.5 protein was expressed, further
analysis could not be performed.
The capsid protein ORF65 is likely to be expressed during the lytic cycle of
viral replication. This gene is homologous to the HHV-8 viral capsid antigen ORF65
and the EBV gene EFRF3 and is assumed to share related biological functions (Lin
et al., 1997). ORF65 was found to be expressed and soluble in the thioredoxin fusion
expression system. Purification by standard metal-affinity chromatography was
unsuccessful, which may reflect either low expression of the pTrxFus-ORF65 protein
or poor affinity for the resin. A further possibility may be poor accessibility of the
epitope tag.
Initially the ORF65 gene was cloned into the pIVEX2.3 vector, with a C-
terminal HisTag. plVEX2.3-ORF65 showed the soluble expression of a range of
bands, using an anti-HisTag monoclonal antibody and MCF-positive and -negative
serum. This indicates a level of histidine binding in the crude lysate as a possible
result of E. coli proteins. Affinity chromatography was performed under both native
and denaturing conditions, but proved unsuccessful in the enrichment and
purification of ORF65. A possible explanation for this result may be that the HisTag
was not exposed to the column, as a result of protein folding. The ORF65 gene was
therefore cloned into a different vector with an N-terminal HiseTag.
Similar to pIVEX2.3-ORF65, the pIVEX2.4a-ORF65 protein product was
found in the soluble fraction using an anti-HisTag monoclonal antibody, however,
affinity chromatography proved ineffective in the enrichment and purification of
ORF65. The requirement for protein purification from contaminating E. coli proteins
meant that this ORF65 protein was not investigated further as a potential
recombinant diagnostic antigen. Further experiments are required to analyse ORF65
expression and protein structure. However, due to the time constraints, further
analyses of the capsid protein were not continued.
In bacterial systems pBAD, pET and the thioredoxin (pTrxFus) fusion
expression system vector, the Ov8 exon 1 2.1 kb was insoluble. In the RTS vector
pIVEX2.3 this 2.1kb protein was detected and shown as insoluble. Extraction of the
insoluble protein using different detergent methods showed a level of non-specific
bands, detected using both anti-HisTag monoclonal antibody and MCF-positive sera.
Therefore as this protein was insoluble, further analysis using MCF-positive and -
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negative serum was not performed to demonstrate the antigenicity of the Ov8 exon 1
2.1 kb protein detected.
Similar to pTrxFus-Ov8 Exon 1, however, pIVEX2.3-Ov8 Exon 1 0.5kb
expressed a soluble protein, at the size expected for the Ov8 fusion protein. As
standard affinity chromatography proved ineffective in the purification of all the
OvHV-2 candidate genes Ov8.5 and ORF65 including pIVEX2.3-Ov8 Exon 1
(0.5kb), the Ov8 Exon 1 RTS extract was additionally fractionated by gel filtration.
Analysis by western blot, using an anti-FlisTag monoclonal antibody showed several
tagged bands although none at the size expected for the plVEX-Ov8 (exon 1) fusion
product.
Purification of the candidate proteins is required due to E. coli background
interference before analysis of their suitability in a diagnostic assay. The use here of
the Roche rapid translation system showed that ORF65 and OV8 exon 1 could be
expressed as soluble proteins, similar to their expression in one or more bacterial
systems. Unfortunately, neither of the polypeptides could be purified by affinity
chromatography suggesting the Flis-tag epitope is not an ideal purification tag for
this work. The RTS approach did not improve the solubility of OV8 (2kb), although
it was expressed at high levels. This protein, however, could not be solubilised by
any approach and could not be studied further. The RTS system, however, proved
effective in the expression of OV8.5, which was previously not expressed in the
bacterial thioredoxin expression system.
The inability to express or purify selected candidate genes by the RTS
approach suggests that bacterial expression may not be the best system for
overexpression of these viral genes, despite its ease of use and performance with
other genes. Expression by eukaryotic systems, such as yeast, insect or mammalian
cells, may prove to be better methods to express viral genes for analysis of their
antigenic behaviour. Of particular interest to analyse further is the capsid protein
ORF65 which has been shown to be antigenic in the In Vitro system, although further
studies must be performed to confirm this finding.
In the absence of good recombinant antigen expression, alternative methods
for identifying potential diagnostic antigens were followed, including the use of
crude antigen preparations from cultured A1HV-1 and OvHV-2 infected cells,
analysed by both ELISA methods and western blotting.
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Establishment of the WC11 -ELISA
Establishment
5.1. Introduction
MCF typically emerges sporadically, with a small number of affected
animals, although epidemics may occur (Brenner et al., 2002). Outbreaks where
several animals in a herd were infected have been reported in Spain (Yus et al.,
1999), Turkey (Dabak and Bulut, 2003), Saudi Arabia (Abu Elzein et al., 2003) and
Great Britain (Hamilton, 1990; Collery and Foley, 1996; Otter, Pow and Reid, 2002).
Generally, the disease is of low prevalence, although herd outbreaks have shown as
many as 50% of animals can be affected. The most common characteristics of the
disease include a high temperature, nasal and ocular secretions, followed in the
majority of cases by death. As MCF has a range of clinical signs and is similar to a
variety of other diseases, initial diagnosis can prove difficult (Holliman, 2005).
MCF infections in cattle can result in clinical signs within weeks although in
some cases they may take months to develop (O'Toole et al., 1995 and 1997;
Brenner et al., 2002). Once an animal presents with clinical signs, mortality
approaches 100%. There is, however, evidence for animals with chronic MCF
recovering (Milne and Reid, 1990; Otter et al., 2002). In addition to these findings,
further studies have shown animals from an MCF outbreak that died without
showing any characteristic signs of MCF (Brenner et al., 2002). This suggests that
cattle may become infected without developing clinical MCF (Powers et al., 2005).
The identification of MCF affected animals is currently based on the
detection of antibodies to A1HV-1 antigens using a variety of assays including virus
neutralisation and indirect-immunofluorescence tests (Plowright et al., 1963; Office
International des Epizooties, 2000), although histopathological examination remains
the most recognised diagnostic procedure to date (Muller-Doblies et al., 1998). PCR
assays are also available for the detection of MCFV (Baxter et al., 1993; Hussy et al.,
2001; Flach et al., 2002; Fi et al., 2005).
Virus neutralisation (VN) and immunofluorescence tests (IFAT) have been
employed to determine the MCF status of animals and for the confirmation of MCF
in susceptible species. Of these tests, the virus neutralisation test is the most virus-
specific (Wan et al., 1988) as indirect immunofluorescence tests may detect
antibodies to other bovine herpesviruses e.g. bovine herpesvirus-4 (BoHV-4). By
immunofluorescence, sera are only considered positive when foci show characteristic
intra-nuclear distribution of antigen with little or no cytoplasmic staining being
detected in the AIHV-1-infected cells (Wan et al., 1988; Fi et al., 1994). No reaction
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should be observed in BoHV-4 infected cells, therefore, a negative control for this
test should include cell monolayers infected with BoHV-4.
As a basis for an MCF-specific assay, a competitive-inhibition ELISA (CI-
EL1SA) was developed (Li et al., 1994) based upon a monoclonal antibody (MAb
15-A) which binds an epitope, on a complex of glycoproteins, conserved among all
MCFV isolates. The Minnesota MCF isolate virus used as the coating antigen for the
Cl-ELISA antigen, is indistinguishable from the WC11 strain of A1HV-1 (Office
International des Epizooties, 2003). Although specificity proved high (91-100%
relative to IFAT), analysis of serum samples using the CI-ELISA proved less
sensitive (56-87%) than diagnosis based either on histopathology or PCR assay
results (Muller-Doblies et al., 1998). The CI-ELISA sensitivity was later improved in
a reformatted ELISA, conjugating the monoclonal antibody directly with horseradish
peroxidase to offer a four-fold increase in analytical sensitivity (Li et al., 2001).
Although the CI-ELISA has the advantage of being faster and more efficient
than IFAT (Office International des Epizooties, 2003), disadvantages of the test
include the potential for false negative results, where antibodies specific to the
conserved epitope have not developed in an infected animal. Additionally, the cost of
the CI-ELISA may explain why the assay is not widely used, especially in
developing countries ($250 per plate excluding shipping costs). The provision of a
simple MCF-antibody specific ELISA would therefore prove beneficial in the routine
surveillance of clinical cases and in the study of MCF in sheep and cattle which
remain asymptomatic.
The principle aim of this study was to test whether an ELISA for MCFV-
specific antibodies, based on a crude infected-cell lysate, could provide a diagnostic
test that may be universally available. Initial stages required in the development of a
new, diagnostic assay such as an ELISA consist of feasibility studies for protocols
and reagents used. Standardisation of the test and its performance should also be
examined prior to tests being routinely used (Office International des Epizooties,
2003).
The MCFV strains (WC11 (Plowright et al., 1963) and C500 (Plowright et
al., 1975), derived from wildebeest, and the OvHV-2 BJ1035 cell line derived from
sheep (Shock et al., 1998) were analysed as possible assay antigen reagents
(described in section 2.7.3). A1HV-1 and OvHV-2 are antigenically related so that
cross-reactivity in MCF serology occurs (Rossiter, 1981: Reid et al., 1989). Positive
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and negative control serum and conjugated antibody solutions were analysed, and
optimal concentrations of each were determined in the absence of diagnostic samples
with a view to designing an MCFV ELISA (section 5.2.1.1).
This chapter describes the development of an A1HV-1 ELISA for MCFV-
specific antibodies based on a crude infected-cell lysate, for the detection of anti-
MCFV antibodies and compares the results obtained with established diagnostic
assays. To complete the establishment and preliminary validation of this assay,
serum samples submitted for MCF testing were collected and analysed in a parallel
study to allow a comparison of IFAT, the commercially available MCF ELISA (CI-
ELISA) and the virus-based WC11-ELISA. The WC11-ELISA was further used to
examine the prevalence of antibodies to OvHV-2 in cattle with clinical MCF and
examine the potential of cross-reactivity to other bovine herpesviruses.
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5.2. Materials and Methods
5.2.1. ELISA antigen preparation
Due to the lack of a productive ceil culture system for OvHV-2, A1HV-1
infected cell culture was analysed. A second reason for the WC11 isolate being
analysed was due to the same strain being used in the diagnostic test, indirect
immunofluorescence assay (IFAT) and the availability of a suitable control antigen.
Four 150cm2 flasks of BT cells were washed twice with Flanks balanced salts
solution (HBSS). Two flasks were inoculated with 4mls (4xl05 TCID5o/ml) of cell
culture-grown virus WC11 supernatant, while the remaining two flasks were
inoculated with 4mls of FIBSS and used both as a negative control and to prepare the
negative coating antigen. All flasks were incubated for one hour at 37°C, with
occasional rocking to ensure even distribution of inoculum. Fifty millilitres of
IMDM (Gibco Invitrogen cell culture, Paisley, UK ) medium supplemented with
10% (v/v) FBS, 1% (w/v) glutamine and 1% (w/v) penicillin with streptomycin
(100pg/ml) were added to each flask and the flasks were incubated at 37°C until 90-
100% CPE was observed in the infected flasks. CPE was seen after 4-5 days.
The supernatant, containing infected and detached cells, was decanted into
50ml centrifuge tubes. Fifty millilitres of 1% PBS (v/v) was added to each flask to
wash remaining cells, and then decanted and centrifuged at 2000 x g for 10 minutes
at 4°C. The infected cell pellet was re-suspended and pooled into lOOmls of PBS and
re-centrifuged. The supernatant from each tube was discarded and the cell pellets re-
suspended in 1.5ml of 1% PBS (v/v) containing 1% Nonylphenylpolyethylene glycol
(Nonidet-P40; NP40) detergent (Merck Bioscience, Nottingham. UK), and placed
back into the original cell culture flask. The flasks were incubated for two hours at
4°C, tilting every 15 minutes, to remove and lyse attached cells. Soluble lysate was
removed from each flask, pooled and clarified at 11,600 x g for 5 minutes at room
temperature (22 ± 5°C). Supernatant was removed and the pellet discarded. The
supernatant was stored at -70°C until required. As the cells were not detached in the
control flasks, supernatant was removed and PBS containing 1% NP40 placed to the
flasks to lyse attached cells. ELISA antigen was also prepared using the A1F1V-1
C500 virus isolate by the same method. Virus inoculum was kindly supplied by the
Virus Surveillance Unit, Moredun Research Institute.
The BJ1035 LGL line from an OvHV-2 infected animal (Shock et al., 1998)
was maintained in IMDM supplemented with antibiotics (as described in section
2.3.1.) and 350 IU/ml of IL-2 (Proleukin, Chiron Therapeutics, Emeryville, CA).
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Medium from two 75cm2 flasks containing the cell line was decanted, when
confluent, into 50ml centrifuge tubes. Cells were non-adherent. Ten millilitres of
PBS was added to each flask to wash the remaining cells, and decanted into
centrifuge tubes. Cells were harvested and centrifuged at 2000 x g for 10 minutes at
4°C. The cell pellets and cells remaining in the flasks were then treated as stated for
the A1HV-1 ELISA antigen.
As there was no simple negative control cell line available for the OvHV-2
BJ1035 cell line, ConA blasts were produced as an appropriate uninfected control.
Blood was collected in preservative-free heparin (200pl/10ml) from a MCF-negative
calf. Under sterile conditions, the blood was centrifuged at 1800 x g for 10 minutes
(22± 5°C). The white cell layer was removed, and was resuspended in 5mls of HBSS
supplemented with 1% FBS and penicillin and streptomycin. The cells were then
layered onto 5mls of lymphoprep (Fresenius, Oslo, Norway) in a 15ml conical tube
and centrifuged at 2000 x g for 45 minutes (22+ 5°C) without active braking. The
lymphocyte layer was removed at the interface between the lymphoprep and the
medium, resuspended in 20mls of wash medium and centrifuged at 1800 x g for 10
minutes. The cell pellet was resuspended in 5mls of medium and a viable cell count
was performed (optimum concentration of lxlO6 cells/ml required). The cells were
pelleted and resuspended in IMDM medium supplemented with antibiotics. Cells
were then inoculated onto 6-well plates, 2xl06 cells/well with 5 pg/ml of ConA and
incubated at 37°C in 5% CO2 until cell aggregation was observed. Cells were
harvested and centrifuged at 2000 x g for 10 minutes at 4°C (described in section
2.6.4.1.2). The soluble lysate of these cells was stored at -70°C until required.
5.2.2. ELISA Optimisation
Titrations to determine optimum reagent concentrations were carried out
under standard test conditions as described by Hebert et al., (1985). Optimum
reagent concentrations were established by varying the concentrations of antigen and
FIRP-conjugated antibody and primary serum antibody. Firstly, the antigen and
conjugate was optimised using a 1/100 serum dilution. On establishing optimised
conditions, the test serum dilution was optimised.
The concentration of virus-infected antigen employed was determined by
BCA protein assay as 0.5mg/ml. Aliquots of infected A1FFV-1 antigen (1 OOjllI) were
coated onto columns 1, 3, 5, 7, 9 and 11, while aliquots of the BT cell line, used to
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propagate the virus and as a control antigen, were coated onto columns 2, 4, 6, 8, 10
and 12 of a M129B microELISA plate (Greiner Bio-one, Frickenhausen, Germany).
To determine the optimal antigen concentration, the A1HV-1 antigen was diluted in
carbonate coating buffer (0.2M Na2C03, 0.2MNaHCO3, pE19.6). Dilutions ranged
from 1/50 to 1/850. The plate was incubated overnight at 4°C. The negative control
was included to differentiate the specific anti-viral antibody from antibodies directed
against antigenic determinants of the cell line used, and therefore aims to reduce the
number of false positives and establish background reactivity for each antiserum.
Between each stage the plates were washed four times in ELISA wash buffer
(PBS plus 0.05% Tween-20, [PBST]) using an automated ELISA plate washer
(Ultrawash plus, Dynatech laboratories).
All subsequent dilutions were made in PBST containing 10% (v/v) horse
serum (PBSTH). One hundred microlitre volumes were used. Control MCF positive
serum, at a 1/100 dilution, was added to all wells. The plate was incubated for 1 hour
at 37°C. After washing, conjugate (Donkey anti-sheep or Rabbit anti-bovine IgG
horseradish peroxidase [Sigma, Poole,UK]) was added at dilutions ranging from
1/500 to 1/5000, to duplicate infected and control wells. The plate was incubated for
a further one hour at 37°C, washed, and lOOp.1 tetramethylbenzidine (TMB)
peroxidase substrate 1-component added (KPL Insight Biotechnology Limited,
Middlesex, UK). The reaction proceeded at room temperature (22±5°C) for 5
minutes before being stopped by the addition of lOOql 0.18M H2SO4. The optical
densities were read using a MRX plate reader (DYNEX Technologies, Virginia,
USA) with a 450nm filter. Results were calculated as an average antigen-specific
optical density, i.e. average OD of infected antigen paired samples minus average
OD of control antigen paired samples.
The tests were deemed valid if there was no significant difference between
the positive and negative controls, performed as standard on each plate tested.
Additionally no significant difference was noted between the first and last plate read,
and the time between reading plates was minimal.
Two horseradish-peroxidase (HRP) conjugates were tested to determine the
optimum conjugate conditions for an A1HV-1 MCF ELISA. Donkey anti-sheep IgG
monoclonal antibody (The Binding Site Limited, Birmingham, UK) was tested as it
is used routinely in the indirect immunofluorescence assay. In addition, Rabbit anti-




Three positive serum controls, from cattle experimentally immunised with
attenuated A1HV-1, were tested (K265, K525 and K856). These samples were MCF
seropositive by IFAT. A positive control serum for OvHV-2 (05-687) was collected
from a cow presenting clinical signs of MCF, positively diagnosed by IFAT. Serum
collected from a clinically healthy cow (700738) was used as a negative control in
the ELISA. All test serum was kindly obtained from Iris Campbell (MCF group
vaccination study) and Janice Gilray, Virus Surveillance Unit, MRI.
To address potential cross-reactivity with other herpesviruses in the WC11-
ELISA, reactivity against bovine herpesvirus-4 (BoHV-4), infectious bovine
rhinotracheitis virus (IBR/BHV-1) and bovine herpesvirus-2 (BHV-2/bovine
mammilitis) sera was tested. BHV-1, BFIV-2 and BoFIV-4 BHV serum samples were
kindly obtained from Janice Gilray, Virus Surveillance Unit, MRI. These samples
were from field cases submitted for routine diagnostic testing by the surveillance
unit.
5.2.4. Positive Reaction Threshold
To establish the range of negative reaction values and a threshold positive
reaction in the WC11-ELISA, negative serum control samples from 197 clinically
healthy cattle, originating from a farm with no history of MCF and no direct contact
with sheep, were kindly provided by George Caldow of Scottish Agricultural
Colleges Veterinary Services. Each sample was tested in duplicate.
5.2.5. Analysis of Field Sera
Using optimum reaction conditions for antigen, control scrum and conjugated
antibody, field sera were analysed. Samples were taken from field sera submitted in
2004 for the detection of antibodies against MCFV by IFAT. These included cattle
with clear signs of MCF and others with clinical signs only indicative of enteric
disease. Sera from cattle with clinical symptoms indicative of potential MCF were
submitted to the Virus Surveillance Unit at the Moredun Research Institute, for
routine testing by IFAT. Serum samples which tested IFAT negative were also
included for analysis. Clinical evaluation and histopathological testing were carried
out to provide a final diagnosis in some cases. All sera were stored at -20°C until
required. Each sample was tested in duplicate and any discrepant results were re-
analysed. As the IFAT values were already known for the sera samples tested, all
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sera were tested blind. This was achieved by coding all the samples randomly. Some




5.3.1. Development of an Enzyme-linked Immunosorbent Assay
5.3.1.1. Determination of optimum ELISA reaction conditions: AIHV-1
MCF antigen, Horseradish peroxidase conjugate and test serum.
In order to determine the optimum conditions for an MCFV ELISA, the
concentrations of all reagents were titrated against each other.
As the Minnesota MCF isolate virus, used as the coating antigen for the CI-
ELISA antigen, is indistinguishable from the WC11 strain of A1FIV-1, routinely used
by IFAT (Office International des Epizooties, 2005), the WC11 antigen was initially
tested. The antigen was tested at dilution from 1/50 to 1/300 (Figure 5.1). The control
antigen used was mock-infected BT cells. No negative control serum was tested at
this initial optimisation. As this test was to determine the conjugate and antigen
dilutions to use, no test serum was analysed. Dilutions were tested in duplicate for
both positive and negative antigen, whereby the mean of negative antigen was
subtracted from the mean of the positive antigen. These results showed no end-point
of activity; therefore larger ranges of dilutions were tested to identify the optimum
antigen dilution. The positive control serum, K856, was used at an initial 1/100
dilution. All titrations were performed in duplicate.
Two HRP-conjugated antibodies were tested, HRP-labelled Donkey anti-
sheep monoclonal antibody and Rabbit anti-bovine IgG polyclonal antibody. The
conjugated antibodies were tested at dilutions ranging between 1/2000 and 1/5000 to
gain an estimated FIRP-conjugate dilution (Figure 5.1). The absorbance values
obtained for the Donkey anti-sheep HRP conjugate were relatively low, between 0.2
and 0.8 absorbance units (AU) (Figure 5.1a.). The Rabbit anti-bovine HRP-conjugate
showed higher activity, between 0.4 and 1.2 AU (Figure 5.1b.). Diluted at 1/2000,
the rabbit anti-bovine IgG conjugated antibody (polyclonal) showed the highest
activity (1.2 AU) and was used in further optimisation tests.
The highest AU450 values was found at a 1/2000 dilution, therefore in order to
determine whether a lower conjugate dilution would be optimal, a dilution range of
1/500 to 1/2000 was analysed. Antigen concentrations were also extended as no
reaction end-point was initially reached (1/50 to 1/850). Activity increased rapidly
between antigen dilutions of 1/50 and 1/200 (Figure 5.2.) where it peaked at an
absorbance of 0.6 AU, and remained relatively constant at approximately 0.5-0.6AU
from 1/200 to a dilution of 1/350, before decreasing rapidly to an absorbance of
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Figure 5.1: Optimisation of MCF direct ELISA. The MCF virus strain WC11and BT cell control
were tested at varying dilutions (1/50-1/300) at a range of conjugate concentrations (1/2000 and
1/5000 shown by legend) to determine the optimal test conditions. Control serum (K856) was
kept at a constant dilution of 1/100 to acquire the optimal antigen and conjugate reaction
conditions. Two HRP conjugates were analysed (a) Donkey anti-ovine IgG and (b) Rabbit anti-
bovine IgG conjugate due to being employed in established MCF diagnostic tests. The y axis
represents the average OD for the positive antigen minus the average OD for the negative




Figure 5.2: Optimisation of MCF direct ELISA conjugate concentration. AIHV-1
virus strain WC11 was tested at varying dilutions (1/50-1/850) at a range of Rabbit anti-
bovine conjugate concentrations (1/500 and 1/2000 shown by legend) to acquire the
optimal antigen and conjugate reaction conditions. The y axis represents the average
OD for the positive antigen minus the average OD for the negative antigen, while the x
axis represents antigen dilution.
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0.2AU. Discrepancies were noted in the OD values obtained at antigen dilutions
1/200 and 1/350, this can be explained by the use of a new ELISA plate, therefore
there may be a difference in absorbance due to the hydration of the individual plate
wells, particularly in the outer wells.
The optimal WC11 antigen concentration selected was 1/200. All dilutions of
conjugate showed similar profiles across the range of antigen dilutions, with a 0.1
absorbance reduction between the 1/500 and 1/1000 dilutions; and a further 0.1
absorbance reduction between 1/1500 and 1/2000, while 1/1500 and 1/2000 dilutions
showed similar results. The selected reaction conditions were therefore at a
conjugated antibody (HRP-rabbit anti-bovine IgG) dilution of 1/500. Discrepant
results
Peak absorbance values in optimisation test two were approximately half that
of the previous test (0.6 AU); this may be explained as a result of leaving the antigen
coated plates an extra 24 hours (+4°C) before washing and adding serum samples.
Although the greatest activity was at a 1/500 dilution, a more economical conjugate
dilution of up to 1/2000 could be employed without altering the outcome.
Using the optimised conditions, three MCF positive serum samples, from
experimentally infected animals, were tested. To establish positive control values, a
series of antigen dilutions were tested, ranging from 1/50 to 1/300 with conjugate
(HRP-rabbit anti-bovine IgG) dilutions ranging from 1/2000-1/5000 using the
positive control sera at a 1/100 dilution (Figure 5.3.).
Sera samples K265 and K525 showed an increase in ELISA reaction between
antigen dilutions of 1/50 and 1/100 with an absorbance of 0.12 AU. Between 1/100
and 1/200 antigen dilutions, the activity reduced before remaining constant at
approximately 0.1 AU at a dilution of 1/250 (Figure 5.3a.). The optical density values
of these sera samples were low due to non-specific background interference. Serum
K856 increased in activity between antigen dilutions of 1/50 and 1/100 (Figure 5.3c.)
and peaked at an absorbance of 1.2 AU. At 1/100 activity remained relatively
constant at approximately 1.2 AU up to a dilution of 1/300. It was found that the
K856 serum showed the greatest activity of the control sera using both conjugates,
and was subsequently employed in the optimisation of the basic ELISA reagents.
Although the K856 results showed no end-point, an antigen dilution of 1/200 and a
conjugate dilution of 1/1000 were employed in subsequent sera tests.
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Figure 5.3: ELISA analysis of MCF-positive sera. Positive bovine serum samples (a)
K265 (b) K525 and (c) K856, tested at a range of AIHV-1 virus (strain WC11) antigen
dilutions (1/50-1/300) at a range of Rabbit anti-bovine conjugate concentrations (1/500




The positive control serum K856 and negative serum sample from a clinically
healthy cow were used for testing with the optimal reaction conditions determined.
Both samples had been previously tested by IFAT, confirming the positive/negative
status of the samples utilised. In order to determine the optimal concentration of
serum required for the test, a series of dilutions were performed (ranging from 1/25
to 1/600) for both serum samples. The data obtained for the positive serum showed a
gradual decline in absorbance values, decreasing from an absorbance value of 1.5
(serum dilution 1/25) to 0.6 (dilution 1/600). No reactivity was observed for the
negative serum. The optimal reaction conditions were therefore at a serum dilution of
1/25 (Figure 5.4.). Although the greatest reaction was under these conditions, a more
economical dilution of 1/100 was employed.
5.3.1.2. Antigen Optimisation
5.3.1.2.1. AIHV-1 C500 strain
To assess other potential ELISA antigens which may be used in a MCF
specific diagnostic test, other MCF virus isolates were analysed. The C500 high-
passage strain of AlHV-l was therefore compared against WCl l. A range of antigen
dilutions (1/50-1/250) and conjugate dilutions (1/500-1/2000) with a serum dilution
of 1/100 were analysed. The results showed the same optimal conditions for both
AIHV-1 viral strains. IFAT results were used as a gold standard in this case. The
C500-EFISA gave a sensitivity of 67% and a specificity of 100% relative to IFAT
results, while the WC11-ELISA showed 100% agreement with the IFAT results
(Table 5.1). Since C500 was no better as an ELISA antigen than WCl 1, studies were
continued with the WCl 1 ELISA.
5.3.1.2.2. Sucrose gradient purified virus, strain WC11.
Sucrose-gradient purified AIHV-1 virus (4xl05 TCIDso/ml), described in
section 2.2.4, was additionally analysed as a potential ELISA antigen. A range of
antigen dilutions (1/100-1/600) and conjugated antibody dilutions (1/500-1/2000)
were analysed, with a serum dilution of 1/100. Results showed no end-point for the
reaction (Figure 5.5.). A comparison of purified and crude WCl 1-infected lysate,
under optimal antigen and conjugated antibody dilutions, showed a difference of 0.9
AU between the two methods.
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Figure 5.4: Comparison of MCF-positive and negative serum samples.
Dilutions of positive (K856) and Negative (700738) bovine serum samples tested using
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Figure 5.5: Sucrose-gradient purified AIHV-1 virus (strain WC11).
Virus tested at varying dilutions (1/100-1/600) at a range of conjugate concentrations
(1/500 and 1/2000 shown by legend) to acquire the optimal antigen and conjugate
reaction conditions. A serum dilution of 1/100 was employed.
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A peak in activity of 2.1 AU at a 1/100 antigen dilution was shown for the
purified virus. Activity showed a gradual decline in absorbance values to 1.9 AU at a
1/200 antigen dilution and remained relatively constant up to a dilution of 1/600.
Therefore compared to the crude lysate optimal antigen dilution of 1/200 and
conjugate dilution of 1/1000, a more economical antigen dilution of up to 1/600 with
a conjugate dilution of 1/2000 could be employed for purified virus. This could result
in a loss in sensitivity with a reduction of 0.2 AU in absorbance. This suggests
purified virus could be employed at a dilution greater than that of the crude lysate.
However, due to the time-consuming protocol required for sucrose-gradient purified
virus, this was not seen as a viable source of antigen.
Sample C500 WC11 IFAT
Optical Result Optical Result Result
Density Density
1 -0.059 Negative 0.014 Negative Negative
2 0.19 Positive 0.397 Positive Positive
3 0.002 Negative 0.259 Positive Positive
4 -0.005 Negative -0.028 Negative Negative
5 -0.05 Negative -0.065 Negative Negative
6 -0.006 Negative -0.062 Negative Negative
7 -0.053 Negative 0 Negative Negative
8 0.215 Positive 0.528 Positive Positive
Positive 0.854 Positive 0.945 Positive Positive
Control
Negative -0.049 Negative -0.003 Negative Negative
Control
Table 5.1: Analysis of selected MCF bovine field serum samples (n = 8), by the
C500-ELISA, WC11-ELISA and I FAT (87.5% agreement).
5.3.1.2.3. Ovine herpesvirus-2
ELISA antigen prepared from OvHV-2 lysate from an infected cell-line
(BJ1035) was tested using an OvHV-2 positive (05-687) and negative (700738)
control serum. A range of antigen dilutions (1/25-1/600) and conjugated antibody
dilutions (1/500-1/2000) with a serum dilution of 1/100 were analysed (Figure 5.6).
The OvHV-2 lysate-based ELISA gave optical density values that were greater for
the control antigen than the infected cell lysate and was, therefore, not seen as a
viable source of antigen (Figure 5.6).
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Figure 5.6: Optimisation of OvHV-2 ELISA antigen
OvHV-2 virus tested at varying dilutions (1/25-1/600) at a conjugate concentration of




Con A blast controls would therefore be unsuitable for a negative control for OvHV-
2 infected lysate from an infected cell-line. No further analysis was performed using
OvHV-2 antigen.
5.3.1.2.4. Clinical sera
A blind selection of 20 clinical samples submitted for MCF testing was used
for further analysis. All sera were tested in duplicate, at a dilution of 1/100 (as
determined in section 5.3.1.3.). Serum K856, employed as a control in the
optimization stages of the ELISA, was used as a positive control. The 20 serum
samples were examined by both the WC11-ELISA and IFAT. Antibodies against
MCFV were detected in seven serum samples by WC11-ELISA. A further three
samples reacted negatively in the WC11-ELISA, but appeared positive by IFAT,
while one sample reacted positively in the WC 11-ELISA, but appeared negative by
IFAT. The remaining nine sera gave negative results in both assays (Table 5.2.). The
efficiency of the WC11-ELISA for the diagnosis of MCF was tested by determining
the relative sensitivity and specificity of the ELISA for the diagnosis of confirmed
cases. Using the above set of 20 serum samples and IFAT as the "gold standard"
(Table 5.2.), the WC11-ELISA gave a sensitivity of 70% and a specificity of 90%.
The Cohen kappa value confirmed moderate agreement between the WC 11-ELISA
and IFAT when plotted against each other (k = 0.6) (Everitt, 1989).
IFAT
WC11-ELISA Positive Negative Total % Agreement
80
Positive (>0.15) T lb 8
Negative (<0.15) 3C 9d 12
Total 10 10 20
Table 5.2: Comparison of the relative sensitivity and specificity of the WC11-
ELISA compared to IFAT. Relative sensitivity a/a+c = 7/10 = 70%. Specificity d/d+b
= 9/10 = 90%.
The four discrepant samples that gave ambiguous results were retested by
both tests. One sample tested negative in the WC11-ELISA, changing from positive,
and remained positive by IFAT. Two samples tested negative by IFAT, changing
from positive, and was confirmed positive by WC11-ELISA (Table 5.3).
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Contradictory results were observed for only one animal which reacted positively by
IFAT but negatively by the WC11-ELISA (0.071 AU).
Sample ELISA Second test
number IFAT Agree
OD Result OD Result
9 Positive 0.352 Positive Yes - -
10 Negative 0.065 Negative Yes - -
11 Positive 0.071 Negative No 0.001 Unchanged
12 Positive 0.256 Positive Yes - -
13 Negative 0.029 Negative Yes - -
14 Positive 0.058 Negative No 0.011 IFAT negative
15 Positive 0.200 Positive Yes - -
16 Positive 0.757 Positive Yes - -
17 Negative 0.015 Negative Yes - -
18 Positive 0.12 Positive Yes - -
19 Negative 0.133 Positive No 0.070 E LISA negative
20 Negative 0.015 Negative Yes - -
21 Positive 1.083 Positive Yes - -
22 Positive 0.587 Positive Yes - -
23 Negative 0.075 Negative Yes - -
24 Positive 0.019 Negative No 0.016 IFAT negative
25 Negative 0.017 Negative Yes - -
26 Negative 0.027 Negative Yes - -
27 Negative 0.021 Negative Yes - -
28 Negative 0.014 Negative Yes - -
Table 5.3: Blind selection of MCF bovine field serum samples. Samples were
analysed by the WC11-ELISA and IFAT (n = 20, 80% agreement).
5.3.1.2.5. Reaction Threshold
Minitab software was used for the statistical analysis of results obtained from
the uninfected population of 197 animals to determine the range of negative values
and optimise a threshold value for positive reactions. Analysis of the data from the
diagnostic tests determined the mean and standard deviation, allowing a 99%
confidence threshold value of 0.15 OD units, to be established (Mean plus 3xSD). A
reaction threshold of 0.15 for the WC11-ELISA was based on assays, which included
a few aberrantly high OD values (Figure 5.7a.), which when retested were all below
0.1 OD. Some of the aberrant values were due to single, aberrant value from a single
well. This fact supports the need for repeat testing of such samples or discounting
results from aberrant wells for an accurate diagnosis. Of the samples tested, eight
samples had an OD value greater than 0.1, of which three had values greater than
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0.15. The remaining 189 samples had an OD value of less than 0.1. All samples were
retested. After retesting discrepant samples from the first test, a threshold value of
0.1 would have been obtained. It was therefore decided that samples which lie
between threshold values of 0.1 and 0.15 should be repeated to obtain a more
accurate diagnosis.
All 197 samples were analysed with the CI-ELISA, which detects the
presence of immunoglobulins specific for an antigen conserved among MCF viruses
(Li et al., 1994, 2001), and association between the tests was analysed. All samples
gave negative results in this assay, with inhibition levels less than the established
threshold of 25% inhibition (range -72% to 21%). Comparative analysis indicated
that the three false positive samples identified by the initial WC11-ELISA were clear
negatives in the CI-ELISA (-18 to -33% inhibition). Five serum samples tested had
high CI-ELISA values, ranging from 3 to 21% inhibition, while the corresponding
WC11-ELISA test results ranged from -0.01 to 0.05 AU. Good correlation was
shown between the tests (Figure 5.7b.). The majority of samples formed a population
showing low readings in both tests. Dot and box plot analysis of these results are
shown in section 5.3.2.
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Figure 5.7: Comparison of MCF ELISA tests
a) WC11-ELISA results from the negative control population (n=197). b) Scatter plot of
the OD readings (expressed as absorbance at 450nm) for the WC11-ELISA plotted
against the percentage inhibition for the CI-ELISA. Cut-offs for each assay are marked
with broken lines (WC11-ELISA positive >0.15, CI-ELISA positive >25%).
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5.3.2. Comparison of MCFV ELISA tests
Sera from 95 cattle, at a single dilution of 1/100 were examined (in duplicate)
by both the CI-ELISA and the WC11-ELISA (Table 5.4.). A single dilution was
performed for test samples as was deemed to be the optimal test conditions during
optimisation (determined in optimisation of ELISA protocol in section 5.3.1.1). By
CI-ELISA, antibodies against the MCFV-specific epitope were detected in twenty-
seven serum samples. A further 6 samples reacted negatively in the CI-ELISA, but
appeared positive by WC11-ELISA (0.15 threshold). The remaining sixty-two
samples gave negative serological results in both assays (Figure 5.8). Of the
discrepant samples, five were just below the 25% CI-ELISA reaction threshold
value, with sample values ranging from 10-19% inhibition (Inhibition threshold
determined by Li et al., 2001). It is unclear why a negative inhibition is caused in the
absence of antibodies in the test serum. The occurrence of negative inhibition is not
described in either the kit information or the available reference and therefore no
explanation can be drawn on the results obtained from the negative values from
MCF-negative animals. The test was performed as described in the kit protocol, in
accordance with the ELISA developed in Li et al., 2001
The six discrepant samples were repeated in duplicate with both tests and the
mean sample OD calculated (mean positive O.D. minus mean negative O.D.). Three
samples subsequently tested positive in the CI-ELISA, remaining positive in the
WC11-ELISA. One sample tested negative in the WC11-ELISA, which was
confirmed negative by the CI-ELISA. The two remaining samples (samples 48 and
87) were again shown to be negative by CI-ELISA (10% and 22% inhibition) and
positive by WC11-ELISA (0.246 and 0.255). Thus, after repeating both tests,
contradictory results were observed for only two animals. However for one of these
samples, MCF was confirmed by histopathology. Clinical signs and
immunofluorescence tests (IFAT) supported this finding. The second CI-ELISA
negative/ WC 11-ELISA positive serum sample had no histopathology results
available but had MCF confirmed by IFAT. No samples that tested negative by
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Figure 5.8: Comparison of CI-ELISA and virus-based WC11-ELISA results.
WC11-ELISA analysis of 95 field sera (a), expressed as absorbance reading at 450nm.
Un-shaded bars represent positive samples by this test (>0.15, shown in descending
order). CI-ELISA analysis of the same samples (b), expressed as percentage inhibition.
Un-shaded bars represent positive samples in the WC11-ELISA. Cut-off values for each












To analyse the data from the two ELISA assays, dot and box plots were
performed. Dot plots are used to illustrate data distribution, while box plots are used
to show the profile of data distribution, central value or median, and variability.
These representations should indicate whether the sample distribution was
skewed. Dot plot and box plot analyses showed positive absorbance ranges ranging
from 0.625 to 1.51, and negative absorbance ranges ranged from -0.1 to -1.5 OD
units in the WC11-ELISA. The CI-ELISA showed positive values ranging from 25 to
55% inhibition and negative values ranged from -60% to 24% inhibition in the CI-
ELISA (Figure 5.9a).
Additionally, the box plot results show the distribution of samples in regards
to the mean and median points calculated (Figure 5.9b). In the case of the WC11-
ELISA, the mean interval point was shown, revealing the negative samples had a
restricted distribution, with only a difference of 0.2AU while the positive samples
showed a wider distribution, with a difference of 0.45AU. In the case of the CI-
ELISA, the distribution was skewed, as results for the majority of the negative
sample distribution ranged between -25 and -45% while positive samples ranged
between 25 and 55%. The percentage inhibition of individual samples was
determined by the tests validation criteria (described in section 2.6.4.2).
5.3.2.1. Evaluation of sensitivity and specificity of the WC11-ELISA
The efficiency of the WC11-ELISA for the diagnosis of MCFV was
measured by determining test sensitivity and specificity of the ELISA for the
diagnosis of confirmed cases, using the above set of 95 serum samples and the CI-
ELISA as the "gold standard" (Table 5.5.). The WC11-ELISA gave a sensitivity of
100% and a specificity of 91% relative to the CI-ELISA. When the CI-ELISA and
the WC11-ELISA results were plotted against each other, the Cohen kappa value
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Figure 5.9a: Dot plots distribution. Distribution of absorbance values in the samples
analysed by MCF ELISA tests (a) distribution of absorbance ratios in the by the WC11-
ELISA and (b) distribution of percentage inhibition by the CI-ELISA Cut-off values for




CI-ELISA Positive CI-ELISA Negative
Figure 5.9b: Box plot analysis. Results obtained by the WC11-ELISA and CI-ELISA
Results indicate the variation in sample distributions, in relation to the calculated
median (indicated by solid line). Vertical line represents sample range, the box
represents the majority of samples and Individual samples (•). Cut-off values for each





Positive Negative (<25%) Total % Agreement
(>25%)
ELISA Result
Positive (>0.15) 27a 6b 33 93.7
Negative (<0.15) 0C 62d 62
Total 27 68 95
Table 5.5: Comparison of relative sensitivity and specificity of the WC11-
ELISA compared to the CI-ELISA (n = 95). WC11-ELISA shows 100% sensitivity
(a/a+c) and 91% specificity (d/d+b) relative to the CI-ELISA.
5.3.2.2. Comparison of MCFV ELISA tests with I FAT
The results obtained from the two ELISA assays were then individually
compared to the IFAT results (Figure 5.10), which was used as the "gold standard".
Antibodies against MCFV were detected in 44 serum samples by IFAT. Fifty
samples gave negative serological results in all assays The WC11 ELISA gave a
sensitivity of 65% and a specificity of 94% (Table 5.6.) and showed an overall
agreement of 81% (k = 0.61) when compared with IFAT. The CI-ELISA gave a
sensitivity of 63% and a specificity of 94% relative to IFAT (Table 5.7.) and showed
an overall agreement of 80% (k = 0.59).
Antibodies against MCFV were detected in twenty-eight serum samples by
WC11-ELISA. Fifteen samples reacted negatively in the WC11-ELISA, but
appeared positive by IFAT (Table 5.6). Antibodies against the MCFV-specific
epitope were detected in twenty-seven serum samples by CI-ELISA. Sixteen samples
reacted negatively in the CI-ELISA, but appeared positive by IFAT. The results for
both ELISA tests showed the same three samples were ELISA positive but IFAT
negative.
IFAT
Positive Negative Total % Agreement
ELISA Result
Positive (>0.15) 28a 3b 31 81
Negative (<0.15) 15c 49d 64
Total 43 52 95
Table 5.6: Comparison of relative sensitivity and specificity of the WC11-
ELISA compared to IFAT. WC11-ELISA showed 65% sensitivity (a/a+c) and 94%




Figure 5.10: Comparison of CI-ELISA, WC11-ELISA and IFAT results.
Scatter plot of the optical density value (expressed as absorbance reading at 450nm)
for the WC11-ELISA plotted against the percentage inhibition for the CI-ELISA
(highlighted blue). Samples positive by IFAT are highlighted in pink. Cut-off value for

















Table 5.7: Comparison of relative sensitivity and specificity of the CI-ELISA
compared to IFAT. CI-ELISA showed 63% sensitivity (a/a+c) and 94% specificity
(d/d+b), relative to IFAT.
5.3.2.3. ELISA Specificity
In order to investigate potential cross-reactivity in the WC11-ELISA, 95
diagnostic serum samples positive for bovine herpesvirus-4 (BoHV-4), infectious
bovine rhinotracheitis virus (BoHV-l/IBR) and bovine viral diarrhoea virus (BVDV)
were tested for reactivity in the WC11-ELISA. The specificity of the WC11-ELISA
for antibodies to antigens of alcelaphine herpesvirus-1 was demonstrated by the
absence of a positive reaction in all cases. Serum samples yielded low OD readings
of less than the established positive reaction threshold of 0.15, with values ranging
from 0 to -0.026. When tested by CI-ELISA, serum samples yielded inhibition levels
considerably less than the established reaction threshold of 25% inhibition, ranging
from -35 to -40% inhibition. Total agreement was therefore shown between the
WC11-ELISA and CI-ELISA.
5.3.2.4. Bovine herpesvirus-4 cross-reactivity
Potential cross-reactivity of the WC11-ELISA with bovine herpesvirus-4 was
also analysed by testing the ninety-five serum samples previously tested (described
in section 5.2.5) by a direct BoEIV-4 ELISA (Bio-X Diagnostics). BoHV-4, like
A1HV-1 is a gammaherpesvirus and was specifically studied since it has been shown
to cross react in tests such as IFAT (Li et al., 1994; Dewals et ah, 2005).
Of the sera tested, sixteen samples were positive by the BoHV-4 ELISA. Of
these samples, the WC11-ELISA determined five BoHV-4 positive samples as MCF
positive (Figure 5.11a.), four of which were also positive by CI-ELISA (Figure
5.1 lb.). All five samples were found positive for MCF by IFAT. No other BoHV-4
positive samples were positive for MCF by IFAT. In the case of the single WC11-
ELISA positive (0.192 OD value)/CI-ELISA negative (17% inhibition) and BoHV-4
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Figure 5.11: Correlation of reactivity of ruminant sera by the MCF and BoHV-4
ELISA assays, a) Correlation of reactivity of ruminant sera by the MCF WC11-ELISA
and BoHV-4 ELISA assay (n= 95, R2 = 0.0004). b) Correlation of reactivity of ruminant
sera by the MCF CI-ELISA and BoHV-4 ELISA assay (n= 95, R2 = 0.0021). Cut-off
value for assay (BoHV-4 >16.35, CI-ELISA >25% and virus-based ELISA >0.15)
marked by axis intercept.
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positive sample (137.15%), MCF was confirmed by both 1FAT and by
histopathogical findings.
5.3.3. Investigation of MCF Outbreaks
5.3.3.1. Case Study One
In one beef farm, seven cows out of seventy-eight became ill and
subsequently died over a 6 month period All of the affected animals showed
characteristic signs of MCF, and were all IFAT-positive, confirming MCF. Sera from
the remaining seventy animals in the herd were submitted for experimental testing of
MCF using the IFAT assay, CI-ELISA and WCl l-ELISA (Table 5.8) and the results
were compared.
There was good correlation between all tests for most serum samples (Figure
5.12). All seventy sera reacted negatively in the C1-EL1SA. Fourteen samples were
positive by IFAT, one of which was positive by the WCl 1-EFISA. None of the cattle
analysed developed clinical signs of MCF. Fourteen IFAT-positive serum samples
were tested for BoHV-4 cross-reactivity in both the IFAT and the WCl 1-EFISA, all
the samples were BoHV-4 negative by the BoHV-4 EFISA.
5.3.3.2. Case Study Two
On a beef suckler farm, four 14-18 month old steers showed signs of MCF
and subsequently died over a period of three weeks. A further four animals were later
affected and subsequently died. No classical MCF head and eye lesions were



























































































































































































































































































































Figure 5.12: ELISA analysis of MCF outbreak (n = 70). Scatter plot of the OD
readings (expressed as absorbance at 450nm) for the WC11-ELISA plotted against the
percentage inhibition for the CI-ELISA. Cut-offs for each assay are marked with broken
lines (WC11-ELISA positive >0.15, CI-ELISA positive >25%).
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Necropsy analysis identified extensive ulcerations of abomasal mucosa, froth and
fibrous ingesta in tracheal and bronchial lumen, pulmonary oedema, generalised
lymphoadenopathy, haemorrhages on the bladder and meningeal opacity.
Histopathology results for two of the four affected animals showed
inflammatory changes in many tissues suggestive of MCF, and OvHV-2 was
confirmed by analysis of spleen tissues by PCR. Blood samples from the surviving
animals in the group (n = 10) were tested for MCF using IFAT, PCR, CI-ELISA and
WC11-ELISA (n = 10) (IFAT performed by VSU, & PCR assay performed by G.
Russell, Moredun Research institute). There was good correlation between test
systems for most specimens. One animal which was shown to be positive for MCF
by CI-EFISA, WC11-EFISA and PCR, subsequently developed clinical MCF. The
remaining nine samples reacted negatively. All samples gave negative serological
results by IFAT.
5.3.3.3. Case Study Three
On a beef suckler farm, seven animals showed signs of MCF and
subsequently died over a period of 5 months. Classical MCF symptoms were
described, including corneal oedema, ocular and nasal discharge and high body
temperatures (>40°C). No histopathology results were available, however, MCF was
confirmed in the 7 animals by IFAT.
Bloods from the surviving animals in the group (n = 58) were submitted for
experimental testing of MCF using IFAT, PCR and WC11-EFISA (IFAT performed
by VSU, & PCR assay performed by D. Grant, MCF group, Moredun Research
Institute) and the results compared. There was good correlation between test systems
for most samples. One animal was positive by WC11-EFISA and OvHV-2 real-time
PCR (described by Baxter et ah, 1993), while the remaining fifty-seven samples




The aim of this research was the development of a reliable, efficient virus-
based ELISA assay for the detection of antibodies against malignant catarrhal fever
virus in serum and to evaluate this assay against established diagnostic assays
including the standard indirect immunofluorescence assay and the competitive-
inhibition ELISA. A validated assay may identify animals as either positive or
negative for an antibody, and can accurately predict the infectious status of an
individual using a predetermined degree of statistical error (Office International des
Epizooties, 2003). Initial stages required in the development of a new diagnostic
assay, such as an ELISA, consist of extensive studies into the feasibility of protocols,
analysis and optimisation of reagents (Office International des Epizooties, 2003).
The variables which were considered prior to sampling field serum included;
dilutions of MCFV antigen, serum samples (antibody) and conjugated antibody
dilutions. The determination of these variables allowed optimum reaction conditions
to be established preceding serum sample testing.
Crude lysate antigens from A1HV-1 strains C500 and WC11 were prepared
and tested with MCF serum samples from cattle with clinical symptoms indicative of
potential MCF infection. The A1HV-1 strain WC11 showed 100% correlation with
IFAT while the A1HV-1 strain C500 ELISA showed one discrepancy. An OvHV-2
lysate-based ELISA was also tested. This gave optical density values that were
greater for the control antigen than the infected cell-lysate. The A1HV-1 strain WC11
ELISA antigen was therefore selected for further analysis.
Good positive agreement between the magnitude of reaction in the WC11-
IFAT and ELISA was demonstrated. Both tests were able to detect animals with
MCF with a moderate degree of accuracy and agreement (k = 0.6). Parallel testing of
20 serum samples, including cattle infected with ovine herpesvirus-2, showed 80%
concordance between IFAT and WC11-ELISA. The number of seropositive cattle
detected by IFAT was greater than the number detected by WC11-ELISA. Although
this suggests the WC11-ELISA was less efficient in its accurate detection of MCF,
giving false negative results, the discrepant samples were repeated by both tests.
After re-testing, only one sample still gave contradictory results reacting positively
by IFAT but negatively by the WC11-ELISA. The fact that results of multiple IFAT
tests changed from positive to negative suggests it may not be an ideal standard
against which to test the direct ELISA. Differences in results may indicate a number
of factors, such as sample deterioration, operator error or changes in reagents
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employed. One result of the ELISA test also changed from a low positive to a
negative. This may be a result of the lack of positive threshold to accurately
discriminate between positive and negative samples. Therefore a threshold should be
determined to ensure test results are repeatedly correct, in addition to analysing the
difference between a high negative and a low positive.
Preliminary studies found a high level of concordance between the standard
1FAT test and the WC11-EL1SA. The data obtained by the described ELISA
indicates its value as a simple, economical, rapid serological assay for the detection
of antibodies against MCFV. To complete the establishment and initial validation of
this assay, serum samples submitted for MCF testing were collected and analysed in
a parallel study to allow a comparison of IFAT, WC11-ELISA and the commercially
available MCF ELISA (CI-ELISA). Good agreement between the magnitude of
reaction in the CI-ELISA and the WC11-ELISA was demonstrated. Both tests were
able to detect animals with MCF to a high degree of accuracy and agreement (k =
0.86). Parallel testing of 95 serum samples from cattle with suspected MCF revealed
over 93% concordance between CI-ELISA and WC11-ELISA. Two more animals
were tested seropositive by WC11-ELISA than CI-ELISA, showing 100% sensitivity
and 91% specificity relative to diagnosis by CI-ELISA. Although this suggests the
WC11-ELISA is less specific in its accurate detection of MCF, one sample that was
CI-ELISA negative/ WC11-ELISA positive, was also IFAT positive and showed
clinical signs of MCF, while a further sample had MCF confirmed by
histopathological evidence. The result of the CI-ELISA for this case was narrowly
under the positive threshold (22% inhibition). This would suggest that the WC11-
ELISA may be more sensitive than the CI-ELISA in its detection of antibodies
against MCF viruses. This difference may be related to the fact that CI-ELISA relies
on inhibition of binding of a monoclonal antibody and hence focuses on a single
epitope whereas the WC11-ELISA relies on a polyclonal response recognising
multiple epitopes and consequently may be more robust where the infected animal
has limited or low antibody production.
The CI-ELISA showed a skewed distribution of the results for the 95 samples
tested. Statistical analysis showed that this distribution was not a direct result of the
calculation used to determine percentage. Li et al., (1994) stated that the
concentration of monoclonal antibody was less critical than antigen concentration to
the sensitivity of the assay. The assay sensitivity may be a result of a low binding
affinity, where a limited amount of antigen means that little blocking antibody is
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necessary to produce a clear inhibitory result. The test reaction conditions used may
explain the skewed distribution of results.
The positive threshold limit of 0.15 for the WC11-ELISA was based on
assays that included a few aberrantly high OD values in individual wells. By
discounting these discrepant samples, a threshold of 0.1 would have been obtained.
Consequently, any samples that gave readings of between 0.1 and 0.15 were recorded
as inconclusive and were re-tested. Of the six samples that were discrepant between
the WC11-ELISA and CI-ELISA, five were close to the CI-ELISA positive threshold
value (10-19% inhibition). Re-testing of these samples showed three of these five
tested positive by CI-ELISA. This indicates that routine use of duplicate CI-ELISA
tests may improve test accuracy.
Parallel testing of the 95 serum samples by both ELISA assays and by IFAT
revealed over 86% concordance between the WC11-ELISA and IFAT assays, and
80% concordance between the CI-ELISA and IFAT. The number of seropositive
cattle detected by IFAT was greater than the number detected by either ELISA assay,
showing 73% sensitivity and 98% relative specificity when compared to the WC11-
ELISA, and 59% sensitivity and 98% relative specificity when compared to the CI-
ELISA. These Endings support the view that the number of seropositive cattle
detected by IFAT was always equal to or greater than the number detected by the two
ELISA tests. IFAT has been reported to show cross-reactivity with other bovine
herpesviruses (Wan et al., 1988). However, in this study BoHV-4, BoHV-1 and
BVDV-specific sera did not cross-react with A1HV-1 infected cells by IFAT.
Other authors have also noted possible serological cross-reactivity between
MCFV and other herpesviruses (Li et al., 1994; Dubuisson et al., 1989; Li et al.,
1995). Studies by Osorio et al., (1985) showed BoHV-1 and BoHV-2 did not
serologically cross-react with other bovine herpesviruses, although they are found to
cross-react with each other. Dewals et al., (2005) showed that BoHV-4 specific
antiserum stained antigens expressed in the nucleus of A1HV-1 infected cells. They
also indicated that this relationship was unidirectional as A1HV-1 specific serum
showed no detectable staining of BoHV-4 infected cells. The lack of cross-reactivity
of BoHV-4 serum in the WC11-ELISA may therefore reflect the loss of cross-
reactive, possibly nuclear, A1HV-1 antigens during preparation/extraction of the
ELISA antigen.
In this study, of the samples tested by the BoHV-4 ELISA, sixteen were
BoHV-4 positive. Of these serum samples, the number of BoHV-4/MCF seropositive
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cattle detected by the WC11-ELISA (n = 5) was greater than the number detected by
CI-ELISA (n = 4). In the case of the single WC11-ELISA positive (0.19)/CI-ELISA
negative (17%) and BoElV-4 positive sample, MCF was confirmed by
histopathogical findings. All five samples were additionally found positive for MCF
by IFAT. These results highlight problems regarding the cross-reactivity between
MCF and BoHV-4. It is possible that the five animals diagnosed as MCF positive
and BoFIV-4 positive have had previous exposure to both viruses and therefore show
antibodies to both. It could alternatively suggest that some animals may develop
antibodies to cross-reacting epitopes. If true, this appears to occur rarely due to the
small number of BoHV-4 animals which are diagnosed MCF positive.
The specificity of the ELISA for antibodies to antigens of alcelaphine
herpesvirus-1 was demonstrated by the absence of a positive reaction to
hyperimmune serum samples specific for other bovine viruses including the
alphaherpesvirus BoFIV-1 and the gammaherpesvirus BoHV-4. Hyperimmune serum
for bovine viral diarrhoea virus (BVDV) also tested negative by the WC11-ELISA.
Although BVDV is a member of the pestivirus family and there is no serological
cross-reactivity between these virus families, it was important to demonstrate that a
differential diagnosis can be made since the clinical signs can be very similar.
MCF typically emerges sporadically, with a small number of affected animals
(Brenner et al., 2002) but outbreaks where several animals in a herd become affected
have been reported and can occur on the same farm in consecutive years. There have
been many reports of outbreaks of multiple cases (Hamilton., 1990; Collery and
Foley., 1996; Yus et al., 1999; Brenner et al., 2002; Dabak and Bulut, 2003; Otter,
Pow & Reid., 2002; Abu Elzein et al., 2003) in contrast to the more characteristically
sporadic disease, the reason for which remains unknown.
As an additional validation step, samples from herds where MCF outbreaks
were reported were tested to assess whether animals showed an antibody response
before the onset of clinical signs and to allow a comparison to be made concerning
the current diagnostic tools. This was shown in the second outbreak analysed where
one of the ten animals tested showed an antibody response by both ELISA tests and
later developed clinical MCF. This suggests that the WC11-ELISA can detect MCF
before the onset of clinical signs and this could be very beneficial when monitoring
outbreaks. Although OvHV-2 infections in cattle commonly result in the
development of clinical signs within weeks, animals have been reported where no
clinical signs develop, and indicate the possibility of silent infections within outbreak
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herds (Otter et al., 2002). The ELISA would therefore prove beneficial for the large-
scale testing of animals present in an infected herd, or just for routine surveillance.
The first outbreak involved a herd consisting of seventy-eight animals, where
seven animals were affected and subsequently died. Heparinised blood samples from
the surviving seventy-one in-contact animals in this group were examined for
serological evidence of MCF. Samples were tested by IFAT, CI-ELISA and WC11-
ELISA. All were negative by the CI-ELISA, while one sample was demonstrated as
a low positive by the WC11-ELISA. By IFAT, fourteen in-contact animals from the
group were positive, including the sample positive by WC11-ELISA, none of which
developed clinical disease. Additionally, all IFAT positive samples tested gave
negative serological results by BoHV-4 ELISA. These findings support the earlier
statement that the number of seropositive cattle detected by IFAT was always greater
than the number detected by other diagnostic methods (Li et al., 1994). This may be
partly due to the test being subject to visual interpretation and partly to cross-
reactivity with other bovine herpesviruses, although cross-reactivity to BoITV-4 was
ruled out in this case study.
A second outbreak of MCF resulted in the deaths of eight cattle in a group of
beef suckler steers. Heparinised blood samples taken from ten in-contact surviving
animals were analysed. The CI-ELISA, WC11-ELISA and PCR results all showed
100% agreement, revealing the infection in one other animal, which later developed
clinical disease. All samples were negative by IFAT. This is the only case where
IFAT did not detect ELISA positive serum. The fact that this sample was taken
before symptoms developed may be significant, suggesting there may be a difference
in serum titre pre-/post development of clinical signs. The delay between sampling
and the onset of clinical signs in these cases is unknown. Knowing the period of time
between clinical signs and sampling could result in differences in antibody responses
and ultimately diagnosis. It would therefore be advised to test animals at regular
intervals; this however would be unlikely as routinely, testing would only be initiated
on suspicion of MCF disease.
Preliminary studies have found a high level of concordance between the
commercially available CI-ELISA and the WC11-ELISA. The data obtained by the
described ELISA indicates its value as an economical, rapid and specific serological
assay for the detection of antibodies against MCFV. The simplicity of the WC11-
ELISA and its lack of cross-reactivity make this assay a suitable test for routine
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MCFV diagnosis and epidemiology in laboratories world-wide. Where appropriate
secondary reagents and conjugates are available, analysis of sera from exotic species






The recent advances in molecular and serological diagnostic assays for the
detection of malignant catarrhal fever have provided powerful tools for investigating
the pathogenesis and epidemiology of MCF (Hsu et al., 1990: Li et al., 2000).
Histopathological examination remains the recognised diagnostic procedure to
confirm MCF infection. However, since PCR assays have proved sensitive and
specific, such methods may be established as a new "gold standard" for diagnosis
following validation studies between laboratory tests. The sensitivity of the PCR
methods has allowed the monitoring of MCF infection in carrier and susceptible
animals, enabling the pathogenesis of the viral disease to be investigated (Baxter et
al., 1993).
There are, however, advantages offered by serological testing. Serology
offers a means of testing large numbers rapidly, providing an increased
understanding regarding epidemiological aspects of MCF. Therefore large groups of
animals at risk of developing MCF in highly susceptible species such as deer and
bison can be monitored (O'Toole et al., 2002). By routine testing using serological
methods, control measures may ultimately be established, whereby no infected
animals may be brought into a non-infected flock or herd (Li et al., 1999). A second
advantage to using serological tests is the demonstration that many animals which
have had past infections may be serologically positive but PCR negative (Colins et
al., 2000; O'Toole et al., 2002). Studies investigating OvHV-2 infections by PCR
and CI-ELISA (O'Toole et al., 2002; Powers et al., 2005) speculated that animals
which were serologically positive but DNA negative may represent a latent form of
infection. During latency, viral load in blood cells may be below detectable levels by
PCR.
Serological tests offer economical, rapid and specific methods for the
detection of antibodies against MCFV. The simplicity of serological assays such as
the CI-ELISA and WC11-ELISA (developed in chapter five) and lack of cross-
reactivity, offer a reliable, low cost method for routine MCFV diagnosis and
epidemiological studies and long-term monitoring.
On preliminary characterisation of the CI-ELISA, a high level of agreement
was found between the ELISA and IFAT (Li et al., 1995). No samples negative by
IFAT were positive by ELISA suggesting that cross-reactivity may be responsible for
the greater number of IFAT positive results (Li et al., 1995; Li et al., 1996). The CI-
ELISA was also compared to the OvHV-2 PCR in parallel testing and revealed a
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substantial agreement between the tests. The difference in the results was thought to
be due to a lower production of antibodies in some cases. PCR was found to be the
most reliable test for the determination of acute clinical MCF cases when compared
to serological tests, although both antibody assays proved beneficial in the
determination of MCF infected animals. A study by Muller-Doblies et al., (1998)
assessing the OvFlV-2 PCR and CI-ELISA in comparison with histopathological
results, also found that PCR was the method of choice for diagnosis. Of the cases
examined by PCR, ELISA and histopathology, two cases inconclusive by pathology
were confirmed positive by PCR, while the CI-ELISA was less sensitive than both
histopathology and PCR (Muller-Doblies et al., 1998).
This chapter describes preliminary validation studies of the WC11 based
ELISA to detect anti-MCF virus antibodies and compares results obtained with
established serological methods. Firstly, a longitudinal study of cattle experimentally
immunised with A1HV-1 was analysed. Animals were sampled at weekly intervals
after inoculation and serum samples were tested using a serum neutralisation assay in
comparison with the WC11-ELISA. A second study into the validation of the WC11-
ELISA was performed. Bovine samples, submitted for MCF diagnosis, were tested
by three serological assays; CI-ELISA, IFAT and WC11 ELISA; the OvHV-2
specific real-time diagnostic PCR and histopathology/veterinary diagnosis. Samples
were additionally tested using a BoHV-4 ELISA (BioX Diagnostics) to examine the
issue of cross-reactivity between the gammaherpesviruses.
6.2 Materials and Methods
6.2.1. DNA preparation
Genomic DNA was extracted from fresh tissues and blood using the Qiagen
DNeasy tissue kit, in accordance with the manufacturer's directions (Qiagen DNeasy
tissue handbook, 03/2004). DNA was quantified by UV absorbance at 260nm (Cecil
Spectrophotometer: CE2041 2000 series).
6.2.2. Serological Methods
Serological methods (WC11-ELISA, CI-ELISA) and reagents were used as




6.3.1. Longitudinal Study of Experimentally Infected Animals
Serum samples from animals intramuscularly vaccinated with AlHV-l strain
C500 (described in section 2.1.2) collected weekly were monitored by the established
virus neutralisation assay (Mushi and Plowright, 1979; Reid et al., 1975) and the
newly developed WC11-ELISA (Section 5.2.1-5.2.2). These animals were
vaccinated in order to induce an immune response to a non-pathogenic, attenuated
MCF virus and were later challenged with a pathogenic viral strain to elicit infection.
Tests were performed to analyse the animals' immune response to the virus.
Initial findings suggested that the virus neutralisation assay was more
sensitive than the ELISA (Table 6.1), detecting an immune response 7-14 days
earlier. This may be a direct result of the ELISA employing a 1/100 test serum
dilution, rather than the serum titration method employed by neutralisation. The virus
neutralisation assays showed high and persistent levels of virus-neutralising
antibodies, particularly in the calves intranasally boosted with AlHV-l (vaccination
trial performed by I. Campbell and G.Russell as described in section 2.1.2, Figures
6.1 and 6.2). Variation was observed between weekly samples which are thought to
be a result of experimental assay variation rather than showing evidence of cyclic
patterns in the neutralisation responses.
The ELISA mirrored the general trend in antibody response for each animal,
and showed less variation than the neutralisation assay. One animal from each group
developed clinical MCF following challenge with virulent AlHV-l (day 154 post-
vaccination). These animals were seropositive until death from clinical MCF at
twenty-three (200819) and forty-three (400251) days post-challenge (Figures 6.4 and
6.1 respectively). Typical histopathological lesions were shown in the lymph nodes
and major organs including liver and intestine. Interestingly, the antigen/chitosan
boosted animal which developed clinical MCF (200819) showed a decline in
antibody response subsequent to challenge (Figure 6.3). This may suggest an effect
of acute MCF on the immune system. This decline in the immune response was not
found in the mock-boosted animal which developed clinical disease. Instead this
animal shows an immediate antibody response to the challenge in the weeks
preceding the development of clinical MCF. These responses were observed in both
neutralisation and ELISA assays (Figure 6.3).
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The remaining calves (400821 and 500815) remained seropositive until the
experiment termination with no clinical signs observed (212 days post inoculation).
The general trend of antibody response was mirrored in both the ELISA and
neutralisation assay. A decline in antibody response was seen in one animal
following challenge with A1HV-1 (400821, Figure 6.4), while a rapid antibody
response to the virus was seen in the second animal (500815, Figure 6.2). This
suggests that the A1HV-1 vaccination did not offer significant protection against the
subsequent development of clinical MCF, as both control and vaccinated groups
showed cases of clinical disease following challenge with virulent virus. The EFISA
offers a consistent demonstration of antibodies throughout the vaccination trial and
therefore may be of benefit for routine testing of herds for the presence of antibody,
whether clinical disease occurs or not. Flowever, it cannot differentiate between
acute, latent or recrudescent infections.
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400251 500815 200819 400821
Day SNT ELISA SNT ELISA SNT ELISA SNT ELISA
0 0 0.013 0 0.012 0 0.029 0 0.023
7 360 0.054 512 0.08 oJ 0.030 3 0.071
14 512 0.036 720 0.038 45 0.070 11 0.09
21 360 0.107 360 0.218 45 0.149 128 0.186
28 720 0.478 1024 0.694 128 0.316 128 0.553
35 1024 0.778 1024 0.918 128 0.477 360 0.689
42 1024 1.027 360 0.978 360 0.653 360 0.854
49 1024 1.008 1024 1.185 180 0.583 512 0.881
56 1024 0.587 512 1.247 512 0.579 180 0.83
63 720 0.999 1024 1.154 720 0.581 1024 0.927
70 720 0.941 1024 1.315 512 0.784 360 1.01
77 1024 0.825 720 1.313 180 0.755 256 1.041
84 1024 1.011 360 1.303 512 0.701 180 0.88
91 n/s n/s n/s n/s n/s n/s n/s n/s
98 1024 0.755 360 1.204 360 0.691 360 0.918
105 n/s n/s n/s n/s n/s n/s n/s n/s
112 512 1.03 1024 1.191 256 0.605 90 0.813
119 512 1.002 1024 1.17 360 0.816 360 0.921
126 90 1.138 720 1.227 22 0.899 45 0.712
133 360 0.987 256 1.224 22 0.672 45 0.652
140 90 0.925 90 1.16 45 0.747 90 0.678
147 360 0.972 90 0.958 90 0.613 90 0.693
154 720 0.995 128 1.03 360 0.775 1024 0.824
168 512 0.715 1024 2.699 1024 1.427 360 0.725
175 ND 0.876 ND 2.504 ND 1.406 ND 0.592
182 ND 0.751 ND 2.422 - - ND 0.592
189 ND 1.375 ND 2.516 - - ND 0.669
198 - - ND 2.436 - - ND 0.59
205 - - ND 2.453 - - ND 0.722
212 - - ND 2.344 - - ND 0.626
Table 6.1: Analysis of experimentally AIHV-1 infected cattle by two diagnostics
assays (Virus neutralisation assay and ELISA). Four animals, experimentally
inoculated with MCFV were analysed by serum neutralisation test (SNT) and WC11-
ELISA. n/s = days not sampled, ND = not tested. Vaccination occurred at day 0.
Animal was boosted with AIHV-1 virus/chitosan on days 14 and 112, and challenged
with virulent AIHV-1 (day 154). Table shows SNT titration results and ELISA OD
values. The OD calculated represents the mean of the control antigen subtracted




Figure 6.1. Immune response to AIHV-1.
Neutralisation assays (VN) and WC11-ELISA (ELISA), were used to
measure MCF virus-specific antibody in plasma of calf 400251 following vaccination
with attenuated AIHV-1 virus and challenge with virulent virus. Vaccination occurred
at day 0. Solid black lines indicate time-points were the animal was boosted with
AIHV-1 virus/chitosan (day 14, 112). Dotted line indicates time-point that the animal
was challenged with virulent AIHV-1 (day 154), while the solid red line indicates





Figure 6.2. Immune response to AIHV-1.
Neutraisation assays (VN) and WC11-ELISA (ELISA), were used to measure
MCF virus-specific antibody in plasma of calf 500815 following vaccination with
attenuated AIHV-1 virus and challenge with virulent virus. Vaccination administered
on day 0. Solid black lines indicate time-points were the animal was boosted with
AIHV-1 virus/chitosan (day 14, 112). Dotted line indicates time-point that the animal
was challenged with virulent AIHV-1 (day 154), while the solid red line indicates
WC11-ELISA cut-off value (>0.15 is considered positive). Animal showed no clinical
signs of MCF at end of experiment.
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Figure 6.3. Immune response to AIHV-1.
Neutralisation assays (VN) and WC11-ELISA (ELISA), were used to
measure MCF virus-specific antibody in plasma of calf 200819 following vaccination
with attenuated AIHV-1 virus and challenge with virulent virus. Vaccine administered
on day 0. Solid black lines indicate time-points were the animal was boosted with
chitosan/medium (day 14, 112). Dotted line indicates time-point that the animal was
challenged with virulent AIHV-1 (day 154), while the solid red line indicates WC11-
ELISA cut-off value (>0.15 is considered positive). Animal died from MCF on day 23.
233
Validation Studies
Figure 6.4. Immune response to AIHV-1.
Neutralisation assays (VN) and WC11-ELISA (ELISA), were used to
measure MCF virus-specific antibody in plasma of calf 400821 following vaccination
with attenuated AIHV-1 virus (day 0) and challenge with virulent virus. Solid black
lines indicate time-points were the animal was boosted with chitosan/medium (day
14, 112). Dotted line indicates time-point that the animal was challenged with
virulent AIHV-1 (day 154), while the solid red line indicates WC11-ELISA cut-off





Clinical signs vary depending on the form of MCF contracted. Typically,
clinical signs characteristic of the head and eye form include corneal opacity,
pyrexia, mucopurulent nasal and ocular discharge and mucosal ulceration. The
alimentary or intestinal form, being the second most recognised form of MCF, can be
characterised by severe enteritis and diarrhoea. Definitive diagnosis remains reliant
on histopathological examination, therefore, histopathology was used as the gold
standard for the comparison of diagnostic tests, where applicable.
In 2006, cases of suspected MCF in domestic cattle were tested by four
diagnostic tests; IFAT, CI-ELISA and WC11-ELISA serological tests and a real-time
OvHV-2 PCR assay (Ftussy et al., 2001). As all samples were from suspected cases
of MCF, all were submitted with clinical signs which were suggestive of MCF and
therefore a confirmed diagnosis was required. In cases where histopathology was not
performed, final veterinary diagnosis was sought from the submitting VI centre.
Parallel testing of forty-two serum samples by the four tests (Table 6.2)
revealed between 57% and 76% concordance. Total concordance between the four
tests was shown for 15 (36%) of the samples analysed. Of the forty-two samples
selected, thirty-one (74%) were positive by PCR, nineteen (45%) were positive by
IFAT, twenty-one (50%) were positive by CI-ELISA and nineteen (45%) were
positive by WC11-ELISA. The agreement between the four assays exceeded 35%.
6.3.2.1. MCF-confirmed by Histopathological examination
Histopathological examination and clinical signs reported MCF in only seven
samples. From the seven samples; all were positive by the OvHV-2 real-time PCR,
one was positive by IFAT, three were positive by the CI-ELISA and three were
positive by the WC11-ELISA (Table 6.3). Samples 16 and 18 showed agreement in
three tests with discrepant results in the CI-ELISA (sample 16 (-22% inhibition) and
IFAT (sample 18). Two samples (22 and 25) were positive by the CI-ELISA (26 and
34%) and PCR and negative by both the IFAT test and WC11-ELISA (0.04 and
0.01). These samples were submitted from a suspected MCF outbreak, where one
animal in the herd underwent histopathological analysis. The examination reported
sub-acute non- suppurative vasocentric meningoencephalitis, sub-acute hyperplastic
lymphadenopathy, sub-acute non-suppurative cholangiohepatitis and acute multifocal
abomasal ulceration. Based on these findings MCF was the confirmed diagnosis. A
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Sample DNA Serology Histopathology Final
OvHV-2 I FAT CI-ELISA WC11-ELISA Diagnosis
PCR
1 + + + + ND MCF
2 + + + + ND MCF
3 + + + + ND MCF
4 + + + + ND MCF
5 + + + + ND MCF
6 + + + + ND MCF
7 + + + + ND MCF
8 + + + + ND MCF
9 + + + + ND MCF
10 + + + - ND MCF
11 + + + - ND MCF
12 + + + - ND MCF
13 + + - + ND MCF
14 + + - + ND MCF
15 + + - + ND MCF
16 + + - + + MCF
17 + - + + ND MCF
18 + - + + + MCF
19 + + - - ND MCF
20 + + - - ND MCF
21 + - + - ND MCF
22 + - + - + MCF
23 + - + - ND MCF
24 + - + - ND MCF
25 + - + - + MCF
26 + - - + + MCF
27 - + - + ND MCF
28 + - - - + MCF
29 + - - - + MCF
30 + - - - ND MCF
31 + - - - ND MCF
32 + - - - ND MCF
33 - - + - ND Unknown
34 - - + - ND Unknown
35 - - - + ND Unknown
36 - - - + ND Unknown
37 - - - - ND Unknown
38 - - - - ND Unknown
39 - - - - ND Unknown
40 - - - - ND Unknown
41 - - - - ND Unknown
42 - - - - ND Unknown
Table 6.3: Detection of MCF infection in Field sera. Comparison of four
diagnostic tests: PCR, I FAT, CI-ELISA and WC11-ELISA. + indicates MCF, - MCF is
undetected and ND means analysis not done.
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further two samples from this outbreak were only positive by the OvHV-2 real-time
PCR, with all negative serological assay results (sample 28 - 0.03, -7% and sample
29- 0.02, 5%). The remaining sample, 26, showed agreement between WC11-ELISA
(0.16 AU) and PCR, with negative results by both the IFAT test and CI-ELISA (3%).
This sample was confirmed as an alimentary/intestinal form of MCF.
Sample Serology
Number PCR IFAT CI-ELISA WC-ELISA
16 + + - +
18 + - + +
22 + - + -
25 + - + -
26 + - - +
28 + - - -
29 + - - -
Table 6.3: Histopathological examination confirming MCF (n = 7). Comparison
of four diagnostic tests to histopathological examination: PCR, IFAT, CI-ELISA and
WC11-ELISA. + indicates MCF, - MCF is undetected.
6.3.2.2. Comparison of DNA and serological assays
In the group of 42 samples, a positive signal was detected by PCR in a total
of thirty-one cases, including all seven positive by histopathology and twenty-four
positive by final veterinary diagnosis. No signal was detected for ten cases, in which
the final diagnosis eliminated MCF (Table 6.4). Interestingly no signal was detected
for one further case (Number 27), which was positive by two serological tests (IFAT
and WC11-ELISA).
This study revealed that the OvHV-2 PCR assay showed a good correlation
with the histopathological evidence and final veterinary diagnosis, and therefore
serological test results will be compared to the PCR assay results for all samples. It
should be recognised, however, that cases of MCF and animals recovered from MCF
have been shown to be serologically positive but PCR negative. Therefore PCR is
not a perfect "gold standard" for this analysis. Results from the three serological
assays were pooled and samples were classed as positive where a positive result was
found in one or more serological test, and were compared to the OvHV-2 PCR
results (Table 6.4). Twenty-six samples were considered positive by both DNA and
serology. Serology test sensitivity was determined as 77% as a result of five




Positive Negative Total % Agreement
PCR Result
Positive 31a 0b 31 97.6
Negative lc 10d II
Total 32 10 42
Table 6.4: Comparison of the relative sensitivity and specificity of the OvHV-2
real-time PCR assay compared to a final veterinary diagnosis. Test sensitivity of
97% (a/a+c), with a specificity of 100% (d/d+b).
DNA
Positive Negative Total % Agreement
Serology Results
Positive 26a 5b 31 76.2
Negative 5C 6d 11
Total 31 11 42
Table 6.5: Comparison of the relative sensitivity and specificity of the
serological assays compared to the OvHV-2 real-time PCR assay. The
serological assays gave a relative sensitivity of 77% (a/a+c) and specificity of 84%
(d/d+b).
to final veterinary diagnosis, four were submitted from a suspected MCF outbreak
where animals in the herd underwent histopathological analysis and confirmed MCF.
A possible explanation for the negative-serology result may be because these cattle,
with possible clinical signs, were tested prior to an antibody response being
established. Low antibody levels might therefore not be detected in the blood sample.
Serology showed 84% specificity when compared to DNA results, with five samples
serology-positive/DNA-negative. Of these five samples, four animals were positive
in only one serological test and are assumed false-positive. Final veterinary diagnosis
for these animals was not conclusive. The remaining six samples were negative in all
DNA and serology assay tests.
Next, the efficiency of each serological assay, for the diagnosis of MCF, was
tested independently by determining their relative sensitivity and specificity, using
the OvHV-2 PCR as the "gold standard".
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6.3.2.3. Comparison of IFAT with OvHV-2 PCR for detection of MCFV
By IFAT, antibodies against MCFV were detected in nineteen serum
samples. One sample reacted positively in the IFAT but appeared negative by PCR,
while a further thirteen samples reacted negatively by IFAT but appeared positive by
PCR. The remaining ten samples gave negative results in both assays. Employing
PCR as the "Gold standard", IFAT gave a sensitivity of 95% and a specificity of
43% and showed an overall agreement of over 66% (fair agreement, k = 0.36) (Table
6.6). The fourteen discrepant samples were compared to final veterinary diagnosis.
Of the thirteen samples OvHV-2 real-time PCR positive/ IFAT-negative, six animals
were confirmed MCF by histopathology. A further seven animals were suspected
MCF cases based on final veterinary diagnosis. Of these seven animals, one showed
classical symptoms for the head and eye form of MCF. A second animal showed
classical symptoms for intestinal MCF. The remaining animals exhibited
characteristic MCF symptoms which included pyrexia, purulent nasal/ocular
discharge and lymphopaenia.
The OvHV-2 real-time PCR negative/ IFAT-positive sample had MCF
confirmed by histopathology with clinical signs of ulcerative stomatitis, pyrexia and





















Table 6.6: Comparison of the relative sensitivity and specificity of IFAT
compared to the OvHV-2 real-time PCR assay. IFAT gave sensitivity of 95%
(a/a+c) and specificity of 43% (d/d+b).
6.3.2.4. Comparison of CI-ELISA with OvHV-2 PCR for detection of
MCFV
Nineteen samples reacted positively by both the OvFIV-2 real-time PCR
assay and the CI-ELISA. Twelve samples were PCR-positive/ CI-ELISA-negative
while a further two samples reacted PCR-negative/ CI-ELISA-positive. The
remaining nine samples gave negative results by both assays. Employing PCR as the
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"Gold standard", the CI-ELISA gave a sensitivity of 61% and a specificity of 82%
and showed an overall agreement of over 66% (fair agreement, k = 0.34) (Table 6.7).
Discrepant samples were compared to a final veterinary diagnosis. Of the twelve
samples positive by PCR but negative by Cl-ELISA, four were MCF confirmed by
histopathology, while the remaining eight samples were suspected MCF cases based
on final veterinary diagnosis. Based on clinical evidence, the two samples positive by
CI-ELISA (29 and 33%) but negative by PCR, were likely MCF-negative (IFAT
negative/WCl 1-ELISA negative). Signs included pyrexia and ocular discharge.
PCR
Positive Negative Total % Agreement
CI-ELISA Result
Positive (>25%) 19a 2b 20 66.6
Negative (<25%) 12° 9d 22
Total 31 11 42
Table 6.7: Comparison of the relative sensitivity and specificity of the CI-
ELISA compared to PCR. CI-ELISA sensitivity of 61% (a/a+c) and specificity of
82% (d/d+b)
6.3.2.5. Comparison of WC11-ELISA with OvHV-2 PCR for detection of
MCFV
Sixteen samples reacted positively by both the OvFIV-2 RT PCR assay and
the WCll-ELISA. Three samples reacted positively in the WC11-ELISA, but
reacted negatively by PCR. A further fifteen samples were WC11-ELISA negative/
PCR-positive. The remaining eight samples gave negative results by both assays
(Table 6.8). Of the fifteen samples PCR-positive/ WC11-ELISA negative, five
samples were negative by both IFAT and WC11-ELISA while two samples were
negative by both ELISA assays. Three samples were only negative by the WCll-
ELISA. All of these discrepant false-negative samples were confirmed MCF by
either histopathology (4 samples) or final veterinary diagnosis (11 samples). The
remaining five samples were negative in all serological assays. Employing PCR as
the "Gold standard", the WC11-ELISA gave a sensitivity of 52% and a specificity of
73% and showed an overall agreement of over 57% (fair agreement, k = 0.22) (Table
6.8).
Three samples were identified as PCR-negative/ WC11-ELISA positive, one
















Table 6.8: Comparison of the relative sensitivity and specificity of the WC11-
ELISA compared to PCR. WC11 -ELISA gave a sensitivity 52% (a/a+c) and
specificity of 73% (d/d+b).
nested-PCR (Baxter et al., 1993). An explanation for this real-time PCR-negative
result could be that the animal had a low viral load, below the threshold of detection
by the real-time PCR. This would suggest that this assay is not as sensitive as the
nested PCR. All other OvHV-2 real time PCR negative samples where tested by
nested PCR and were confirmed as MCF-negative. Of the two remaining WC11-
ELISA positive/ PCR negative samples, one was diagnosed MCF negative. The
second animal remained undiagnosed, although it was assumed to be MCF negative.
Both samples were negative by IFAT and CI-ELISA.
6.3.3. Cross-reactivity
Potential cross-reactivity of the serological MCF tests with bovine
herpesvirus-4 was also analysed using a direct BoHV-4 ELISA (Bio-X Diagnostics).
Of the 42 sera tested, only two samples were BoHV-4 positive. Of these samples,
one was positive by the CI-ELISA (29%), but negative by WC11-ELISA, IFAT and
PCR. The second sample was positive by both MCF ELISAs (low WC11-ELISA
positive 0.17, CI-ELISA positive 31%) and PCR. This result confirms previous





The initial objective of this study was to follow a longitudinal study of cattle
experimentally immunised with A1HV-1. The infection status of each animal was
examined from pre-inoculation to termination, using two diagnostic methods: virus
neutralisation assays and the WC11-ELISA. The virus neutralisation assays showed
high and persistent levels of virus-neutralising antibodies were demonstrable,
especially in calves intranasally boosted with A1HV-1. The WC11-ELISA showed
corresponding patterns of antibody response for each animal. The main difference
between the tests was the sensitivity, where the neutralisation assay detected specific
antibody at least one week earlier than the WC11-ELISA. This lack of sensitivity
may be explained by the use of diluted test serum (1/100) in the ELISA, where serum
is titrated from neat in the neutralisation test. By changing the serum dilution in the
ELISA or possibly by using a similar titration method, a better indication of the
ELISA sensitivity compared to the neutralisation assay might be obtained.
In this longitudinal study the ELISA demonstrated an antibody response in all
animals throughout the vaccination trial and therefore may be of benefit for
epidemiological studies in routine testing herds for the presence of antibody, whether
clinical disease occurs or not. An obvious limitation of the ELISA in this context was
its inability to differentiate between acute, latent and recrudescent infections or
between neutralising and non-neutralising antibody. The ELISA antigen was derived
from lytic BT infection. Of further consideration was the use of experimental
animals. As the animals were vaccinated their immune response may not represent a
natural infection.
As a further validation measure, parallel DNA and serum samples submitted
for MCF testing were collected and analysed to compare the diagnostic methods
available for the detection of MCF, namely an OvHV-2 specific diagnostic PCR,
IFAT, CI-ELISA and WC11-ELISA. IFAT and the WC11-ELISA employ a crude
lysate antigen for the detection of antibodies against MCF viruses. This enables the
test to detect antibodies specific for a wide range of structural components of the
virus. The CI-ELISA is based on a monoclonal antibody (MAb 15-A) specific to a
single epitope conserved among MCFV isolates (Li et al., 1994, 2005).
Flistopathological examinations revealed that the 7 tested cattle displayed lesions
typical of MCF. In cases where all four diagnostic tests were in agreement (n = 15),
no histopathological data was available, while in sixteen cases MCF was diagnosed
based on clinical evidence. The remaining four cases were diagnosed MCF negative
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based on a final diagnosis supplied by the veterinarian. Results indicate that the
WC11-ELISA is a useful method for the determination of antibodies to A1HV-1 in
cattle, and showed good agreement with established diagnostic methods for detecting
MCF. Of the MCF-infected animals diagnosed by either histopathology or clinical
evidence, 97% also had positive test results by PCR, 59% had positive test results by
IFAT, 61% had positive test results by CI-ELISA and 53% also had positive test
results by WC11-ELISA. Of the animals clearly negative by either histopathology or
clinical evidence, 100% also had negative test results by PCR, 100% had negative
test results by IFAT, 80% had negative test results by CI-ELISA and 80% also had
negative test results by WC11-ELISA (Table 6.9).
The OvHV-2 PCR showed over 97% concordance with histopathology and
final diagnosis and therefore appeared to be the most reliable diagnostic test
analysed. One explanation for the PCR showing enhanced diagnosis when compared
to the serological tests is that animals, particularly those involved in an outbreak,
may have acute infections with virus being present in the blood but the immune
response has not developed a sufficient antibody response to be detected in serum.
Certainly, in A1HV-1 challenged animals, virus is detected in the blood before
clinical signs are seen (G. Russell, Unpublished finding).
Test Test Sensitivity (%) Test Specificity (%) % Agreement
PCR 97 100 97
IFAT 59 100 59
CI-ELISA 59 80 61
WC11-ELISA 55 80 53
Table 6.9: Comparison of test sensitivity and specificity for all diagnostic
tests, compared to a final diagnosis.
Antibody to OvHV-2 has only been detected by using A1HV-1 as the source
of antigen. Antibody to A1HV-1 can be detected in 70-80% of clinically affected
cattle by IFAT procedures, but generally is not present in affected deer or animals
that develop acute or peracute disease and succumb within a few days of the onset of
symptoms (Klieforth et al., 2002). A report by Herring et al., (1989) investigating
virus neutralisation by serum from animals with terminal MCF, suggested antibody
was either absent or present only at a low titre. Following A1HV-1 infection, the
humoral response of the bovine host affected with acute MCF is ineffective in
preventing disease (Herring et al., 1989). This could suggest cattle only react to a
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limited number of viral components, either as a result of low levels of viral
replication or an incomplete expression of the full genetic range of A1HV-1 antigens.
It could also indicate that the immune response is severely compromised by virus
infection.
Serological tests such as the CI-ELISA may indicate previous infection but
may not necessarily indicate current infection. It can also not discriminate between
acute infection and long-term infections such as might be found in chronic or
recovered cases of MCF (Powers et al., 2005).
Examining the serological assays, the number of seropositive cattle detected
by IFAT was greater than the number detected by either of the ELISA assays,
showing 95% sensitivity but only 43% specificity when compared to the PCR assay.
This finding reinforces the supposition in chapter six that the number of seropositive
cattle detected by IFAT was usually equal to or greater than the number detected by
the two ELISA tests (section 6.2.4).
In contrast with the findings in the establishment of the WC11-ELISA
(chapter five), only slight positive agreement between the magnitude of reaction in
the CI-ELISA and the WC11-ELISA has been demonstrated, with both tests
detecting animals with MCF with a degree of accuracy and agreement. Parallel
testing of forty-two field serum samples from cattle, revealed over 57% concordance
between CI-ELISA and WC11-ELISA. In contrast to the 97.3% concordance shown
in chapter five, the number of seropositive cattle detected by the CI-ELISA was
greater than the number detected by the WC11-ELISA, showing 61% and 52%
sensitivity and 73% and 82% specificity respectively.
This result implies that the WC11 -ELISA was not as accurate in the detection
of MCF as the CI-ELISA in this group of samples. Of the ten samples that were CI-
ELISA positive/ WC11-ELISA negative, two cases were confirmed by
histopathology and six were confirmed by a final veterinary diagnosis. The
remaining two samples may be considered false-positive as a final diagnosis of MCF
was not reached. Of the eight samples that were CI-ELISA negative/ WC11-ELISA
positive, two cases were confirmed by histopathology and four were confirmed by a
final veterinary diagnosis. Similar to the CI-ELISA, two samples may be considered
false-positive as a final diagnosis of MCF was not reached, and no other test showed
virus or antibody present. Therefore the fact that there were 33% discrepant samples
between the tests was not simply due to the accuracy of one test in particular. Both
the CI-ELISA and WC11-ELISA incorrectly diagnosed 13-15 positive samples (31%
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and 36% respectively). Furthermore, thirteen samples were also incorrectly
diagnosed by IFAT (31%). It is possible that these cases represent animals previously
exposed to MCF viruses, with no or low levels of detectable antibody to MCF.
Although the PCR assay proved the most reliable test in this study, samples
where an antibody response was detected but no virus DNA was found were
observed (five samples PCR negative/serology positive). Although in four of the five
samples, the positive serology result appeared to be false-positive results, one sample
was confirmed positive by histopathology or final veterinary diagnosis. A possible
explanation for the negative PCR result may be due to the sensitivity of the real-time
PCR assay, as this sample was confirmed positive by the more sensitive nested PCR.
It was generally observed that in clinical cases of MCF, viral DNA was
readily detected in the blood and tissues of the infected animal (Baxter et al., 1993;
Li et al., 1995; Collins et al., 2000). Some validation studies, however, have shown
contrasting results where the PCR result differs from serology or histopathology.
Powers et al., (2005) showed a different observation in a study of cattle from a farm
with history of MCF, where serology-positive/DNA-negative animals were present.
This may indicate animals which have had past infections and therefore may have an
antibody response, but no viral DNA. Other possible explanations may include the
viral DNA being present at a low level, undetectable by PCR. This could represent a
form of latent infection of an animal, and therefore levels of virus circulating in the
blood would be considerably lower. It is also suggested asymptomatic infections may
not cause the production of virus and therefore indicates the PCR assay may fail in
some cases to consistently detect OvHV-2 infection (Powers et al., 2005).
Additionally, samples where no antibody response was detected, but viral
DNA was determined by PCR, were also found (five samples PCR positive /serology
negative). In these five cases, all three serology tests gave a negative result. Lahijani
et al., (1994) studied the application of a PCR test in exotic ruminants and showed
samples which were positive by DNA but negative by serology. Samples tested by a
virus neutralisation assay and PCR showed that some animals had no detectable
neutralising antibodies present in the blood. It was suggested that the animals were
either sampled during a non-replicative stage in the virus life cycle or that
immunological tolerance had been established. Li et al., (1995) suggested that a
further explanation for serology negative animals may be the lack of sufficient time
to mount an immune response due to the rapid clinical progression of infection. With
particular reference to the CI-ELISA, it is possible that individual animals may lack
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humoral immune response to the viral antigen targeted by the monoclonal antibody
used in the assay (Li et al., 1996), as appeared to be the case for two samples in
chapter five.
Further validation studies have shown concordance between the four
diagnostic methods tested. Comparative studies demonstrated that IFAT, CI-ELISA
and WC11-ELISA were specific for MCFV antibody, although in this study PCR
appeared to be more reliable for diagnosis of clinical MCF. Therefore these results
agree with previous studies comparing serological assays to histopathology
examination and PCR (Li et al., 1996; Muller-Doblies et al., 1998; Powers et al.,
2005). Few samples were serologically positive/PCR negative, while the majority
were PCR positive/serology negative. This finding supports the view that animals
may be infected and sampled before a serological response has developed, or the
animal develops MCF before the serological response is able to occur. A much lower
number of chronic, latent or recovered cases of MCF occur, where the viral load in
blood has reduced below the level of detection by Real-time PCR.
The data obtained in this comparative study indicate the WC11-ELISA as a
useful, specific and economical serological assay for the detection of antibodies
against MCFV. This study also demonstrated that the WC11-ELISA is capable of
detecting the presence of anti-MCF antibodies in cattle prior to the appearance of






Pathogenesis and epidemiology of OvHV-2 is still not entirely understood,
fundamentally due to the lack of effective detection methods for the etiologic agent
or antibody against it. Furthermore, serological cross-reactivity remains a concern.
Early work to determine A1HV-1 proteins with diagnostic significance demonstrated
a preliminary characterisation of virus-induced proteins using serum from infected
and uninfected rabbits (Adams and Hutt-Fletcher, 1990). Virus-induced proteins
from the A1HV-1 virus strain WC11 were shown at 48, 78, 95, 105, 110, 115, 130
and 145kDa. These proteins were not detected in uninfected animals. A more
definitive characterisation of A1HV-1 virus-induced proteins was then performed
with monoclonal sera. Fifteen monoclonal antibodies were obtained and
immunoprecipitation studies grouped the antibodies into three types (Adams and
Hutt-Fletcher, 1990). Type 1 and 2 antibodies precipitated proteins of 45 and
145kDa, while the type 3 antibodies immunoprecipitated a protein complex (gp 115
complex), which contained five polypeptides (48, 78, 105, 110 and 115kDa) as
shown by SDS-PAGE run under reducing conditions.
As a basis for a specific serological assay, an attempt was made to identify an
epitope conserved among all isolates of MCF viruses, by using a monoclonal
antibody (MAb) produced against a previously reported isolate of MCF virus
recognizing the gpl 15 complex (Li et al., 1994). The identified MAb (15-A) bound
to a conserved epitope on four isolates of MCF virus. On analysis by
immunoprecipitation, MAb 15-A was located on the viral glycoprotein complex
(gpl 15), which contains polypeptides of 45, 78, 105, 110 and 115kDa. Further
analysis of the components of MCFV was required for the purpose of developing a
diagnostic test (Li et al., 1995). Lysates from A1HV-1 infected cells were
immunoprecipitated with polyclonal antisera from either an A1HV-1 naturally
infected wildebeest or from A1HV-1 experimentally-infected sheep. When analysed
by western blot, eleven major bands were identified, and constituted six major
antigenic groups, one of which was the gpl 15 complex (115, 110, 105, 78 and
48kDa). Viral proteins at molecular masses of 17, 24, 34, 36, 110 and 130kDa were
additionally identified (Li et al., 1995). Potential candidates, which may be employed
in diagnostic tests were determined from this study. The earlier work by Li et al.,
(1994) identified an epitope conserved among isolates of MCFV and defined by the
MAb 15-A which suggested its usefulness in a diagnostic assay. MAb 15-A binds to
an epitope on the glycosylation-dependent glycoprotein complex gpl 15. Analysis of
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MAb 15-A showed the antibody was MCF-positive by IFAT and
immunoprecipitation and was inhibited by sera. Furthermore, analysis of the gp 115
complex under reducing conditions showed that protein fragments at 115, 110 and
105 were related by glycosylation. Under reducing electrophoretic conditions, the
gpl 15 complex reduced into bands of 48 and 78kDa in size. The proteins identified
in these studies (Li et ah, 1994; Li et ah, 1995) were consistent with previous studies
of AlHV-i envelope proteins (Adams and Hutt-Fletcher, 1990).
Analysis using the competitive ELISA approach with field sera suggested
cattle naturally infected with OvHV-2 produce antibodies to A1HV-1 that can
compete with monoclonal antibodies, in binding to a virus-infected cell lysate
(Adams & Fletcher, 1990; unpublished findings; Li et ah, 1994). This suggests that
the gpl 15 complex is highly conserved and may be considered important to study in
order to gain a further insight into the understanding of A1HV-1 pathogenesis
(Adams & Fletcher, 1990).
The sequencing of both the A1F1V-1 (Ensser et ah, 1997) and the OvHV-2
genomes (Hart et ah, 2007) provides an opportunity to identify genes unique to the
MCF viruses and particularly potential diagnostic antigens. As an ELISA (Fraser et
ah, 2006), based on a crude AlHV-l-infected cell lysate, was developed as part of
this study (described in chapter five), it would be of particular interest to identify the
antigens recognised by sera from clinically infected MCF-positive animals. To
develop a specific diagnostic assay to detect MCF in infected animals, the approach
of identifying viral components specific to A1HV-1 may prove valuable. Specific
antibody or antigen can be separated from antisera and crude extracts by methods
such as affinity purification, or conventional chromatography combined with western
blotting.
This chapter describes three approaches used to identify potential MCFV
antigens. In the first approach, A1HV-1 crude antigens were immobilised on
Sepharose and used to isolate antibodies specific for those antigens in order to
identify and purify A1HV-1 antigens with diagnostic significance. The second
approach involved the use of IgG fractions isolated from MCF positive sera and
immobilised on Sepharose to bind specific A1HV-1 antigens. The final approach
investigated the use of a variety of conventional chromatographic techniques to
isolate MCF specific antigens from cells infected with A1HV-1.
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7.2. Materials and methods
7.2.1. Preparation of whole cell lysate antigens
Crude whole virus antigen was prepared from bovine turbinate (BT) cells
grown in 150cm2 flasks using Iscove's Modified Dulbecco's Medium (IMDM)
supplemented with 10% foetal bovine serum, 1% Glutamine and 1% penicillin and
streptomycin. Cell monolayers were inoculated, at a multiplicity of infection (MOI)
of 0.1 PFU/cell, with 4ml of the cytopathic isolate of MCF causative agent, A1HV1
strain WC11 (Plowright et al., 1965). This was incubated for one hour before the
addition of 100ml of medium with 2% FBS. When 90-100% of the cells showed
virally-induced cytopathic effect (rounding of infected cells), supernatant was
removed and cells were harvested into phosphate buffered saline (PBS). Cells were
sedimented by centrifugation at 2000 x g for 10 minutes (4°C) and resuspended in
0.5ml of SDS-PAGE sample buffer. The cell lysate was then heated at ~85°C for 5
minutes, centrifuged for 10 minutes at 1000 x g, before being analysed by gel
electrophoresis and western blot. Whole cell lysates from BT cells infected with
herpesviruses; BFIV-1, BHV-2 and BoHV-4; were prepared in a similar manner.
Control antigen was prepared from mock-infected cells. Cells in the control flasks
were detached by gently scraping the flask. The supernatant was then harvested and
centrifuged at 2000 x g for 10 minutes (4°C). The cell lysate was then resuspended in
0.5ml of SDS-PAGE sample buffer.
Crude whole virus antigen was prepared from the BJ1035 LGL cell-line from
an OvHV-2-infected animal (Shock et al., 1998). BJ1035 was grown and maintained
as described in section 2.3.1. Cells were resuspended in the flasks by pipetting, and
the supernatant harvested. Cells were sedimented by centrifugation at 2000 x g for 10
minutes (4°C) and resuspended in 0.5ml of SDS-PAGE sample buffer. The cell
lysate was then heated at ~85°C for 5 minutes, centrifuged for 10 minutes at 1000 x
g, before being analysed by gel electrophoresis and western blot.
7.2.1.1. Preparation of whole cell lysate antigens
Crude whole virus antigen was prepared from bovine turbinate (BT) cells
grown in 150cm2 flasks using Iscove's Modified Dulbecco's Medium (IMDM)
supplemented as stated in section 7.2.1. Cell monolayers were inoculated, at a
multiplicity of infection (MOI) of 0.1 PFU/cell, with 4ml of the cytopathic isolate of
MCF causative agent, A1F1V1 strain WC11 (Plowright et al., 1965). When 90-100%
of the cells showed virally-induced cytopathic effect (rounding of infected cells),
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supernatant was removed and cells were harvested into phosphate buffered saline
(PBS). Cells were sedimented by centrifugation at 2000 x g for 10 minutes (4°C) and
resuspended in PBS. Control antigen was prepared using the same protocol, using
mock-infected BT cells.
7.2.2. Western Blotting
Gel electrophoresis and western blotting were performed (as described in
sections 2.5.2. and 2.5.6) to determine the predominant proteins, present in the
infected cell lysate, and recognise sera from MCFV infected cells The western blots
were performed as described in Chapter 2 (section 2.5.5). After transfer, non-specific
binding sites on 5mm-wide nitrocellulose strips were blocked using 3% non-fat milk
in high-salt wash buffer for 30 minutes at room temperature (22±5°C). The
nitrocellulose strips were then incubated for a further 60 minutes at room
temperature with a 1/100 dilution of test serum. Strips were washed to remove excess
test antibody (3x 10 minutes in wash buffer) followed by incubation with HRP-
labeled rabbit anti-bovine IgG for 60 minutes at room temperature (1/1000 dilution).
Chemiluminescent substrate (Pierce SuperSignal West Dura) was applied to the
membrane prior to exposure to x-ray film. The exposed film was developed using an
automatic film processor (Compact X2: Xograph Imaging systems, Wiltshire, UK).
7.2.3. Coupling to HiTrap Column
Affinity chromatography, utilising an immobilised A1HV-1 antigen lysate,
was used enrich antigen-specific antibodies from anti-MCF serum. Antigens were
covalently bound to a column, and antibodies, specific to these bound antigens, were
bound and isolated. HiTrap columns are designed for the covalent coupling of
ligands containing primary amino groups, based on cross-linked agarose bead-resin
(6% sepharose, 34pm mean particle size).
Briefly, crude antigen lysate, prepared as described in section 7.2.1.1, was
dialysed against coupling buffer (0.1M NaHPCX, 0.5M NaCl, pH 8.3). The dialysed
antigen (1.2pg) was covalently coupled to an NHS activated Sepharose 1ml HiTrap
column (GE Healthcare, Munich, Germany) following the manufacturer's
instructions. The column was washed for several cycles with 3x 2mls 0.5M
ethanolamine, 0.5M NaCl, pH8.3, followed by 3x 2mls 0.1M sodium acetate, 0.5M
NaCl, pH4. The efficiency of coupling was checked by following the manufacturer's
calculation (GE Healthcare: Instructions 71-7006-00 AT);
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Coupling solution loaded (A280 x nil) = A
(Coupling solution x volume of coupling solution loaded).
Amount not coupled (A280 x ml) = B
(Post-coupling wash x volume of post-column wash x 2).
Percentage coupling yield: (A-B)/A x 100.
The column (1ml) was then equilibrated with coupling buffer (0.1M
NaHP04, 0.5M NaCl, pH 8.3) and incubated for 30 minutes at room temperature.
The antigen-HiTrap column was attached to an Akta FPLC system and 50mls (1:10
dilution) of crude serum was passed through the column. Bound antibodies were then
eluted with 0.1M glycine (pH 2.8), neutralized with 1M Tris (pH9) and analysed by
gel electrophoresis and western blotting. Samples were stored at -70°C.
Affinity chromatography was also performed using an immobilized MCF-
positive purified IgG to enrich specific antibody-antigen binding.
7.2.4. Purification of MCFV specific immunoglobulin G (IgG) from serum
In order to minimise non specific binding, IgG was purified from serum.
Serum samples (0.5ml), diluted 10 fold in 50mM Tris, 150mM NaCl pH 8.3 (TBS)
and clarified by filtration through a 0.45p.M membrane filter (Sartorius, Germany),
were applied to a 1ml Protein-A FliTrap column (GE Healthcare) equilibrated with
TBS. Bound IgG was eluted with 0.1M glycine pH 2.8 into neutralising 1M Tris pH
8.5. Prior to analysis, purified IgG was stored at -70°C.
7.2.5. Gel filtration - Superdex200
A1HV-1 WC11 crude lysate (0.5ml 1.2ng/ml) was applied to the
Superdex200 column on the Akta FPLC system (described in section 2.7.2). The
column was equilibrated with 0.04% CHAPS in PBS (pH8.2) to minimise protein
aggregation. Fractions (lml) were collected and fractions corresponding to protein
peaks, as measured by absorbance at 280nm, were analysed by gel electrophoresis




7.2.6. Ion exchange - Q-Sepharose
Ion exchange chromatography separates molecules based on differences in pi
electrostatic potential. Elution was achieved by increasing the ionic strength of the
column buffer by applying a linear salt gradient from 20mM Tris (pH 8.2) to 20mM
Tris 1M Nacl (pH 8.2).Gel fdtration samples that were reactive with MCF serum
were further separated by Q-Sepharose. Prior to application to the column, samples
were dialysed against 20mM Tris (pH8.2). The protein mixture was separated by
increasing the NaCl concentration of the buffer and fractions (lml) were collected.
Absorbance peak fractions were analysed by SDS-PAGE and western blotting.
7.2.7. WC11 virus extraction using alternative detergents
WCl 1 supernatant from a 150cm2 flask was removed and virus pelleted in an
ultracentrifuge at 75000 x g for 16 hours. The supernatant was discarded and the
virus and insoluble cellular material resuspended in lOOpl of buffer containing a
detergent (either: 1% Triton X-100, 1% NP40, 0.8% CHAPS/TBS or in TNE buffer
plus 1.5M NaCl or in lx sample loading buffer). The solubilised pellets were then
incubated for 1 hour on ice and centrifuged at 13000 x g for 15 minutes. The
supernatant was removed, and aliquots were stored at -20°C. The remaining cell
pellet was resuspended in 20pl of lx sample loading buffer.
The samples from different extraction methods were run on 10% tris-glycine
polyacrylamide gels under reducing conditions, and were analysed by
chemiluminescent western blot using MCF-positive sera. As the 1.5M NaCl-
extracted lysate had a salt concentration too high to be run on a polyacrylamide gel,
10% (w/v) Trichloroacetic acid (TCA) was used to precipitate the protein from the
salt solution, lml of 10% ice-cold TCA was added to 50pl of supernatant and
incubated for 30 minutes on ice. Samples were centrifuged at 13000rpm for 10
minutes. The supernatant was then removed and the pellet resuspended in lx sample
loading buffer.
This work was done in collaboration with David Deane and Ann Percival,




7.3.1. Identification of MCFV antigens by western blot.
7.3.1.1. Analysis of bovine serum by western blot
In order to identify OvHV-2 antigens recognised by sera from animals with
MCF, western blots of an OvHV-2 LGL-infected cell lysate using MCF-positive and
negative clinical sera were performed using an OvHV-2 infected cell lysate. As a
negative control, mock-infected BT cell lysate was blotted to determine the level of
non-specific binding.
Two MCF-positive sera with different levels of antigen binding as
determined by IFAT were tested (with weak and strong positive immunofluorescence
detected) and shown to have the same pattern of reactivity against the OvHV-2
whole cell lysate (Figure 7.1). Four protein bands, estimated at 38, 48, 62 and 188
kDa were recognised by both MCF-positive sera. The MCF-negative clinical serum
showed a different pattern of reactivity to the positive sera (Figure 7.1), with protein
bands at 17, 28, 50 and 62kDa being recognised. Therefore the 62kDa is a non¬
specific protein, detected with both MCF-positive and negative sera. No reactivity
was observed with the negative control mock-infected BT cell lysate. These initial
findings suggested that sera from infected animals bound a set of specific proteins
associated with the disease and indicated that MCF specific antigens might be
identified by these sera.
In order to test the significance of these findings and to minimise any
potential variation of antibody-antigen binding patterns between individual animals,
a group of 20 clinical sera were tested. For the eighteen MCF-positive sera, a similar
pattern of reactivity was seen in the majority of samples, with strong reactive protein
bands at 17, 38, 48, 62, 140 and 188kDa, and weak bands at 28, 40 and 98kDa seen
in some cases (Figure 7.2). This result differs from the banding pattern shown in the
initial western blot with positive sera, as a larger number of proteins were observed
overall. However there was a similarity in the reactivity pattern, suggesting that the
difference in pattern may be a result of test sensitivity. This is supported by the fact
that four of the six bands shown in the larger trial were seen in the preliminary test.
Bands at 17 and 140kDa were not previously observed in MCF-positive serum
samples (Figure 7.1). Other individual variations were also seen (Figure 7.2). Animal
number 4, showed only two major protein bands, at high molecular weights of 50
and 65kDa. A second animal, number 11, showed only a weakly reacting band at
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Figure 7.1: Chemiluminescent western blot of OvHV-2 crude lysate using MCF
sera. Western blot using OvHV-2, BJ1035 whole cell lysate, with MCF positive (+)
and negative (-) serum samples. As a negative control (represented by C), mock-
infected BT cell lysate was blotted to determine the level of non-specific binding.
The red arrows indicate protein bands present in the MCF-negative serum, while the
white arrows indicate protein bands present in the MCF-positive serum.
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Figure 7.2: Chemiluminescent western blot of OvHV-2 crude lysate using MCF
sera. Western blot using OvHV-2, BJ1035 whole cell lysate, with MCF positive and
negative serum samples. C indicates secondary antibody used as a control (rabbit
anti-bovine IgG). Red arrows indicate protein bands seen in the MCF-positive
serum. Black arrows indicate protein bands seen in the MCF-negative serum (N)
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65kDa, while animals 7 and 20 showed strong reactions to protein bands at
molecular weights of 17 and 38kDa. Two animals, numbers 7 and 8, also showed a
band at an estimated molecular weight of lOOkDa, which was not detected by any
other serum analysed. Of the two samples which were confirmed MCF-negative by
IFAT (animal numbers 16 and 17), three protein bands, estimated at 17, 28 and
62kDa were recognised by both MCF-negative sera on analysis by western blot. As
these bands were also recognised by MCF-positive sera, they were therefore
eliminated as potential OvHV-2 antigens. As with the earlier findings, the secondary
conjugated antibody showed no reactivity (lanes 11 and 12, Figure 7.1)
7.3.1.2. Comparison of clinical and experimental sera.
Serum from an immunised A1HV-1 (strain C500 high-pass) animal was
compared to a clinical case of OvHV-2 MCF, confirmed by IFAT, in order to
determine whether there was a difference in reactive proteins identified possibly due
to the differences in infection, such as transmission, viral load and stage of infection.
For the experimental animal, there is control over these aspects, while in naturally-
infected field samples the precise onset and transmission of disease is unknown.
Furthermore, conditions in which the clinical animals are exposed allow the
possibility of other bacterial and viral infections.
The A1HV-1 strain WC11 was used as the source of virus antigen, being the
antigen routinely used by IFAT and the WC11-ELISA (described in chapter five).
The field sample showed a weak response, with bands present at 17, 36 and 48kDa
and a double band at around 98kDa (Figure 7.3). In contrast, the experimental serum
showed a strong response against the WC11 lysate, with bands observed between 28
and 188kDa, and three distinct bands at 36, 62 and 98kDa. Faint protein bands were
also detected at 34, 48 and 188kDa.
7.3.1.3. Analysis of Immunized rabbit antisera by western blot
Serum samples from rabbits experimentally-infected with A1HV-1 and
OvHV-2 (described in section 2.1.3) were analysed by western blot using an OvHV-
2-infected LGL cell line whole cell lysate (Rosbottom et al., 2002; Flart et al., 2007),
A1HV-I strains WC11 and C500 cell lysates and a non-infected rabbit lymphocyte
whole cell lysate (Figure 7.4).
The OvHV-2 rabbit antiserum is shown to react with more proteins in the
OvHV-2 lysate than the A1HV-1 lysates. A strong pattern of reactivity was seen, with
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Figure 7.3: Chemiluminescent western blot of clinical OvHV-2 and
experimentally infected AIHV-1 serum, a) Clinically-infected OvHV-2 bovine
serum submitted for MCF testing and b) experimentally infected AIHV-1 MCF bovine
serum, were analysed by western blot against MCF AIHV-1 strain WC11 cell lysate.




distinct bands at 18, 28, 30, 36, 40, 45, 58, 64 and 80kDa (Figure 7.4a). The WC11
crude lysate showed distinct bands at 48, 64, 80, 175 and 180kDa. The C500 lysate
also showed a distinct banding pattern, with a major band at 48 and 96kDa (Figure
7.4a). This result may imply that there is a lack of cross-reactivity between the anti-
OvHV-2 serum and some A1F1V-1 proteins. The A1HV-1 rabbit antiserum showed a
similar pattern of reactivity with the majority of bands seen in all lysates at 50, 75,
80, 98 and 175kDa (Figure 7.4b). Additional bands were seen in the OvFlV-2 lysate,
at 30, 36 and 45kDa. The 45kDa was also seen in the WC11 lysate, but not the C500
lysate. The higher activity in A1HV-1 serum may be due to a higher viral load in
infection.
Interestingly, both rabbit antisera showed a 54kDa band in the control rabbit
lymphocyte lysate. Further bands seen in the control lane, include bands at 18, 80, 98
and 175kda, and suggest a degree of non-specific reaction possibly due to the
conditions in which the virus inoculum and whole cell lysates are maintained. These
proteins may therefore be excluded from further analysis as they indicate non¬
specific protein interaction.
7.3.1.4. Electrophoretic analysis of herpesvirus cross-reactivity
The lack of cross-reactivity between antibodies to bovine herpesvirus was
previously analysed by the WC11-ELISA in chapter six (section 6.3.3). The
specificity of the WCl 1-ELISA for antibodies against MCF antigens was confirmed
in all cases. To identify MCF-specific virus proteins and conserved herpesvirus
antigens, western blots were performed using infected cell lysates for A1HV-1
(WC11), OvHV-2, BHV-1, BHV-2, BoHV-4 and an uninfected BT cell control
(described in section 2.2.2). The viral lysates were blotted with positive antiserum for
each bovine herpesvirus as well as MCF-positive and negative antiserum from
experimental animals (described in 5.2.3). The serum from an MCF-recovered
animal (06-1176) was also used to analyse whether banding patterns from affected
and recovered animals varied.
For the WCl 1 crude lysate, the bovine herpesvirus sera (BHV-1, 2 and 4)
showed the same pattern of reactivity as the rabbit anti-bovine IgG control, with
protein bands detected at 16 and 64kDa. This suggests the proteins recognised are
conserved and may be immunoglobulins (Figure 7.5a). The MCF-positive serum
showed a distinct pattern of six bands at 16, 40, 64, 98, 148 and 250kDa with weaker
bands at 25, 55, 80 and 1 lOkDa. The MCF-negative serum showed the same bands as
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Figure 7.4: Analysis of experimentally-infected rabbit sera. Rabbits immunised
with (a) OvHV-2 virus-infected mesenteric lymph node and (b) low-pass AIHV-1
strain C500, raised from liquid nitrogen and raised in bovine turbinate cells. Blood
was collected on onset of clinical signs, were and serum was analysed using
extracts from OvHV-2 (Ov), MCF AIHV-1 strains WC11 (Aw) and C500 (Ac), a rabbit
lymphocyte cell (RL) extract and BT lysate (BT) present as a control. Western blot
performed using an HRP-labelled polyclonal goat anti-rabbit conjugate.
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Figure 7.5: Chemiluminescent western blot to determine cross-reactivity
herpesviruses, (a) WC11 and (b) OvHV-2 whole cell lysate were analysed with MCF
positive (+) and negative (-) serum samples, a recovered clinical MCF serum sample
(R+), BoHV-1 (1), BoHV-2 (2) and BoHV-4 (4). (C) Indicates a secondary anti-bovine
IgG antibody control. The red arrows indicate protein bands unique to the MCF-positive






















seen for the IgG control and BoHV anti-serum (16 and 64kDa). The serum from an
MCF-recovered animal was expected to show a similar banding pattern to that of the
MCF-positive. However, only three bands were observed, two of which were the 16
and 64kDa bands seen in the control which appear to correspond to IgG heavy and
light chains. The third band, at approximately 148kDa, was also seen in the positive
serum sample, while the 40and 250kDa bands were absent. The lack of additional,
MCF-specific, bands in the recovered serum may identify the 148kDa band as an
important protective antigen.
Analysis of the OvHV-2 whole cell lysate showed the MCF-negative serum
sample and the IgG control showed a single band at 64kDa (Figure 7.5b). The MCF
positive serum sample and the recovered clinical serum sample both show the same
band at 64kDa, again probably corresponding to the IgG heavy chain. Faint protein
bands are additionally seen at estimated molecular masses of 16, 45, 48, 60 and
68kDa. These bands are also found in all of the bovine herpesvirus antisera tested.
The lack of unique bands reacting in the OvHV-2 whole cell lysate may be a result of
the test sensitivity or poor expression of OvHV-2 antigens in these cells.
It was assumed the BT cell lysate would not react strongly with any of the
antiserum samples tested, as this lysate was the basis for the control in the ELISA.
However, as seen in the IgG control for the WC11-lysate, two bands were seen at 16
and 64kDa, corresponding in size to IgG heavy and light chains. A third band at
approximately 250kDa was also seen in the BT cells with all antisera tested (Figure
7.5c). As the bovine cells are grown in bovine serum, bovine serum proteins may be
present on both the polyacrylamide gel and blot, and may consequently be detected
by the rabbit anti-bovine conjugate.
BHV-1 and BHV-2 have been shown not to cross-react with MCF viruses
(Osorio et al., 1985) and this finding was supported by results from the ELISA
validation, where no serological cross-reactivity between MCF strain WC11 and
BoHV-1 was shown. For the BHV-1 crude lysate (Figure 7.5d), the anti-bovine
herpesvirus sera, BHV-1 and 4, all showed the same pattern of reactivity, with
protein bands at 16, 50, 60, 64, 68, 98, 148 and 250kDa. The BHV-2, MCF-positive
and negative sera detected bands at 16, 60 and 250kDa, all of which are bovine
serum proteins recognised by rabbit anti-bovine conjugate. The MCF-recovered
serum and the BoHV-4 antiserum showed the same pattern of reactivity as the BHV-
1 antiserum, with the exception of a band at 50kDa. The 50kDa band was also
detected by the MCF-positive serum. The secondary antibody control showed the
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Figure 7.5: Chemiluminescent western blot to determine cross-reactivity
herpesviruses, (c) Control BT lysate and (d) BoHV-1 whole cell lysate were analysed
with MCF positive (+) and negative (-) serum samples, a recovered clinical MCF serum
sample (R+), BoHV-1 (1), BoHV-2 (2) and BoHV-4 (4). (C) Indicates a secondary anti-
bovine IgG antibody control. The red arrows indicate protein bands unique to bovine
herpesvirus-1, while the black arrows indicate protein bands conserved in all antisera
tested.
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same two protein bands expressed in the WC11 lysate, corresponding to the IgG
heavy and light chains at 16 and 64kDa (Figure 7.5a).
The BHV-2 crude lysate showed a distinct pattern with protein bands
detected at 16, 64, 155 and 250kDa for all sera tested, with the exception of BHV-1
and BHV-2. BHV-1 antiserum only detected at 155 and 250kDa. The BHV-2
positive antiserum showed an additional band at approximately 68kDa (Figure 7.5e)
that might therefore be BoHV-2 specific.
A western blot of the BoHV-4 crude lysate against the BoHV-4 positive
antiserum shows bands at molecular weights of 16, 45, 64, 110, 148 and 250kDa
(Figure 7.5f). This pattern of reactivity was conserved in all sera tested, with the
exception of a band at 70kDa, only detected by BoHV-4 antiserum. The 70kDa may
therefore be BoHV-4 specific. A band at 98kda was also detected using the MCF-
positive antiserum, which was not detected with any other serum analysed.
Furthermore the same bands were detected by the IgG control. This suggests that the
BoHV-4 anti-serum cross-reacts with a number of bands detected by MCF antisera.
These bands, which may be conserved among herpesviruses, may consequently be
eliminated from further analysis for potential recombinant candidate proteins.
7.3.1.5. Electrophoretic analysis of ELISA lysate
To define the MCF antigens recognised in the ELISA, the crude ELISA
lysate was analysed by staining with SimplyBlue SafeStain. Supernatant from the
clarification centrifugation in the preparation of the ELISA antigen (5 minute
clarification at 12,000 x g), the discarded cellular debris and subsequent ELISA
antigen were compared to ELISA antigen prepared with C500, OvHV-2 and the
control BT lysate (Figure 7.6a) by electrophoresis. Six distinct protein bands at 45,
55, 65, 97, 100 and 188kDa were seen in both the ELISA antigen and cell pellet and
may be host proteins. These bands were extracted and analysed by MALDI mass
spectrometry. Four bands were observed in the cell pellet at 15, 17, 18 and 19kDa
which were not seen in the ELISA antigen. It is possible these proteins were present
in the ELISA antigen at a lower concentration and were therefore not detected using
SimplyBlue stain. These bands were additionally sent for MS analysis.
Analysis by western blotting (Figure 7.6b), using MCF-positive serum,
showed two distinct bands expressed in the ELISA antigen at 64kDa (Figure 7.7
band 6) and 148kDa (Figure 7.7 band 3), with faint bands at 20kDa (Figure 7.7 band
10) and 50kDa (Figure 7.7 band 7). The cell pellet showed the same pattern of
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Figure 7.5: Chemiluminescent western blot to determine cross-reactivity
herpesviruses, (e) BoHV-2 and (f) BoHV-4 whole cell lysate were analysed with MCF
positive (+) and negative (-) serum samples, a recovered clinical MCF serum sample
(R+), BoHV-1 (1), BoHV-2 (2) and BoHV-4 (4). (C) Indicates a secondary anti-bovine
IgG antibody control. The red arrows indicate protein bands unique to the bovine
herpesvirus, black arrows indicate protein bands conserved in all antisera tested. Pink




Figure 7.6: SDS-PAGE analysis of ELISA antigen. The clarified supernatant (Snt),
cell pellet (P) and the ELISA antigen (WC11E) were compared to crude C500,
OvHV-2 and control BT lysates. Lysates resuspended in 2x SDS loading buffer, run
at 200v on a 12% tris-glycine polyacrylamide gel. Gels were either stained with
SimplyBlue SafeStain (a) or analysed by western blot using MCF-positive sera (b).
SeeBlue Plus2 Prestained protein marker was used as size standard (250-6kDa).
Protein bands in the ELISA antigen shown by arrows.
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reactivity, with additional bands at 98kDa (band 5) andl20kDa (Figure 7.7 band 4).
Analysis of the A1HV-1 strain C500 and OvHV-2 BJ1035 lysate showed a single
band at approximately 148kDa. No bands were seen in the BT lysate control.
Proteomic analysis showed that most of the major bands in SimplyBlue
stained gels were host proteins (Figure 7.7). One protein (band 10) was shown to
have 51% sequence coverage for A1HV-1 ORF52 identified from a band present in
the cell pellet at 17kDa. OvHV-2 ORF52 encodes a 136 amino acid (16kDa),
homologous to FISV UL49 which encodes VP22. This is one of the components of
the tegument although its role in viral infection has not been defined. UL49 is
conserved among all alphaherpesviruses including bovine herpesvirus-1. A band of
the expected molecular mass was subsequently shown in the ELISA antigen by
western blot, using MCF-positive serum. Therefore the protein was possibly masked
by the presence of IgG in the serum.
7.3.2. Analysis of AIHV-1 antigen using affinity chromatography
As the experimental bovine serum (tested in 7.2.1.2) showed high reactivity
to AIHV-1 and OvHV-2 lysates, alternative methods were sought to identify
candidate proteins by purification or fractionation of potential MCF antigens present
in the lysate. Affinity chromatography was used to enrich antigen-specific antibodies
from anti-MCF serum (described in section 7.2.3).
Protein-A purified AIHV-1 serum was used in a western blot against AIHV-1
WC11 and OvFlV-2 BJ1035 crude infected cell lysate. Purification of the MCF
AIHV-1 antiserum appeared successful as less background interference was seen
than previously observed when using crude sera (Figure 7.8). There were slight
differences observed between the proteins detected on the two MCF lysates. Five
distinct protein bands at 30, 34, 64, 130 and 250kDa (Figure 7.8a) were recognised in
the AIHV-1 lysate. The purified IgG recognised three bands in the OvHV-2 lysate
(34, 64 and 250kDa) which were also present in AIHV-1 as well as additional bands
with molecular weights of 36, 46, 48, 52 and 80kDa (Figure 7.4b). As the serum has
been purified using the WC11 lysate affinity column it is possible that only





















Figure 7.7: WC11-ELISA antigen analysed by Proteomic MALDI mass
spectroscopy. Distinct bands from the cell pellet (P) and the ELISA antigen





Figure 7.8: Chemiluminescent western blot of MCF-positive serum. MCF serum
taken from an animal experimentally infected with AIHV-1 was purified using an
AIHV-1 affinity purification column. Purified serum was analysed by western blot
using AIHV-1 WC11 crude lysate (a) and OvHV-2 BJ1035 crude infected cell lysate
(b). Arrows (black) indicate the major bands observed while red arrows indicate
bands only seen in the OvHV-2 lysate.
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7.3.2.1. Affinity chromatography using IgG purified serum
A second affinity purification column was prepared with IgG purified, using
HiTrap protein-A, from MCF-positive serum in order to directly bind specific
antigens. Purified bovine IgG (5ml 325pg/ml) was dialysed against coupling buffer
(0.1M NaHPCU, 0.5M NaCl, pH 8.3) prior to injecting on to the column. WC11
lysate (5mls 589pg/ml) was loaded onto the column. The chromatogram showed a
single peak (not shown) containing 55pg of eluted protein (fractions 14-16). The
fractions were concentrated 30-fold and analysed by electrophoresis and western blot
(Figure 7.9). No protein was detected in the three fractions when stained with
SimplyBlue safestain, suggesting the protein was lost during concentration.
Alternatively, this result may also indicate that there was a high level of non-specific
antigens which may be masking the MCF specific antibodies. Furthermore the
antigens specific to the bovine sera may be at a low concentration in the lysate and
are therefore not detected. To increase the sensitivity of detection, concentrated
fractions were pooled and electrophoresed. The gel was then stained using Sypro
Ruby stain which can detect lng of protein per band. Similar to findings with
SimplyBlue SafeStain, no protein was detected in the fractions, however protein was
again observed in the controls and fall-through material (Figure 7.10). This again
suggests that the protein was lost during concentration.
The lack of protein bands observed in the eluted fractions by two sensitive
staining methods suggests that the protein content was insufficient. This may suggest
that there were not enough specific antibodies loaded onto the column resulting in a
low binding capacity. The amount of MCF-specific antibody bound to the column is
unknown. A second explanation for the lack of protein may be a result of the
detergent used in the preparation of the ELISA antigen, inhibiting binding.
The experiment was repeated, using a second column prepared with Protein-
A purified A1HV-1 MCF-positive serum. To check that the Ig bound to the column,
an ELISA was performed on Ig samples before and after binding to the column
(Figure 7.11). There was a noticeable difference between crude (0.9AU) and
unbound (0.26AU) samples, where there was a difference of 0.65 absorbance units,
about a third of the initial absorbance value present in the unbound sample. This
suggests that the column had bound most of the antibody. However, one
consideration that must be made is to the dilution of the unbound serum sample in
comparison to the crude serum.
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Figure 7.9: SDS-PAGE analysis of fractions from an anti-MCF serum affinity
purification (NHS-HiTrap) column. Cr represents crude WC11 lysate. C
represents BT cell lysate control and F represents column fall-through material.
Crude AIHV-1 WC11 lysate (5mls 589pg/ml) diluted ten-fold with PBS was loaded
onto the column. Thirty 1ml fractions were collected where activity was shown o the
chromatogram as a single peak, contained in three 1ml fractions (Fraction 14-1.
Fraction 15 -2, Fraction 16 -3). The three fractions were concentrated 5-fold and
25pl was loaded on a 14% tris-glycine polyacrylamide gel. The gel was analysed by
gel staining SimplyBlue SafeStain. No protein was detected by western blot (not
shown), using MCF-positive sera and a rabbit anti-bovine (IgG) HRP conjugate.
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Figure 7.10: SDS-PAGE analysis of AIHV-1 fractions taken from an anti-MCF
serum affinity purification (NHS-HiTrap) column. Cr represents crude WC11
lysate, C represents BT cell lysate control, CrD represents crude WC11 lysate
following dialysis and F represents column fall-through material. Crude AIHV-1
WC11 lysate (5mls 589pg/ml) diluted ten-fold with PBS was loaded onto the column.
Thirty 1ml fractions were collected and three fractions were concentrated 30-fold
(S). Twenty-five microlitres of pooled fraction sample was loaded on a 14% tris-
glycine polyacrylamide gel, were analysed by gel staining with Sypro Ruby stain.
1
20 40 80 160 240 320 640 1280
Sera Dilution
Figure 7.11: Analysis of HiTrap column binding efficiency. HiTrap Protein-A
purified AIHV-1 MCF-positive serum was analysed using the MCF WC11-ELISA
Samples of crude and sample which remained unbound to the HiTrap Protein-A
affinity column, were analysed at a range of serial dilutions (1/20 - 1/1280). Optical
density was measured at 450nm. Dilutions were analysed in duplicate.
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Having checked the binding capacity of the column, crude WC11 lysate
(1.5mg/ml), diluted 10-fold in PBS, was injected onto the column using the FPLC
system. The unbound fraction was washed off the column and the bound protein was
eluted in a single fraction containing 16pg of protein.
To investigate whether there was a difference in the antigenic proteins
expressed within the two related viruses, OvHV-2 crude lysate (0.48mg/ml) was
injected on to the column (5mls diluted 10-fold in PBS) and a single fraction
containing I5pg bound antigen was eluted. Both A1HV-1 and OvHV-2 eluted
fractions were concentrated 10-fold and analysed by SDS-PAGE gel electrophoresis
and western blotting. No bands were detected in either lysate eluant when stained
(Figure 7.12). Proteins with molecular masses ranging from 191 to 39kDa were seen
in the unbound cell lysate, with a major band at 64kDa. This band was also seen in
the unbound material. Western blotting using experimental serum (described in
section 7.2.1.2) showed a faint band in the eluant, with a molecular mass of 55kDa.
No bands were detected in the unbound cell lysate (Figure 7.12).
As no protein was detected by SDS-PAGE electrophoresis, work on affinity
purification methods was not continued. A possible explanation for the failure to
identify MCF specific antigens by this method may be the presence of the non-ionic
detergent used to prepare the EL1SA antigen (NP40) inhibiting active binding to the
column.
7.3.3. Fractionation of MCFV lysates
Further purification methods were sought for the identification of antigens
recognised by the ELISA that were more compatible with the ELISA antigen
preparation. Fractionation of the ELISA lysate to isolate proteins of interest was
performed by gel filtration in order to simplify the crude lysate protein mixture.
Crude WC11 lysate (0.5mg/ml) was injected into a Superdex200 gel filtration
column using an FPLC system. Thirty-five (1ml) fractions were collected and
fractions which corresponded to peaks on the FPLC system UV trace were analysed
by Coomassie staining and western blot (Figure 7.13). The analysis was repeated for
a BT control lysate (Figure 7.14)
For the WC11 crude lysate, stained gels showed protein in only the initial
three protein peaks, with proteins ranging from 28 to lOOkDa. Fraction 5, which
corresponded to the highest peak from the fractionation trace (Fractions 5-7), showed
a smear of detected bands (Figure 7.13b). Fractions 6 and 7 also taken from the
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Figure 7.12: SDS-PAGE analysis of AIHV-1 and OvHV-2 lysates purified using
an anti-MCF serum affinity column (NHS-HiTrap). Cr represents crude WC11
lysate (Crw) and BJ1035 crude infected cell lysate (Crov), U represents unbound
material and E represents eluted material from the anti-MCF serum affinity column,
for both AIHV-1 (EA) and OvHV-2 (E0v)- Gel stained with SimplyBlue Safestain.
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Figure 7.13: SDS-PAGE analysis of AIHV-1 WC11 lysate purified by gel
filtration. Using the Akta FPLC system, fractions showing any presence of protein
by OD were analysed by electrophoresis (a) and western blot (b) using MCF
antisera. A 14% tris-glycine polyacrylamide stained gel shows fractions
corresponding to highest activity on the chromatogram. Arrows on stained gel
represent bands recognised by MCF antisera by chemiluminescent western blot.
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Figure 7.14: SDS-PAGE analysis of control lysate (BT) purified by gel filtration.
Using the Akta FPLC system, BT lysate fractions showing any presence of protein
by OD were analysed by electrophoresis (a) and western blot (b) using MCF
antisera. A 14% tris-glycine polyacrylamide stained gel shows fractions
corresponding to highest activity on the chromatogram.
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initial fractionation peak showed less protein than fraction 5. Fractions corresponding
to the second peak (Fractions 9-11) showed distinct protein bands at 45, 48, 60, 64,
66 and 70kDa. Fraction 12, which corresponded to the third peak, showed a similar
banding pattern to the previous fractions with bands at 36, 40, 45, 48, 55, 60, 64, 66
and 70kDa. The strong band at 60kDa shown by staining was thought to be bovine
serum albumin. By western blot, using MCF positive antisera (Figure 7.13b), fraction
5 showed a smear of detected bands with a distinct band at 97kDa, while fractions 6
and 7 showed only a triple band at 97kDa. Fractions 9 and 10 showed bands around
1 lOkDa, while the third protein peak showed no distinct proteins recognised by MCF
antisera. Although a high number of protein bands were visible by staining, no other
antigenic bands were detected by the positive MCF crude serum.
For the BT crude lysate the chromatography trace showed the same protein
peaks and therefore the corresponding fractions were analysed. Similar to the WC11
fractionation, the stained gels showed detectable protein bands in only the initial
three peaks, with proteins ranging from 28 to lOOkDa (Figure 7.14a). No bands were
observed by western blotting using positive MCF crude serum (Figure 7.14b). This
suggests that proteins detected in the WC11 lysate were specific to MCF.
Proteomic analysis was performed on the bands at 97kDa recognised by MCF
positive sera (Figures 7.15). The only sequence match identified bovine serum
albumin. This suggests that the high level of serum albumin present in the lysate may
mask the identification of A1HV-1 viral proteins.
7.3.3.1. Purification of WC11 crude lysate using Ion Exchange
A further purification step was performed, to reduce background interference
seen in the fractionated samples, using ion-exchange with Q-sepharose columns. A
pool (1ml) of fractions 5, 6 and7, taken from the initial peak of the WC11 crude
lysate, was diluted in binding buffer (20mM Tris pF18.2) and injected onto a Q-
sepharose column using an FPLC system. Forty-five (1ml) fractions were eluted
using a linear salt gradient to 1M NaCl and fractions containing protein, by
absorbance at 280nm, were concentrated 10-fold, resuspended in SDS loading buffer
and analysed by staining and western blot (Figure 7.16). A control was also tested,
using the corresponding samples from the BT crude lysate fractionation (fractions 8-
10).
By staining, protein could be detected in the initial peaks taken from the salt
gradient, ranging in size from 50 to 191 kDa. There was some background smearing
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Figure 7.15: AIHV-1 gel purified proteins analysed by Proteomic MALDI mass
spectroscopy. Proteomic analysis was performed on the bands at 97kDa,
recognised by MCF positive sera (Figures 7.13). Fractions run on a 12% bis-tris
polyacrylamide gel and stained with SimplyBlue Safestain, were analysed by MALDI
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Figure 7.16: AIHV-1 fractions purified using a Q-Sepharose column. A pool of
fractions (fractions 5-7) taken from AIHV-1 lysate, previously purified by gel filtration
were further subjected to purification using a salt-gradient Q-Sepharose column.
Forty-five 1ml fractions were eluted from the column and fractions showing any
presence of protein by OD were concentrated 10-fold and analysed by SDS-PAGE.
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on the gel, resulting in difficult interpretation between individual bands. Fraction 22
showed three distinct bands at 30, 40 and 45kDa, while fractions 24 and 25 showed a
single protein band at 50kDa. No antigenic proteins were detected by western blot.
This was possibly due to the use of the detergent NP-40 to lyse the WC11 infected
BT cells. NP-40 can interfere with the binding of proteins to columns because of its
low micelle size and strong binding properties. It is therefore possible that the
antigenic proteins remained in the unbound fraction. The experiment was repeated
using the collected unbound fraction, no protein was eluted using the Q-sepharose
column, and therefore no analysis was performed on this fraction.
7.3.3.2. Fractionation of OvHV-2 BJ1035 ELISA antigen lysate
Fractionation of the OvHV-2 ELISA lysate to isolate specific proteins was
also performed. BJ1035 lysate (0.5ml; 0.48mg/ml) was injected into a Superdex2oo
fractionation column using an Akta FPLC system. Twenty-five (1ml) fractions were
collected and fractions corresponding to peaks on the FPLC system trace were
analysed by Coomassie staining and western blot (Figure 7.17). Analysis by stained
gel showed low levels of protein, with faint bands at 52, 55 and 64kDa (Figure
7.17a) observed in fractions from the second protein peak (fractions 12-15). By
western blot, only one strong protein band at about 97kDa reacted with the MCF
specific serum (Figure 7.17b). Although this was the only protein shown on the
western blot, additional protein bands were seen at the top of the gel, possibly
indicating the presence of insoluble or very high molecular weight protein
complexes.
Proteomic analysis was performed on the 97kDa band recognised by MCF
positive serum, identified in OvHV-2 fraction 11. Identification of the protein proved
unsuccessful as the only sequence match identified an IgG-associated protein
(Figures 7.18). This would suggest that contamination by host proteins masked the
presence OvHV-2 antigens.
7.3.4. CHAPS lysed AIHV-1 lysate
To determine whether inhibition by NP-40 was observed in the affinity
purification, lysis of the viral pellet was performed using a variety of detergents:
Triton X-100 (non ionic); CHAPS (3-[(3-Cholamidopropyl) dimethylammonio]-l-
propanesulfonate), a high ionic strength buffer (NaCl/TNE); and sodium dodecyl
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Figure 7.17: SDS-PAGE analysis of OvHV-2 lysate purified by gel filtration.
Using the Akta FPLC system, fractions showing any presence of protein by OD were
concentrated 10-fold and analysed by electrophoresis (a) and western blot (b) using
anti-MCF serum. A stained 14% tris-glycine polyacrylamide gel shows fractions
corresponding to highest OD on the chromatogram. Arrows on stained gel represent
bands recognised by MCF antisera by chemiluminescent western blot.
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Figure 7.18: OvHV-2 gel purified proteins analysed by Proteomic MALDI mass
spectroscopy. Proteomic analysis was performed on bands recognised by MCF
positive sera (Figures 7.17). Concentrated ractions run on a 12% bis-tris
polyacrylamide gel and stained with SimplyBlue Safestain, were analysed by MALDI
mass spectrometry. Arrows indicate two bands analysed.
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sulphate (anionic) (Figure 7.19). Four major bands were identified in each extraction
lysate at 32, 35, 43 and 45kDa. Extraction by CHAPS and the high ionic strength
buffer, when compared to the remaining lysates, showed the clearest banding pattern
with additional bands observed at 58, 62 and 66kDa.
Analysis of the CHAPS and NP-40 extracted lysates by western blotting
(Figure 7.19b), using anti-MCF serum, showed distinct bands expressed in the WC11
pellet at 32, 35, 43 and 55kDa. As seen by staining, extraction by CHAPS showed a
stronger response with additional bands observed at 45, 50, 60 and 66kDa. These
bands were not seen in the NP-40 extract.
As CHAPS is an ionic detergent, it may not inhibit the binding of proteins to
an affinity or fractionation column. Therefore the CHAPS lysed cell-free virus pellet
was further analysed by SDS-PAGE gel electrophoresis (Figure 7.20). Furthermore,
to reduce contaminants observed in previous proteomic analysis, the WC11 virus for
this experiment was grown in serum-free medium, rather than in the presence of 2%
foetal calf serum. Four distinct protein bands could be discerned at 48, 66, and a
double band at 130kDa. Faint bands were also shown at 36, 38 and 40kDa.
Proteomic analysis was performed to identify the four major bands shown by
the SimplyBlue stained gel (Figure 7.21). All bands had positive sequence matches
to the A1HV-1 genome. Bands 1 and 2, with estimated molecular weighs of 130kDa,
identified A1HV-1 ORF25, with 31% and 22% sequence coverage respectively. Band
3, estimated molecular weight of 66kDa, identified A1HV-1 ORF21 showing 16%
sequence coverage. Band 4, estimated molecular weight of 45kDa, initially showed a
positive hit to actin (bovine), which is one of the most highly conserved proteins.
When analysed in the absence of actin, A1HV-1 ORF54 was identified, with 18%
sequence coverage. A1HV-1 ORF21 encodes a 569 amino acid protein, thymidine
kinase, homologous to HVS ORF21 (26%) and EBV BXLF1 (29%). A1HV-1 ORF25
encodes the 1370 amino acid major capsid protein. A1HV-1 ORF25 is homologous to
HVS ORF25 (56%), EBV BCLF1 (54%). A1HV-1 ORF54 encodes a 298 amino acid
protein with homology to dUTPase (deoxyribouridine-triphosphate
pyrophosphatase), an enzyme involved in viral replication and which is found in the
virus particle (Chen et al., 2002). A1HV-1 ORF54 is homologous to HVS ORF54
(36%), EBV BLLF1 (27%).
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Figure 7.19: Comparison of A1HV-1 WC11 virus pellet extraction methods, a)
Five extraction methods were compared using WC11 cell-free virus. Different
extraction methods include the use of detergents, Triton X-100 (TX), NP-40 (IMP),
0.08% CHAPS (CH), High-salt buffer (HS) and SDS loading buffer (SDS). The
CHAPS extracted AIHV-1 WC11 pellet showed the strongest banding pattern and
was analysed against NP-40 by western blot (b), using anti-MCF serum. Arrows
indicate bands not shown in the NP-40 extract.
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Figure 7.20: SDS-PAGE analysis of 0.08% CHAPS extracted AIHV-1 WC11
lysate. Thirty microlitre sample of CHAPS extracted lysate was run on a 12% bis-tris
polyacrylamide gel and stained with SimplyBlue SafeStain. Approximate molecular
















Figure 7.21: 0.08% CHAPS extracted AIHV-1 lysate analysed by Proteomic
MALDI mass spectroscopy. Thirty microlitres of CHAPS extracted lysate was run
on a 12% bis-tris polyacrylamide gel and stained with SimplyBlue Safestain. Bands




As the lysate-based ELISA described in chapter five proved effective, it
raised the question of what antigens are being detected. This aim of this chapter was
to identify potential MCFV antigens using several strategies such as affinity
purification, chromatography and virus fractionation.
An initial identification of OvHV-2 antigens, recognised by clinical MCF
antisera, was done by western blots, using an OvFIV-2 infected cell. Although
individual variations were seen in some cases, a similar pattern of reactivity was seen
in the majority of samples, with strong reactive protein bands at 17, 28, 38, 40, 48,
62, 98, 140 and 188kDa. The major 140kDa component is assumed to be a
nucleocapsid protein (Floness and Watson, 1977). Protein bands at 17, 28 and 62kDa
were also recognised by MCF-negative sera. Therefore, as these bands were
recognised by both MCF-positive and negative sera they can be eliminated for
analysis as potential OvHV-2 antigens. A previous study analysing the reaction of
cattle, sheep and wildebeest sera with A1HV-1 strain WC11 (Herring et al., 1989),
showed wildebeest sera from an animal infected with A1HV-1 reacted with six
reactive polypeptides (32, 34, 35, 50, 77 and 140kDa), while bovine sera from an
animal with A1HV-1 -induced MCF showed reactivity in a small proportion of
samples tested, reacting to a small number of polypeptides (34, 35, 50 and 140kDa).
This may suggest that cattle may only produce antibodies to a limited number of
viral components as a result of either a low level of viral replication or an incomplete
expression of the MCF virus DNA within the host (Herring et al., 1989). It is also
possible that in an MCF-infected animal, the immune system may either not have
had time to make a complete response, due to a level of immunosuppression or the
time of sampling. A further explanation for the difference in banding patterns
observed between animals may be a result of variation in the major
histocompatibility complex (MHC) restricted response shown by individual animals.
The MHC is a main source of variation in immune responses and in cattle is termed
the bovine lymphocyte antigen system, or BoLA (Lewin et al., 1999). Differences in
allelic forms of MHC may influence T-cell function and recognition of antigens.
Immunoprecipitation of virus-induced proteins was performed using infected
and control rabbit polyclonal antibody in order to identify envelope and membrane
proteins of the virus virion. Results suggested at least six glycoproteins as well as a
non-glycosylated molecule possibly located in the viral envelope. Using monoclonal
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antibodies, able to recognise virion envelope proteins, proteins of the gp 115
complex, 48, 78, 105, 110 and 115kDa were shown to be antigenically related.
Furthermore the 115kDa protein appears to be composed of two fragments, 48 and
78kDa proteins, linked by disulphide bonds. Ten viral-induced proteins, ranging
from 48 to 145kDa, were shown of which two were assumed glycoproteins at 46 and
62kDa and a further two were cell proteins (45 and 200kDa) (Adams and Hutt-
Fletcher, 1990).
Antiserum reacted with virions by immunofluorescence (Lahijani et al.,
1995) and a western blot detected three proteins at 15, 37-38kda and 55kDa. The 38
and 55kDa proteins were detected in both infected and control cell lysates. The
37kDa protein was only present in infected cells. A cDNA library, constructed using
mRNA from A1HV-1 infected cells, was screened and identified a cDNA clone. The
insert hybridised strongly with A1HV-1 DNA but did not hybridise with DNA from
bovine herpesviruses 1, 2 or 4 and alcelaphine herpesvirus-2. This lack of cross-
reactivity suggests that this sequence (ORF73) would be a good candidate for the
development of an A1HV-1 specific diagnostic test, such as an EL1SA or PCR.
Similar work, by Coulter and Reid (2002) analysed the expression of viral antigens
by western blotting, using polyclonal sheep serum. Using an OvHV-2 infected
lymphoblastoid cell line, antigens at 60, 75 and a major antigen at 83kDa were
identified.
In order to identify MCF-specific viral proteins, western blots were
performed using infected cell lysates and sera from other bovine herpesviruses.
While a previous study (Flerring et al., 1989) suggested BoHV-1 serum showed
cross-reactivity with A1HV-1 polypeptides (25, 44, 57 and 65kDa), in this study all
of the bovine herpesvirus antisera tested (BoHV-1, 2 and 4) showed the same pattern
of reactivity as the IgG control. Bands were detected at 16 and 64kDa, suggestive of
immunoglobulins. The A1HV-1 antiserum showed a distinct pattern of bands at 16,
25, 40, 55, 64, 98, 148 and 250kDa while the OvHV-2 antiserum detected only
proteins bands detected by all bovine herpesviruses analysed. This may be due to the
sensitivity of the test, or the optimisation of the serum samples using OvHV-2 lysate.
Analysis using an OvHV-2 lysate showed that both the experimental serum
sample (A1HV-1) and the recovered clinical serum sample (OvHV-2) detected the
same bands at 16, 32, 45, 48, 60, 62 and 64kDa. As this is latently infected cell
lysate, there is a possibility that very little viral antigen is expressed. These bands are
additionally detected by all of the bovine herpesvirus antisera tested. The lack of
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unique bands reacting in the OvHV-2 whole cell lysate may be a result of the test
sensitivity or lack of antigen expression by the cell line. The fact that the serum
sample was from a clinical animal, allows the possibility of reactivity with other
viruses and pathogens, and poses to the question of what MCF antigens are
recognised by ELISA.
On analysis of the ELISA antigen by electrophoresis, six distinct protein
bands at 45, 55, 64, 97, 100 and 188kDa were shown, while a western blot, using
MCF-positive serum showed four bands expressed at 20, 50, 64 and 148kDa.
Proteomic analysis of these bands, however, indicated a high level of host
contamination which may have masked viral proteins.
Fractionation of the ELISA lysate was performed to isolate proteins of
interest. A triple band at 97kDa and a band at HOkDa were identified as possible
proteins specific to MCF. Proteomic analysis only identified a contaminant; bovine
serum albumin. Fractionation of the OvElV-2 ELISA lysate was also performed and
identified one strong protein band at 150kDa. Proteomic analysis identified an IgG
associated protein, which suggests that contamination by host proteins may mask the
presence A1HV-1 and OvHV-2 antigens. A possible explanation for the ineffective
binding of the A1HV-1 lysate to the affinity or ion-exchange columns, may be the
presence of Nonidet P-40 (Nonylphenylpolyethylene glycol), commonly used in
extraction protocols to solubilize membranes. Nonidet P-40 is a non-ionic detergent
and cannot be dialysed so that the concentration of detergent contained within the
samples could be higher than recommended for chromatography.
Extraction using other detergents commonly used for cell lysis was
performed on A1HV-1 WC11 maintained in serum-free medium. Protein bands could
be discerned at 36, 38, 40, 48, 66, and a double band at 155kDa. Proteomic analysis
identified ALHV-1 ORF21, ORF25 and ORF54. A1HV-1 ORF21 encodes a 569
amino acid protein, thymidine kinase homologous to HVS ORF21 (26%) and EBV
BXLF1 (29%). A1HV-1 ORF25 encodes the 1370 amino acid major capsid protein.
A1HV-1 ORF25 is homologous to HVS ORF25 (56%) and EBV BCLF1 (54%).
A1HV-1 ORF54 encodes a 298 amino acid protein with homology to dUTPase
(deoxyribouridine-triphosphate pyrophosphatase), an enzyme involved in viral
replication and which is found in the virus particle (Chen et al., 2002). A1HV-1
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Table 7.1: Summary of proteomic results
Using three approaches for the identification of potential MCFV antigens of
diagnostic significance, a number of potential candidate recombinant antigens have
been determined. Future studies would include the analysis of each of the A1FIV-1
antigens: ORF21, ORF25, ORF52 and ORF54, identified in the crude viral extract
with MCF-specific antibodies. Initial tests should be performed to define whether
they are highly conserved within other bovine herpesviruses and therefore likely to
be cross-reactive. A number of bands were additionally shown to be unique to MCF
viruses by western blot using MCF antisera. Further analysis should be performed to
identify these proteins.
The identification of these OvHV-2 genes as possible candidates offer
encouraging possibilities for the development of a recombinant assay due to the
evidence supporting their identification with positive MCF antiserum. Furthermore
the identification of structural proteins, and in particular the major capsid protein, is
particularly preferred as they are to be exported or expressed on the cell surface and






Accurate diagnostic tests for infectious diseases and viruses are crucial for the
detection and control of most diseases (Peeling et al., 2006). The diagnosis of a
disease within an animal plays an important role in understanding disease
transmission, prevalence of infection and the host immune response. In addition to
the diagnosis of individual animals, tests are used for surveillance and monitoring of
herd health status with an aim of establishing preventative measures and eradication
programmes (Office International des Epizooties, 2006).
The primary objective of this study was to advance the current position in the
diagnosis of OvHV-2. Current diagnostic methods include histopathological
examination, indirect immunofluorescence test, virus neutralisation, conventional
and real-time PCR assays and ELISAs. ELISAs are reliable, widespread, economical
tests designed for the rapid throughput of samples for the specific detection of
antibodies against an antigen such as MCFV. However, ELISA tests are often
difficult to validate due to the signal amplification of specific and non-specific
components. Methods and reagents may reduce assay specificity and increase test
variability. Viral antigen derived from a whole-cell viral culture preparation may
contain non-specific antigenic components. OvHV-2 lysate may contain non-specific
antigens as a result of the method of preparation, including cellular proteins and
serum proteins present in the culture medium. Development of a detection assay,
using the recombinant expression of antigens, would therefore be beneficial for the
specific detection of OvHV-2 infection.
Recombinant technology aiming at expression includes the identification,
isolation and expression of genes in non-host organisms such as bacteria, yeast,
insect cells and eukaryotic cells. Large quantities of specific gene product may be
obtained as recombinant proteins. Ideal candidate antigens are natural proteins which
are major stimulants of cellular and humoral immunity against the disease, such as
structural epitopes, which may be continuously produced in both infected animals
and cell culture (Office International des Epizooties, 2006). Prerequisites of
recombinant antigens for use in immunoassays include the reproducibility of the
antigen and the purity. The production of large amounts of antigen is favoured for
ensuring reproducible results within a diagnostic assay. As many proteins are present
in recombinant expression systems, purification is required to remove potential non¬
specific antigenic targets (Schmitt and Papisch, 2002; Schmitt, 2003).
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The determination of the DNA sequence for the OvHV-2 genome (Hart et al.,
2007) has confirmed the identification of twelve genes unique to MCF viruses and
three genes unique to OvHV-2 (Table 1.2, Figure 1.10). The use of such unique
genes for a diagnostic assay would be advantageous as it would reduce potential
cross-reactivity with other herpesviruses. The OvHV-2 genes selected for analysis in
this study were divided into three categories. Genes were firstly selected on the basis
of use in diagnostic approaches in related herpesvirus systems. Secondly, of the MCF
specific genes, potential antigens were selected if they were expressed on the surface
of the virus, as polypeptides likely to be exported or expressed on the cell surface
may be exposed to the immune system. Finally genes which were unique to the
OvHV-2 genome were selected as they are potentially less likely to cross-react with
other herpesviruses. Knowing the sequence of the OvHV-2 genome enabled PCR
primers to be designed to amplify candidate genes or gene fragments and create in-
frame fusions when cloned into the expression vectors. Bacterial systems are simple,
stable, continuous systems for the production of large quantities of protein. For the
expression of candidate genes, bacterial expression systems were selected that could
add an epitope tag, HisTag, to aid purification. Bacterial systems showed expression
of glycoprotein Ov8 and capsid protein ORF65 both of which appeared to be
recognised by anti-MCF sera. Purification by affinity chromatography using an
epitope tag was ineffective in all cases attempted. In the absence of a clean
purification method, a diagnostic test would not be deemed reliable due to the
possibility of false-positive results generated from impurities. The candidate genes
were subsequently not analysed by ELISA due to the lack of protein expressed and
purity.
Disadvantages of the bacterial systems include the formation of insoluble
aggregates and the need for purification. Purification of recombinant antigens is
essentially due to the presence of antibodies against E. coli proteins in most
livestock. Furthermore the fusion partner may be antigenic. In the case of the
thioredoxin expression system, the thioredoxin protein may cross-react with the
fusion proteins expressed. The alternative approach of the in vitro, novel rapid
translation system resolved solubility issues regarding the expression of some
OvHV-2 proteins, but, an improved purification method is required to separate the
target protein from potential non-specific cross-reacting proteins in the E. coli
extract. It can be concluded from this initial study, that in order to develop a
diagnostic assay based on recombinant proteins, further work on protein expression
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is required and specifically, improved purification of target proteins is needed before
work using MCF-specific serum may be attempted. Future studies on the expression
of recombinant OvHV-2 antigens should include the investigation of different
expression systems. Unlike prokaryotic hosts, the eukaryotic cellular organisation of
yeast expression systems allow for post-translational folding and modification of the
protein to mammalian proteins with native epitopes (Schmitt, 2003). Further
advantages of using a yeast system include rapid growth in culture and the relative
simplicity of genetic manipulation (Buckholz and Gleeson, 1991). Insect
cells/baculovirus expression systems are also commonly used for the expression of
proteins. Baculovirus expression systems have been used in the characterisation and
assembly of the herpes simplex virus capsid (Newcomb et al., 1996), and in the
expression of KSHV latent and lytic genes, capsid protein ORF65 and glycoprotein
K8.1 (Zhu, et al., 1999). Mammalian cell systems offer ideal expression conditions
for mammalian antigens. An example of the effective expression of antigens using
mammalian systems has been shown for Epstein-Barr virus, with the successful
expression of the glycoprotein gp350/220 in rodent and primate cells (Whang et al.,
1987). Subsequent studies should therefore include the analysis of the glycoprotein
Ov8 and capsid protein ORF65 in eukaryotic expression systems, with an aim to
resolving solubility and purification issues, as these antigens show potential for
recombinant assay development.
Recombinant antigens and synthetic peptides (Davis et al., 1997; Pau et al.,
1998) have been used in ELISA development for the detection of antibodies against
KSHV. Immunoreactive lytic-cycle proteins were considered as potential candidates
for serological analysis (Simpson et al., 1996). ORF52 and ORF65 segments were
analysed in bacterial vectors (pEQ 42 HisTag), although only the capsid protein,
ORF65, showed reactivity to anti-KSHV sera. ORF52 and ORF65 are homologues of
EBV genes BLRF3 and BFRF3 respectively. The carboxyl terminal of ORF65
(ORF65.2) was used as an ELISA antigen and showed over 80% of KS sera were
reactive. On comparison with immunofluorescence, a percentage of KSHV-positive
sera were missed by both assays. Antibodies to the capsid protein were not detected
in all cases of KSHV and suggest that for a more sensitive method, a combination of
antigens would be required for an accurate diagnosis (Simpson et al., 1996).
Assays were additionally developed using synthetic peptides of unique sequence
from the capsid proteins ORF26 and ORF65. These peptide-based assays showed
similar findings to those of the recombinant-based ELISA. The general lack of
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sensitivity may be a result of the restricted antigenic epitopes in the peptide assay,
where patients may not have mounted a specific antibody response. The poor general
sensitivity of the ELISA may be due to the candidate peptides selected. ORF26 and
ORF65, like their EBV homologues, are only produced during lytic infection and
may not be appropriate to detect long-standing latent infections. Efsing discrete
peptides and single recombinant antigens, assays may miss antibodies to
immunogenic viral proteins present in the virus. Also, individuals may differ in the
main focus of their antibody response. A highly sensitive assay for the detection of
KSHV infection may, therefore, require a cocktail of peptides or proteins derived
from both lytic and latent infections (Davis et al., 1997; Pau et al., 1998). Latent
antigen (ORF73) and lytic antigens (ORF65, K81A and K8.1B) were expressed in
both bacterial and baculovirus-insect cell expression systems and purified as GST
fusion proteins. All proteins reacted with anti-KSFIV sera by western blotting.
Increased sensitivity was shown for the lytic proteins. This may be explained by a
higher number of immunogenic proteins being produced during lytic infection.
Antigens recognised by sera were shown to vary. This difference in the detection of
antibodies during infection may be due to a number of factors, such as low antibody
titres and differences in ability to recognise proteins in individual patients. Low
antibody titres may be a result of the pathogenesis of infection, in which only limited
replication occurs. A comparison of western blotting and immunofluorescence
indicate this group of latent and lytic-associated proteins may be employed to detect
serological responses to KSF1V infection (Zhu et al., 1999).
Despite being a rapid and specific approach for the development of a
diagnostic assay, recombinant expression antigen assays have their disadvantages.
Problems with protein expression can occur due to instability, insolubility or toxicity
of the recombinant protein in an expression vector. Furthermore, unless several
recombinant proteins are used for diagnosis, the assay focuses on a single epitope
which may or may not be recognised by an individual's immune response. A general
lack of sensitivity may be a result of the lack of sufficient time required to mount an
immune response due to the rapid clinical progression of infection. It is therefore
possible that individuals may lack humoral immune responses to the viral antigen
targeted in the assay (Li et al., 1996). Analysis of OvFIV-2 lysate by western blot,
using a range of MCF antiserum samples identified a number of antigenic proteins.
The majority of sera were shown to recognise a number of distinct proteins, with
strong reactive bands at 17, 28, 38, 40, 48, 62, 98, 140 and 188kDa. Variation,
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however, was seen between individual serum samples. Possible explanations for
these variations include a variation in the duration of infection, variation in MHC
responses shown by individual animals or a difference in the level of viral
replication. This difference in antigens recognised by serum samples indicates
potential difficulties in the specific diagnosis of MCF infection. Therefore, a large
pool of animals would have to be tested before an antigen could be assumed to
reliably indicate disease.
There are, therefore, advantages to using a crude antigen in diagnostic tests.
These include the low cost of production, increased antigen yield and the detection of
a wider range of antibody specificities. An ELISA was developed for the detection of
antibodies against KSHV using whole-cell viral lysate, prepared from the KS-1 cell
line. Using this crude virus lysate, it was assumed that viral structural and non¬
structural proteins are present, with both lytic and latent proteins represented. This
assay was specific and detected antibodies present in the sera before infection
developed (Chatlynne et al., 1998) and showed good correlation with
immunofluorescence assays (Topino et al., 2001). Further studies using whole-
antigen have also proved effective (Baeten et al., 2002; Cholan et al., 2004) in
studying the prevalence of KSHV in Kenya.
In the absence of sufficient recombinant antigen expression, trial ELISA
experiments were done using whole-cell viral culture preparations from cultured
A1HV-1 and OvHV-2 infected cells. The crude antigen ELISA relies on a polyclonal
response and may consequently be more robust where the infected animal has limited
or low antibody production. Evaluation of extracts showed that only the A1HV-1
antigen could be used to differentiate MCF-positive and negative sera and showed
good concordance to other MCF diagnostic tests (Fraser et al., 2006). The OvHV-2
lysate from an infected cell culture did not show any ELISA signal and so did not
appear to express antigens suitable for the detection of MCF virus specific serum
antibodies. OvHV-2 infects cells productively before establishing latency (Thonur et
al., 2006). A difficulty with OvHV-2 is the lack of a productive culture system for
propagating virus, so that analysis of the virus replication cycle is limited
(Rosbottom et al., 2002). OvHV-2 can be cultured in an LGL cell-line infected
lymphoid cells derived from MCF affected animals. On analysis by ELISA, OvHV-2
antigens from the LGL cell line proved ineffective for the analysis of MCFV
infection. Possible reasons for this inability to discriminate between positive and
negative samples may have been the result of a lack of an adequate negative control
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antigen. In the case of the A1HV-1 antigen, which is prepared in bovine turbinate
cells, mock infected cells can be used as a suitable control. As a control is required
for an ELISA experiment, with no OvHV-2 negative LGL cell line available, a
suitable control had to be established. Concanavalin A (Con A)-treatment of
peripheral blood lymphocytes has been shown to stimulate proliferative responses.
The use of ConA stimulated blast cells from a known MCF-negative animal were
therefore used as a control, representing activated bovine cells without infection. An
additional control should have been the inclusion of lymphocytes not stimulated by
ConA, so the level of background from the stimulated cells could be analysed. On
analysis with an MCF-positive serum, the signal for the ConA stimulated cells was
equal to the OvHV-2 infected cells. This suggests a lack of antigens expressed within
the OvHV-2 lysate. On analysis of the OvHV-2 lysate by gel filtration, there was a
significant difference in the antigens that were recognised by an MCF-positive
antiserum compared to those recognised in the A1HV-1 lysate.
OvHV-2 infected bovine LGFs have been shown to predominantly contain
circular genomes with linear genome scarcely detectable (Rosbottom et al., 2002;
Thonur et al., 2005). In contrast rabbit FGFs contained mainly linear genomes. This
suggests that the OvHV-2 infected cells used in these ELISA tests contained
predominantly latently infected cells (Rosbottom et al., 2002) and may explain the
lack of suitable antigens within the crude lysate.
Future studies should include the continued validation of the established
A1HV-1 based ELISA assay. The development and validation of a diagnostic assay is
essentially comprised of five phases; (1) the feasibility of the method for a particular
use, (2) optimisation and standardisation of reagents and techniques, (3)
determination of assay's performance characteristics (4) continuous monitoring of
assay performance and (5) maintenance of validation criteria during routine usage
(Figure 8.1). Initial feasibility studies have been carried out to establish a selected
protocol and assess whether reagents possess the ability to discriminate between
ranges of antibody concentrations, in the presence of minimal background
interference. By carrying out such studies, an insight into the estimated repeatability,
test sensitivity and specificity may be gained (Office International des Epizooties,
2006). In order to calculate the assay sensitivity and specificity, it is recommended
that at least 300 reference samples from known-infected animals and 1000 samples
from known uninfected animals should be tested to give an accurate test sensitivity
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Figure 8.1: Stages involved in assay development (Illustration adapted from Office des
Epizootes, 2006).
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virus-based ELISA, approximately 100 known-infected animals and 350 samples
from known uninfected animals have been tested. Therefore only an estimated
sensitivity and specificity can be confirmed. An important stage in determining test
sensitivity and specificity is the estimated prevalence in a target population, in order
to gain predictive positive and negative test results. In the absence of test sensitivity
and specificity, predictions regarding the infection status can not be drawn.
Characterisation of the assay should include the continued sampling of known
infected and uninfected animals and may include the sampling of reservoir hosts
wildebeest and sheep to further assess test sensitivity. The preliminary analysis of
cattle experimentally infected with A1HV-1 and natural MCF outbreaks suggest a
high level of sensitivity. A further objective should be the determination of
prevalence of antibodies against MCFV in domestic and wild ruminants, using the
developed ELISA (Fraser et al., 2006). Once an assay has been validated, it requires
constant monitoring and maintenance. This may be performed by internal controls to
assess the tests repeatability and accuracy. External controls may also be tested.
Reference laboratories distribute panels of samples to several laboratories using the
same test. If the test results are found within acceptable limits, with evidence of
accuracy and reproducibility, the laboratory receives certification as an official
laboratory for that assay. With the constant need for reagents, it is essential to test
replacement reagents to establish new test conditions. If the assay is moved to a new
geographical location, re-evaluation must be performed. This may result in a
difference in population, under local conditions.
Validation of a diagnostic serological test routinely involves the comparison
of the new test with a method or combination of methods, routinely used. The routine
method may therefore be termed as a gold standard. The term "gold standard" should
only be limited to methods that clearly classify animals as infected or uninfected
(Office International des Epizooties, 2006). In the absence of a reliable gold
standard, the validation of a new test may involve the comparison of multiple test
methods. In this case, all tests are assessed equally. A reliable diagnosis of MCF may
only be guaranteed by histopathology. Therefore, in the absence of histopathological
examination, a comparison of diagnostic tests may indicate a general trend in the
ability of a correct diagnosis. Four diagnostic tests for MCF were tested and showed
good agreement. Of particular interest in this preliminary validation study, a group of
samples were shown to be DNA positive but serology negative. These samples are of
particular interest, suggesting the presence of virus within an individual that has not
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developed an immune response. A second group of interest include DNA negative,
serology positive samples. These samples may indicate cases of recovered or latent
viral infection. These samples may indicate the possibility of false-negative samples
in both DNA tests and serological tests and, therefore, highlight the need for further
validation.
In parallel with validation studies, future studies should include the continued
analysis of the antigenic components contained within the crude A1HV-1 lysate, with
the aim of identifying possible candidates for expression as recombinant antigens. In
initial experiments for the identification of antigenic components of the ELISA,
western blotting with anti-MCF antiserum was used to guide fractionation of the
ELISA antigen by gel fdtration, ion exchange and affinity chromatography. Clear
fractionation of antigenic bands in the lysate was detected but subsequent proteomic
analysis identified host proteins. One virus antigen was identified as ORF52. A1HV-1
ORF52 is a homologue to KSHV ORF52, EBV BLRF3 and the HSV-1 outer
tegument protein VP22 (UL49). It is assumed that the majority of tegument is added
to the HSV-1 capsid in the cytoplasm. Capsids are assembled in the nucleus before
they cross the inner and outer nuclear membrane. At this stage of assembly, the inner
tegument proteins are added to the capsid, while outer tegument proteins interact
with the cytoplasmic tail of viral glycoproteins. The outer tegument and membrane-
anchored glycoproteins then form the final viral particle. HSV ORF52 is therefore
thought to play a structural role in HSV assembly (Vittone et al., 2005).
In contrast, sequential detergent extraction of A1HV-1 strain WC11 revealed
several antigenic bands, ORF21, ORF25 and ORF54. This finding may suggest a
means towards the identification of the antigenic components of the ELISA and
possible candidates for recombinant studies. It may also suggest a method for
fractionating the lysate for an improved ELISA method. A1HV-1 ORF21 is
homologous to HSV ORF21 (HSV UL23) which encodes viral thymidine kinase.
A1HV-1 ORF54 is homologous to HSV UL50 which encodes dUTPase, located in
the viral particle. A1HV-1 ORF25 is a major virus capsid protein, with homology to
HSV ORF25 (UL19). The major capsid protein, VP5, coded by the UL19 gene, is a
predominant structural subunit of hexons and pentons.
Studies of KSHV diagnostic assays demonstrated that a recombinant based
assay might not confidently identify all cases of infection if the assay was solely
based on a lytic-phase protein. Zhu et al., (1999) determined that expression of a
complex of proteins, comprised of both latent and lytic-phase proteins, may be
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beneficial for the diagnosis of infection. The four genes identified through proteomic
analysis of the whole-cell viral lysate were shown to be proteins expressed during
lytic replication, ORF21, ORF25, ORF52 and ORF54. The identification of only
lytic proteins may simply be a result of the lysate being prepared from a lytic culture.
From the KSHV literature it seems likely that an assay based on only lytic proteins
may not accurately diagnose all cases of MCF infection, although lytic antigens are
seen by MCF sera. KSFIV antiserum was shown to react with the latency-associated
nuclear antigen, KSHV ORF73, (Zhu et al., 1999). The inclusion of a latent protein
such as ORF73 in a recombinant antigen based assay, or added to the crude lysate
assay, may therefore be beneficial. During the construction of a cDNA library
generated from lymphoblastoid cell lines, a clone containing a partial ORF with
similarity to A1HV-1 ORF73 was identified (Lahijani et al., 1995; Zhu et al., 1999;
Coulter and Reid, 2002). On analysing the reactivity of the OvHV-2 ORF73 C-
terminal fragment, against sera from OvHV-2 infected sera, the fusion protein was
recognised by both MCF positive and negative bovine sera. This indicated the
ORF73 antigen may not be suitable for use in the diagnosis of OvHV-2 infection.
Future studies would include the analysis of each of the four A1HV-1
antigens identified in the crude viral extract with MCF-specific antibodies. A further
consideration for the suitability of these genes in a diagnostic test is to define
whether they are highly conserved within other bovine herpesviruses and so likely to
be cross-reactive. ORF25 and ORF54 are conserved within all herpesviruses while
ORF21, ORF52 and ORF73 are conserved within gammaherpesviruses. These highly
conserved genes may therefore not be suitable for the detection of MCF-specific
antibodies. AIHV-1 ORF25 has recently been expressed in mammalian cells, but was
not detected by MCF sera on western blot suggesting that ORF25 is not a major
antigen (Russell and Dasari, unpublished finding). In contrast, glycoprotein B
expressed in the same system was shown to be antigenic by MCF-positive sera and
therefore may be a candidate recombinant antigen. Glycoprotein B (gB) of AIHV-1,
encoded by ORF8, is one of the most conserved herpesvirus glycoproteins
(Dunowska et al., 2001) and plays a role in viral entry. Expression of a band at
approximately 105kDa was detected using IgG purified from AIHV-1-infected
bovine sera. The MAb 15A used in the commercially available CI-ELISA binds an
epitope located on a glycoprotein complex which, on reducing polyacrylamide gels,
resolves into five bands at 45, 78, 105, 110 and 115kDa. Proteomic analysis of
AIHV-1 virions (Dry et al., unpublished observation) has shown gB is present in the
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mature virion as 2 furin-cleaved polypeptide complexes of 50 and 80kDa, and
suggests MAb 15-A recognises gB. MAb 15A also recognises the recombinant gB
expressed in mammalian cells. Thus gp 115, a highly conserved and immunogenic
complex (Adams and Hutt-Fletcher, 1990) seems to include gB. Further work should
therefore include the analysis of glycoprotein B, for its potential as a diagnostic
antigen for the detection of antibodies against MCFV.
In conclusion, while this study has not described the development of a
diagnostic test specific for ovine herpesvirus-2, it has identified a number of
candidates that may provide a starting point for future experiments. The development
of a working MCF ELISA based on a crude A1HV-1 infected-cell lysate has
facilitated alternative methods for the identification of antigenic proteins.
Additionally, a number of reagents have been generated, including recombinant
antigens and crude MCF lysates, which could prove useful in other investigations.
This work will offer new contributions to scientific knowledge within the
field of MCF, as not only has the crude antigen ELISA (WC11-ELISA) the potential
to offer a rapid alternative to the diagnosis of disease, the discovery of potential
recombinant antigens offers the development of a recombinant based assay which
may prove more sensitive in its diagnosis. The ELISA will firstly be assessed and
validated for its reproducibility in a commercial market. On validation, the assay
should benefit studies regarding the continued immune status of animals, studies for
screening animals before entering an MCF free herd and for the addition to exotic
collections. ELISA validation is currently ongoing.
Analysis of several candidate antigens performed during this thesis may
prove advantageous to others studying this field, whereby these candidates may be
discounted. The negative findings of this study were presented at PhD meetings, and
hopefully may offer information regarding the solubility issues observed when using
the described expression methods. Furthermore, the work performed on the
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Add deionized H20 to a final volume of 1 liter
Autoclave
Add 2.5ml sterile 20% dextrose and 1 ml of 100 mg/ml filter-
sterilized ampicillin
Pour into petri dishes (-25 ml/100-mm plate)
SOC Medium (per 100 ml)
2 ml of filter-sterilized 20% (w/v) glucose or 1 ml of filter-
sterilized
2 M glucose
SOB medium (autoclaved) to a final volume of 100 ml
SOB Medium (per Liter)
20.Og of tryptone
5.0g of yeast extract
0.5g of NaCl
Add deionized H20 to a final volume of 1 liter
Autoclave
Add 10 ml of filter-sterilized 1 M MgC12 and 10 ml of filter-
sterilized
LB Agar (per Liter)
lOg of NaCl
1 Og of tryptone
5g of yeast extract
20g of agar
Add deionized H20 to a final volume of 1 liter
Adjust pH to 7.0 with 5 N NaOH
Autoclave
LB-Ampicillin Agar (per Liter)
1 liter of LB agar, autoclaved
Cool to 55°C
Add 10 ml of 10 mg/ml filter-sterilized ampicillin
Pour into petri dishes (-25 ml/100-mm plate)
